Selegiline	B-Chemical
-	O
induced	T-1
postural	O
hypotension	O
in	O
Parkinson	O
'	O
s	O
disease	O
:	O
a	O
longitudinal	O
study	O
on	O
the	O
effects	T-0
of	T-0
drug	O
withdrawal	O
.	O

Selegiline	O
-	O
induced	T-0
postural	B-Disease
hypotension	I-Disease
in	O
Parkinson	O
'	O
s	O
disease	O
:	O
a	O
longitudinal	O
study	O
on	O
the	O
effects	O
of	O
drug	O
withdrawal	O
.	O

Selegiline	O
-	O
induced	T-1
postural	O
hypotension	O
in	T-0
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
:	O
a	O
longitudinal	O
study	O
on	O
the	O
effects	O
of	O
drug	O
withdrawal	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	T-1
mortality	T-1
in	T-1
patients	T-1
with	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
randomized	O
to	O
receive	O
10	T-0
mg	T-0
selegiline	O
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	T-0
mortality	T-1
in	O
patients	T-2
with	T-2
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	O
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	O
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	T-0
patients	T-0
with	T-0
Parkinson	O
'	O
s	O
disease	O
(	O
PD	B-Disease
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	O
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
randomized	O
to	O
receive	O
10	T-0
mg	T-0
selegiline	B-Chemical
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	T-0
mortality	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	O
per	O
day	O
and	T-2
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
compared	T-1
with	T-1
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	O
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	T-1
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
alone	T-0
.	O

Recently	O
,	O
we	O
found	T-4
that	T-4
therapy	T-1
with	O
selegiline	B-Chemical
and	O
L	O
-	O
dopa	O
was	T-0
associated	T-5
with	T-5
selective	O
systolic	T-2
orthostatic	T-2
hypotension	T-2
which	O
was	O
abolished	O
by	O
withdrawal	T-3
of	T-3
selegiline	T-3
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	T-3
with	T-3
selegiline	O
and	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
was	T-2
associated	T-2
with	O
selective	O
systolic	T-0
orthostatic	T-0
hypotension	T-0
which	O
was	O
abolished	O
by	O
withdrawal	T-1
of	T-1
selegiline	T-1
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	O
with	O
selegiline	O
and	O
L	O
-	O
dopa	O
was	O
associated	T-1
with	T-1
selective	O
systolic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
which	T-0
was	T-0
abolished	O
by	O
withdrawal	O
of	O
selegiline	O
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	T-0
with	O
selegiline	O
and	O
L	T-1
-	T-1
dopa	T-1
was	O
associated	O
with	O
selective	O
systolic	T-2
orthostatic	T-2
hypotension	T-2
which	O
was	O
abolished	O
by	O
withdrawal	T-3
of	T-3
selegiline	B-Chemical
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
confirm	O
our	O
previous	O
findings	O
in	O
a	O
separate	O
cohort	O
of	O
patients	T-0
and	O
to	O
determine	O
the	O
time	O
course	O
of	O
the	O
cardiovascular	T-4
consequences	T-4
of	T-4
stopping	T-4
selegiline	B-Chemical
in	T-3
the	T-3
expectation	T-3
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechanisms	O
by	O
which	O
the	O
drug	O
causes	O
orthostatic	O
hypotension	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
confirm	O
our	O
previous	O
findings	O
in	O
a	O
separate	O
cohort	T-2
of	T-2
patients	T-2
and	O
to	O
determine	O
the	O
time	O
course	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
stopping	T-0
selegiline	O
in	O
the	O
expectation	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechanisms	O
by	O
which	O
the	O
drug	O
causes	T-1
orthostatic	B-Disease
hypotension	I-Disease
.	O

METHODS	O
:	O
The	T-4
cardiovascular	T-4
responses	T-4
to	O
standing	O
and	O
head	O
-	O
up	O
tilt	O
were	O
studied	T-0
repeatedly	T-3
in	T-3
PD	B-Disease
patients	T-2
receiving	O
selegiline	O
and	O
as	O
the	O
drug	O
was	O
withdrawn	O
.	O

METHODS	O
:	O
The	O
cardiovascular	O
responses	O
to	O
standing	O
and	O
head	O
-	O
up	O
tilt	O
were	O
studied	O
repeatedly	O
in	O
PD	O
patients	T-2
receiving	T-2
selegiline	B-Chemical
and	T-3
as	T-3
the	T-3
drug	T-3
was	O
withdrawn	O
.	O

RESULTS	O
:	O
Head	O
-	O
up	O
tilt	O
caused	T-2
systolic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
which	T-3
was	T-3
marked	T-0
in	T-0
six	O
of	O
20	O
PD	O
patients	T-1
on	O
selegiline	O
,	O
one	O
of	O
whom	O
lost	O
consciousness	O
with	O
unrecordable	O
blood	O
pressures	O
.	O

RESULTS	O
:	O
Head	T-3
-	T-3
up	T-3
tilt	O
caused	T-0
systolic	T-4
orthostatic	T-4
hypotension	T-4
which	O
was	O
marked	O
in	O
six	T-6
of	T-6
20	T-6
PD	B-Disease
patients	O
on	O
selegiline	O
,	O
one	O
of	O
whom	O
lost	T-1
consciousness	O
with	O
unrecordable	T-2
blood	O
pressures	O
.	T-5

RESULTS	O
:	O
Head	O
-	O
up	O
tilt	O
caused	O
systolic	O
orthostatic	O
hypotension	O
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	O
patients	T-0
on	T-0
selegiline	B-Chemical
,	O
one	O
of	O
whom	O
lost	O
consciousness	O
with	O
unrecordable	O
blood	O
pressures	O
.	O

A	O
lesser	O
degree	T-0
of	T-0
orthostatic	B-Disease
hypotension	I-Disease
occurred	T-1
with	O
standing	O
.	O

Orthostatic	B-Disease
hypotension	I-Disease
was	O
ameliorated	T-0
4	O
days	O
after	O
withdrawal	O
of	O
selegiline	T-1
and	O
totally	O
abolished	O
7	O
days	O
after	O
discontinuation	O
of	O
the	O
drug	T-2
.	O

Orthostatic	T-0
hypotension	T-0
was	O
ameliorated	O
4	O
days	O
after	O
withdrawal	T-1
of	O
selegiline	B-Chemical
and	O
totally	O
abolished	O
7	O
days	O
after	O
discontinuation	O
of	O
the	O
drug	T-2
.	O

Stopping	T-0
selegiline	B-Chemical
also	O
significantly	O
reduced	T-2
the	O
supine	O
systolic	O
and	O
diastolic	O
blood	O
pressures	O
consistent	O
with	O
a	O
previously	O
undescribed	O
supine	O
pressor	O
action	T-1
.	O

Stopping	T-0
selegiline	O
also	O
significantly	O
reduced	B-Disease
the	I-Disease
supine	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
blood	I-Disease
pressures	I-Disease
consistent	T-1
with	T-1
a	O
previously	O
undescribed	O
supine	O
pressor	O
action	O
.	O

CONCLUSION	O
:	O
This	O
study	O
confirms	O
our	O
previous	O
finding	T-1
that	T-1
selegiline	B-Chemical
in	T-2
combination	T-2
with	O
L	T-0
-	T-0
dopa	T-0
is	O
associated	O
with	O
selective	O
orthostatic	O
hypotension	O
.	O

CONCLUSION	O
:	O
This	O
study	O
confirms	O
our	O
previous	O
finding	O
that	O
selegiline	T-2
in	O
combination	T-1
with	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
is	T-0
associated	T-0
with	O
selective	T-3
orthostatic	T-3
hypotension	T-3
.	O

CONCLUSION	O
:	O
This	O
study	O
confirms	O
our	O
previous	O
finding	O
that	O
selegiline	O
in	T-0
combination	T-0
with	T-0
L	O
-	O
dopa	O
is	O
associated	T-1
with	T-2
selective	T-2
orthostatic	B-Disease
hypotension	I-Disease
.	O

The	O
possibilities	O
that	O
these	O
cardiovascular	T-2
findings	T-2
might	T-2
be	T-2
the	T-2
result	T-2
of	T-2
non	O
-	O
selective	O
inhibition	T-0
of	O
monoamine	O
oxidase	O
or	T-1
of	T-1
amphetamine	B-Chemical
and	O
metamphetamine	O
are	O
discussed	O
.	O

The	O
possibilities	O
that	O
these	O
cardiovascular	O
findings	O
might	T-2
be	T-2
the	T-2
result	T-2
of	T-2
non	O
-	O
selective	O
inhibition	O
of	O
monoamine	O
oxidase	O
or	O
of	O
amphetamine	O
and	T-0
metamphetamine	B-Chemical
are	T-1
discussed	T-1
.	O

The	O
results	O
have	O
shown	O
that	O
the	O
degradation	O
product	T-0
p	B-Chemical
-	I-Chemical
choloroaniline	I-Chemical
is	T-1
not	T-1
a	O
significant	O
factor	O
in	O
chlorhexidine	T-2
-	O
digluconate	O
associated	O
erosive	O
cystitis	O
.	O

The	O
results	O
have	O
shown	O
that	O
the	O
degradation	T-2
product	T-2
p	O
-	O
choloroaniline	O
is	O
not	O
a	O
significant	O
factor	T-0
in	T-0
chlorhexidine	B-Chemical
-	I-Chemical
digluconate	I-Chemical
associated	T-1
erosive	O
cystitis	O
.	O

The	O
results	O
have	O
shown	O
that	O
the	O
degradation	O
product	O
p	O
-	O
choloroaniline	O
is	O
not	O
a	O
significant	O
factor	O
in	O
chlorhexidine	O
-	O
digluconate	O
associated	O
erosive	T-0
cystitis	B-Disease
.	O

A	O
high	O
percentage	T-2
of	T-2
kanamycin	B-Chemical
-	O
colistin	O
and	O
povidone	O
-	O
iodine	O
irrigations	O
were	O
associated	T-0
with	O
erosive	O
cystitis	O
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	T-1
.	O

A	O
high	O
percentage	O
of	O
kanamycin	T-2
-	T-2
colistin	B-Chemical
and	T-3
povidone	T-3
-	O
iodine	O
irrigations	O
were	O
associated	T-0
with	O
erosive	O
cystitis	O
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	T-1
.	O

A	O
high	O
percentage	O
of	O
kanamycin	O
-	O
colistin	T-3
and	T-3
povidone	B-Chemical
-	I-Chemical
iodine	I-Chemical
irrigations	T-2
were	O
associated	O
with	O
erosive	O
cystitis	O
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	T-0
.	O

A	O
high	O
percentage	O
of	O
kanamycin	O
-	O
colistin	O
and	O
povidone	O
-	O
iodine	O
irrigations	O
were	O
associated	T-0
with	T-2
erosive	T-2
cystitis	B-Disease
and	T-3
suggested	T-3
a	O
possible	O
complication	O
with	O
human	O
usage	O
.	O

Picloxydine	B-Chemical
irrigations	T-1
appeared	T-1
to	O
have	O
a	O
lower	O
incidence	O
of	O
erosive	O
cystitis	O
but	O
further	O
studies	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
recommended	O
for	O
use	O
in	O
urological	O
procedures	O
.	O

Picloxydine	O
irrigations	O
appeared	O
to	O
have	O
a	O
lower	T-1
incidence	T-1
of	T-1
erosive	T-1
cystitis	B-Disease
but	O
further	O
studies	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
recommended	O
for	O
use	O
in	O
urological	O
procedures	O
.	O

Effects	T-0
of	T-0
tetrandrine	B-Chemical
and	O
fangchinoline	O
on	O
experimental	O
thrombosis	O
in	O
mice	O
and	O
human	O
platelet	O
aggregation	O
.	O

Effects	T-1
of	T-1
tetrandrine	T-1
and	O
fangchinoline	B-Chemical
on	O
experimental	O
thrombosis	O
in	O
mice	O
and	O
human	O
platelet	O
aggregation	O
.	O

Effects	T-1
of	T-1
tetrandrine	O
and	O
fangchinoline	O
on	O
experimental	T-0
thrombosis	B-Disease
in	O
mice	O
and	O
human	O
platelet	O
aggregation	O
.	O

Effects	O
of	O
tetrandrine	O
and	O
fangchinoline	O
on	O
experimental	O
thrombosis	T-1
in	O
mice	O
and	O
human	T-0
platelet	B-Disease
aggregation	I-Disease
.	O

Tetrandrine	O
(	O
TET	B-Chemical
)	O
and	O
fangchinoline	O
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	T-0
a	T-0
bisbenzylisoquinoline	O
structure	O
.	O

Tetrandrine	O
(	O
TET	O
)	O
and	T-0
fangchinoline	B-Chemical
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	O
a	O
bisbenzylisoquinoline	O
structure	O
.	O

Tetrandrine	O
(	O
TET	O
)	O
and	O
fangchinoline	T-1
(	O
FAN	B-Chemical
)	O
are	T-2
two	T-2
naturally	T-2
occurring	T-2
analogues	O
with	O
a	O
bisbenzylisoquinoline	O
structure	O
.	O

Tetrandrine	O
(	O
TET	O
)	O
and	O
fangchinoline	O
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	T-0
analogues	O
with	O
a	O
bisbenzylisoquinoline	B-Chemical
structure	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	T-1
of	T-1
TET	B-Chemical
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	T-0
by	O
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	T-0
effects	T-0
of	T-0
TET	O
and	O
FAN	B-Chemical
on	O
the	O
experimental	O
thrombosis	O
induced	O
by	O
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	T-2
the	T-2
experimental	T-2
thrombosis	B-Disease
induced	T-1
by	T-1
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	T-1
by	T-1
collagen	O
plus	O
epinephrine	B-Chemical
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	T-2
of	T-2
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	T-3
by	T-3
collagen	O
plus	O
epinephrine	O
(	O
EP	B-Chemical
)	O
in	T-1
mice	T-1
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	T-0
by	O
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	T-1
platelet	B-Disease
aggregation	I-Disease
and	T-2
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	T-0
by	T-0
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	T-1
blood	B-Disease
coagulation	I-Disease
in	O
vitro	O
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	T-2
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	T-0
TET	B-Chemical
and	T-1
FAN	O
in	O
mice	O
showed	O
the	O
inhibition	T-3
of	O
thrombosis	O
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	O
acid	O
(	O
ASA	O
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
30	O
%	O
inhibition	T-4
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	T-2
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	O
and	O
FAN	B-Chemical
in	O
mice	O
showed	O
the	O
inhibition	T-3
of	O
thrombosis	T-1
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	O
acid	O
(	O
ASA	O
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
30	O
%	O
inhibition	O
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	T-0
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	O
and	O
FAN	O
in	O
mice	O
showed	O
the	O
inhibition	T-2
of	O
thrombosis	B-Disease
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	O
acid	O
(	O
ASA	O
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
30	O
%	O
inhibition	T-1
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	T-2
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	O
and	O
FAN	O
in	O
mice	O
showed	O
the	O
inhibition	T-0
of	O
thrombosis	O
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	B-Chemical
acid	I-Chemical
(	O
ASA	O
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
30	O
%	O
inhibition	T-1
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	T-0
administration	T-0
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	O
and	O
FAN	O
in	O
mice	O
showed	O
the	O
inhibition	T-1
of	T-1
thrombosis	O
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	O
acid	O
(	O
ASA	B-Chemical
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
30	O
%	O
inhibition	O
.	O

In	O
the	O
vitro	O
human	O
platelet	B-Disease
aggregations	I-Disease
induced	T-2
by	O
the	O
agonists	O
used	T-0
in	O
tests	O
,	O
TET	O
and	O
FAN	O
showed	T-3
the	O
inhibitions	T-1
dose	O
dependently	O
.	O

In	O
the	O
vitro	O
human	O
platelet	O
aggregations	O
induced	T-0
by	T-0
the	O
agonists	O
used	O
in	O
tests	O
,	O
TET	B-Chemical
and	T-1
FAN	O
showed	O
the	O
inhibitions	O
dose	O
dependently	O
.	O

In	O
the	O
vitro	O
human	O
platelet	O
aggregations	O
induced	T-1
by	O
the	O
agonists	O
used	O
in	O
tests	O
,	O
TET	O
and	O
FAN	B-Chemical
showed	T-0
the	O
inhibitions	T-2
dose	O
dependently	O
.	O

In	O
addition	O
,	O
neither	T-0
TET	B-Chemical
nor	O
FAN	O
showed	O
any	O
anticoagulation	O
activities	O
in	O
the	O
measurement	O
of	O
the	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
thrombin	O
time	O
(	O
TT	O
)	O
using	O
human	O
-	O
citrated	O
plasma	O
.	O

In	O
addition	O
,	O
neither	T-0
TET	O
nor	O
FAN	B-Chemical
showed	T-2
any	O
anticoagulation	O
activities	O
in	O
the	O
measurement	O
of	O
the	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
thrombin	O
time	O
(	O
TT	O
)	O
using	O
human	O
-	O
citrated	O
plasma	O
.	O

These	O
results	T-0
suggest	T-1
that	T-1
antithrombosis	O
of	O
TET	B-Chemical
and	O
FAN	O
in	O
mice	O
may	O
be	O
mainly	O
related	O
to	O
the	O
antiplatelet	O
aggregation	O
activities	O
.	O

These	O
results	O
suggest	T-0
that	T-0
antithrombosis	O
of	O
TET	O
and	O
FAN	B-Chemical
in	O
mice	O
may	O
be	O
mainly	O
related	O
to	O
the	O
antiplatelet	O
aggregation	O
activities	O
.	O

Angioedema	B-Disease
due	T-0
to	T-0
ACE	O
inhibitors	O
:	O
common	O
and	O
inadequately	O
diagnosed	T-1
.	O

Angioedema	O
due	T-1
to	T-1
ACE	B-Chemical
inhibitors	I-Chemical
:	O
common	O
and	O
inadequately	O
diagnosed	T-0
.	O

The	O
estimated	O
incidence	T-0
of	T-0
angioedema	B-Disease
during	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
treatment	O
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
patients	O
.	O

The	O
estimated	O
incidence	O
of	O
angioedema	O
during	T-0
angiotensin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzyme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inhibitor	I-Chemical
treatment	T-1
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
patients	O
.	O

Cocaine	B-Chemical
-	T-1
induced	T-1
mood	O
disorder	O
:	O
prevalence	O
rates	O
and	O
psychiatric	O
symptoms	O
in	O
an	O
outpatient	O
cocaine	O
-	O
dependent	O
sample	O
.	O

Cocaine	O
-	O
induced	T-1
mood	B-Disease
disorder	I-Disease
:	T-0
prevalence	T-0
rates	T-0
and	O
psychiatric	O
symptoms	O
in	O
an	O
outpatient	O
cocaine	O
-	O
dependent	O
sample	O
.	O

Cocaine	O
-	O
induced	T-2
mood	O
disorder	O
:	O
prevalence	T-3
rates	T-3
and	T-0
psychiatric	B-Disease
symptoms	T-1
in	T-1
an	O
outpatient	O
cocaine	O
-	O
dependent	O
sample	O
.	O

Cocaine	O
-	O
induced	T-0
mood	O
disorder	O
:	O
prevalence	O
rates	O
and	O
psychiatric	O
symptoms	T-1
in	O
an	O
outpatient	O
cocaine	B-Chemical
-	O
dependent	T-2
sample	O
.	O

This	O
paper	O
attempts	O
to	O
examine	O
and	O
compare	O
prevalence	T-1
rates	T-1
and	O
symptom	T-2
patterns	T-2
of	T-2
DSM	O
substance	T-3
-	T-3
induced	T-3
and	T-0
other	T-0
mood	B-Disease
disorders	I-Disease
.	O

243	O
cocaine	B-Chemical
-	O
dependent	T-1
outpatients	T-1
with	O
cocaine	O
-	O
induced	O
mood	O
disorder	O
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	T-0
of	T-0
psychiatric	O
symptoms	O
.	O

243	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	B-Chemical
-	O
induced	T-0
mood	O
disorder	O
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

243	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	O
-	O
induced	T-0
mood	B-Disease
disorder	I-Disease
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

243	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	O
-	O
induced	T-0
mood	O
disorder	O
(	O
CIMD	B-Disease
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

243	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	O
-	O
induced	O
mood	O
disorder	O
(	O
CIMD	O
)	O
,	O
other	T-0
mood	B-Disease
disorders	I-Disease
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	T-1

243	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	O
-	O
induced	T-2
mood	O
disorder	O
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	B-Disease
disorder	I-Disease
were	O
compared	T-1
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

243	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	O
-	O
induced	T-0
mood	O
disorder	O
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	T-1
on	T-1
measures	T-2
of	T-2
psychiatric	B-Disease
symptoms	T-3
.	O

The	O
prevalence	T-1
rate	T-1
for	T-1
CIMD	B-Disease
was	O
12	O
%	O
at	O
baseline	O
.	O

Introduction	T-0
of	T-0
the	O
DSM	O
-	O
IV	T-2
diagnosis	T-2
of	T-2
CIMD	B-Disease
did	O
not	O
substantially	O
affect	T-1
rates	O
of	O
the	O
other	O
depressive	O
disorders	O
.	O

Introduction	T-0
of	O
the	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
CIMD	O
did	O
not	O
substantially	O
affect	T-1
rates	O
of	O
the	O
other	O
depressive	B-Disease
disorders	I-Disease
.	O

Patients	T-2
with	T-2
CIMD	B-Disease
had	T-1
symptom	T-1
severity	O
levels	O
between	O
those	O
of	O
patients	O
with	O
and	O
without	O
a	O
mood	O
disorder	O
.	O

These	O
findings	O
suggest	O
some	O
validity	O
for	O
the	O
new	O
DSM	O
-	O
IV	O
diagnosis	T-1
of	T-1
CIMD	B-Disease
,	O
but	O
also	O
suggest	O
that	O
it	O
requires	O
further	O
specification	O
and	O
replication	O
.	O

Effect	T-0
of	T-0
fucoidan	B-Chemical
treatment	T-1
on	O
collagenase	O
-	O
induced	T-2
intracerebral	O
hemorrhage	O
in	O
rats	O
.	O

Effect	O
of	O
fucoidan	O
treatment	T-0
on	O
collagenase	O
-	O
induced	T-1
intracerebral	B-Disease
hemorrhage	I-Disease
in	O
rats	O
.	O

Inflammatory	O
cells	O
are	O
postulated	O
to	O
mediate	T-0
some	O
of	O
the	O
brain	B-Disease
damage	I-Disease
following	O
ischemic	O
stroke	O
.	O

Inflammatory	O
cells	O
are	O
postulated	O
to	O
mediate	O
some	O
of	O
the	O
brain	O
damage	O
following	T-0
ischemic	B-Disease
stroke	I-Disease
.	O

Intracerebral	B-Disease
hemorrhage	I-Disease
is	T-0
associated	T-1
with	T-1
more	O
inflammation	O
than	O
ischemic	O
stroke	O
.	O

Intracerebral	O
hemorrhage	T-0
is	O
associated	T-2
with	O
more	O
inflammation	B-Disease
than	O
ischemic	T-1
stroke	O
.	O

Intracerebral	O
hemorrhage	O
is	O
associated	T-0
with	T-0
more	O
inflammation	O
than	T-1
ischemic	B-Disease
stroke	I-Disease
.	O

We	O
tested	O
the	O
sulfated	O
polysaccharide	O
fucoidan	B-Chemical
,	O
which	O
has	O
been	O
reported	O
to	O
reduce	T-1
inflammatory	O
brain	O
damage	O
,	O
in	O
a	O
rat	O
model	O
of	O
intracerebral	O
hemorrhage	O
induced	T-0
by	O
injection	O
of	O
bacterial	O
collagenase	O
into	O
the	O
caudate	O
nucleus	O
.	O

We	O
tested	O
the	O
sulfated	O
polysaccharide	O
fucoidan	O
,	O
which	O
has	O
been	O
reported	O
to	O
reduce	T-0
inflammatory	O
brain	B-Disease
damage	I-Disease
,	O
in	O
a	O
rat	O
model	O
of	O
intracerebral	O
hemorrhage	O
induced	O
by	O
injection	O
of	O
bacterial	O
collagenase	O
into	O
the	O
caudate	O
nucleus	O
.	O

We	O
tested	O
the	O
sulfated	O
polysaccharide	O
fucoidan	O
,	O
which	O
has	O
been	O
reported	O
to	O
reduce	O
inflammatory	O
brain	O
damage	O
,	O
in	O
a	O
rat	O
model	T-0
of	T-0
intracerebral	B-Disease
hemorrhage	I-Disease
induced	T-1
by	T-1
injection	O
of	O
bacterial	O
collagenase	O
into	O
the	O
caudate	O
nucleus	O
.	O

Rats	O
were	O
treated	T-1
with	T-0
seven	O
day	O
intravenous	O
infusion	T-2
of	O
fucoidan	B-Chemical
(	O
30	O
micrograms	O
h	O
-	O
1	O
)	O
or	O
vehicle	O
.	O

The	T-0
hematoma	B-Disease
was	T-1
assessed	T-1
in	O
vivo	O
by	O
magnetic	O
resonance	O
imaging	O
.	O

Fucoidan	B-Chemical
-	T-1
treated	T-1
rats	T-1
exhibited	O
evidence	O
of	O
impaired	O
blood	O
clotting	O
and	O
hemodilution	O
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	O
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	T-0
evidence	O
of	O
impaired	B-Disease
blood	I-Disease
clotting	I-Disease
and	O
hemodilution	O
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	T-1
to	O
have	O
less	O
inflammation	O
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	O
evidence	O
of	O
impaired	O
blood	O
clotting	O
and	T-0
hemodilution	B-Disease
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	O
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	O
evidence	O
of	O
impaired	O
blood	O
clotting	O
and	O
hemodilution	O
,	O
had	T-0
larger	T-0
hematomas	B-Disease
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	O
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	T-1
evidence	O
of	O
impaired	O
blood	O
clotting	O
and	O
hemodilution	O
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	O
to	T-0
have	T-0
less	T-0
inflammation	B-Disease
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

They	O
showed	O
significantly	O
more	O
rapid	O
improvement	T-2
of	O
motor	O
function	O
in	O
the	O
first	O
week	O
following	T-0
hemorrhage	B-Disease
and	T-1
better	O
memory	O
retention	O
in	O
the	O
passive	O
avoidance	O
test	O
.	O

Acute	T-1
white	B-Disease
matter	I-Disease
edema	I-Disease
and	O
eventual	O
neuronal	O
loss	O
in	O
the	O
striatum	O
adjacent	O
to	O
the	O
hematoma	O
did	O
not	O
differ	T-0
between	O
the	O
two	O
groups	O
.	O

Acute	O
white	O
matter	O
edema	O
and	O
eventual	O
neuronal	O
loss	O
in	O
the	O
striatum	O
adjacent	T-0
to	T-0
the	O
hematoma	B-Disease
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O

Investigation	O
of	O
more	O
specific	O
anti	O
-	O
inflammatory	O
agents	O
and	O
hemodiluting	O
agents	O
are	O
warranted	T-1
in	T-1
intracerebral	B-Disease
hemorrhage	I-Disease
.	O

Accumulation	T-0
of	O
atracurium	B-Chemical
in	O
the	O
intravenous	O
line	O
led	O
to	O
recurarization	O
after	O
flushing	O
the	O
line	O
in	O
the	O
recovery	O
room	O
.	O

A	T-0
respiratory	B-Disease
arrest	I-Disease
with	T-1
severe	O
desaturation	O
and	O
bradycardia	O
occurred	T-2
.	O

A	O
respiratory	O
arrest	T-0
with	O
severe	T-2
desaturation	B-Disease
and	O
bradycardia	O
occurred	T-1
.	O

A	O
respiratory	O
arrest	O
with	O
severe	O
desaturation	O
and	O
bradycardia	B-Disease
occurred	T-0
.	O

Circumstances	O
leading	O
to	O
this	O
event	O
and	O
the	O
mechanisms	T-0
enabling	T-0
a	O
neuromuscular	B-Disease
blockade	I-Disease
to	O
occur	O
,	O
following	O
the	O
administration	T-1
of	T-1
a	O
small	O
dose	O
of	O
relaxant	O
,	O
are	O
discussed	O
.	O

The	O
haemodynamic	O
effects	T-0
of	O
propofol	B-Chemical
in	O
combination	T-1
with	T-1
ephedrine	O
in	O
elderly	O
patients	O
(	O
ASA	O
groups	O
3	O
and	O
4	O
)	O
.	O

The	O
haemodynamic	O
effects	O
of	O
propofol	O
in	T-0
combination	T-0
with	T-0
ephedrine	B-Chemical
in	O
elderly	O
patients	O
(	O
ASA	O
groups	O
3	O
and	O
4	O
)	O
.	O

The	O
marked	O
vasodilator	O
and	O
negative	O
inotropic	O
effects	T-1
of	T-1
propofol	B-Chemical
are	T-2
disadvantages	T-2
in	O
frail	O
elderly	O
patients	O
.	O

We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
adding	O
different	O
doses	T-0
of	T-0
ephedrine	B-Chemical
to	O
propofol	O
in	O
order	O
to	O
obtund	O
the	O
hypotensive	O
response	O
.	O

We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
adding	O
different	O
doses	T-1
of	O
ephedrine	O
to	O
propofol	B-Chemical
in	T-0
order	T-0
to	T-0
obtund	T-2
the	O
hypotensive	O
response	O
.	O

We	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
adding	T-2
different	O
doses	O
of	O
ephedrine	O
to	O
propofol	O
in	O
order	O
to	O
obtund	T-0
the	T-0
hypotensive	B-Disease
response	T-1
.	O

The	O
haemodynamic	O
effects	O
of	O
adding	O
15	O
,	O
20	O
or	O
25	T-0
mg	T-2
of	T-2
ephedrine	B-Chemical
to	T-1
200	T-1
mg	T-1
of	O
propofol	O
were	O
compared	O
to	O
control	O
in	O
40	O
ASA	O
3	O
/	O
4	O
patients	O
over	O
60	O
years	O
presenting	O
for	O
genito	O
-	O
urinary	O
surgery	O
.	O

The	O
haemodynamic	O
effects	T-2
of	T-2
adding	O
15	O
,	O
20	O
or	O
25	O
mg	O
of	O
ephedrine	O
to	O
200	T-1
mg	T-1
of	T-1
propofol	B-Chemical
were	O
compared	T-3
to	T-3
control	O
in	O
40	O
ASA	O
3	O
/	O
4	O
patients	O
over	O
60	O
years	O
presenting	O
for	O
genito	O
-	O
urinary	O
surgery	O
.	O

The	O
addition	O
of	O
ephedrine	B-Chemical
to	T-0
propofol	T-0
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	O
response	O
to	O
propofol	O
at	O
all	O
doses	O
used	O
in	O
this	O
study	O
.	O

The	O
addition	O
of	O
ephedrine	T-1
to	T-1
propofol	B-Chemical
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	O
response	O
to	O
propofol	O
at	O
all	O
doses	T-0
used	O
in	O
this	O
study	O
.	O

The	O
addition	O
of	O
ephedrine	O
to	O
propofol	O
appears	O
to	O
be	O
an	O
effective	O
method	O
of	T-2
obtunding	T-2
the	T-2
hypotensive	B-Disease
response	T-0
to	O
propofol	O
at	O
all	O
doses	O
used	T-1
in	O
this	O
study	O
.	O

The	O
addition	O
of	O
ephedrine	O
to	O
propofol	O
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	O
response	T-1
to	T-1
propofol	B-Chemical
at	T-2
all	T-2
doses	T-2
used	O
in	O
this	O
study	O
.	O

However	O
,	O
marked	O
tachycardia	B-Disease
associated	T-0
with	T-0
the	O
use	O
of	O
ephedrine	O
in	O
combination	O
with	O
propofol	O
occurred	T-1
in	T-1
the	O
majority	O
of	O
patients	O
,	O
occasionally	O
reaching	O
high	O
levels	O
in	T-2
individual	O
patients	T-3
.	O

However	O
,	O
marked	O
tachycardia	O
associated	O
with	T-1
the	T-1
use	T-1
of	T-1
ephedrine	B-Chemical
in	T-2
combination	T-2
with	T-2
propofol	O
occurred	O
in	O
the	O
majority	O
of	O
patients	O
,	O
occasionally	O
reaching	O
high	O
levels	O
in	O
individual	O
patients	O
.	O

However	O
,	O
marked	O
tachycardia	O
associated	T-0
with	T-0
the	O
use	O
of	O
ephedrine	O
in	O
combination	T-1
with	T-1
propofol	B-Chemical
occurred	T-2
in	T-2
the	O
majority	O
of	O
patients	O
,	O
occasionally	O
reaching	O
high	O
levels	O
in	O
individual	O
patients	O
.	O

Due	O
to	O
the	O
risk	T-0
of	T-0
this	T-0
tachycardia	B-Disease
inducing	T-1
myocardial	O
ischemia	O
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	O
/	O
propofol	O
/	O
mixtures	O
studied	O
.	O

Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	O
inducing	T-1
myocardial	B-Disease
ischemia	I-Disease
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	O
/	O
propofol	O
/	O
mixtures	O
studied	O
.	O

Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	O
inducing	O
myocardial	O
ischemia	O
,	O
we	T-1
would	T-1
not	T-1
recommend	T-1
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	T-0
of	T-0
the	T-0
ephedrine	B-Chemical
/	O
propofol	O
/	O
mixtures	O
studied	O
.	O

Due	O
to	O
the	O
risk	T-0
of	T-0
this	O
tachycardia	O
inducing	T-1
myocardial	O
ischemia	O
,	O
we	O
would	O
not	T-2
recommend	T-2
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	O
/	O
propofol	B-Chemical
/	O
mixtures	O
studied	O
.	O

Gemcitabine	B-Chemical
plus	O
vinorelbine	O
in	O
nonsmall	O
cell	O
lung	O
carcinoma	O
patients	O
age	O
70	O
years	O
or	O
older	O
or	O
patients	O
who	O
cannot	T-0
receive	T-0
cisplatin	O
.	O

Gemcitabine	O
plus	O
vinorelbine	O
in	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
patients	T-0
age	O
70	O
years	O
or	O
older	O
or	O
patients	O
who	T-1
cannot	T-1
receive	T-1
cisplatin	O
.	O

Gemcitabine	O
plus	O
vinorelbine	O
in	O
nonsmall	O
cell	O
lung	O
carcinoma	O
patients	O
age	O
70	O
years	O
or	O
older	O
or	O
patients	T-0
who	T-0
cannot	T-0
receive	T-0
cisplatin	B-Chemical
.	O

BACKGROUND	O
:	O
Although	O
the	O
prevalence	T-0
of	T-1
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
(	O
NSCLC	O
)	O
is	O
high	O
among	O
elderly	O
patients	O
,	O
few	O
data	O
are	O
available	O
regarding	O
the	O
efficacy	O
and	O
toxicity	O
of	O
chemotherapy	O
in	O
this	O
group	O
of	O
patients	O
.	T-1

BACKGROUND	O
:	O
Although	O
the	O
prevalence	T-0
of	T-0
nonsmall	O
cell	O
lung	O
carcinoma	O
(	O
NSCLC	B-Disease
)	O
is	O
high	O
among	O
elderly	O
patients	O
,	O
few	O
data	O
are	O
available	O
regarding	O
the	O
efficacy	O
and	O
toxicity	O
of	O
chemotherapy	O
in	O
this	O
group	O
of	O
patients	O
.	O

BACKGROUND	O
:	O
Although	O
the	O
prevalence	O
of	O
nonsmall	O
cell	O
lung	O
carcinoma	O
(	O
NSCLC	O
)	O
is	O
high	O
among	O
elderly	O
patients	O
,	O
few	O
data	O
are	O
available	O
regarding	O
the	O
efficacy	T-0
and	O
toxicity	B-Disease
of	O
chemotherapy	O
in	O
this	O
group	O
of	O
patients	O
.	O

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	T-0
with	T-0
vinorelbine	B-Chemical
(	O
VNB	O
)	O
or	O
gemcitabine	O
(	O
GEM	O
)	O
may	O
obtain	O
a	O
response	O
rate	O
of	O
20	O
-	O
30	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	O
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	T-1
with	T-1
vinorelbine	T-0
(	T-0
VNB	T-0
)	T-0
or	T-0
gemcitabine	B-Chemical
(	O
GEM	O
)	O
may	T-2
obtain	T-2
a	O
response	O
rate	O
of	O
20	O
-	O
30	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	O
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	T-0
with	T-0
vinorelbine	O
(	O
VNB	O
)	O
or	O
gemcitabine	O
(	O
GEM	B-Chemical
)	O
may	T-1
obtain	T-1
a	O
response	O
rate	O
of	O
20	O
-	O
30	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	O
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	O
with	O
vinorelbine	O
(	O
VNB	O
)	O
or	O
gemcitabine	O
(	O
GEM	O
)	O
may	O
obtain	O
a	O
response	T-0
rate	T-0
of	O
20	O
-	O
30	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	B-Disease
and	T-2
improvement	T-2
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	T-0
toxicity	B-Disease
of	T-1
the	T-1
combination	T-1
of	O
GEM	O
and	O
VNB	O
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	O
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
were	O
assessed	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	T-0
of	O
the	O
combination	T-1
of	T-1
GEM	B-Chemical
and	T-2
VNB	T-2
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	O
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
were	O
assessed	O
.	O

In	O
the	O
current	O
study	O
the	T-0
efficacy	T-0
and	T-0
toxicity	T-0
of	T-0
the	O
combination	O
of	O
GEM	O
and	O
VNB	B-Chemical
in	T-1
elderly	O
patients	T-2
with	O
advanced	O
NSCLC	O
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
were	O
assessed	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
combination	O
of	O
GEM	O
and	O
VNB	O
in	O
elderly	O
patients	T-0
with	T-0
advanced	T-1
NSCLC	B-Disease
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
were	O
assessed	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
combination	O
of	O
GEM	O
and	O
VNB	O
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	O
or	O
those	O
with	O
some	O
contraindication	O
to	T-1
receiving	T-1
cisplatin	B-Chemical
were	O
assessed	O
.	O

METHODS	O
:	O
Forty	O
-	O
nine	O
patients	O
with	T-1
advanced	T-1
NSCLC	B-Disease
were	T-2
included	T-2
,	O
38	O
of	O
whom	O
were	O
age	O
>	O
/	O
=	O
70	O
years	O
and	O
11	O
were	O
age	O
<	O
70	O
years	O
but	O
who	O
had	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
.	O

METHODS	O
:	O
Forty	O
-	O
nine	O
patients	O
with	O
advanced	O
NSCLC	O
were	O
included	O
,	O
38	O
of	O
whom	O
were	O
age	O
>	O
/	O
=	O
70	O
years	O
and	O
11	O
were	O
age	O
<	O
70	O
years	O
but	O
who	O
had	O
some	O
contraindication	T-0
to	O
receiving	T-1
cisplatin	B-Chemical
.	O

Treatment	O
was	O
comprised	T-0
of	O
VNB	B-Chemical
,	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
plus	O
GEM	O
,	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
both	O
on	O
Days	O
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
days	O
.	O

Treatment	O
was	T-1
comprised	T-1
of	T-1
VNB	O
,	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
plus	O
GEM	B-Chemical
,	O
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
both	O
on	O
Days	O
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
days	O
.	O

Toxicity	B-Disease
was	T-0
mild	T-0
.	O

Six	O
patients	O
(	O
12	O
%	O
)	O
had	O
World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	O
,	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	T-0
3	T-0
-	T-0
4	T-0
thrombocytopenia	B-Disease
,	O
and	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
neurotoxicity	O
.	O

Six	O
patients	O
(	O
12	O
%	O
)	O
had	O
World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	O
,	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	O
3	O
-	O
4	O
thrombocytopenia	O
,	O
and	O
2	O
patients	O
(	O
4	O
%	O
)	O
had	O
Grade	T-0
3	T-0
neurotoxicity	B-Disease
.	O

Three	O
patients	O
with	O
severe	T-1
neutropenia	B-Disease
(	T-2
6	T-2
%	T-2
)	T-2
died	T-2
of	T-0
sepsis	T-0
.	T-0

Three	O
patients	O
with	O
severe	T-0
neutropenia	O
(	O
6	O
%	O
)	O
died	T-2
of	T-2
sepsis	B-Disease
.	O

The	O
median	O
age	O
of	O
those	O
patients	O
developing	O
Grade	T-0
3	T-0
-	T-0
4	T-0
neutropenia	B-Disease
was	T-1
significantly	T-1
higher	O
than	O
that	O
of	O
the	O
remaining	O
patients	O
(	O
75	O
years	O
vs	O
.	O
72	O
years	O
;	O
P	O
=	O
0	O
.	O
047	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	T-0
of	T-0
GEM	B-Chemical
and	T-1
VNB	O
is	O
moderately	T-2
active	T-2
and	O
well	O
tolerated	O
except	O
in	O
patients	O
age	O
>	O
/	O
=	O
75	O
years	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	T-0
of	T-0
GEM	O
and	T-2
VNB	B-Chemical
is	O
moderately	O
active	O
and	O
well	T-1
tolerated	T-1
except	O
in	O
patients	O
age	O
>	O
/	O
=	O
75	O
years	O
.	O

This	O
age	O
group	O
had	O
an	O
increased	O
risk	T-0
of	T-0
myelosuppression	B-Disease
.	O

New	O
chemotherapy	O
combinations	O
with	O
higher	O
activity	O
and	O
lower	O
toxicity	B-Disease
are	O
needed	T-0
for	T-0
elderly	O
patients	O
with	O
advanced	O
NSCLC	O
.	O

New	O
chemotherapy	O
combinations	T-0
with	O
higher	O
activity	O
and	O
lower	T-2
toxicity	T-2
are	O
needed	O
for	O
elderly	O
patients	T-1
with	T-1
advanced	T-1
NSCLC	B-Disease
.	O

A	O
selective	T-1
dopamine	B-Chemical
D4	T-0
receptor	T-0
antagonist	O
,	O
NRA0160	O
:	O
a	O
preclinical	O
neuropharmacological	O
profile	O
.	O

A	O
selective	O
dopamine	O
D4	O
receptor	O
antagonist	O
,	O
NRA0160	B-Chemical
:	T-0
a	T-0
preclinical	T-0
neuropharmacological	O
profile	O
.	O

NRA0160	T-0
,	O
5	B-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
fluorobenzylidene	I-Chemical
)	I-Chemical
piperidin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
fluorophenyl	I-Chemical
)	I-Chemical
thiazole	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
carboxamide	I-Chemical
,	O
has	O
a	O
high	O
affinity	O
for	O
human	O
cloned	O
dopamine	O
D4	O
.	O
2	O
,	O
D4	O
.	O
4	O
and	O
D4	O
.	O
7	O
receptors	O
,	O
with	O
Ki	O
values	O
of	O
0	O
.	O
5	O
,	O
0	O
.	O
9	O
and	O
2	O
.	O
7	O
nM	O
,	O
respectively	O
.	O

NRA0160	B-Chemical
is	O
over	O
20	O
,	O
000fold	O
more	T-0
potent	T-0
at	O
the	O
dopamine	O
D4	O
.	O
2	O
receptor	O
compared	O
with	O
the	O
human	O
cloned	O
dopamine	O
D2L	O
receptor	O
.	O

NRA0160	O
is	O
over	O
20	O
,	O
000fold	O
more	T-0
potent	T-0
at	T-0
the	T-0
dopamine	B-Chemical
D4	T-1
.	T-1
2	T-1
receptor	T-1
compared	O
with	O
the	O
human	O
cloned	O
dopamine	O
D2L	O
receptor	O
.	O

NRA0160	O
is	O
over	O
20	O
,	O
000fold	O
more	O
potent	O
at	O
the	O
dopamine	O
D4	O
.	O
2	O
receptor	O
compared	T-0
with	O
the	O
human	O
cloned	O
dopamine	B-Chemical
D2L	O
receptor	O
.	O

NRA0160	B-Chemical
has	O
negligible	T-0
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	O
D3	O
receptor	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	O
serotonin	O
(	O
5	O
-	O
HT	O
)	O
2A	O
receptors	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	O
has	O
negligible	T-1
affinity	T-1
for	T-1
the	O
human	O
cloned	O
dopamine	B-Chemical
D3	T-0
receptor	T-0
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	O
serotonin	O
(	O
5	O
-	O
HT	O
)	O
2A	O
receptors	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	O
has	O
negligible	T-0
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	O
D3	O
receptor	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	O
serotonin	B-Chemical
(	O
5	O
-	O
HT	O
)	O
2A	O
receptors	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	O
has	O
negligible	T-0
affinity	T-0
for	O
the	O
human	O
cloned	O
dopamine	O
D3	O
receptor	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	O
serotonin	O
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
2A	O
receptors	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

NRA0160	B-Chemical
and	T-0
clozapine	O
antagonized	T-1
locomotor	T-1
hyperactivity	T-1
induced	O
by	O
methamphetamine	O
(	O
MAP	O
)	O
in	O
mice	O
.	O

NRA0160	T-0
and	T-0
clozapine	B-Chemical
antagonized	O
locomotor	O
hyperactivity	O
induced	T-1
by	T-1
methamphetamine	O
(	O
MAP	O
)	O
in	O
mice	O
.	O

NRA0160	O
and	O
clozapine	O
antagonized	T-0
locomotor	T-0
hyperactivity	B-Disease
induced	T-1
by	T-1
methamphetamine	O
(	O
MAP	O
)	O
in	O
mice	O
.	O

NRA0160	O
and	O
clozapine	O
antagonized	T-0
locomotor	O
hyperactivity	O
induced	T-1
by	T-1
methamphetamine	B-Chemical
(	O
MAP	O
)	O
in	O
mice	O
.	O

NRA0160	O
and	O
clozapine	O
antagonized	O
locomotor	O
hyperactivity	O
induced	T-0
by	T-0
methamphetamine	O
(	O
MAP	B-Chemical
)	O
in	O
mice	O
.	O

NRA0160	B-Chemical
and	O
clozapine	O
antagonized	O
MAP	O
-	O
induced	T-2
stereotyped	O
behavior	O
in	O
mice	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
inhibition	T-1
,	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	T-0
and	T-0
clozapine	B-Chemical
antagonized	O
MAP	O
-	O
induced	T-1
stereotyped	O
behavior	O
in	O
mice	O
,	O
although	O
their	O
effects	T-2
did	O
not	O
exceed	O
50	O
%	O
inhibition	O
,	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	O
and	O
clozapine	T-0
antagonized	T-2
MAP	B-Chemical
-	T-1
induced	T-3
stereotyped	O
behavior	O
in	O
mice	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
inhibition	O
,	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	B-Chemical
and	O
clozapine	O
significantly	O
induced	T-1
catalepsy	O
in	O
rats	O
,	O
although	O
their	O
effects	T-2
did	O
not	O
exceed	O
50	O
%	O
induction	T-3
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	O
and	O
clozapine	B-Chemical
significantly	O
induced	T-0
catalepsy	O
in	O
rats	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
induction	O
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	O
and	O
clozapine	O
significantly	O
induced	T-1
catalepsy	B-Disease
in	O
rats	O
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
induction	T-0
even	O
at	O
the	O
highest	O
dose	O
given	O
.	O

NRA0160	B-Chemical
and	T-0
clozapine	T-0
significantly	O
reversed	O
the	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
rats	O
produced	O
by	O
apomorphine	O
.	O

NRA0160	O
and	O
clozapine	B-Chemical
significantly	O
reversed	T-2
the	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
rats	O
produced	T-1
by	O
apomorphine	O
.	O

NRA0160	O
and	O
clozapine	O
significantly	T-3
reversed	T-3
the	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
rats	O
produced	T-2
by	T-2
apomorphine	B-Chemical
.	O

NRA0160	B-Chemical
and	O
clozapine	O
significantly	T-0
shortened	T-0
the	O
phencyclidine	O
(	O
PCP	O
)	O
-	O
induced	T-1
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

NRA0160	O
and	T-0
clozapine	B-Chemical
significantly	O
shortened	O
the	O
phencyclidine	O
(	O
PCP	O
)	O
-	O
induced	O
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

NRA0160	O
and	O
clozapine	O
significantly	O
shortened	T-1
the	T-1
phencyclidine	B-Chemical
(	O
PCP	O
)	O
-	O
induced	T-0
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

NRA0160	O
and	O
clozapine	O
significantly	O
shortened	O
the	O
phencyclidine	O
(	O
PCP	B-Chemical
)	O
-	T-1
induced	T-1
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

These	O
findings	T-0
suggest	T-1
that	T-1
NRA0160	B-Chemical
may	T-2
have	T-2
unique	O
antipsychotic	O
activities	O
without	O
the	O
liability	O
of	O
motor	O
side	O
effects	O
typical	O
of	O
classical	O
antipsychotics	O
.	O

Warfarin	B-Chemical
-	O
induced	T-0
artery	O
calcification	O
is	O
accelerated	T-1
by	T-1
growth	O
and	O
vitamin	O
D	O
.	T-2

Warfarin	O
-	O
induced	T-1
artery	B-Disease
calcification	I-Disease
is	O
accelerated	T-2
by	T-2
growth	O
and	O
vitamin	O
D	O
.	O

Warfarin	O
-	O
induced	O
artery	O
calcification	O
is	T-1
accelerated	T-1
by	T-1
growth	O
and	O
vitamin	B-Chemical
D	I-Chemical
.	O

The	O
present	O
studies	O
demonstrate	T-1
that	O
growth	T-2
and	O
vitamin	B-Chemical
D	I-Chemical
treatment	T-0
enhance	T-3
the	T-3
extent	T-3
of	O
artery	O
calcification	O
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	O
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	O
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	O
D	O
treatment	O
enhance	T-0
the	O
extent	O
of	O
artery	B-Disease
calcification	I-Disease
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	O
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	O
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	O
D	O
treatment	O
enhance	O
the	O
extent	O
of	O
artery	O
calcification	O
in	O
rats	O
given	O
sufficient	O
doses	T-1
of	T-1
Warfarin	B-Chemical
to	O
inhibit	T-0
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	O
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	O
D	O
treatment	O
enhance	O
the	O
extent	O
of	O
artery	O
calcification	O
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	O
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	B-Disease
inhibitor	T-1
known	T-1
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
first	O
series	O
of	O
experiments	O
examined	O
the	O
influence	T-1
of	T-1
age	O
and	O
growth	O
status	T-0
on	T-0
artery	B-Disease
calcification	I-Disease
in	O
Warfarin	O
-	O
treated	O
rats	O
.	O

The	O
first	O
series	O
of	O
experiments	O
examined	O
the	T-0
influence	T-0
of	O
age	O
and	O
growth	O
status	O
on	O
artery	O
calcification	O
in	O
Warfarin	B-Chemical
-	O
treated	O
rats	O
.	O

Treatment	T-0
for	O
2	O
weeks	O
with	T-1
Warfarin	B-Chemical
caused	T-2
massive	O
focal	O
calcification	O
of	O
the	O
artery	O
media	O
in	O
20	O
-	O
day	O
-	O
old	O
rats	O
and	O
less	O
extensive	O
focal	O
calcification	O
in	O
42	O
-	O
day	O
-	O
old	O
rats	O
.	O

Treatment	O
for	O
2	O
weeks	O
with	O
Warfarin	O
caused	T-1
massive	T-1
focal	T-1
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
20	O
-	O
day	O
-	O
old	O
rats	O
and	O
less	O
extensive	O
focal	O
calcification	O
in	O
42	O
-	O
day	O
-	O
old	O
rats	O
.	O

Treatment	T-1
for	T-1
2	T-1
weeks	T-1
with	T-1
Warfarin	T-1
caused	T-1
massive	O
focal	O
calcification	O
of	O
the	O
artery	O
media	O
in	O
20	O
-	O
day	O
-	O
old	O
rats	O
and	O
less	T-0
extensive	T-0
focal	O
calcification	B-Disease
in	O
42	O
-	O
day	O
-	O
old	O
rats	O
.	O

In	O
contrast	O
,	O
no	O
artery	B-Disease
calcification	I-Disease
could	T-0
be	T-0
detected	T-0
in	O
10	O
-	O
month	O
-	O
old	O
adult	O
rats	O
even	O
after	O
4	O
weeks	O
of	O
Warfarin	O
treatment	O
.	O

In	O
contrast	O
,	O
no	O
artery	O
calcification	O
could	O
be	O
detected	O
in	O
10	O
-	O
month	O
-	O
old	O
adult	O
rats	O
even	O
after	O
4	O
weeks	O
of	T-2
Warfarin	B-Chemical
treatment	T-1
.	T-1

To	O
directly	O
examine	O
the	O
importance	O
of	O
growth	O
to	O
Warfarin	B-Chemical
-	O
induced	T-0
artery	O
calcification	O
in	O
animals	O
of	O
the	O
same	O
age	O
,	O
20	O
-	O
day	O
-	O
old	O
rats	O
were	O
fed	O
for	O
2	O
weeks	O
either	O
an	O
ad	O
libitum	O
diet	O
or	O
a	O
6	O
-	O
g	O
/	O
d	O
restricted	O
diet	O
that	O
maintains	O
weight	O
but	O
prevents	O
growth	O
.	O

To	O
directly	O
examine	O
the	O
importance	O
of	O
growth	O
to	O
Warfarin	O
-	O
induced	T-0
artery	B-Disease
calcification	I-Disease
in	O
animals	O
of	O
the	O
same	O
age	O
,	O
20	O
-	O
day	O
-	O
old	O
rats	O
were	O
fed	O
for	O
2	O
weeks	O
either	O
an	O
ad	O
libitum	O
diet	O
or	O
a	O
6	O
-	O
g	O
/	O
d	O
restricted	O
diet	O
that	O
maintains	O
weight	O
but	O
prevents	O
growth	O
.	O

Concurrent	O
treatment	O
of	O
both	O
dietary	O
groups	O
with	O
Warfarin	B-Chemical
produced	T-0
massive	O
focal	O
calcification	O
of	O
the	O
artery	O
media	O
in	O
the	O
ad	O
libitum	O
-	O
fed	O
rats	O
but	O
no	O
detectable	O
artery	O
calcification	O
in	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
group	O
.	O

Concurrent	O
treatment	O
of	O
both	O
dietary	O
groups	O
with	O
Warfarin	O
produced	T-0
massive	T-0
focal	T-0
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
the	O
ad	O
libitum	O
-	O
fed	O
rats	O
but	O
no	O
detectable	O
artery	O
calcification	O
in	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
group	O
.	O

Concurrent	O
treatment	O
of	O
both	O
dietary	O
groups	O
with	O
Warfarin	O
produced	O
massive	O
focal	O
calcification	O
of	O
the	O
artery	O
media	O
in	O
the	O
ad	O
libitum	O
-	O
fed	O
rats	O
but	O
no	T-1
detectable	T-1
artery	B-Disease
calcification	I-Disease
in	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
group	O
.	O

Although	O
the	O
explanation	O
for	O
the	T-0
association	T-0
between	T-0
artery	B-Disease
calcification	I-Disease
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	O
and	O
susceptibility	O
to	O
artery	O
calcification	O
,	O
with	O
30	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	O
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	O
-	O
induced	O
artery	O
calcification	O
,	O
ie	O
,	O
the	O
10	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	O
calcification	O
and	O
growth	O
status	O
cannot	T-1
be	T-1
determined	T-1
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	T-0
between	T-0
higher	O
serum	O
phosphate	B-Chemical
and	O
susceptibility	O
to	O
artery	O
calcification	O
,	O
with	O
30	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	O
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	T-2
to	T-2
Warfarin	O
-	O
induced	O
artery	O
calcification	O
,	O
ie	O
,	O
the	O
10	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	T-1
between	T-1
artery	O
calcification	O
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	T-0
between	T-0
higher	O
serum	O
phosphate	O
and	O
susceptibility	O
to	O
artery	B-Disease
calcification	I-Disease
,	O
with	O
30	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	O
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	O
-	O
induced	T-2
artery	O
calcification	O
,	O
ie	O
,	O
the	O
10	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	T-3
young	O
rats	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	O
calcification	O
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study	T-0
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	O
and	O
susceptibility	O
to	O
artery	O
calcification	O
,	O
with	O
30	O
%	O
higher	O
levels	O
of	T-2
serum	T-2
phosphate	B-Chemical
in	T-3
young	T-3
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	T-1
to	T-1
Warfarin	O
-	O
induced	O
artery	O
calcification	O
,	O
ie	O
,	O
the	O
10	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	O
calcification	O
and	O
growth	O
status	O
cannot	O
be	O
determined	T-0
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	O
and	O
susceptibility	T-1
to	O
artery	O
calcification	O
,	O
with	O
30	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	O
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	T-3
to	T-3
Warfarin	B-Chemical
-	O
induced	T-2
artery	O
calcification	O
,	O
ie	O
,	O
the	O
10	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	O
calcification	O
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	O
and	O
susceptibility	O
to	O
artery	O
calcification	O
,	O
with	O
30	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	O
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	O
-	O
induced	T-0
artery	B-Disease
calcification	I-Disease
,	O
ie	O
,	O
the	O
10	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

This	O
observation	O
suggests	O
that	O
increased	O
susceptibility	T-1
to	O
Warfarin	B-Chemical
-	O
induced	T-2
artery	O
calcification	O
could	O
be	O
related	T-3
to	T-3
higher	O
serum	O
phosphate	O
levels	O
.	O

This	O
observation	O
suggests	O
that	O
increased	O
susceptibility	O
to	O
Warfarin	O
-	O
induced	T-0
artery	B-Disease
calcification	I-Disease
could	T-1
be	T-1
related	O
to	O
higher	O
serum	O
phosphate	O
levels	O
.	O

This	O
observation	O
suggests	O
that	O
increased	O
susceptibility	T-0
to	O
Warfarin	O
-	O
induced	T-1
artery	O
calcification	O
could	O
be	O
related	O
to	O
higher	O
serum	O
phosphate	B-Chemical
levels	O
.	O

The	O
second	O
set	O
of	O
experiments	O
examined	O
the	O
possible	O
synergy	T-2
between	T-2
vitamin	B-Chemical
D	I-Chemical
and	T-1
Warfarin	O
in	O
artery	O
calcification	O
.	O

The	O
second	O
set	O
of	O
experiments	T-2
examined	T-2
the	O
possible	O
synergy	T-4
between	T-4
vitamin	T-1
D	T-1
and	T-5
Warfarin	B-Chemical
in	O
artery	O
calcification	O
.	O

The	O
second	O
set	O
of	O
experiments	O
examined	O
the	O
possible	O
synergy	T-0
between	T-0
vitamin	O
D	O
and	O
Warfarin	O
in	O
artery	B-Disease
calcification	I-Disease
.	O

High	T-1
doses	T-1
of	T-1
vitamin	B-Chemical
D	I-Chemical
are	T-2
known	T-2
to	T-2
cause	T-2
calcification	O
of	O
the	O
artery	O
media	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
days	O
.	O

High	O
doses	O
of	O
vitamin	O
D	O
are	T-2
known	T-2
to	T-2
cause	T-2
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
as	O
little	O
as	O
3	O
to	O
4	O
days	O
.	O

High	O
doses	O
of	T-1
the	T-1
vitamin	B-Chemical
K	I-Chemical
antagonist	O
Warfarin	O
are	T-0
also	T-0
known	T-0
to	T-0
cause	T-0
calcification	O
of	O
the	O
artery	O
media	O
,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O

High	T-1
doses	T-1
of	O
the	O
vitamin	O
K	T-0
antagonist	T-0
Warfarin	B-Chemical
are	O
also	O
known	O
to	O
cause	T-2
calcification	T-2
of	T-2
the	O
artery	O
media	O
,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O

High	O
doses	O
of	O
the	O
vitamin	O
K	O
antagonist	O
Warfarin	O
are	O
also	O
known	O
to	T-0
cause	T-0
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
,	O
but	O
at	O
treatment	O
times	O
of	O
2	O
weeks	O
or	O
longer	O
yet	O
not	O
at	O
1	O
week	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	T-2
that	T-2
concurrent	O
Warfarin	B-Chemical
administration	T-0
dramatically	T-3
increased	T-3
the	O
extent	O
of	O
calcification	O
in	O
the	O
media	O
of	O
vitamin	O
D	O
-	O
treated	O
rats	O
at	O
3	O
and	O
4	O
days	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	O
that	O
concurrent	O
Warfarin	O
administration	O
dramatically	O
increased	T-2
the	T-3
extent	T-3
of	T-3
calcification	B-Disease
in	T-1
the	T-1
media	O
of	O
vitamin	O
D	O
-	O
treated	O
rats	O
at	O
3	O
and	O
4	O
days	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	O
that	O
concurrent	O
Warfarin	O
administration	O
dramatically	T-1
increased	T-1
the	O
extent	O
of	O
calcification	O
in	T-2
the	T-2
media	T-2
of	O
vitamin	B-Chemical
D	I-Chemical
-	O
treated	T-3
rats	O
at	O
3	O
and	O
4	O
days	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	T-3
effect	T-3
of	T-3
vitamin	B-Chemical
D	I-Chemical
dose	T-4
on	T-4
artery	T-4
calcification	O
and	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	O
artery	O
calcification	O
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	T-0
effect	T-0
of	T-0
vitamin	O
D	O
dose	T-2
on	O
artery	B-Disease
calcification	I-Disease
and	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	T-1
that	T-1
vitamin	O
D	O
may	O
induce	O
artery	O
calcification	O
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	T-0
of	T-0
vitamin	B-Chemical
D	I-Chemical
dose	T-1
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	O
artery	O
calcification	O
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	T-0
of	O
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	T-1
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	T-3
of	T-3
serum	O
calcium	B-Chemical
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	T-4
artery	O
calcification	O
through	O
its	O
effect	T-2
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	T-0
that	T-0
vitamin	B-Chemical
D	I-Chemical
may	T-1
induce	T-1
artery	O
calcification	O
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	T-0
of	T-0
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	T-3
of	T-3
vitamin	O
D	O
dose	O
on	O
the	O
elevation	T-1
of	T-1
serum	O
calcium	O
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	T-4
induce	T-4
artery	B-Disease
calcification	I-Disease
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	T-0
of	O
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	T-1
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	T-3
artery	O
calcification	O
through	O
its	O
effect	T-2
on	O
serum	T-4
calcium	B-Chemical
.	O

Because	O
Warfarin	B-Chemical
treatment	T-0
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	T-1
on	T-1
the	O
elevation	O
in	O
serum	T-0
calcium	B-Chemical
produced	T-2
by	T-2
vitamin	O
D	O
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	T-1
by	T-1
vitamin	B-Chemical
D	I-Chemical
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	T-3
in	T-3
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	O
between	T-0
Warfarin	B-Chemical
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	T-1
by	O
the	O
hypothesis	T-2
that	O
Warfarin	O
inhibits	T-4
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	T-1
between	T-1
Warfarin	T-0
and	T-0
vitamin	B-Chemical
D	I-Chemical
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	B-Chemical
inhibits	T-1
the	O
activity	T-0
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	T-0

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	T-0
by	T-0
vitamin	O
D	O
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	T-1
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	B-Disease
inhibitor	T-2
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	T-0
of	T-0
artery	B-Disease
calcification	I-Disease
in	O
rats	O
treated	T-1
with	T-1
vitamin	O
D	O
plus	O
Warfarin	O
,	O
and	O
chemical	O
analysis	O
showed	T-2
that	T-2
the	O
protein	O
that	O
accumulated	T-3
was	O
indeed	O
not	O
gamma	O
-	O
carboxylated	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	O
calcification	O
in	O
rats	O
treated	T-1
with	T-1
vitamin	B-Chemical
D	I-Chemical
plus	T-2
Warfarin	O
,	O
and	O
chemical	O
analysis	O
showed	T-0
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	O
-	O
carboxylated	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	O
calcification	O
in	O
rats	O
treated	T-0
with	T-0
vitamin	O
D	O
plus	O
Warfarin	B-Chemical
,	O
and	O
chemical	O
analysis	O
showed	O
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	O
-	O
carboxylated	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	O
calcification	O
in	O
rats	T-2
treated	T-2
with	T-0
vitamin	O
D	O
plus	O
Warfarin	O
,	O
and	O
chemical	T-3
analysis	T-3
showed	O
that	O
the	O
protein	O
that	O
accumulated	T-1
was	O
indeed	O
not	O
gamma	B-Chemical
-	I-Chemical
carboxylated	I-Chemical
.	O

These	O
observations	O
indicate	O
that	O
although	T-0
the	T-0
gamma	B-Chemical
-	I-Chemical
carboxyglutamate	I-Chemical
residues	T-1
of	O
matrix	O
Gla	O
protein	O
are	O
apparently	O
required	O
for	O
its	O
function	O
as	O
a	O
calcification	O
inhibitor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulation	O
at	O
calcification	O
sites	O
.	O

These	O
observations	O
indicate	O
that	O
although	O
the	O
gamma	O
-	O
carboxyglutamate	O
residues	O
of	O
matrix	O
Gla	O
protein	O
are	O
apparently	O
required	O
for	O
its	O
function	T-0
as	T-0
a	T-0
calcification	B-Disease
inhibitor	T-1
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulation	O
at	O
calcification	O
sites	O
.	O

These	O
observations	T-2
indicate	T-2
that	O
although	O
the	O
gamma	O
-	O
carboxyglutamate	O
residues	O
of	O
matrix	O
Gla	O
protein	O
are	O
apparently	O
required	O
for	O
its	O
function	O
as	O
a	O
calcification	O
inhibitor	O
,	O
they	O
are	O
not	O
required	O
for	O
its	O
accumulation	O
at	T-0
calcification	B-Disease
sites	T-1
.	O

Apomorphine	B-Chemical
,	O
a	O
nonselective	O
dopamine	O
agonist	O
,	O
was	T-0
selected	T-0
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	O
hypothermia	O
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	O
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

Apomorphine	O
,	O
a	O
nonselective	O
dopamine	B-Chemical
agonist	I-Chemical
,	O
was	T-0
selected	T-0
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	O
hypothermia	O
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	O
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

Apomorphine	O
,	O
a	O
nonselective	O
dopamine	O
agonist	O
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	T-0
hypothermia	B-Disease
,	T-1
and	T-1
to	T-1
produce	T-1
distinct	O
changes	O
to	O
dopamine	O
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

Apomorphine	O
,	O
a	O
nonselective	T-0
dopamine	O
agonist	O
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	T-1
hypothermia	O
,	O
and	O
to	O
produce	O
distinct	O
changes	T-2
to	T-2
dopamine	B-Chemical
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

From	O
such	O
experiments	O
there	O
is	O
evidence	O
that	O
characterization	O
and	O
detection	T-1
of	T-1
apomorphine	B-Chemical
-	O
induced	T-2
activity	O
in	O
rodents	O
critically	O
depends	T-0
upon	O
the	O
test	O
conditions	O
employed	O
.	O

In	O
rats	O
,	O
detection	T-3
of	T-3
apomorphine	B-Chemical
-	O
induced	T-4
hyperactivity	O
was	O
facilitated	O
by	O
a	O
period	O
of	O
acclimatization	O
to	O
the	O
test	O
conditions	O
.	O

In	O
rats	O
,	O
detection	O
of	O
apomorphine	O
-	O
induced	T-0
hyperactivity	B-Disease
was	T-1
facilitated	T-1
by	O
a	O
period	O
of	O
acclimatization	O
to	O
the	O
test	O
conditions	O
.	O

Moreover	O
,	O
test	O
conditions	O
can	O
impact	T-0
upon	O
other	O
physiological	O
responses	O
to	O
apomorphine	B-Chemical
such	O
as	O
drug	O
-	O
induced	T-1
hypothermia	O
.	O

Moreover	O
,	O
test	O
conditions	O
can	O
impact	T-1
upon	O
other	O
physiological	O
responses	O
to	O
apomorphine	O
such	O
as	O
drug	O
-	O
induced	T-2
hypothermia	B-Disease
.	O

In	O
mice	O
,	O
apomorphine	B-Chemical
produced	T-0
qualitatively	O
different	O
responses	T-1
under	O
novel	O
conditions	O
when	O
compared	O
to	O
those	O
behaviors	O
elicited	O
in	O
the	O
home	O
test	O
cage	O
.	O

By	T-1
contrast	T-1
,	O
apomorphine	B-Chemical
-	T-0
induced	T-0
locomotion	O
was	O
more	O
prominent	O
in	O
the	O
novel	O
exploratory	O
box	O
.	O

Dopamine	B-Chemical
turnover	T-1
ratios	T-1
(	O
DOPAC	O
:	O
DA	O
and	O
HVA	O
:	O
DA	O
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	T-0
to	T-0
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

Dopamine	O
turnover	T-1
ratios	T-1
(	O
DOPAC	B-Chemical
:	O
DA	O
and	O
HVA	O
:	O
DA	O
)	O
were	T-0
found	T-0
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

Dopamine	O
turnover	O
ratios	O
(	O
DOPAC	O
:	O
DA	O
and	O
HVA	B-Chemical
:	O
DA	O
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	T-0
to	T-0
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

Dopamine	O
turnover	O
ratios	O
(	O
DOPAC	O
:	O
DA	O
and	O
HVA	O
:	O
DA	B-Chemical
)	O
were	T-1
found	T-1
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	T-0
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

However	O
,	O
apomorphine	B-Chemical
-	O
induced	T-1
reductions	O
in	O
striatal	O
dopamine	O
turnover	O
were	O
detected	T-2
in	O
both	O
novel	O
and	O
home	O
cage	O
environments	O
.	O

However	O
,	O
apomorphine	O
-	O
induced	O
reductions	T-0
in	T-0
striatal	O
dopamine	B-Chemical
turnover	O
were	O
detected	O
in	O
both	O
novel	O
and	O
home	O
cage	O
environments	O
.	O

Hemolysis	B-Disease
of	T-1
human	T-1
erythrocytes	T-1
induced	O
by	O
tamoxifen	O
is	O
related	O
to	O
disruption	O
of	O
membrane	O
structure	O
.	O

Hemolysis	O
of	O
human	O
erythrocytes	O
induced	T-1
by	T-1
tamoxifen	B-Chemical
is	T-2
related	T-2
to	T-0
disruption	O
of	O
membrane	O
structure	O
.	O

Tamoxifen	B-Chemical
(	O
TAM	O
)	O
,	O
the	O
antiestrogenic	O
drug	T-0
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	O
cancer	O
,	O
induces	T-2
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	O
anemia	O
.	O

Tamoxifen	T-0
(	O
TAM	B-Chemical
)	O
,	T-1
the	T-1
antiestrogenic	T-1
drug	T-1
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	O
cancer	O
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	O
anemia	O
.	O

Tamoxifen	O
(	O
TAM	O
)	O
,	O
the	O
antiestrogenic	O
drug	O
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	T-0
of	T-0
breast	B-Disease
cancer	I-Disease
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	O
anemia	O
.	O

Tamoxifen	O
(	O
TAM	O
)	O
,	O
the	O
antiestrogenic	O
drug	O
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	O
cancer	O
,	O
induces	T-0
changes	T-0
in	T-0
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	B-Disease
anemia	I-Disease
.	O

This	O
work	O
evaluates	O
the	O
effects	T-0
of	T-0
TAM	B-Chemical
on	T-1
isolated	T-1
human	O
erythrocytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechanisms	O
on	O
TAM	O
-	O
induced	O
hemolytic	O
anemia	O
and	O
the	O
involvement	O
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	O
mechanisms	O
.	O

This	O
work	O
evaluates	O
the	O
effects	O
of	O
TAM	O
on	O
isolated	O
human	O
erythrocytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechanisms	T-1
on	T-1
TAM	B-Chemical
-	O
induced	T-0
hemolytic	O
anemia	O
and	O
the	O
involvement	O
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	O
mechanisms	O
.	O

This	O
work	O
evaluates	O
the	O
effects	O
of	O
TAM	O
on	O
isolated	O
human	O
erythrocytes	O
,	O
attempting	O
to	O
identify	O
the	O
underlying	O
mechanisms	O
on	O
TAM	T-0
-	T-0
induced	T-1
hemolytic	B-Disease
anemia	I-Disease
and	O
the	O
involvement	O
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	O
mechanisms	O
.	O

TAM	B-Chemical
induces	T-0
hemolysis	O
of	O
erythrocytes	O
as	O
a	O
function	O
of	O
concentration	O
.	O

TAM	T-1
induces	T-1
hemolysis	B-Disease
of	T-2
erythrocytes	T-2
as	O
a	O
function	O
of	O
concentration	O
.	O

The	O
extension	T-0
of	T-0
hemolysis	B-Disease
is	T-1
variable	T-1
with	O
erythrocyte	O
samples	O
,	O
but	O
12	O
.	O
5	O
microM	O
TAM	O
induces	O
total	O
hemolysis	O
of	O
all	O
tested	O
suspensions	O
.	O

The	O
extension	O
of	O
hemolysis	O
is	O
variable	O
with	O
erythrocyte	O
samples	O
,	O
but	O
12	O
.	O
5	O
microM	O
TAM	B-Chemical
induces	T-0
total	O
hemolysis	O
of	O
all	O
tested	O
suspensions	O
.	O

The	O
extension	O
of	O
hemolysis	O
is	O
variable	O
with	O
erythrocyte	O
samples	O
,	O
but	O
12	O
.	O
5	O
microM	O
TAM	O
induces	T-0
total	T-0
hemolysis	B-Disease
of	O
all	O
tested	O
suspensions	O
.	O

Despite	O
inducing	T-2
extensive	O
erythrocyte	O
lysis	O
,	O
TAM	B-Chemical
does	T-1
not	T-1
shift	T-1
the	O
osmotic	O
fragility	O
curves	O
of	O
erythrocytes	O
.	O

The	T-0
hemolytic	B-Disease
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	T-2
effect	T-2
of	T-2
TAM	B-Chemical
is	O
prevented	T-1
by	T-1
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	T-0
by	O
low	O
concentrations	T-2
of	T-2
alpha	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
(	T-3
alpha	T-3
-	T-3
T	T-3
)	T-3
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	T-1
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	T-1
by	O
low	O
concentrations	T-0
of	T-0
alpha	O
-	O
tocopherol	O
(	O
alpha	B-Chemical
-	I-Chemical
T	I-Chemical
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	T-2
of	T-2
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	T-0
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
acetate	I-Chemical
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	T-3
that	T-3
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	T-1
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	T-0
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	T-2
acetate	T-2
(	O
alpha	B-Chemical
-	I-Chemical
TAc	I-Chemical
)	O
(	T-3
inactivated	T-3
functional	T-3
hydroxyl	T-3
)	T-3
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	T-1
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	B-Chemical
)	O
indicating	O
that	O
TAM	O
-	O
induced	T-0
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	T-0
that	T-0
TAM	B-Chemical
-	O
induced	T-1
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	T-0
hemolysis	B-Disease
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

This	O
was	O
further	O
evidenced	O
by	O
absence	T-1
of	T-1
oxygen	B-Chemical
consumption	T-2
and	O
hemoglobin	O
oxidation	O
both	O
determined	O
in	O
parallel	O
with	O
TAM	O
-	O
induced	T-0
hemolysis	O
.	O

This	O
was	O
further	O
evidenced	O
by	O
absence	O
of	O
oxygen	O
consumption	O
and	O
hemoglobin	O
oxidation	O
both	O
determined	T-0
in	T-0
parallel	T-0
with	O
TAM	B-Chemical
-	T-2
induced	T-2
hemolysis	O
.	O

This	O
was	O
further	O
evidenced	O
by	O
absence	O
of	O
oxygen	O
consumption	O
and	O
hemoglobin	O
oxidation	O
both	O
determined	O
in	O
parallel	O
with	O
TAM	O
-	O
induced	T-0
hemolysis	B-Disease
.	O

Furthermore	O
,	O
it	O
was	O
observed	T-0
that	T-0
TAM	B-Chemical
inhibits	O
the	O
peroxidation	O
of	O
human	O
erythrocytes	O
induced	O
by	O
AAPH	O
,	O
thus	O
ruling	O
out	O
TAM	O
-	O
induced	O
cell	O
oxidative	O
stress	O
.	O

Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	O
inhibits	O
the	O
peroxidation	O
of	O
human	O
erythrocytes	O
induced	T-0
by	T-0
AAPH	B-Chemical
,	O
thus	O
ruling	O
out	O
TAM	O
-	O
induced	O
cell	O
oxidative	O
stress	O
.	O

Furthermore	O
,	O
it	T-1
was	T-1
observed	T-1
that	T-0
TAM	O
inhibits	T-2
the	O
peroxidation	O
of	O
human	O
erythrocytes	O
induced	O
by	O
AAPH	O
,	O
thus	O
ruling	O
out	O
TAM	B-Chemical
-	O
induced	T-3
cell	O
oxidative	O
stress	O
.	O

Hemolysis	B-Disease
caused	T-0
by	T-0
TAM	O
was	O
not	O
preceded	O
by	O
the	O
leakage	O
of	O
K	O
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	O
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O
.	O

Hemolysis	O
caused	T-0
by	T-0
TAM	B-Chemical
was	O
not	O
preceded	O
by	O
the	O
leakage	O
of	O
K	O
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	O
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O
.	O

Hemolysis	O
caused	O
by	O
TAM	O
was	O
not	O
preceded	T-0
by	T-0
the	O
leakage	O
of	O
K	B-Chemical
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	O
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O
.	O

Hemolysis	O
caused	O
by	O
TAM	O
was	O
not	T-1
preceded	T-1
by	T-1
the	O
leakage	O
of	O
K	O
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	T-0
of	T-0
hemolysis	B-Disease
,	O
according	O
to	O
the	O
effects	T-2
on	T-2
osmotic	O
fragility	O
curves	O
.	O

However	O
,	O
TAM	B-Chemical
induces	T-0
release	O
of	O
peripheral	O
proteins	O
of	O
membrane	O
-	O
cytoskeleton	O
and	O
cytosol	O
proteins	O
essentially	O
bound	O
to	O
band	O
3	O
.	O

Either	O
alpha	B-Chemical
-	I-Chemical
T	I-Chemical
or	O
alpha	O
-	O
TAc	O
increases	T-0
membrane	O
packing	O
and	O
prevents	T-1
TAM	O
partition	O
into	O
model	O
membranes	O
.	O

Either	O
alpha	O
-	O
T	O
or	T-1
alpha	B-Chemical
-	I-Chemical
TAc	I-Chemical
increases	T-2
membrane	O
packing	O
and	O
prevents	T-0
TAM	O
partition	O
into	O
model	O
membranes	O
.	O

Either	O
alpha	O
-	O
T	O
or	O
alpha	O
-	O
TAc	O
increases	O
membrane	O
packing	O
and	O
prevents	T-1
TAM	B-Chemical
partition	O
into	T-0
model	T-0
membranes	T-0
.	O

These	O
effects	O
suggest	O
that	O
the	O
protection	T-1
from	T-1
hemolysis	B-Disease
by	O
tocopherols	O
is	O
related	O
to	O
a	O
decreased	O
TAM	O
incorporation	O
in	O
condensed	O
membranes	O
and	O
the	O
structural	O
damage	O
of	O
the	O
erythrocyte	O
membrane	O
is	O
consequently	O
avoided	O
.	O

These	O
effects	O
suggest	O
that	O
the	O
protection	O
from	O
hemolysis	O
by	O
tocopherols	B-Chemical
is	O
related	T-0
to	T-0
a	O
decreased	O
TAM	O
incorporation	O
in	O
condensed	O
membranes	O
and	O
the	O
structural	O
damage	T-1
of	O
the	O
erythrocyte	O
membrane	O
is	O
consequently	O
avoided	O
.	O

These	O
effects	O
suggest	O
that	O
the	O
protection	T-0
from	T-0
hemolysis	O
by	O
tocopherols	O
is	O
related	O
to	O
a	O
decreased	T-1
TAM	B-Chemical
incorporation	T-2
in	O
condensed	O
membranes	O
and	O
the	O
structural	O
damage	O
of	O
the	O
erythrocyte	O
membrane	O
is	O
consequently	O
avoided	O
.	O

Therefore	O
,	O
TAM	B-Chemical
-	T-1
induced	T-1
hemolysis	O
results	O
from	O
a	O
structural	O
perturbation	O
of	O
red	O
cell	O
membrane	O
,	O
leading	O
to	O
changes	O
in	O
the	O
framework	O
of	O
the	O
erythrocyte	O
membrane	O
and	O
its	O
cytoskeleton	O
caused	O
by	O
its	O
high	O
partition	O
in	O
the	O
membrane	O
.	O

Therefore	O
,	O
TAM	O
-	O
induced	T-0
hemolysis	B-Disease
results	T-1
from	O
a	O
structural	O
perturbation	O
of	O
red	O
cell	O
membrane	O
,	O
leading	O
to	O
changes	O
in	O
the	O
framework	O
of	O
the	O
erythrocyte	O
membrane	O
and	O
its	O
cytoskeleton	O
caused	O
by	O
its	O
high	O
partition	O
in	O
the	O
membrane	O
.	O

These	O
defects	O
explain	O
the	O
abnormal	O
erythrocyte	O
shape	O
and	O
decreased	O
mechanical	O
stability	O
promoted	T-0
by	T-0
TAM	B-Chemical
,	O
resulting	T-1
in	T-1
hemolytic	O
anemia	O
.	O

These	O
defects	O
explain	O
the	O
abnormal	O
erythrocyte	O
shape	O
and	O
decreased	O
mechanical	T-0
stability	T-0
promoted	O
by	O
TAM	O
,	O
resulting	T-1
in	T-1
hemolytic	B-Disease
anemia	I-Disease
.	O

Additionally	O
,	O
since	O
membrane	O
leakage	O
is	O
a	O
final	O
stage	O
of	O
cytotoxicity	O
,	O
the	T-0
disruption	T-0
of	T-0
the	O
structural	O
characteristics	O
of	O
biomembranes	O
by	T-1
TAM	B-Chemical
may	T-2
contribute	T-2
to	O
the	O
multiple	O
mechanisms	O
of	O
its	O
anticancer	O
action	O
.	O

Changes	T-0
of	T-0
sodium	B-Chemical
and	T-1
ATP	O
affinities	O
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	O
oxide	O
deficient	O
hypertension	O
.	O

Changes	O
of	O
sodium	O
and	T-0
ATP	B-Chemical
affinities	O
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	O
oxide	O
deficient	O
hypertension	O
.	O

Changes	T-0
of	T-0
sodium	O
and	O
ATP	O
affinities	T-1
of	T-1
the	O
cardiac	O
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	O
oxide	O
deficient	O
hypertension	O
.	O

Changes	O
of	O
sodium	O
and	O
ATP	O
affinities	O
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
during	T-0
and	O
after	T-1
nitric	O
oxide	O
deficient	O
hypertension	O
.	O

Changes	T-1
of	T-1
sodium	O
and	O
ATP	O
affinities	T-2
of	T-2
the	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
during	T-3
and	T-3
after	T-3
nitric	B-Chemical
oxide	I-Chemical
deficient	T-0
hypertension	O
.	O

Changes	O
of	O
sodium	O
and	O
ATP	O
affinities	O
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	O
oxide	O
deficient	T-0
hypertension	B-Disease
.	O

In	O
the	O
cardiovascular	O
system	O
,	O
NO	B-Chemical
is	T-0
involved	T-2
in	T-2
the	O
regulation	T-1
of	O
a	O
variety	O
of	O
functions	O
.	O

Inhibition	T-0
of	T-0
NO	B-Chemical
synthesis	O
induces	T-1
sustained	O
hypertension	O
.	O

Inhibition	O
of	O
NO	O
synthesis	O
induces	T-0
sustained	O
hypertension	B-Disease
.	O

In	T-1
several	T-1
models	T-1
of	T-1
hypertension	B-Disease
,	O
elevation	O
of	O
intracellular	O
sodium	O
level	O
was	O
documented	O
in	O
cardiac	O
tissue	O
.	O

In	O
several	O
models	O
of	O
hypertension	O
,	O
elevation	T-1
of	T-1
intracellular	O
sodium	B-Chemical
level	T-0
was	O
documented	O
in	O
cardiac	O
tissue	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	T-3
of	T-3
Na	B-Chemical
+	O
,	O
we	O
studied	O
the	O
response	T-0
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	T-1
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	T-2
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	T-0
of	T-0
cardiac	O
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	O
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	T-1
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	T-0
of	T-0
cardiac	O
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	O
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	B-Chemical
-	O
deficient	O
hypertension	O
induced	T-0
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	B-Disease
induced	T-0
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	T-1
in	O
rats	O
by	T-2
NO	B-Chemical
-	T-0
synthase	T-0
inhibition	O
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	T-0
in	T-0
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
40	T-1
mg	T-1
/	T-1
kg	T-1
/	T-1
day	T-1
N	B-Chemical
(	I-Chemical
G	I-Chemical
)	I-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
methyl	I-Chemical
ester	I-Chemical
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	T-0
of	T-0
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	T-1
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	T-2
with	O
40	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
)	O
for	O
4	O
four	O
weeks	O
.	O

After	O
4	O
-	O
week	O
administration	T-2
of	T-2
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
,	O
the	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
increased	T-3
by	O
36	O
%	O
.	O

When	O
activating	T-0
the	O
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
with	O
its	O
substrate	O
ATP	O
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

When	O
activating	T-0
the	T-0
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
with	O
its	O
substrate	O
ATP	O
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

When	O
activating	T-0
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
with	O
its	O
substrate	O
ATP	B-Chemical
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

When	O
activating	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
with	O
its	O
substrate	O
ATP	O
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	T-1
in	T-1
NO	B-Chemical
-	T-0
deficient	T-0
rats	O
.	O

During	O
activation	T-2
with	T-2
Na	B-Chemical
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K	O
(	O
Na	O
)	O
increased	O
by	O
50	O
%	O
,	O
indicating	T-1
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na	O
+	O
-	O
binding	O
site	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

During	T-0
activation	T-0
with	O
Na	O
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	T-1
the	T-1
K	B-Chemical
(	O
Na	O
)	O
increased	T-2
by	T-2
50	O
%	O
,	O
indicating	O
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na	O
+	O
-	O
binding	O
site	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

During	O
activation	O
with	O
Na	O
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K	T-0
(	O
Na	B-Chemical
)	O
increased	T-1
by	T-1
50	O
%	O
,	O
indicating	O
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na	O
+	O
-	O
binding	O
site	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

During	O
activation	O
with	O
Na	O
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K	O
(	O
Na	O
)	O
increased	O
by	O
50	O
%	O
,	O
indicating	O
a	O
profound	O
decrease	T-1
in	O
the	O
affinity	T-0
of	T-0
the	T-0
Na	B-Chemical
+	O
-	O
binding	T-2
site	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

During	O
activation	O
with	O
Na	O
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K	O
(	O
Na	O
)	O
increased	O
by	O
50	O
%	O
,	O
indicating	O
a	T-1
profound	T-1
decrease	T-1
in	O
the	O
affinity	O
of	O
the	O
Na	O
+	O
-	O
binding	T-0
site	O
in	O
NO	B-Chemical
-	O
deficient	O
rats	O
.	O

After	O
recovery	T-0
from	T-0
hypertension	B-Disease
,	O
the	O
activity	O
of	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	O
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	O
.	O

After	O
recovery	O
from	O
hypertension	O
,	O
the	O
activity	T-0
of	T-0
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	O
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	O
.	O

After	O
recovery	O
from	O
hypertension	O
,	O
the	T-0
activity	T-0
of	T-0
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	O
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	O
.	O

After	O
recovery	O
from	O
hypertension	O
,	O
the	O
activity	O
of	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	T-0
affinity	T-0
of	T-0
the	O
ATP	B-Chemical
-	O
binding	T-1
site	T-1
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	O
.	O

After	O
recovery	O
from	O
hypertension	O
,	O
the	O
activity	O
of	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	O
-	O
binding	O
site	O
,	O
as	T-0
revealed	T-0
from	T-0
the	O
lowered	O
Km	O
value	T-1
for	T-1
ATP	B-Chemical
.	O

The	O
K	B-Chemical
(	O
Na	O
)	O
value	T-0
for	O
Na	T-1
+	T-1
returned	O
to	O
control	O
value	O
.	O

The	O
K	T-0
(	T-0
Na	T-0
)	T-0
value	T-2
for	T-2
Na	B-Chemical
+	O
returned	O
to	O
control	T-1
value	T-1
.	O

Inhibition	T-2
of	T-2
NO	B-Chemical
-	O
synthase	T-0
induced	T-3
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	T-1
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
.	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	T-3
a	T-3
reversible	T-0
hypertension	B-Disease
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	T-1
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	T-2
Na	O
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
.	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	T-0
a	O
reversible	O
hypertension	O
accompanied	T-1
by	T-1
depressed	B-Disease
Na	O
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
.	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	T-0
Na	B-Chemical
+	O
-	O
extrusion	T-1
from	O
cardiac	O
cells	O
as	O
a	O
consequence	T-2
of	O
deteriorated	O
Na	O
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
.	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	T-2
deteriorated	T-2
Na	B-Chemical
+	T-1
-	T-1
binding	T-1
properties	T-1
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
.	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	T-0
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	O
binding	T-1
properties	T-1
of	T-1
the	T-1
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
.	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	T-0
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	O
binding	T-1
properties	T-1
of	O
the	O
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
.	O

After	O
recovery	T-0
of	O
blood	O
pressure	O
to	O
control	O
values	O
,	O
the	O
extrusion	O
of	O
Na	B-Chemical
+	O
from	O
cardiac	O
cells	O
was	O
normalized	T-1
,	O
as	O
revealed	O
by	O
restoration	T-2
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
activity	O
.	O

After	O
recovery	O
of	O
blood	O
pressure	O
to	O
control	O
values	O
,	O
the	O
extrusion	O
of	O
Na	O
+	O
from	O
cardiac	O
cells	O
was	O
normalized	O
,	O
as	O
revealed	O
by	O
restoration	T-0
of	T-0
the	O
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
activity	O
.	O

After	O
recovery	O
of	O
blood	O
pressure	O
to	O
control	O
values	O
,	O
the	O
extrusion	O
of	O
Na	O
+	O
from	O
cardiac	O
cells	O
was	O
normalized	O
,	O
as	O
revealed	T-0
by	T-0
restoration	O
of	O
the	O
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
activity	O
.	O

Effects	T-1
of	T-1
long	O
-	O
term	O
pretreatment	T-2
with	T-2
isoproterenol	B-Chemical
on	O
bromocriptine	O
-	O
induced	T-0
tachycardia	O
in	O
conscious	O
rats	O
.	O

Effects	O
of	O
long	O
-	O
term	O
pretreatment	O
with	O
isoproterenol	O
on	O
bromocriptine	B-Chemical
-	T-1
induced	T-1
tachycardia	O
in	O
conscious	O
rats	O
.	O

Effects	O
of	O
long	O
-	O
term	O
pretreatment	O
with	O
isoproterenol	T-0
on	O
bromocriptine	T-1
-	O
induced	T-3
tachycardia	B-Disease
in	O
conscious	O
rats	T-2
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	B-Chemical
-	T-3
induced	T-3
tachycardia	O
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	T-1
by	T-1
central	O
dopamine	O
D2	O
receptor	O
activation	T-2
and	O
(	O
ii	O
)	O
reduced	O
by	O
5	O
-	O
day	O
isoproterenol	O
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	O
-	O
induced	T-0
tachycardia	B-Disease
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
central	O
dopamine	O
D2	O
receptor	O
activation	O
and	O
(	O
ii	O
)	O
reduced	O
by	O
5	O
-	O
day	O
isoproterenol	O
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	O
-	O
induced	O
tachycardia	O
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	T-0
by	T-2
central	T-2
dopamine	B-Chemical
D2	T-1
receptor	T-1
activation	O
and	O
(	O
ii	O
)	O
reduced	O
by	O
5	O
-	O
day	O
isoproterenol	O
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	O
-	O
induced	O
tachycardia	O
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
central	O
dopamine	O
D2	O
receptor	O
activation	O
and	O
(	O
ii	O
)	O
reduced	T-0
by	T-0
5	O
-	O
day	O
isoproterenol	B-Chemical
pretreatment	T-1
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

This	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
prolonged	O
pretreatment	T-0
with	T-0
isoproterenol	B-Chemical
could	T-1
abolish	T-1
bromocriptine	O
-	O
induced	O
tachycardia	O
in	O
conscious	O
rats	O
.	O

This	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
prolonged	O
pretreatment	O
with	O
isoproterenol	O
could	O
abolish	O
bromocriptine	B-Chemical
-	T-0
induced	T-1
tachycardia	T-1
in	O
conscious	O
rats	O
.	O

This	O
study	O
was	O
conducted	O
to	O
examine	O
whether	O
prolonged	O
pretreatment	O
with	O
isoproterenol	O
could	O
abolish	O
bromocriptine	O
-	O
induced	T-0
tachycardia	B-Disease
in	O
conscious	O
rats	O
.	O

Isoproterenol	B-Chemical
pretreatment	T-0
for	O
15	O
days	O
caused	O
cardiac	O
hypertrophy	O
without	O
affecting	O
baseline	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

Isoproterenol	O
pretreatment	T-1
for	O
15	O
days	O
caused	T-0
cardiac	B-Disease
hypertrophy	I-Disease
without	O
affecting	O
baseline	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

In	O
control	O
rats	O
,	O
intravenous	T-0
bromocriptine	B-Chemical
(	O
150	O
microg	O
/	O
kg	O
)	O
induced	T-1
significant	O
hypotension	O
and	O
tachycardia	O
.	O

In	O
control	O
rats	O
,	O
intravenous	O
bromocriptine	O
(	O
150	O
microg	O
/	O
kg	O
)	O
induced	T-0
significant	T-0
hypotension	B-Disease
and	O
tachycardia	O
.	O

In	O
control	O
rats	O
,	O
intravenous	O
bromocriptine	O
(	O
150	O
microg	O
/	O
kg	O
)	O
induced	O
significant	O
hypotension	O
and	T-0
tachycardia	B-Disease
.	O

Bromocriptine	B-Chemical
-	O
induced	T-0
hypotension	O
was	T-1
unaffected	T-1
by	O
isoproterenol	O
pretreatment	O
,	O
while	O
tachycardia	O
was	O
reversed	O
to	O
significant	O
bradycardia	O
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	O
-	O
induced	T-2
hypotension	B-Disease
was	O
unaffected	T-3
by	T-3
isoproterenol	O
pretreatment	O
,	O
while	O
tachycardia	T-0
was	O
reversed	O
to	O
significant	O
bradycardia	T-1
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	O
-	O
induced	O
hypotension	O
was	O
unaffected	T-0
by	T-0
isoproterenol	B-Chemical
pretreatment	O
,	O
while	O
tachycardia	O
was	O
reversed	O
to	O
significant	O
bradycardia	O
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	O
-	O
induced	T-2
hypotension	O
was	O
unaffected	O
by	O
isoproterenol	O
pretreatment	O
,	O
while	O
tachycardia	B-Disease
was	T-1
reversed	T-1
to	T-1
significant	T-1
bradycardia	T-1
,	O
an	O
effect	O
that	O
was	O
partly	T-3
reduced	T-3
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	O
-	O
induced	O
hypotension	O
was	O
unaffected	O
by	O
isoproterenol	O
pretreatment	O
,	O
while	O
tachycardia	O
was	O
reversed	T-2
to	T-0
significant	T-0
bradycardia	B-Disease
,	O
an	T-1
effect	T-1
that	T-1
was	O
partly	O
reduced	T-3
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	O
-	O
induced	O
hypotension	O
was	O
unaffected	O
by	O
isoproterenol	O
pretreatment	O
,	O
while	O
tachycardia	O
was	O
reversed	O
to	O
significant	O
bradycardia	O
,	O
an	O
effect	T-0
that	O
was	O
partly	O
reduced	T-1
by	O
i	O
.	O
v	O
.	O
domperidone	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Neither	O
cardiac	O
vagal	O
nor	O
sympathetic	O
tone	O
was	T-3
altered	T-3
by	T-2
isoproterenol	B-Chemical
pretreatment	T-1
.	O

In	O
isolated	O
perfused	O
heart	O
preparations	O
from	T-2
isoproterenol	B-Chemical
-	O
pretreated	O
rats	O
,	O
the	O
isoproterenol	O
-	O
induced	O
maximal	O
increase	T-1
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
significantly	O
reduced	O
,	O
compared	O
with	O
saline	O
-	O
pretreated	O
rats	O
(	O
the	O
EC50	O
of	O
the	O
isoproterenol	O
-	O
induced	T-0
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
enhanced	O
approximately	O
22	O
-	O
fold	O
)	O
.	O

In	O
isolated	O
perfused	O
heart	O
preparations	O
from	O
isoproterenol	O
-	O
pretreated	O
rats	O
,	O
the	T-0
isoproterenol	B-Chemical
-	O
induced	T-1
maximal	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
significantly	O
reduced	O
,	O
compared	O
with	O
saline	O
-	O
pretreated	O
rats	O
(	O
the	O
EC50	O
of	O
the	O
isoproterenol	O
-	O
induced	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
enhanced	O
approximately	O
22	O
-	O
fold	O
)	O
.	O

In	O
isolated	O
perfused	O
heart	O
preparations	O
from	O
isoproterenol	O
-	O
pretreated	O
rats	O
,	O
the	O
isoproterenol	O
-	O
induced	O
maximal	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
significantly	O
reduced	O
,	O
compared	O
with	O
saline	O
-	O
pretreated	O
rats	O
(	O
the	O
EC50	O
of	T-0
the	T-0
isoproterenol	B-Chemical
-	O
induced	T-1
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
was	O
enhanced	O
approximately	O
22	O
-	O
fold	O
)	O
.	O

These	O
results	T-2
show	T-2
that	O
15	O
-	O
day	O
isoproterenol	B-Chemical
pretreatment	O
not	O
only	O
abolished	T-0
but	O
reversed	T-1
bromocriptine	O
-	O
induced	O
tachycardia	O
to	O
bradycardia	O
,	O
an	T-3
effect	T-3
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

These	O
results	O
show	O
that	O
15	O
-	O
day	O
isoproterenol	O
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	T-0
bromocriptine	B-Chemical
-	O
induced	T-1
tachycardia	O
to	O
bradycardia	O
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

These	O
results	O
show	O
that	O
15	O
-	O
day	O
isoproterenol	O
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	O
bromocriptine	O
-	T-1
induced	T-1
tachycardia	B-Disease
to	T-2
bradycardia	T-2
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

These	O
results	T-2
show	T-2
that	T-2
15	O
-	O
day	O
isoproterenol	O
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	O
bromocriptine	O
-	O
induced	T-0
tachycardia	O
to	O
bradycardia	B-Disease
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	T-1
to	T-1
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	T-0
tachycardia	B-Disease
of	T-1
bromocriptine	T-1
appears	O
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	O
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	O
D2	O
receptors	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	O
of	O
bromocriptine	B-Chemical
appears	T-2
to	T-2
predominate	T-0
and	O
to	O
mask	T-1
the	O
bradycardia	O
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	O
D2	O
receptors	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	O
of	O
bromocriptine	O
appears	T-1
to	O
predominate	O
and	O
to	T-0
mask	T-0
the	T-0
bradycardia	B-Disease
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	O
D2	O
receptors	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	O
of	O
bromocriptine	O
appears	O
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	O
of	T-2
this	T-2
agonist	T-2
at	T-0
peripheral	T-0
dopamine	B-Chemical
D2	O
receptors	T-1
.	O

A	O
developmental	O
analysis	O
of	O
clonidine	B-Chemical
'	T-0
s	T-0
effects	T-0
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
in	O
infant	O
rats	O
.	O

Under	O
controlled	O
conditions	O
,	O
infant	O
rats	O
emit	T-0
ultrasonic	O
vocalizations	O
during	O
extreme	O
cold	O
exposure	O
and	O
after	O
administration	T-1
of	O
the	O
alpha	O
(	O
2	O
)	O
adrenoceptor	O
agonist	O
,	O
clonidine	B-Chemical
.	O

Previous	O
investigations	O
have	O
determined	O
that	O
,	O
in	T-0
response	T-0
to	T-0
clonidine	B-Chemical
,	O
ultrasound	O
production	O
increases	O
through	O
the	O
2nd	O
-	O
week	O
postpartum	O
and	O
decreases	O
thereafter	O
.	O

Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern	O
,	O
and	O
given	O
that	O
clonidine	B-Chemical
induces	T-1
sympathetic	O
withdrawal	O
and	O
bradycardia	O
,	O
we	O
hypothesized	O
that	O
clonidine	O
'	O
s	O
developmental	O
effects	T-2
on	T-2
cardiac	O
rate	O
and	O
ultrasound	O
production	O
would	O
mirror	O
each	O
other	O
.	O

Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern	O
,	O
and	O
given	O
that	O
clonidine	O
induces	T-1
sympathetic	O
withdrawal	O
and	O
bradycardia	B-Disease
,	O
we	O
hypothesized	O
that	O
clonidine	O
'	O
s	O
developmental	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
would	O
mirror	O
each	O
other	O
.	O

Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern	O
,	O
and	O
given	O
that	O
clonidine	O
induces	T-0
sympathetic	O
withdrawal	O
and	O
bradycardia	O
,	O
we	O
hypothesized	T-1
that	O
clonidine	B-Chemical
'	O
s	O
developmental	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
would	O
mirror	O
each	O
other	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
experiment	O
,	O
the	O
effects	T-0
of	T-0
clonidine	B-Chemical
administration	T-1
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
were	O
examined	O
in	O
2	O
-	O
,	O
8	O
-	O
,	O
15	O
-	O
,	O
and	O
20	O
-	O
day	O
-	O
old	O
rats	O
.	O

Age	O
-	O
related	O
changes	O
in	O
ultrasound	O
production	O
corresponded	O
with	O
changes	O
in	O
cardiovascular	O
variables	O
,	O
including	O
baseline	O
cardiac	O
rate	O
and	T-0
clonidine	B-Chemical
-	O
induced	T-1
bradycardia	O
.	O

Age	O
-	O
related	O
changes	O
in	O
ultrasound	O
production	O
corresponded	O
with	O
changes	O
in	O
cardiovascular	O
variables	O
,	O
including	O
baseline	O
cardiac	O
rate	O
and	O
clonidine	O
-	T-1
induced	T-1
bradycardia	B-Disease
.	O

This	O
experiment	O
is	O
discussed	O
with	O
regard	O
to	O
the	O
hypothesis	O
that	O
ultrasound	O
production	O
is	O
the	O
acoustic	O
by	O
-	O
product	O
of	O
a	O
physiological	O
maneuver	O
that	O
compensates	T-0
for	T-0
clonidine	B-Chemical
'	O
s	O
detrimental	O
effects	T-1
on	O
cardiovascular	O
function	O
.	O

Recurrent	O
use	T-1
of	T-1
newer	O
oral	B-Chemical
contraceptives	I-Chemical
and	O
the	O
risk	O
of	O
venous	O
thromboembolism	O
.	T-0

Recurrent	O
use	O
of	O
newer	O
oral	O
contraceptives	O
and	O
the	O
risk	T-1
of	T-1
venous	B-Disease
thromboembolism	I-Disease
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	T-0
of	T-0
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	O
)	O
associated	O
with	O
newer	O
oral	O
contraceptives	O
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	B-Disease
)	O
associated	T-0
with	T-0
newer	O
oral	O
contraceptives	O
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	T-0
the	T-0
risk	T-0
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	O
with	O
newer	O
oral	B-Chemical
contraceptives	I-Chemical
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	T-0
with	T-0
newer	O
oral	O
contraceptives	O
(	O
OC	B-Chemical
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	O
with	O
newer	O
oral	O
contraceptives	O
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	T-0
of	T-0
OC	B-Chemical
use	T-1
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

Data	O
from	O
a	O
Transnational	O
case	O
-	O
control	O
study	O
were	O
used	O
to	O
assess	O
the	O
risk	T-0
of	T-0
VTE	B-Disease
for	O
the	O
latter	O
patterns	O
of	O
use	O
,	O
while	O
accounting	O
for	O
duration	O
of	O
use	O
.	O

Over	O
the	O
period	O
1993	O
-	O
1996	O
,	O
551	O
cases	T-2
of	T-2
VTE	B-Disease
were	T-0
identified	T-1
in	O
Germany	O
and	O
the	O
UK	O
along	O
with	O
2066	O
controls	O
.	O

The	O
adjusted	T-1
rate	T-0
ratio	T-0
of	T-0
VTE	B-Disease
for	O
repeat	O
users	O
of	O
third	O
generation	O
OC	O
was	O
0	O
.	O
6	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
3	O
-	O
1	O
.	O
2	O
)	O
relative	O
to	O
repeat	O
users	O
of	O
second	O
generation	O
pills	O
,	O
whereas	O
it	O
was	O
1	O
.	O
3	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
-	O
2	O
.	O
4	O
)	O
for	O
switchers	O
from	O
second	O
to	O
third	O
generation	O
pills	O
relative	O
to	O
switchers	O
from	O
third	O
to	O
second	O
generation	O
pills	O
.	O

The	O
adjusted	O
rate	O
ratio	O
of	O
VTE	O
for	O
repeat	O
users	T-0
of	T-0
third	O
generation	O
OC	B-Chemical
was	T-1
0	O
.	O
6	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
3	O
-	O
1	O
.	O
2	O
)	O
relative	O
to	O
repeat	O
users	O
of	O
second	O
generation	O
pills	O
,	O
whereas	O
it	O
was	O
1	O
.	O
3	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
-	O
2	O
.	O
4	O
)	O
for	O
switchers	O
from	O
second	O
to	O
third	O
generation	O
pills	O
relative	O
to	O
switchers	O
from	O
third	O
to	O
second	O
generation	O
pills	O
.	O

We	O
conclude	O
that	O
second	O
and	O
third	O
generation	O
agents	O
are	O
associated	O
with	O
equivalent	O
risks	T-1
of	T-1
VTE	B-Disease
when	O
the	O
same	O
agent	O
is	O
used	T-0
repeatedly	O
after	O
interruption	O
periods	O
or	O
when	O
users	O
are	O
switched	O
between	O
the	O
two	O
generations	O
of	O
pills	O
.	O

These	O
analyses	O
suggest	O
that	O
the	O
higher	O
risk	O
observed	T-1
for	T-1
the	O
newer	O
OC	B-Chemical
in	O
other	O
studies	O
may	O
be	O
the	O
result	O
of	O
inadequate	T-0
comparisons	T-0
of	O
pill	O
users	O
with	O
different	O
patterns	O
of	O
pill	O
use	O
.	O

Differential	O
effects	O
of	O
systemically	T-1
administered	T-1
ketamine	B-Chemical
and	O
lidocaine	O
on	O
dynamic	O
and	O
static	O
hyperalgesia	O
induced	T-0
by	O
intradermal	O
capsaicin	O
in	O
humans	O
.	O

Differential	O
effects	T-1
of	T-1
systemically	O
administered	O
ketamine	O
and	O
lidocaine	B-Chemical
on	O
dynamic	O
and	O
static	O
hyperalgesia	O
induced	T-2
by	T-2
intradermal	O
capsaicin	O
in	O
humans	O
.	O

Differential	O
effects	O
of	O
systemically	O
administered	T-2
ketamine	O
and	O
lidocaine	O
on	O
dynamic	T-1
and	T-1
static	T-1
hyperalgesia	B-Disease
induced	T-3
by	O
intradermal	O
capsaicin	O
in	T-0
humans	T-0
.	O

Differential	O
effects	T-0
of	T-0
systemically	O
administered	O
ketamine	O
and	O
lidocaine	O
on	O
dynamic	O
and	O
static	O
hyperalgesia	O
induced	T-1
by	T-1
intradermal	O
capsaicin	B-Chemical
in	T-2
humans	T-2
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	T-1
of	O
ketamine	B-Chemical
and	O
lidocaine	O
on	O
brush	O
-	O
evoked	O
(	O
dynamic	O
)	O
pain	O
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	T-2
induced	T-0
by	T-0
capsaicin	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	O
of	O
ketamine	T-2
and	T-2
lidocaine	B-Chemical
on	T-1
brush	T-1
-	O
evoked	O
(	O
dynamic	O
)	O
pain	O
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	O
induced	O
by	O
capsaicin	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	T-0
of	O
ketamine	O
and	O
lidocaine	O
on	O
brush	O
-	O
evoked	T-1
(	O
dynamic	O
)	O
pain	B-Disease
and	O
punctate	O
-	O
evoked	T-2
(	O
static	O
)	O
hyperalgesia	O
induced	T-3
by	O
capsaicin	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	O
of	O
ketamine	O
and	O
lidocaine	O
on	O
brush	O
-	O
evoked	T-0
(	O
dynamic	O
)	O
pain	O
and	O
punctate	O
-	O
evoked	T-1
(	O
static	O
)	O
hyperalgesia	B-Disease
induced	T-2
by	O
capsaicin	O
.	O

We	O
have	O
examined	T-0
the	O
effect	O
of	O
systemic	O
administration	T-1
of	O
ketamine	O
and	O
lidocaine	O
on	O
brush	O
-	O
evoked	O
(	O
dynamic	O
)	O
pain	O
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	O
induced	T-2
by	T-2
capsaicin	B-Chemical
.	O

Capsaicin	B-Chemical
100	T-1
micrograms	T-1
was	T-1
injected	T-1
intradermally	O
on	O
the	O
volar	O
forearm	O
followed	O
by	O
an	O
i	O
.	O
v	O
.	O
infusion	O
of	O
ketamine	O
(	O
bolus	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
over	O
10	O
min	O
followed	O
by	O
infusion	O
of	O
7	O
micrograms	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
,	O
lidocaine	O
5	O
mg	O
kg	O
-	O
1	O
or	O
saline	O
for	O
50	O
min	O
.	O

Capsaicin	O
100	O
micrograms	O
was	O
injected	O
intradermally	O
on	O
the	O
volar	O
forearm	O
followed	O
by	O
an	O
i	O
.	O
v	O
.	O
infusion	T-0
of	T-0
ketamine	B-Chemical
(	O
bolus	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
over	O
10	O
min	O
followed	O
by	O
infusion	O
of	O
7	O
micrograms	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
,	O
lidocaine	O
5	O
mg	O
kg	O
-	O
1	O
or	O
saline	O
for	O
50	O
min	O
.	O

Capsaicin	O
100	O
micrograms	O
was	O
injected	O
intradermally	O
on	O
the	O
volar	O
forearm	O
followed	O
by	O
an	O
i	O
.	O
v	O
.	O
infusion	O
of	O
ketamine	O
(	O
bolus	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
over	O
10	O
min	O
followed	O
by	O
infusion	T-0
of	T-0
7	O
micrograms	O
kg	O
-	O
1	O
min	O
-	O
1	O
)	O
,	O
lidocaine	B-Chemical
5	O
mg	O
kg	O
-	O
1	O
or	O
saline	O
for	O
50	O
min	O
.	O

Infusion	O
started	O
15	O
min	O
after	O
injection	T-0
of	T-0
capsaicin	B-Chemical
.	O

The	O
following	O
were	O
measured	O
:	O
spontaneous	T-1
pain	B-Disease
,	T-0
pain	T-0
evoked	O
by	O
punctate	O
and	O
brush	O
stimuli	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	O
.	O

The	O
following	O
were	O
measured	O
:	O
spontaneous	O
pain	O
,	O
pain	B-Disease
evoked	T-0
by	T-0
punctate	O
and	O
brush	O
stimuli	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	O
.	O

The	O
following	O
were	O
measured	O
:	O
spontaneous	O
pain	O
,	O
pain	O
evoked	O
by	O
punctate	O
and	O
brush	O
stimuli	O
(	O
VAS	O
)	O
,	O
and	O
areas	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	T-0
hyperalgesia	B-Disease
.	O

Ketamine	B-Chemical
reduced	T-0
both	O
the	O
area	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	O
-	O
evoked	O
hyperalgesia	O
significantly	O
and	O
it	O
tended	O
to	O
reduce	O
brush	O
-	O
evoked	O
pain	O
.	O

Ketamine	O
reduced	T-0
both	O
the	O
area	O
of	O
brush	O
-	O
evoked	O
and	O
punctate	T-4
-	T-4
evoked	T-4
hyperalgesia	B-Disease
significantly	O
and	O
it	O
tended	O
to	O
reduce	T-1
brush	O
-	O
evoked	T-3
pain	O
.	O

Lidocaine	B-Chemical
reduced	T-0
the	O
area	O
of	O
punctate	O
-	O
evoked	O
hyperalgesia	O
significantly	O
.	O

Lidocaine	O
reduced	O
the	O
area	O
of	O
punctate	O
-	O
evoked	T-0
hyperalgesia	B-Disease
significantly	O
.	O

It	O
tended	O
to	O
reduce	O
VAS	O
scores	O
of	O
spontaneous	T-1
pain	B-Disease
but	O
had	O
no	O
effect	O
on	O
evoked	O
pain	T-2
.	O

It	O
tended	O
to	O
reduce	O
VAS	O
scores	O
of	O
spontaneous	O
pain	O
but	O
had	O
no	T-0
effect	T-0
on	T-0
evoked	T-1
pain	B-Disease
.	O

The	O
differential	T-2
effects	T-2
of	T-0
ketamine	B-Chemical
and	O
lidocaine	O
on	O
static	O
and	O
dynamic	O
hyperalgesia	O
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	O
are	O
mediated	T-1
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

The	O
differential	O
effects	T-0
of	T-0
ketamine	T-1
and	T-1
lidocaine	B-Chemical
on	O
static	O
and	O
dynamic	O
hyperalgesia	O
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	O
are	O
mediated	O
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

The	O
differential	O
effects	O
of	O
ketamine	O
and	O
lidocaine	O
on	O
static	T-0
and	T-0
dynamic	T-0
hyperalgesia	B-Disease
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	O
are	O
mediated	T-1
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

The	O
differential	O
effects	O
of	O
ketamine	O
and	O
lidocaine	O
on	O
static	O
and	O
dynamic	O
hyperalgesia	O
suggest	T-2
that	T-2
the	O
two	O
types	T-0
of	T-0
hyperalgesia	B-Disease
are	T-1
mediated	T-1
by	T-1
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

Development	T-2
of	T-2
apomorphine	B-Chemical
-	O
induced	T-3
aggressive	O
behavior	O
:	O
comparison	O
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
.	O

Development	T-0
of	T-0
apomorphine	O
-	O
induced	T-1
aggressive	B-Disease
behavior	I-Disease
:	O
comparison	O
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
.	O

The	O
development	T-0
of	T-0
apomorphine	B-Chemical
-	T-1
induced	T-1
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
once	O
daily	O
)	O
aggressive	O
behavior	O
of	O
adult	O
male	O
and	O
female	O
Wistar	O
rats	O
obtained	O
from	O
the	O
same	O
breeder	O
was	O
studied	O
in	O
two	O
consecutive	O
sets	O
.	O

The	O
development	O
of	O
apomorphine	O
-	O
induced	T-0
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
once	O
daily	O
)	O
aggressive	B-Disease
behavior	I-Disease
of	T-1
adult	T-1
male	T-1
and	O
female	O
Wistar	O
rats	O
obtained	O
from	O
the	O
same	O
breeder	O
was	O
studied	O
in	O
two	O
consecutive	O
sets	O
.	O

In	O
male	O
animals	O
,	O
repeated	O
apomorphine	B-Chemical
treatment	T-0
induced	O
a	O
gradual	T-1
development	T-1
of	T-1
aggressive	O
behavior	O
as	O
evidenced	T-2
by	T-2
the	O
increased	O
intensity	O
of	O
aggressiveness	O
and	O
shortened	O
latency	O
before	O
the	O
first	O
attack	O
toward	O
the	O
opponent	O
.	O

In	O
male	O
animals	O
,	O
repeated	O
apomorphine	O
treatment	T-0
induced	T-2
a	O
gradual	O
development	T-3
of	T-3
aggressive	B-Disease
behavior	I-Disease
as	O
evidenced	O
by	O
the	O
increased	O
intensity	O
of	O
aggressiveness	O
and	O
shortened	O
latency	O
before	O
the	O
first	O
attack	O
toward	O
the	O
opponent	O
.	O

In	O
male	O
animals	O
,	O
repeated	O
apomorphine	O
treatment	O
induced	T-1
a	O
gradual	O
development	O
of	O
aggressive	O
behavior	O
as	O
evidenced	O
by	O
the	O
increased	T-2
intensity	T-0
of	T-0
aggressiveness	B-Disease
and	O
shortened	O
latency	O
before	O
the	O
first	O
attack	O
toward	O
the	O
opponent	O
.	O

In	O
female	O
rats	O
,	O
only	O
a	O
weak	O
tendency	T-1
toward	T-1
aggressiveness	B-Disease
was	O
found	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
gender	O
differences	O
in	O
the	O
development	T-0
of	T-0
the	O
apomorphine	B-Chemical
-	T-2
induced	T-2
aggressive	O
behavior	O
and	O
indicates	O
that	O
the	O
female	O
rats	O
do	O
not	O
fill	O
the	O
validation	O
criteria	O
for	O
use	O
in	O
this	O
method	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrates	O
gender	O
differences	O
in	O
the	O
development	O
of	O
the	O
apomorphine	O
-	O
induced	T-0
aggressive	B-Disease
behavior	I-Disease
and	O
indicates	O
that	O
the	O
female	O
rats	O
do	O
not	O
fill	O
the	O
validation	O
criteria	O
for	O
use	O
in	O
this	O
method	O
.	O

Intracranial	B-Disease
aneurysms	I-Disease
and	T-0
cocaine	O
abuse	O
:	O
analysis	O
of	O
prognostic	O
indicators	O
.	O

Intracranial	O
aneurysms	O
and	T-0
cocaine	B-Disease
abuse	I-Disease
:	O
analysis	O
of	O
prognostic	O
indicators	O
.	O

OBJECTIVE	O
:	O
The	T-1
outcome	T-1
of	T-1
subarachnoid	B-Disease
hemorrhage	I-Disease
associated	T-0
with	T-0
cocaine	O
abuse	O
is	O
reportedly	O
poor	O
.	O

OBJECTIVE	O
:	O
The	O
outcome	O
of	O
subarachnoid	O
hemorrhage	O
associated	T-0
with	T-0
cocaine	B-Disease
abuse	I-Disease
is	O
reportedly	O
poor	O
.	O

METHODS	O
:	O
A	O
review	O
of	O
admissions	O
during	O
a	O
6	O
-	O
year	O
period	O
revealed	T-1
14	O
patients	O
with	O
cocaine	B-Chemical
-	O
related	T-0
aneurysms	O
.	O

METHODS	O
:	O
A	O
review	O
of	O
admissions	O
during	O
a	O
6	O
-	O
year	O
period	O
revealed	O
14	O
patients	T-0
with	T-0
cocaine	O
-	O
related	T-1
aneurysms	B-Disease
.	O

This	O
group	O
was	O
compared	T-0
with	T-0
a	O
control	O
group	O
of	O
135	O
patients	T-1
with	T-1
ruptured	B-Disease
aneurysms	I-Disease
and	O
no	O
history	O
of	O
cocaine	O
abuse	O
.	O

This	O
group	O
was	O
compared	O
with	O
a	O
control	O
group	O
of	O
135	O
patients	T-1
with	O
ruptured	O
aneurysms	O
and	O
no	T-2
history	T-2
of	T-2
cocaine	B-Disease
abuse	I-Disease
.	O

Age	O
at	O
presentation	O
,	O
time	O
of	O
ictus	O
after	O
intoxication	O
,	O
Hunt	O
and	O
Hess	O
grade	T-2
of	T-2
subarachnoid	B-Disease
hemorrhage	I-Disease
,	O
size	T-0
of	T-0
the	T-0
aneurysm	T-0
,	O
location	T-1
of	T-1
the	T-1
aneurysm	T-1
,	O
and	O
the	O
Glasgow	O
Outcome	O
Scale	O
score	O
were	O
assessed	O
and	O
compared	O
.	O

Age	O
at	O
presentation	O
,	O
time	O
of	O
ictus	O
after	O
intoxication	O
,	O
Hunt	O
and	O
Hess	O
grade	O
of	O
subarachnoid	O
hemorrhage	O
,	O
size	T-1
of	T-1
the	T-1
aneurysm	B-Disease
,	O
location	T-0
of	T-0
the	O
aneurysm	O
,	O
and	O
the	O
Glasgow	O
Outcome	O
Scale	O
score	O
were	O
assessed	O
and	O
compared	O
.	O

Age	O
at	O
presentation	O
,	O
time	O
of	O
ictus	T-0
after	O
intoxication	O
,	O
Hunt	O
and	O
Hess	O
grade	O
of	O
subarachnoid	O
hemorrhage	O
,	O
size	O
of	O
the	O
aneurysm	O
,	O
location	T-1
of	T-1
the	O
aneurysm	B-Disease
,	O
and	O
the	O
Glasgow	O
Outcome	O
Scale	O
score	O
were	O
assessed	O
and	O
compared	O
.	O

In	O
patients	O
in	O
the	O
study	O
group	O
,	O
all	T-0
aneurysms	B-Disease
were	T-1
located	T-1
in	O
the	O
anterior	O
circulation	O
.	O

The	O
majority	O
of	O
these	O
aneurysms	B-Disease
were	O
smaller	T-0
than	T-0
those	O
of	O
the	O
control	O
group	O
(	O
8	O
+	O
/	O
-	O
6	O
.	O
08	O
mm	O
versus	O
11	O
+	O
/	O
-	O
5	O
.	O
4	O
mm	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

Hunt	O
and	O
Hess	O
grade	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
age	O
(	O
P	O
<	O
0	O
.	O
007	O
)	O
were	O
significant	O
predictors	O
of	O
outcome	O
for	O
the	O
patients	T-0
with	T-0
cocaine	B-Chemical
-	O
related	T-1
aneurysms	O
.	O

Hunt	O
and	O
Hess	O
grade	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
age	O
(	O
P	O
<	O
0	O
.	O
007	O
)	O
were	O
significant	O
predictors	O
of	O
outcome	T-0
for	O
the	O
patients	T-1
with	T-1
cocaine	O
-	O
related	T-2
aneurysms	B-Disease
.	O

CONCLUSION	O
:	O
Cocaine	B-Chemical
use	T-0
predisposed	O
aneurysmal	O
rupture	O
at	O
a	O
significantly	O
earlier	O
age	O
and	O
in	O
much	O
smaller	O
aneurysms	O
.	O

CONCLUSION	O
:	O
Cocaine	O
use	O
predisposed	T-0
aneurysmal	B-Disease
rupture	I-Disease
at	O
a	O
significantly	O
earlier	O
age	O
and	O
in	O
much	O
smaller	O
aneurysms	O
.	O

CONCLUSION	O
:	O
Cocaine	O
use	O
predisposed	O
aneurysmal	O
rupture	O
at	O
a	O
significantly	T-0
earlier	T-0
age	T-0
and	O
in	O
much	O
smaller	O
aneurysms	B-Disease
.	O

Effect	T-0
of	T-0
intravenous	O
nimodipine	B-Chemical
on	O
blood	O
pressure	O
and	O
outcome	O
after	O
acute	O
stroke	O
.	O

Effect	O
of	O
intravenous	O
nimodipine	O
on	O
blood	O
pressure	O
and	O
outcome	O
after	T-0
acute	B-Disease
stroke	I-Disease
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	T-0
Intravenous	T-0
Nimodipine	B-Chemical
West	O
European	O
Stroke	O
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	O
-	O
induced	T-1
reduction	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
an	O
unfavorable	T-2
outcome	T-2
in	O
acute	O
stroke	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	O
West	O
European	O
Stroke	B-Disease
Trial	T-0
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	O
-	O
induced	O
reduction	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	O
stroke	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	O
West	O
European	O
Stroke	O
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	T-0
between	O
nimodipine	B-Chemical
-	O
induced	T-1
reduction	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	O
stroke	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	O
West	O
European	O
Stroke	O
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	O
-	O
induced	T-0
reduction	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	O
stroke	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	O
West	O
European	O
Stroke	O
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	O
-	O
induced	O
reduction	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
an	O
unfavorable	T-1
outcome	T-1
in	T-1
acute	B-Disease
stroke	I-Disease
.	O

We	O
sought	O
to	O
confirm	O
this	O
correlation	O
with	O
and	O
without	O
adjustment	O
for	O
prognostic	O
variables	O
and	O
to	O
investigate	O
outcome	O
in	O
subgroups	O
with	O
increasing	T-1
levels	T-0
of	T-0
BP	B-Disease
reduction	I-Disease
.	O

METHODS	O
:	O
Patients	O
with	O
a	O
clinical	T-0
diagnosis	T-1
of	T-1
ischemic	B-Disease
stroke	I-Disease
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	O
to	O
receive	O
placebo	O
(	O
n	O
=	O
100	O
)	O
,	O
1	O
mg	O
/	O
h	O
(	O
low	O
-	O
dose	O
)	O
nimodipine	O
(	O
n	O
=	O
101	O
)	O
,	O
or	O
2	O
mg	O
/	O
h	O
(	O
high	O
-	O
dose	O
)	O
nimodipine	O
(	O
n	O
=	O
94	O
)	O
.	O

METHODS	O
:	O
Patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
ischemic	O
stroke	O
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	T-1
to	T-1
receive	O
placebo	O
(	O
n	O
=	O
100	O
)	O
,	O
1	T-0
mg	T-0
/	T-0
h	T-0
(	T-0
low	T-0
-	T-0
dose	T-0
)	T-0
nimodipine	B-Chemical
(	O
n	O
=	O
101	O
)	O
,	O
or	O
2	O
mg	O
/	O
h	O
(	O
high	O
-	O
dose	O
)	O
nimodipine	O
(	O
n	O
=	O
94	O
)	O
.	O

METHODS	O
:	O
Patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
ischemic	O
stroke	O
(	O
within	O
24	O
hours	O
)	O
were	O
consecutively	O
allocated	T-1
to	T-1
receive	T-0
placebo	O
(	O
n	O
=	O
100	O
)	O
,	O
1	O
mg	O
/	O
h	O
(	O
low	O
-	O
dose	O
)	O
nimodipine	O
(	O
n	O
=	O
101	O
)	O
,	O
or	O
2	O
mg	O
/	O
h	O
(	O
high	O
-	O
dose	O
)	O
nimodipine	B-Chemical
(	O
n	O
=	O
94	O
)	O
.	O

Nimodipine	B-Chemical
treatment	T-3
resulted	T-3
in	T-3
a	O
statistically	O
significant	O
reduction	T-2
in	T-2
systolic	O
BP	O
(	O
SBP	O
)	O
and	O
diastolic	O
BP	O
(	O
DBP	O
)	O
from	O
baseline	O
compared	O
with	O
placebo	O
during	O
the	O
first	O
few	O
days	O
.	O

Nimodipine	O
treatment	O
resulted	T-1
in	T-1
a	O
statistically	T-0
significant	T-0
reduction	B-Disease
in	I-Disease
systolic	I-Disease
BP	I-Disease
(	O
SBP	O
)	O
and	O
diastolic	O
BP	O
(	O
DBP	O
)	O
from	O
baseline	O
compared	O
with	O
placebo	O
during	O
the	O
first	O
few	O
days	O
.	O

In	O
multivariate	O
analysis	O
,	O
a	O
significant	O
correlation	O
between	T-0
DBP	B-Disease
reduction	I-Disease
and	O
worsening	T-1
of	O
the	O
neurological	O
score	O
was	O
found	O
for	O
the	O
high	O
-	O
dose	O
group	O
(	O
beta	O
=	O
0	O
.	O
49	O
,	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O

Patients	O
with	O
a	O
DBP	B-Disease
reduction	I-Disease
of	O
>	O
or	O
=	O
20	O
%	O
in	O
the	O
high	O
-	O
dose	O
group	O
had	O
a	O
significantly	O
increased	T-0
adjusted	T-0
OR	O
for	O
the	O
compound	O
outcome	O
variable	O
death	O
or	O
dependency	O
(	O
Barthel	O
Index	O
<	O
60	O
)	O
(	O
n	O
/	O
N	O
=	O
25	O
/	O
26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
to	O
101	O
.	O
74	O
)	O
and	O
death	O
alone	O
(	O
n	O
/	O
N	O
=	O
9	O
/	O
26	O
,	O
OR	O
4	O
.	O
336	O
,	O
95	O
%	O
CI	O
1	O
.	O
131	O
16	O
.	O
619	O
)	O
compared	O
with	O
all	O
placebo	O
patients	O
(	O
n	O
/	O
N	O
=	O
62	O
/	O
92	O
and	O
14	O
/	O
92	O
,	O
respectively	O
)	O
.	O

Patients	O
with	O
a	O
DBP	O
reduction	O
of	O
>	O
or	O
=	O
20	O
%	O
in	O
the	O
high	O
-	O
dose	O
group	O
had	O
a	O
significantly	O
increased	O
adjusted	O
OR	O
for	O
the	O
compound	O
outcome	O
variable	O
death	B-Disease
or	T-0
dependency	O
(	O
Barthel	O
Index	O
<	O
60	O
)	O
(	O
n	O
/	O
N	O
=	O
25	O
/	O
26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
to	O
101	O
.	O
74	O
)	O
and	O
death	O
alone	O
(	O
n	O
/	O
N	O
=	O
9	O
/	O
26	O
,	O
OR	O
4	O
.	O
336	O
,	O
95	O
%	O
CI	O
1	O
.	O
131	O
16	O
.	O
619	O
)	O
compared	O
with	O
all	O
placebo	O
patients	O
(	O
n	O
/	O
N	O
=	O
62	O
/	O
92	O
and	O
14	O
/	O
92	O
,	O
respectively	O
)	O
.	O

Patients	O
with	O
a	O
DBP	O
reduction	T-2
of	T-2
>	O
or	O
=	O
20	O
%	O
in	O
the	O
high	O
-	O
dose	O
group	O
had	O
a	O
significantly	O
increased	O
adjusted	O
OR	O
for	O
the	O
compound	O
outcome	O
variable	O
death	T-0
or	O
dependency	T-1
(	O
Barthel	O
Index	O
<	O
60	O
)	O
(	O
n	O
/	O
N	O
=	O
25	O
/	O
26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
to	O
101	O
.	O
74	O
)	O
and	O
death	B-Disease
alone	O
(	O
n	O
/	O
N	O
=	O
9	O
/	O
26	O
,	O
OR	O
4	O
.	O
336	O
,	O
95	O
%	O
CI	O
1	O
.	O
131	O
16	O
.	O
619	O
)	O
compared	O
with	O
all	O
placebo	O
patients	O
(	O
n	O
/	O
N	O
=	O
62	O
/	O
92	O
and	O
14	O
/	O
92	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
:	O
DBP	O
,	O
but	O
not	O
SBP	O
,	O
reduction	O
was	O
associated	O
with	O
neurological	O
worsening	O
after	O
the	O
intravenous	O
administration	T-1
of	T-1
high	O
-	O
dose	T-0
nimodipine	B-Chemical
after	O
acute	O
stroke	O
.	O

CONCLUSIONS	O
:	O
DBP	O
,	O
but	O
not	O
SBP	O
,	O
reduction	O
was	O
associated	O
with	O
neurological	O
worsening	O
after	O
the	O
intravenous	O
administration	O
of	O
high	O
-	O
dose	O
nimodipine	O
after	T-0
acute	B-Disease
stroke	I-Disease
.	O

For	O
low	T-2
-	T-2
dose	T-2
nimodipine	B-Chemical
,	O
the	T-0
results	T-0
were	T-1
not	O
conclusive	O
.	O

These	O
results	O
do	O
not	O
confirm	O
or	O
exclude	O
a	O
neuroprotective	O
property	T-0
of	T-0
nimodipine	B-Chemical
.	O

Neonatal	T-0
pyridoxine	B-Chemical
responsive	T-1
convulsions	O
due	T-2
to	T-2
isoniazid	O
therapy	O
.	O

Neonatal	O
pyridoxine	O
responsive	T-0
convulsions	B-Disease
due	O
to	O
isoniazid	O
therapy	O
.	O

Neonatal	O
pyridoxine	O
responsive	O
convulsions	T-0
due	T-1
to	T-1
isoniazid	B-Chemical
therapy	T-2
.	O

A	O
17	O
-	O
day	O
-	O
old	O
infant	O
on	T-0
isoniazid	B-Chemical
therapy	T-1
13	O
mg	O
/	O
kg	O
daily	O
from	O
birth	O
because	O
of	O
maternal	O
tuberculosis	O
was	O
admitted	O
after	O
4	O
days	O
of	O
clonic	O
fits	O
.	O

A	O
17	O
-	O
day	O
-	O
old	O
infant	O
on	O
isoniazid	O
therapy	O
13	O
mg	O
/	O
kg	O
daily	O
from	O
birth	O
because	O
of	O
maternal	O
tuberculosis	B-Disease
was	O
admitted	O
after	O
4	O
days	O
of	O
clonic	T-0
fits	T-0
.	O

A	O
17	O
-	O
day	O
-	O
old	O
infant	O
on	O
isoniazid	O
therapy	O
13	O
mg	O
/	O
kg	O
daily	O
from	O
birth	O
because	O
of	O
maternal	O
tuberculosis	O
was	O
admitted	O
after	O
4	T-0
days	T-0
of	T-0
clonic	B-Disease
fits	I-Disease
.	O

The	O
fits	B-Disease
ceased	T-0
within	T-0
4	O
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	O
,	O
suggesting	T-1
an	O
aetiology	O
of	O
pyridoxine	O
deficiency	O
secondary	O
to	O
isoniazid	O
medication	O
.	O

The	O
fits	O
ceased	O
within	O
4	O
hours	O
of	O
administering	T-1
intramuscular	T-1
pyridoxine	B-Chemical
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	O
deficiency	O
secondary	O
to	O
isoniazid	O
medication	O
.	O

The	O
fits	O
ceased	O
within	O
4	O
hours	O
of	O
administering	T-1
intramuscular	O
pyridoxine	O
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	B-Chemical
deficiency	O
secondary	O
to	O
isoniazid	O
medication	O
.	O

The	O
fits	O
ceased	O
within	O
4	O
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	O
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	O
deficiency	O
secondary	T-0
to	T-0
isoniazid	B-Chemical
medication	T-1
.	O

Ketamine	B-Chemical
sedation	T-0
for	O
the	O
reduction	T-1
of	O
children	O
'	O
s	O
fractures	O
in	O
the	O
emergency	O
department	O
.	O

Ketamine	O
sedation	O
for	O
the	O
reduction	T-0
of	T-0
children	O
'	O
s	O
fractures	B-Disease
in	O
the	O
emergency	O
department	O
.	O

BACKGROUND	O
:	O
There	O
recently	O
has	O
been	O
a	O
resurgence	O
in	O
the	O
utilization	T-0
of	T-0
ketamine	B-Chemical
,	O
a	O
unique	O
anesthetic	O
,	O
for	O
emergency	O
-	O
department	O
procedures	O
requiring	O
sedation	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	T-0
to	T-0
examine	T-0
the	O
safety	O
and	O
efficacy	T-2
of	T-2
ketamine	B-Chemical
for	T-3
sedation	T-3
in	T-1
the	T-1
treatment	T-1
of	O
children	O
'	O
s	O
fractures	O
in	O
the	O
emergency	O
department	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
safety	O
and	O
efficacy	O
of	O
ketamine	O
for	O
sedation	O
in	O
the	O
treatment	O
of	T-0
children	O
'	O
s	O
fractures	B-Disease
in	O
the	O
emergency	O
department	O
.	T-0

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5	O
.	O
3	O
years	O
;	O
range	O
,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	O
closed	T-2
reduction	T-2
of	O
an	O
isolated	T-3
fracture	B-Disease
or	O
dislocation	T-1
in	O
the	O
emergency	O
department	O
at	O
a	O
level	O
-	O
I	O
trauma	O
center	O
were	O
prospectively	O
evaluated	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5	O
.	O
3	O
years	O
;	O
range	O
,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	T-1
closed	O
reduction	O
of	O
an	O
isolated	O
fracture	T-0
or	T-0
dislocation	B-Disease
in	T-2
the	T-2
emergency	T-2
department	T-2
at	O
a	O
level	O
-	O
I	O
trauma	O
center	O
were	O
prospectively	O
evaluated	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5	O
.	O
3	O
years	O
;	O
range	O
,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	O
closed	O
reduction	O
of	O
an	O
isolated	O
fracture	O
or	O
dislocation	O
in	O
the	O
emergency	O
department	O
at	O
a	O
level	T-0
-	T-0
I	T-0
trauma	B-Disease
center	O
were	O
prospectively	O
evaluated	O
.	O

Ketamine	B-Chemical
hydrochloride	I-Chemical
was	T-0
administered	T-0
intravenously	O
(	O
at	O
a	O
dose	O
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
ninety	O
-	O
nine	O
of	O
the	O
patients	O
and	O
intramuscularly	O
(	O
at	O
a	O
dose	O
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
in	O
the	O
other	O
fifteen	O
.	O

Any	T-0
pain	B-Disease
during	T-1
the	O
reduction	O
was	O
rated	O
by	O
the	O
orthopaedic	O
surgeon	O
treating	O
the	O
patient	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	O
Scale	O
(	O
CHEOPS	O
)	O
.	O

Any	O
pain	O
during	O
the	O
reduction	T-0
was	O
rated	O
by	O
the	O
orthopaedic	O
surgeon	O
treating	O
the	O
patient	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	B-Disease
Scale	O
(	O
CHEOPS	O
)	O
.	O

RESULTS	O
:	O
The	O
average	O
time	O
from	O
intravenous	O
administration	T-0
of	T-0
ketamine	B-Chemical
to	O
manipulation	O
of	O
the	O
fracture	O
or	O
dislocation	O
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
minutes	O
)	O
,	O
and	O
the	O
average	O
time	O
from	O
intramuscular	O
administration	O
to	O
manipulation	T-1
was	O
four	O
minutes	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutes	O
)	O
.	O

RESULTS	O
:	O
The	O
average	O
time	O
from	O
intravenous	O
administration	O
of	O
ketamine	O
to	O
manipulation	T-1
of	T-1
the	T-0
fracture	B-Disease
or	O
dislocation	O
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
minutes	O
)	O
,	O
and	O
the	O
average	O
time	O
from	O
intramuscular	O
administration	O
to	O
manipulation	O
was	O
four	O
minutes	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutes	O
)	O
.	O

RESULTS	O
:	O
The	O
average	O
time	O
from	O
intravenous	O
administration	O
of	O
ketamine	O
to	O
manipulation	T-1
of	T-1
the	O
fracture	O
or	T-0
dislocation	B-Disease
was	O
one	O
minute	O
and	O
thirty	O
-	O
six	O
seconds	O
(	O
range	O
,	O
twenty	O
seconds	O
to	O
five	O
minutes	O
)	O
,	O
and	O
the	O
average	O
time	O
from	O
intramuscular	O
administration	O
to	O
manipulation	O
was	O
four	O
minutes	O
and	O
forty	O
-	O
two	O
seconds	O
(	O
range	O
,	O
sixty	O
seconds	O
to	O
fifteen	O
minutes	O
)	O
.	O

The	O
average	O
score	O
according	T-0
to	T-0
the	O
Children	O
'	O
s	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	B-Disease
Scale	T-2
was	O
6	O
.	O
4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	T-1
minimal	O
or	O
no	O
pain	O
during	O
fracture	O
reduction	O
.	O

The	O
average	O
score	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	O
Scale	O
was	O
6	O
.	O
4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	T-0
minimal	O
or	O
no	O
pain	B-Disease
during	O
fracture	O
reduction	O
.	O

The	O
average	O
score	O
according	O
to	O
the	O
Children	O
'	O
s	O
Hospital	O
of	O
Eastern	O
Ontario	O
Pain	O
Scale	O
was	O
6	O
.	O
4	O
points	O
(	O
range	O
,	O
5	O
to	O
10	O
points	O
)	O
,	O
reflecting	O
minimal	T-2
or	T-2
no	T-2
pain	T-2
during	T-0
fracture	B-Disease
reduction	T-1
.	O

Adequate	O
fracture	B-Disease
reduction	T-0
was	O
obtained	O
in	O
111	O
of	O
the	O
children	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	B-Disease
(	O
thirteen	O
patients	O
)	O
,	O
emesis	O
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	O
)	O
,	O
clumsiness	O
(	O
evident	O
as	O
ataxic	O
movements	O
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	O
reaction	T-0
(	O
one	O
patient	O
)	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	O
(	T-0
thirteen	T-0
patients	T-0
)	T-0
,	T-0
emesis	B-Disease
(	T-1
eight	T-1
of	T-1
the	T-1
thirteen	T-1
patients	T-1
with	T-1
nausea	T-1
)	T-1
,	O
clumsiness	O
(	O
evident	O
as	O
ataxic	O
movements	O
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	O
reaction	T-2
(	O
one	O
patient	O
)	O
.	O

Minor	O
side	O
effects	O
included	T-1
nausea	O
(	O
thirteen	O
patients	O
)	O
,	O
emesis	O
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	B-Disease
)	O
,	O
clumsiness	O
(	O
evident	O
as	O
ataxic	O
movements	O
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	O
reaction	T-0
(	O
one	O
patient	O
)	O
.	O

Minor	O
side	O
effects	O
included	T-1
nausea	O
(	O
thirteen	O
patients	O
)	O
,	O
emesis	O
(	T-2
eight	T-2
of	T-2
the	T-2
thirteen	T-2
patients	T-2
with	T-2
nausea	T-2
)	T-2
,	T-2
clumsiness	B-Disease
(	T-3
evident	T-3
as	T-3
ataxic	T-3
movements	T-3
in	T-3
ten	T-3
patients	T-3
)	T-3
,	O
and	O
dysphoric	O
reaction	T-0
(	O
one	O
patient	O
)	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	O
(	O
thirteen	O
patients	O
)	O
,	O
emesis	O
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	O
)	O
,	O
clumsiness	O
(	O
evident	T-0
as	T-0
ataxic	B-Disease
movements	I-Disease
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	O
reaction	T-1
(	O
one	O
patient	O
)	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	O
(	O
thirteen	O
patients	O
)	O
,	O
emesis	O
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	O
)	O
,	O
clumsiness	O
(	O
evident	O
as	O
ataxic	O
movements	O
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	B-Disease
reaction	I-Disease
(	T-0
one	T-0
patient	T-0
)	T-0
.	O

No	O
long	O
-	O
term	O
sequelae	O
were	O
noted	O
,	O
and	O
no	T-0
patients	T-0
had	T-0
hallucinations	B-Disease
or	O
nightmares	O
.	O

CONCLUSIONS	O
:	O
Ketamine	B-Chemical
reliably	O
,	O
safely	O
,	O
and	O
quickly	O
provided	T-0
adequate	O
sedation	T-1
to	T-1
effectively	O
facilitate	T-2
the	T-2
reduction	T-2
of	T-2
children	O
'	O
s	O
fractures	O
in	O
the	O
emergency	O
department	O
at	O
our	O
institution	O
.	O

CONCLUSIONS	O
:	O
Ketamine	O
reliably	O
,	O
safely	O
,	O
and	O
quickly	O
provided	O
adequate	O
sedation	O
to	O
effectively	O
facilitate	O
the	O
reduction	T-0
of	T-0
children	O
'	O
s	O
fractures	B-Disease
in	O
the	O
emergency	O
department	O
at	O
our	O
institution	O
.	O

Ketamine	B-Chemical
should	T-0
only	T-0
be	T-1
used	T-1
in	T-1
an	O
environment	O
such	O
as	O
the	O
emergency	O
department	O
,	O
where	O
proper	O
one	O
-	O
on	O
-	O
one	O
monitoring	O
is	O
used	O
and	O
board	O
-	O
certified	O
physicians	O
skilled	O
in	O
airway	O
management	O
are	O
directly	O
involved	T-2
in	O
the	O
care	O
of	O
the	O
patient	O
.	O

Cyclosporine	B-Chemical
and	O
tacrolimus	O
-	O
associated	T-0
thrombotic	O
microangiopathy	O
.	O

Cyclosporine	O
and	T-1
tacrolimus	B-Chemical
-	O
associated	T-0
thrombotic	O
microangiopathy	O
.	O

Cyclosporine	O
and	O
tacrolimus	O
-	T-1
associated	T-1
thrombotic	B-Disease
microangiopathy	I-Disease
.	O

The	O
development	T-2
of	T-2
thrombotic	B-Disease
microangiopathy	I-Disease
(	O
TMA	O
)	O
associated	O
with	O
the	O
use	T-1
of	T-1
cyclosporine	O
has	O
been	O
well	O
documented	T-0
.	O

The	O
development	T-0
of	T-0
thrombotic	O
microangiopathy	O
(	O
TMA	B-Disease
)	O
associated	T-1
with	T-1
the	O
use	O
of	O
cyclosporine	O
has	O
been	O
well	O
documented	O
.	O

The	O
development	O
of	O
thrombotic	O
microangiopathy	O
(	O
TMA	O
)	O
associated	T-1
with	T-1
the	T-1
use	T-1
of	T-1
cyclosporine	B-Chemical
has	O
been	O
well	O
documented	O
.	O

Treatments	O
have	O
included	O
discontinuation	O
or	O
reduction	T-1
of	T-1
cyclosporine	B-Chemical
dose	T-2
with	O
or	O
without	O
concurrent	O
plasma	O
exchange	T-0
,	O
plasma	O
infusion	O
,	O
anticoagulation	O
,	O
and	O
intravenous	O
immunoglobulin	O
G	O
infusion	O
.	O

The	O
last	O
decade	O
has	O
seen	O
the	O
emergence	T-0
of	T-0
tacrolimus	B-Chemical
as	T-1
a	T-1
potent	T-1
immunosuppressive	O
agent	O
with	O
mechanisms	O
of	O
action	O
virtually	O
identical	O
to	O
those	O
of	O
cyclosporine	O
.	O

The	O
last	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
tacrolimus	O
as	O
a	O
potent	O
immunosuppressive	O
agent	O
with	O
mechanisms	O
of	O
action	O
virtually	T-0
identical	T-0
to	T-0
those	O
of	O
cyclosporine	B-Chemical
.	O

As	O
a	O
result	O
,	O
switching	T-0
to	T-0
tacrolimus	B-Chemical
has	O
been	O
reported	O
to	O
be	O
a	O
viable	O
therapeutic	O
option	O
in	O
the	O
setting	O
of	O
cyclosporine	O
-	O
induced	O
TMA	O
.	O

As	O
a	O
result	O
,	O
switching	O
to	O
tacrolimus	O
has	O
been	O
reported	O
to	O
be	O
a	O
viable	O
therapeutic	O
option	O
in	O
the	T-2
setting	T-2
of	T-2
cyclosporine	B-Chemical
-	O
induced	T-1
TMA	O
.	O

As	O
a	O
result	O
,	O
switching	O
to	O
tacrolimus	O
has	O
been	O
reported	O
to	O
be	O
a	O
viable	O
therapeutic	T-0
option	T-0
in	O
the	O
setting	O
of	O
cyclosporine	T-2
-	T-2
induced	T-2
TMA	B-Disease
.	O

With	O
the	O
more	O
widespread	O
application	T-1
of	T-1
tacrolimus	B-Chemical
in	O
organ	O
transplantation	O
,	O
tacrolimus	O
-	O
associated	T-0
TMA	O
has	O
also	O
been	O
recognized	O
.	O

With	O
the	O
more	O
widespread	O
application	T-0
of	T-0
tacrolimus	O
in	O
organ	O
transplantation	O
,	O
tacrolimus	B-Chemical
-	O
associated	T-1
TMA	O
has	O
also	O
been	O
recognized	T-2
.	T-2

With	O
the	O
more	O
widespread	O
application	T-0
of	T-0
tacrolimus	O
in	O
organ	O
transplantation	O
,	O
tacrolimus	O
-	O
associated	T-1
TMA	B-Disease
has	T-2
also	T-2
been	O
recognized	O
.	O

However	O
,	O
literature	O
regarding	O
the	O
incidence	O
of	O
the	O
recurrence	T-0
of	T-0
TMA	B-Disease
in	T-1
patients	T-1
exposed	O
sequentially	O
to	O
cyclosporine	O
and	O
tacrolimus	O
is	O
limited	O
.	O

However	O
,	O
literature	O
regarding	O
the	O
incidence	O
of	O
the	O
recurrence	T-0
of	T-0
TMA	T-0
in	O
patients	O
exposed	T-1
sequentially	T-1
to	T-1
cyclosporine	B-Chemical
and	O
tacrolimus	O
is	O
limited	O
.	O

However	O
,	O
literature	O
regarding	O
the	O
incidence	O
of	O
the	O
recurrence	O
of	O
TMA	O
in	O
patients	O
exposed	O
sequentially	O
to	O
cyclosporine	O
and	T-0
tacrolimus	B-Chemical
is	T-1
limited	T-1
.	O

We	O
report	O
a	O
case	O
of	O
a	O
living	O
donor	O
renal	O
transplant	O
recipient	O
who	T-2
developed	T-2
cyclosporine	B-Chemical
-	O
induced	O
TMA	O
that	O
responded	O
to	O
the	O
withdrawal	T-1
of	O
cyclosporine	O
in	O
conjunction	O
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	O
replacement	O
therapy	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
living	O
donor	O
renal	O
transplant	O
recipient	O
who	O
developed	O
cyclosporine	O
-	O
induced	T-0
TMA	B-Disease
that	O
responded	T-1
to	O
the	O
withdrawal	O
of	O
cyclosporine	O
in	O
conjunction	O
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	O
replacement	O
therapy	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
living	O
donor	O
renal	O
transplant	O
recipient	O
who	O
developed	O
cyclosporine	O
-	O
induced	T-0
TMA	O
that	O
responded	T-1
to	O
the	O
withdrawal	T-3
of	T-3
cyclosporine	B-Chemical
in	O
conjunction	O
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	O
replacement	O
therapy	O
.	O

Introduction	T-0
of	T-0
tacrolimus	B-Chemical
as	T-1
an	T-1
alternative	T-1
immunosuppressive	O
agent	O
resulted	O
in	O
the	O
recurrence	O
of	O
TMA	O
and	O
the	O
subsequent	O
loss	O
of	O
the	O
renal	O
allograft	O
.	O

Introduction	O
of	O
tacrolimus	O
as	O
an	O
alternative	O
immunosuppressive	O
agent	O
resulted	O
in	O
the	O
recurrence	T-1
of	O
TMA	B-Disease
and	O
the	O
subsequent	O
loss	O
of	O
the	O
renal	O
allograft	O
.	O

Patients	O
who	O
are	O
switched	O
from	O
cyclosporine	B-Chemical
to	O
tacrolimus	O
or	O
vice	O
versa	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
signs	O
and	O
symptoms	O
of	O
recurrent	T-0
TMA	O
.	O

Patients	O
who	O
are	O
switched	T-0
from	O
cyclosporine	O
to	T-1
tacrolimus	B-Chemical
or	O
vice	O
versa	O
should	O
be	O
closely	O
monitored	T-2
for	O
the	O
signs	O
and	O
symptoms	O
of	O
recurrent	O
TMA	O
.	O

Patients	O
who	O
are	O
switched	O
from	O
cyclosporine	O
to	O
tacrolimus	O
or	O
vice	O
versa	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
signs	T-0
and	T-0
symptoms	T-0
of	O
recurrent	T-1
TMA	B-Disease
.	O

Analgesic	O
effect	T-0
of	T-0
intravenous	T-0
ketamine	B-Chemical
in	T-1
cancer	T-1
patients	O
on	O
morphine	O
therapy	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Analgesic	O
effect	T-0
of	T-0
intravenous	O
ketamine	O
in	O
cancer	B-Disease
patients	T-1
on	O
morphine	O
therapy	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Analgesic	O
effect	O
of	O
intravenous	O
ketamine	O
in	O
cancer	O
patients	T-0
on	T-0
morphine	B-Chemical
therapy	T-1
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Pain	B-Disease
not	T-1
responsive	T-1
to	T-1
morphine	O
is	O
often	O
problematic	O
.	O

Pain	O
not	T-1
responsive	T-1
to	T-1
morphine	B-Chemical
is	O
often	O
problematic	O
.	O

Animal	O
and	O
clinical	O
studies	T-1
have	O
suggested	T-2
that	T-2
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	O
)	O
antagonists	O
,	O
such	O
as	O
ketamine	O
,	O
may	O
be	O
effective	O
in	O
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	B-Chemical
)	O
antagonists	T-0
,	O
such	O
as	O
ketamine	O
,	O
may	O
be	O
effective	O
in	O
improving	T-1
opioid	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
antagonists	O
,	O
such	T-1
as	T-1
ketamine	B-Chemical
,	T-0
may	T-0
be	T-0
effective	T-0
in	O
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Animal	T-2
and	T-2
clinical	T-2
studies	T-2
have	O
suggested	O
that	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
antagonists	O
,	O
such	O
as	O
ketamine	O
,	O
may	O
be	O
effective	T-3
in	T-3
improving	T-3
opioid	O
analgesia	O
in	T-1
difficult	O
pain	B-Disease
syndromes	T-0
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
antagonists	O
,	O
such	O
as	O
ketamine	O
,	O
may	T-0
be	T-0
effective	T-0
in	T-0
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	B-Disease
pain	I-Disease
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	B-Chemical
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	T-0
to	T-0
10	O
cancer	O
patients	O
whose	O
pain	O
was	O
unrelieved	O
by	O
morphine	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	O
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cancer	B-Disease
patients	T-0
whose	O
pain	O
was	O
unrelieved	O
by	O
morphine	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	O
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cancer	O
patients	T-2
whose	T-2
pain	B-Disease
was	T-1
unrelieved	T-1
by	O
morphine	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	O
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	T-1
to	T-1
10	O
cancer	O
patients	O
whose	O
pain	O
was	O
unrelieved	T-0
by	T-0
morphine	B-Chemical
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Pain	B-Disease
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	T-1
scale	T-1
;	O
nausea	O
and	O
vomiting	O
,	O
drowsiness	O
,	O
confusion	O
,	O
and	O
dry	O
mouth	O
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	T-2
of	T-2
drugs	T-2
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

Pain	O
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	O
;	O
nausea	B-Disease
and	O
vomiting	O
,	O
drowsiness	O
,	O
confusion	O
,	O
and	O
dry	O
mouth	O
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	T-0
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

Pain	O
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	O
;	O
nausea	O
and	O
vomiting	B-Disease
,	O
drowsiness	O
,	O
confusion	O
,	O
and	O
dry	O
mouth	O
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	T-0
of	T-0
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

Pain	T-2
intensity	T-2
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	O
;	O
nausea	O
and	O
vomiting	O
,	O
drowsiness	T-0
,	T-0
confusion	B-Disease
,	T-1
and	T-1
dry	T-1
mouth	T-1
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

Pain	O
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	O
;	O
nausea	O
and	O
vomiting	O
,	O
drowsiness	O
,	O
confusion	O
,	O
and	T-1
dry	B-Disease
mouth	I-Disease
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	T-0

Ketamine	B-Chemical
,	O
but	T-0
not	T-0
saline	O
solution	O
,	O
significantly	T-1
reduced	T-1
the	O
pain	O
intensity	O
in	O
almost	O
all	O
the	O
patients	O
at	O
both	O
doses	O
.	O

Ketamine	O
,	O
but	O
not	O
saline	O
solution	O
,	O
significantly	O
reduced	T-1
the	T-1
pain	B-Disease
intensity	T-2
in	T-2
almost	T-2
all	T-2
the	T-2
patients	T-2
at	O
both	O
doses	O
.	O

Hallucinations	B-Disease
occurred	T-1
in	T-1
4	O
patients	O
,	O
and	O
an	O
unpleasant	O
sensation	O
(	O
"	O
empty	O
head	O
"	O
)	O
was	O
also	O
reported	O
by	O
2	O
patients	O
.	O

These	O
episodes	O
reversed	T-0
after	O
the	O
administration	T-2
of	T-2
diazepam	B-Chemical
1	O
mg	O
intravenously	T-1
.	O

Significant	O
increases	O
in	O
drowsiness	O
were	O
reported	O
in	O
patients	O
treated	T-0
with	T-0
ketamine	B-Chemical
in	O
both	O
groups	O
and	O
were	O
more	O
marked	O
with	O
ketamine	O
0	O
.	O
50	O
mg	O
/	O
kg	O
.	O

Significant	O
increases	O
in	O
drowsiness	O
were	O
reported	O
in	O
patients	O
treated	O
with	O
ketamine	O
in	O
both	O
groups	O
and	O
were	O
more	O
marked	T-1
with	T-1
ketamine	B-Chemical
0	T-0
.	T-0
50	T-0
mg	T-0
/	T-0
kg	T-0
.	O

A	O
significant	O
difference	O
in	O
MMSE	O
was	O
observed	T-2
at	O
T30	O
in	O
patients	T-0
who	T-0
received	T-0
0	O
.	O
50	T-1
mg	T-1
/	T-1
kg	T-1
of	T-1
ketamine	B-Chemical
.	O

Ketamine	B-Chemical
can	T-0
improve	T-0
morphine	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Ketamine	O
can	O
improve	T-1
morphine	B-Chemical
analgesia	T-0
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Ketamine	O
can	O
improve	T-1
morphine	O
analgesia	O
in	O
difficult	O
pain	B-Disease
syndromes	T-0
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Ketamine	O
can	T-0
improve	T-0
morphine	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	B-Disease
pain	I-Disease
.	O

This	O
observation	T-0
should	O
be	O
tested	O
in	O
studies	T-1
of	O
prolonged	T-2
ketamine	B-Chemical
administration	T-3
.	O

Paclitaxel	B-Chemical
,	T-1
cisplatin	T-1
,	O
and	O
gemcitabine	O
combination	O
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	T-0
in	O
metastatic	O
nonsmall	O
cell	O
lung	O
carcinoma	O
.	O

Paclitaxel	O
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	O
combination	O
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	T-0
in	O
metastatic	O
nonsmall	O
cell	O
lung	O
carcinoma	O
.	O

Paclitaxel	T-0
,	O
cisplatin	T-1
,	O
and	O
gemcitabine	B-Chemical
combination	O
chemotherapy	T-2
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	O
in	O
metastatic	O
nonsmall	O
cell	O
lung	O
carcinoma	O
.	O

Paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
combination	O
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	T-0
in	O
metastatic	T-1
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
.	O

BACKGROUND	O
:	O
Cisplatin	B-Chemical
-	O
based	T-1
chemotherapy	T-1
combinations	O
improve	T-0
quality	O
of	O
life	O
and	O
survival	O
in	O
advanced	O
nonsmall	O
cell	O
lung	O
carcinoma	O
(	O
NSCLC	O
)	O
.	O

BACKGROUND	O
:	O
Cisplatin	O
-	O
based	O
chemotherapy	T-2
combinations	O
improve	T-1
quality	O
of	O
life	O
and	O
survival	O
in	T-0
advanced	O
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
(	O
NSCLC	O
)	O
.	O

BACKGROUND	O
:	O
Cisplatin	O
-	O
based	O
chemotherapy	O
combinations	O
improve	T-1
quality	O
of	O
life	O
and	O
survival	O
in	O
advanced	O
nonsmall	O
cell	O
lung	T-0
carcinoma	T-0
(	O
NSCLC	B-Disease
)	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	B-Disease
of	O
a	O
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
combination	T-1
to	O
treat	T-0
metastatic	O
NSCLC	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	T-1
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	T-2
of	T-2
a	T-2
paclitaxel	B-Chemical
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
combination	T-3
to	O
treat	O
metastatic	O
NSCLC	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	T-2
determine	T-2
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	O
of	O
a	O
paclitaxel	O
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	O
combination	O
to	T-1
treat	T-1
metastatic	O
NSCLC	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	T-0
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	O
of	O
a	O
paclitaxel	O
,	O
cisplatin	T-1
,	T-1
and	T-1
gemcitabine	B-Chemical
combination	T-2
to	O
treat	O
metastatic	O
NSCLC	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	O
of	O
a	O
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
combination	O
to	T-1
treat	T-1
metastatic	T-1
NSCLC	B-Disease
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	T-1
IV	T-1
NSCLC	B-Disease
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
2	O
were	O
treated	T-0
with	T-0
a	O
combination	O
of	O
paclitaxel	O
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	O
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	O
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
2	O
were	O
treated	O
with	O
a	O
combination	T-1
of	T-1
paclitaxel	B-Chemical
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	T-0
intravenously	T-0
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	O
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	O
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
2	O
were	O
treated	O
with	O
a	O
combination	O
of	O
paclitaxel	O
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	B-Chemical
(	T-1
120	T-1
mg	T-1
/	T-1
m	T-1
(	T-1
2	T-1
)	T-1
given	T-0
intravenously	T-0
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	O
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
2	O
were	O
treated	T-2
with	T-2
a	O
combination	O
of	O
paclitaxel	O
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	O
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	B-Chemical
(	T-1
800	T-1
mg	T-1
/	T-1
m	T-1
(	T-1
2	T-1
)	T-1
given	T-0
intravenously	T-0
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O

Although	O
responding	O
patients	O
were	O
scheduled	O
to	T-0
receive	T-0
consolidation	O
radiotherapy	O
and	O
24	O
patients	O
received	O
preplanned	O
second	O
-	O
line	O
chemotherapy	O
after	T-2
disease	T-2
progression	T-2
,	O
the	T-3
response	T-3
and	O
toxicity	B-Disease
rates	O
reported	O
refer	O
only	O
to	O
the	O
chemotherapy	O
regimen	O
given	O
.	O

RESULTS	O
:	O
All	O
the	O
patients	T-0
were	O
examined	T-1
for	T-1
toxicity	B-Disease
;	O
34	O
were	O
examinable	O
for	O
response	O
.	O

After	O
154	O
courses	T-1
of	T-1
therapy	T-1
,	O
the	O
median	T-2
dose	T-2
intensity	T-2
was	O
131	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	T-0
paclitaxel	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
117	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
cisplatin	O
(	O
97	O
.	O
3	O
%	O
)	O
,	O
and	O
1378	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
gemcitabine	O
(	O
86	O
.	O
2	O
%	O
)	O
.	O

After	O
154	O
courses	O
of	O
therapy	O
,	O
the	O
median	O
dose	O
intensity	O
was	O
131	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
paclitaxel	O
(	O
97	O
.	O
3	O
%	O
)	O
,	O
117	T-0
mg	T-0
/	T-0
m	T-0
(	T-0
2	T-0
)	T-0
for	O
cisplatin	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
and	O
1378	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
gemcitabine	O
(	O
86	O
.	O
2	O
%	O
)	O
.	O

After	O
154	O
courses	T-1
of	T-1
therapy	T-1
,	O
the	O
median	O
dose	T-0
intensity	T-0
was	T-0
131	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
paclitaxel	O
(	O
97	O
.	O
3	O
%	O
)	O
,	O
117	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
cisplatin	O
(	O
97	O
.	O
3	O
%	O
)	O
,	O
and	O
1378	T-2
mg	T-2
/	T-2
m	T-2
(	T-2
2	T-2
)	T-2
for	T-2
gemcitabine	B-Chemical
(	O
86	O
.	O
2	O
%	O
)	O
.	O

World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	B-Disease
and	T-0
thrombocytopenia	O
occurred	T-1
in	T-1
39	O
.	O
9	O
%	O
and	O
11	O
.	O
4	O
%	O
of	O
patients	O
,	O
respectively	O
.	O

World	T-1
Health	T-1
Organization	T-1
Grade	O
3	O
-	O
4	O
neutropenia	T-2
and	O
thrombocytopenia	B-Disease
occurred	T-0
in	O
39	O
.	O
9	O
%	O
and	O
11	O
.	O
4	O
%	O
of	O
patients	T-3
,	O
respectively	O
.	O

There	O
was	O
one	O
treatment	T-0
-	T-0
related	T-1
death	B-Disease
.	O

Nonhematologic	T-1
toxicities	B-Disease
were	T-0
mild	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	T-0
of	T-0
paclitaxel	B-Chemical
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
is	O
well	T-1
tolerated	T-1
and	O
shows	O
high	T-2
activity	T-2
in	O
metastatic	O
NSCLC	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	T-1
of	T-1
paclitaxel	O
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	O
is	O
well	T-0
tolerated	T-0
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	T-2
of	T-2
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	B-Chemical
is	T-0
well	T-0
tolerated	T-1
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
is	O
well	O
tolerated	O
and	O
shows	T-2
high	O
activity	O
in	T-0
metastatic	T-1
NSCLC	B-Disease
.	O

This	O
treatment	O
merits	T-0
further	O
comparison	O
with	O
other	O
cisplatin	B-Chemical
-	O
based	O
regimens	O
.	O

Serotonergic	O
antidepressants	O
and	T-0
urinary	B-Disease
incontinence	I-Disease
.	O

Many	O
new	O
serotonergic	B-Chemical
antidepressants	I-Chemical
have	O
been	O
introduced	T-0
over	O
the	O
past	O
decade	O
.	O

Although	O
urinary	B-Disease
incontinence	I-Disease
is	T-1
listed	T-1
as	T-1
one	O
side	O
effect	O
of	O
these	O
drugs	O
in	O
their	O
package	O
inserts	O
there	O
is	O
only	O
one	O
report	O
in	O
the	O
literature	O
.	O

This	O
concerns	O
2	O
male	O
patients	O
who	O
experienced	T-0
incontinence	B-Disease
while	O
taking	O
venlafaxine	O
.	O

This	O
concerns	O
2	O
male	O
patients	O
who	O
experienced	T-0
incontinence	O
while	T-1
taking	T-1
venlafaxine	B-Chemical
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	T-0
incontinence	B-Disease
secondary	T-1
to	T-1
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
paroxetine	O
and	O
sertraline	O
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	T-0
incontinence	T-0
secondary	O
to	T-1
the	T-1
selective	T-1
serotonin	B-Chemical
reuptake	O
inhibitors	O
paroxetine	O
and	O
sertraline	O
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	T-0
developed	T-0
incontinence	O
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
paroxetine	B-Chemical
and	T-1
sertraline	O
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	T-1
incontinence	O
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
paroxetine	T-0
and	T-0
sertraline	B-Chemical
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	T-2
effect	T-2
on	O
venlafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
2	O
female	O
patients	O
who	O
developed	O
incontinence	O
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
paroxetine	O
and	O
sertraline	O
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	T-1
effect	T-1
on	T-1
venlafaxine	B-Chemical
.	O

In	O
2	O
of	O
the	O
3	O
cases	O
the	T-3
patients	T-3
were	O
also	O
taking	T-1
lithium	B-Chemical
carbonate	I-Chemical
and	T-2
beta	O
-	O
blockers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	T-0
to	O
the	O
incontinence	O
.	O

In	O
2	O
of	O
the	O
3	O
cases	O
the	O
patients	O
were	O
also	O
taking	O
lithium	O
carbonate	O
and	O
beta	O
-	O
blockers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	T-1
to	T-1
the	T-1
incontinence	B-Disease
.	O

Animal	O
studies	O
suggest	T-3
that	T-3
incontinence	O
secondary	T-0
to	T-0
serotonergic	B-Chemical
antidepressants	I-Chemical
could	T-2
be	T-2
mediated	T-1
by	T-1
the	O
5HT4	O
receptors	O
found	O
on	O
the	O
bladder	O
.	O

Acute	O
cocaine	B-Chemical
-	O
induced	T-0
seizures	O
:	O
differential	O
sensitivity	O
of	O
six	O
inbred	O
mouse	O
strains	O
.	O

Acute	T-0
cocaine	O
-	O
induced	T-1
seizures	B-Disease
:	O
differential	O
sensitivity	O
of	O
six	O
inbred	O
mouse	O
strains	O
.	O

Mature	O
male	O
and	O
female	O
mice	O
from	O
six	O
inbred	O
stains	O
were	O
tested	O
for	O
susceptibility	T-0
to	O
behavioral	O
seizures	B-Disease
induced	T-1
by	O
a	O
single	O
injection	O
of	O
cocaine	O
.	O

Mature	O
male	O
and	O
female	O
mice	O
from	O
six	O
inbred	O
stains	O
were	O
tested	O
for	O
susceptibility	O
to	O
behavioral	O
seizures	O
induced	T-0
by	O
a	O
single	O
injection	T-1
of	T-1
cocaine	B-Chemical
.	O

Cocaine	B-Chemical
was	T-0
injected	T-0
ip	O
over	O
a	O
range	O
of	O
doses	O
(	O
50	O
-	O
100	O
mg	O
/	O
kg	O
)	O
and	O
behavior	O
was	O
monitored	O
for	O
20	O
minutes	O
.	O

Seizure	O
end	O
points	O
included	O
latency	T-0
to	O
forelimb	O
or	O
hindlimb	O
clonus	O
,	O
latency	T-2
to	O
clonic	O
running	O
seizure	B-Disease
and	O
latency	T-1
to	O
jumping	O
bouncing	O
seizure	O
.	O

Seizure	O
end	O
points	O
included	O
latency	O
to	O
forelimb	O
or	O
hindlimb	O
clonus	O
,	O
latency	O
to	O
clonic	O
running	O
seizure	O
and	O
latency	T-0
to	O
jumping	O
bouncing	O
seizure	B-Disease
.	O

Additionally	O
,	O
levels	O
of	O
cocaine	B-Chemical
determined	T-0
in	T-0
hippocampus	O
and	O
cortex	O
were	O
not	O
different	O
between	O
sensitive	O
and	O
resistant	O
strains	O
.	O

Additional	O
studies	O
of	O
these	O
murine	O
strains	O
may	O
be	O
useful	O
for	O
investigating	O
genetic	O
influences	T-1
on	O
cocaine	B-Chemical
-	O
induced	T-2
seizures	O
.	O

Additional	O
studies	T-0
of	O
these	O
murine	O
strains	T-1
may	O
be	O
useful	O
for	O
investigating	O
genetic	T-2
influences	T-2
on	O
cocaine	T-4
-	T-4
induced	T-4
seizures	B-Disease
.	O

Hypotension	B-Disease
following	T-1
the	T-1
initiation	T-1
of	T-1
tizanidine	O
in	O
a	O
patient	O
treated	O
with	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	O
.	O

Hypotension	O
following	O
the	O
initiation	T-0
of	T-0
tizanidine	B-Chemical
in	T-1
a	T-1
patient	T-1
treated	O
with	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	O
.	O

Hypotension	O
following	O
the	O
initiation	O
of	O
tizanidine	O
in	O
a	O
patient	O
treated	T-0
with	T-1
an	T-1
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	O
.	O

Hypotension	O
following	O
the	O
initiation	O
of	O
tizanidine	O
in	O
a	O
patient	O
treated	T-1
with	T-1
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
for	O
chronic	T-0
hypertension	B-Disease
.	O

Centrally	O
acting	O
alpha	O
-	O
2	O
adrenergic	O
agonists	O
are	O
one	O
of	O
several	O
pharmacologic	O
agents	O
used	O
in	O
the	O
treatment	T-2
of	T-2
spasticity	B-Disease
related	T-1
to	T-1
disorders	O
of	O
the	O
central	O
nervous	O
system	O
.	O

Centrally	O
acting	O
alpha	O
-	O
2	O
adrenergic	O
agonists	O
are	O
one	O
of	O
several	O
pharmacologic	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
spasticity	O
related	T-1
to	T-1
disorders	B-Disease
of	I-Disease
the	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
.	O

In	O
addition	O
to	O
their	O
effects	T-0
on	T-0
spasticity	B-Disease
,	T-1
certain	T-1
adverse	T-1
cardiorespiratory	O
effects	O
have	O
been	O
reported	O
.	O

Adults	O
chronically	O
treated	T-0
with	T-0
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitors	O
may	O
have	O
a	O
limited	O
ability	O
to	O
respond	O
to	O
hypotension	O
when	O
the	O
sympathetic	O
response	O
is	O
simultaneously	O
blocked	O
.	O

Adults	O
chronically	O
treated	O
with	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
may	O
have	O
a	O
limited	O
ability	O
to	O
respond	T-1
to	T-1
hypotension	B-Disease
when	T-0
the	T-0
sympathetic	T-0
response	T-0
is	O
simultaneously	O
blocked	O
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	T-0
with	T-0
lisinopril	B-Chemical
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	O
hypotension	O
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	O
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	T-1
with	T-1
lisinopril	O
,	O
an	O
angiotensin	B-Chemical
converting	T-2
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	T-3
hypotension	O
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	T-0
the	T-0
treatment	T-0
of	T-0
spasticity	O
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	T-0
control	T-0
hypertension	B-Disease
who	T-1
developed	T-1
hypotension	O
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	O
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	T-0
hypotension	B-Disease
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	O
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	T-0
with	T-0
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	O
hypotension	O
following	T-2
the	T-2
addition	T-2
of	T-2
tizanidine	B-Chemical
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	O
.	O

The	O
authors	O
present	O
a	O
10	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	O
hypotension	O
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
2	O
agonist	O
,	O
for	O
the	T-1
treatment	T-1
of	T-1
spasticity	B-Disease
.	O

The	O
possible	O
interaction	T-1
of	O
tizanidine	B-Chemical
and	T-0
other	T-0
antihypertensive	O
agents	O
should	O
be	O
kept	O
in	O
mind	O
when	O
prescribing	O
therapy	O
to	O
treat	O
either	O
hypertension	O
or	O
spasticity	O
in	O
such	O
patients	O
.	O

The	O
possible	O
interaction	O
of	O
tizanidine	O
and	O
other	O
antihypertensive	O
agents	O
should	O
be	O
kept	O
in	O
mind	O
when	O
prescribing	O
therapy	O
to	T-0
treat	T-1
either	O
hypertension	B-Disease
or	O
spasticity	O
in	O
such	O
patients	O
.	O

The	O
possible	O
interaction	O
of	O
tizanidine	O
and	O
other	O
antihypertensive	O
agents	O
should	O
be	O
kept	O
in	O
mind	O
when	O
prescribing	O
therapy	O
to	O
treat	T-0
either	O
hypertension	O
or	O
spasticity	B-Disease
in	O
such	O
patients	O
.	O

Two	O
mouse	O
lines	O
selected	O
for	O
differential	O
sensitivities	T-1
to	T-1
beta	B-Chemical
-	I-Chemical
carboline	I-Chemical
-	O
induced	T-2
seizures	T-2
are	O
also	O
differentially	O
sensitive	O
to	O
various	O
pharmacological	O
effects	O
of	O
other	O
GABA	O
(	O
A	O
)	O
receptor	O
ligands	O
.	O

Two	O
mouse	O
lines	O
selected	O
for	O
differential	O
sensitivities	O
to	O
beta	O
-	O
carboline	O
-	O
induced	T-1
seizures	B-Disease
are	O
also	O
differentially	O
sensitive	O
to	O
various	O
pharmacological	O
effects	O
of	O
other	O
GABA	O
(	O
A	O
)	O
receptor	O
ligands	O
.	O

Two	O
mouse	O
lines	O
selected	O
for	O
differential	O
sensitivities	O
to	O
beta	O
-	O
carboline	O
-	O
induced	O
seizures	O
are	O
also	O
differentially	O
sensitive	O
to	O
various	O
pharmacological	O
effects	T-0
of	O
other	O
GABA	B-Chemical
(	O
A	O
)	O
receptor	O
ligands	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	B-Disease
induced	T-0
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
methyl	O
beta	O
-	O
carboline	O
-	O
3	O
-	O
carboxylate	O
(	O
beta	O
-	O
CCM	O
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
benzodiazepine	O
site	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	O
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	T-0
of	T-0
methyl	B-Chemical
beta	I-Chemical
-	I-Chemical
carboline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	T-1
beta	T-1
-	T-1
CCM	T-1
)	T-1
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
benzodiazepine	O
site	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	O
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	T-0
of	T-0
methyl	O
beta	O
-	O
carboline	O
-	O
3	O
-	O
carboxylate	O
(	O
beta	B-Chemical
-	I-Chemical
CCM	I-Chemical
)	O
,	O
an	T-1
inverse	T-1
agonist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
benzodiazepine	O
site	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	O
induced	T-1
by	T-1
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
methyl	O
beta	O
-	O
carboline	O
-	O
3	O
-	O
carboxylate	O
(	O
beta	O
-	O
CCM	O
)	O
,	O
an	O
inverse	T-3
agonist	T-3
of	T-3
the	O
GABA	B-Chemical
(	T-0
A	T-0
)	T-0
receptor	T-0
benzodiazepine	O
site	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	O
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
methyl	O
beta	O
-	O
carboline	O
-	O
3	O
-	O
carboxylate	O
(	O
beta	O
-	O
CCM	O
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
benzodiazepine	B-Chemical
site	T-0
.	O

Our	O
aim	O
was	O
to	O
characterize	O
both	O
lines	O
'	O
sensitivities	T-2
to	T-2
various	O
physiological	O
effects	O
of	O
other	O
ligands	O
of	T-0
the	T-0
GABA	B-Chemical
(	O
A	O
)	O
receptor	T-1
.	O

We	T-0
measured	T-0
diazepam	B-Chemical
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	O
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	O
-	O
and	O
pentylenetetrazol	O
-	O
induced	O
seizures	O
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

We	O
measured	O
diazepam	O
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	B-Chemical
-	O
induced	T-0
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	O
-	O
and	O
pentylenetetrazol	O
-	O
induced	O
seizures	O
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

We	O
measured	O
diazepam	O
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	O
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	B-Chemical
-	O
and	O
pentylenetetrazol	O
-	O
induced	T-0
seizures	O
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

We	O
measured	O
diazepam	O
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	O
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	O
-	O
and	O
pentylenetetrazol	B-Chemical
-	T-1
induced	T-1
seizures	O
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

We	O
measured	O
diazepam	O
-	O
induced	T-0
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	O
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	O
-	O
and	O
pentylenetetrazol	O
-	O
induced	T-1
seizures	B-Disease
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	T-1
sensitivities	T-1
of	O
BS	O
and	O
BR	O
lines	T-0
to	T-0
beta	B-Chemical
-	I-Chemical
CCM	I-Chemical
can	O
be	O
extended	O
to	O
diazepam	O
,	O
picrotoxin	O
,	O
and	O
pentylenetetrazol	O
,	O
suggesting	O
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	T-2
sensitivities	T-2
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	T-0
be	T-0
extended	T-3
to	O
diazepam	B-Chemical
,	O
picrotoxin	O
,	O
and	O
pentylenetetrazol	O
,	O
suggesting	T-1
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	O
be	O
extended	T-0
to	T-0
diazepam	O
,	O
picrotoxin	B-Chemical
,	O
and	T-1
pentylenetetrazol	O
,	O
suggesting	O
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	T-0
be	T-0
extended	T-0
to	T-0
diazepam	O
,	O
picrotoxin	O
,	O
and	O
pentylenetetrazol	B-Chemical
,	O
suggesting	T-1
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	O
be	O
extended	O
to	O
diazepam	O
,	O
picrotoxin	O
,	O
and	O
pentylenetetrazol	O
,	O
suggesting	T-1
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	T-0
the	T-0
GABA	B-Chemical
(	T-2
A	T-2
)	T-2
receptor	T-2
.	O

Propylthiouracil	B-Chemical
-	T-0
induced	T-0
perinuclear	O
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibody	O
-	O
positive	O
vasculitis	O
in	O
conjunction	O
with	O
pericarditis	O
.	O

Propylthiouracil	O
-	O
induced	T-1
perinuclear	O
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibody	T-0
-	T-0
positive	T-0
vasculitis	B-Disease
in	O
conjunction	O
with	O
pericarditis	O
.	O

Propylthiouracil	O
-	O
induced	T-0
perinuclear	O
-	O
staining	O
antineutrophil	O
cytoplasmic	O
autoantibody	O
-	O
positive	O
vasculitis	O
in	T-1
conjunction	T-1
with	T-1
pericarditis	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	T-0
case	T-0
of	T-0
propylthiouracil	B-Chemical
-	O
induced	T-1
vasculitis	O
manifesting	O
with	O
pericarditis	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
propylthiouracil	O
-	O
induced	T-1
vasculitis	B-Disease
manifesting	T-2
with	T-2
pericarditis	T-2
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
propylthiouracil	O
-	O
induced	O
vasculitis	O
manifesting	T-0
with	T-0
pericarditis	B-Disease
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	B-Disease
treated	T-1
with	O
propylthiouracil	O
in	O
whom	O
a	O
syndrome	O
of	O
pericarditis	O
,	O
fever	O
,	O
and	O
glomerulonephritis	O
developed	T-0
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	O
treated	T-0
with	T-0
propylthiouracil	B-Chemical
in	O
whom	O
a	O
syndrome	O
of	O
pericarditis	O
,	O
fever	O
,	O
and	O
glomerulonephritis	O
developed	O
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	O
treated	O
with	O
propylthiouracil	O
in	O
whom	O
a	O
syndrome	T-0
of	T-0
pericarditis	B-Disease
,	T-1
fever	T-1
,	O
and	O
glomerulonephritis	O
developed	O
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	O
treated	O
with	O
propylthiouracil	O
in	O
whom	O
a	O
syndrome	T-3
of	T-3
pericarditis	T-0
,	T-0
fever	B-Disease
,	T-1
and	T-1
glomerulonephritis	T-1
developed	T-2
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	O
treated	T-1
with	T-1
propylthiouracil	O
in	O
whom	O
a	O
syndrome	T-0
of	T-0
pericarditis	O
,	O
fever	O
,	O
and	O
glomerulonephritis	B-Disease
developed	T-2
.	O

RESULTS	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
had	T-0
a	T-0
febrile	T-0
illness	T-0
and	O
evidence	T-1
of	T-1
pericarditis	O
,	O
which	O
was	O
confirmed	T-2
by	O
biopsy	O
.	O

RESULTS	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
Graves	O
'	O
disease	T-0
had	T-0
a	T-0
febrile	B-Disease
illness	I-Disease
and	O
evidence	T-1
of	T-1
pericarditis	O
,	O
which	O
was	O
confirmed	O
by	O
biopsy	O
.	O

RESULTS	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
Graves	O
'	O
disease	O
had	O
a	O
febrile	O
illness	O
and	O
evidence	T-0
of	T-0
pericarditis	B-Disease
,	O
which	O
was	O
confirmed	T-1
by	O
biopsy	O
.	O

Propylthiouracil	B-Chemical
therapy	T-0
was	O
withdrawn	O
,	O
and	O
she	O
was	O
treated	O
with	O
a	O
1	O
-	O
month	O
course	O
of	O
prednisone	O
,	O
which	O
alleviated	O
her	O
symptoms	O
.	O

Propylthiouracil	O
therapy	O
was	O
withdrawn	T-0
,	O
and	O
she	O
was	O
treated	T-1
with	T-1
a	O
1	O
-	O
month	O
course	T-2
of	T-2
prednisone	B-Chemical
,	O
which	T-3
alleviated	O
her	O
symptoms	O
.	O

A	O
literature	O
review	O
revealed	O
no	O
prior	O
reports	O
of	O
pericarditis	B-Disease
in	O
anti	O
-	O
MPO	O
pANCA	O
-	O
positive	O
vasculitis	O
associated	T-0
with	T-0
propylthio	O
-	O
uracil	O
therapy	O
.	O

A	O
literature	O
review	O
revealed	O
no	O
prior	O
reports	O
of	O
pericarditis	O
in	O
anti	O
-	O
MPO	O
pANCA	O
-	O
positive	O
vasculitis	B-Disease
associated	T-0
with	T-0
propylthio	O
-	O
uracil	O
therapy	O
.	O

A	O
literature	O
review	O
revealed	O
no	O
prior	O
reports	O
of	O
pericarditis	O
in	O
anti	O
-	O
MPO	O
pANCA	O
-	O
positive	O
vasculitis	O
associated	T-0
with	T-0
propylthio	B-Chemical
-	I-Chemical
uracil	I-Chemical
therapy	T-1
.	O

CONCLUSION	O
:	O
Pericarditis	B-Disease
may	T-0
be	T-0
the	O
initial	O
manifestation	O
of	O
drug	O
-	O
induced	O
vasculitis	O
attributable	O
to	O
propylthio	O
-	O
uracil	O
therapy	O
.	O

CONCLUSION	O
:	O
Pericarditis	O
may	O
be	O
the	O
initial	O
manifestation	T-1
of	O
drug	O
-	O
induced	T-2
vasculitis	B-Disease
attributable	O
to	O
propylthio	O
-	O
uracil	O
therapy	O
.	O

CONCLUSION	O
:	O
Pericarditis	O
may	O
be	O
the	O
initial	O
manifestation	O
of	O
drug	O
-	O
induced	T-0
vasculitis	O
attributable	O
to	O
propylthio	B-Chemical
-	I-Chemical
uracil	I-Chemical
therapy	O
.	O

Repeated	O
transient	O
anuria	B-Disease
following	O
losartan	O
administration	T-0
in	O
a	O
patient	T-1
with	O
a	O
solitary	T-2
kidney	T-2
.	O

Repeated	O
transient	O
anuria	O
following	T-2
losartan	B-Chemical
administration	T-3
in	O
a	O
patient	O
with	O
a	O
solitary	O
kidney	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
hypertensive	O
man	T-0
with	T-0
a	O
solitary	O
kidney	O
and	O
chronic	B-Disease
renal	I-Disease
insufficiency	I-Disease
who	O
developed	O
two	O
episodes	O
of	O
transient	O
anuria	O
after	O
losartan	O
administration	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
hypertensive	O
man	O
with	O
a	O
solitary	O
kidney	O
and	O
chronic	O
renal	O
insufficiency	O
who	O
developed	T-1
two	O
episodes	O
of	O
transient	T-0
anuria	B-Disease
after	T-2
losartan	O
administration	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
hypertensive	O
man	O
with	O
a	O
solitary	O
kidney	O
and	O
chronic	O
renal	O
insufficiency	O
who	O
developed	T-1
two	O
episodes	O
of	O
transient	O
anuria	O
after	O
losartan	B-Chemical
administration	T-0
.	O

He	O
was	O
hospitalized	O
for	T-0
a	T-0
myocardial	B-Disease
infarction	I-Disease
with	T-1
pulmonary	O
edema	O
,	O
treated	O
with	O
high	O
-	O
dose	O
diuretics	O
.	O

He	O
was	O
hospitalized	T-0
for	T-0
a	O
myocardial	O
infarction	O
with	O
pulmonary	B-Disease
edema	I-Disease
,	O
treated	O
with	O
high	O
-	O
dose	O
diuretics	O
.	O

Due	T-0
to	T-0
severe	T-0
systolic	B-Disease
dysfunction	I-Disease
losartan	O
was	T-1
prescribed	T-1
.	O

Due	O
to	O
severe	T-0
systolic	T-0
dysfunction	T-0
losartan	B-Chemical
was	T-1
prescribed	T-1
.	O

Surprisingly	O
,	O
the	O
first	O
dose	T-0
of	T-0
50	O
mg	O
of	O
losartan	B-Chemical
resulted	T-1
in	T-1
a	O
sudden	O
anuria	O
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
dose	O
furosemide	O
and	O
amine	O
infusion	O
.	O

Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
50	O
mg	O
of	O
losartan	O
resulted	T-0
in	T-0
a	O
sudden	T-2
anuria	B-Disease
,	O
which	T-1
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
dose	O
furosemide	O
and	O
amine	O
infusion	O
.	O

Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
50	O
mg	O
of	O
losartan	O
resulted	T-1
in	T-1
a	O
sudden	O
anuria	O
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	T-0
-	T-0
dose	T-0
furosemide	B-Chemical
and	O
amine	O
infusion	O
.	O

Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
50	O
mg	O
of	O
losartan	O
resulted	O
in	O
a	O
sudden	T-1
anuria	O
,	O
which	O
lasted	O
eight	O
hours	O
despite	T-2
high	T-0
-	T-0
dose	T-0
furosemide	O
and	O
amine	B-Chemical
infusion	T-3
.	O

One	O
week	O
later	O
,	O
by	O
mistake	O
,	O
losartan	B-Chemical
was	T-0
prescribed	T-0
again	O
and	O
after	O
the	O
second	O
dose	O
of	O
50	O
mg	O
,	O
the	O
patient	O
developed	O
a	O
second	O
episode	O
of	O
transient	O
anuria	O
lasting	O
10	O
hours	O
.	O

One	O
week	O
later	O
,	O
by	O
mistake	O
,	O
losartan	O
was	O
prescribed	O
again	O
and	O
after	O
the	O
second	O
dose	O
of	O
50	O
mg	O
,	O
the	O
patient	O
developed	O
a	O
second	O
episode	O
of	T-1
transient	T-1
anuria	B-Disease
lasting	T-2
10	O
hours	O
.	O

During	O
these	O
two	O
episodes	O
,	O
his	O
blood	O
pressure	O
diminished	T-0
but	O
no	O
severe	O
hypotension	B-Disease
was	T-1
noted	T-1
.	O

Ultimately	O
,	O
an	O
arteriography	O
showed	T-0
a	O
70	O
-	O
80	O
%	O
renal	B-Disease
artery	I-Disease
stenosis	I-Disease
.	O

In	O
this	O
patient	O
,	O
renal	B-Disease
artery	I-Disease
stenosis	I-Disease
combined	T-0
with	T-0
heart	O
failure	O
and	O
diuretic	O
therapy	O
certainly	O
resulted	O
in	O
a	O
strong	O
activation	T-1
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
.	O

In	O
this	O
patient	O
,	O
renal	O
artery	O
stenosis	O
combined	T-0
with	T-0
heart	B-Disease
failure	I-Disease
and	O
diuretic	O
therapy	O
certainly	O
resulted	T-3
in	T-3
a	O
strong	O
activation	T-2
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
.	O

In	O
this	O
patient	O
,	O
renal	O
artery	O
stenosis	O
combined	O
with	O
heart	O
failure	O
and	O
diuretic	O
therapy	O
certainly	O
resulted	O
in	O
a	O
strong	T-1
activation	T-1
of	T-1
the	O
renin	O
-	O
angiotensin	B-Chemical
system	O
(	O
RAS	O
)	O
.	O

Under	T-1
such	T-1
conditions	T-1
,	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
blockade	O
by	O
losartan	O
probably	O
induced	T-2
a	O
critical	O
fall	T-0
in	O
glomerular	O
filtration	O
pressure	O
.	O

Under	O
such	O
conditions	O
,	O
angiotensin	O
II	O
receptor	O
blockade	O
by	O
losartan	B-Chemical
probably	O
induced	T-0
a	O
critical	O
fall	O
in	O
glomerular	O
filtration	O
pressure	O
.	O

This	O
case	O
report	O
highlights	O
the	O
fact	O
that	O
the	O
angiotensin	B-Chemical
II	I-Chemical
receptor	T-3
antagonist	T-3
losartan	O
can	T-0
cause	T-0
serious	O
unexpected	O
complications	T-1
in	T-1
patients	O
with	O
renovascular	O
disease	O
and	O
should	O
be	T-2
used	T-2
with	T-2
extreme	O
caution	O
in	O
this	O
setting	O
.	O

This	O
case	O
report	O
highlights	O
the	O
fact	O
that	O
the	O
angiotensin	O
II	O
receptor	O
antagonist	O
losartan	B-Chemical
can	T-0
cause	T-0
serious	O
unexpected	O
complications	O
in	O
patients	O
with	O
renovascular	O
disease	O
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

This	O
case	O
report	O
highlights	O
the	O
fact	O
that	O
the	O
angiotensin	O
II	O
receptor	O
antagonist	O
losartan	O
can	O
cause	O
serious	O
unexpected	O
complications	T-0
in	T-0
patients	T-0
with	T-0
renovascular	B-Disease
disease	I-Disease
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

Calcineurin	O
-	O
inhibitor	O
induced	T-2
pain	B-Disease
syndrome	T-0
(	O
CIPS	O
)	O
:	O
a	O
severe	T-1
disabling	T-1
complication	T-1
after	O
organ	O
transplantation	O
.	O

Calcineurin	O
-	O
inhibitor	O
induced	T-3
pain	O
syndrome	T-0
(	O
CIPS	B-Disease
)	O
:	T-2
a	T-2
severe	T-2
disabling	T-2
complication	T-4
after	O
organ	O
transplantation	O
.	O

Bone	O
pain	B-Disease
after	O
transplantation	T-0
is	O
a	O
frequent	O
complication	O
that	O
can	O
be	O
caused	T-1
by	T-1
several	O
diseases	O
.	O

Treatment	O
strategies	O
depend	T-1
on	T-1
the	O
correct	O
diagnosis	T-0
of	T-0
the	O
pain	B-Disease
.	O

Nine	O
patients	T-0
with	T-0
severe	T-1
pain	B-Disease
in	O
their	O
feet	O
,	O
which	O
was	O
registered	O
after	O
transplantation	O
,	O
were	O
investigated	O
.	O

Magnetic	T-2
resonance	T-2
imaging	O
demonstrated	T-1
bone	B-Disease
marrow	I-Disease
oedema	I-Disease
in	T-0
the	T-0
painful	O
bones	O
.	O

Pain	B-Disease
was	O
not	O
explained	T-0
by	O
other	O
diseases	O
causing	O
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	T-0
explained	T-0
by	T-0
other	O
diseases	O
causing	T-1
foot	T-1
pain	B-Disease
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	T-0
by	T-0
other	O
diseases	O
causing	T-1
foot	O
pain	O
,	O
like	O
reflex	B-Disease
sympathetic	I-Disease
dystrophy	I-Disease
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	T-0
causing	T-0
foot	T-0
pain	T-0
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	B-Disease
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	T-0
by	T-0
other	O
diseases	O
causing	T-1
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	B-Disease
'	I-Disease
s	I-Disease
neuralgia	I-Disease
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	T-0
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	T-1
'	T-1
s	T-1
neuralgia	T-1
,	O
gout	B-Disease
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	T-0
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	B-Disease
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	T-2
explained	T-2
by	T-2
other	O
diseases	O
causing	O
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	T-0
,	T-0
avascular	B-Disease
necrosis	I-Disease
,	T-1
intermittent	T-1
claudication	T-1
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	T-0
by	T-1
other	T-1
diseases	T-1
causing	O
foot	O
pain	O
,	O
like	T-2
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	B-Disease
claudication	I-Disease
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	O
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	T-0
foot	B-Disease
deformities	I-Disease
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	O
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	B-Disease
fractures	I-Disease
,	O
and	T-0
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	O
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	T-0
hyperparathyroidism	B-Disease
.	O

The	O
reduction	T-0
of	T-0
cyclosporine	B-Chemical
-	O
or	O
tacrolimus	O
trough	O
levels	O
and	O
the	O
administration	T-1
of	T-1
calcium	O
channel	O
blockers	O
led	O
to	O
relief	T-2
of	O
pain	O
.	O

The	O
reduction	T-0
of	O
cyclosporine	O
-	O
or	O
tacrolimus	B-Chemical
trough	O
levels	O
and	O
the	O
administration	T-1
of	O
calcium	O
channel	O
blockers	O
led	T-2
to	T-2
relief	T-2
of	T-2
pain	T-2
.	O

The	O
reduction	O
of	O
cyclosporine	O
-	O
or	O
tacrolimus	O
trough	O
levels	T-0
and	O
the	O
administration	T-2
of	T-2
calcium	B-Chemical
channel	O
blockers	O
led	O
to	O
relief	O
of	O
pain	O
.	O

The	O
reduction	O
of	O
cyclosporine	O
-	O
or	O
tacrolimus	O
trough	O
levels	O
and	O
the	O
administration	O
of	O
calcium	O
channel	O
blockers	O
led	T-2
to	T-2
relief	T-1
of	T-1
pain	B-Disease
.	O

The	O
Calcineurin	O
-	O
inhibitor	O
Induced	T-0
Pain	B-Disease
Syndrome	O
(	O
CIPS	O
)	O
is	O
a	O
rare	O
but	O
severe	O
side	O
effect	O
of	O
cyclosporine	O
or	O
tacrolimus	O
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

The	O
Calcineurin	O
-	O
inhibitor	O
Induced	T-0
Pain	O
Syndrome	O
(	O
CIPS	B-Disease
)	O
is	T-1
a	T-1
rare	T-1
but	O
severe	O
side	O
effect	O
of	O
cyclosporine	O
or	O
tacrolimus	O
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

The	O
Calcineurin	O
-	O
inhibitor	O
Induced	O
Pain	O
Syndrome	O
(	O
CIPS	O
)	O
is	O
a	O
rare	O
but	O
severe	O
side	T-0
effect	T-0
of	T-0
cyclosporine	B-Chemical
or	O
tacrolimus	O
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

The	O
Calcineurin	O
-	O
inhibitor	O
Induced	T-0
Pain	O
Syndrome	O
(	O
CIPS	O
)	O
is	O
a	O
rare	O
but	O
severe	O
side	T-2
effect	T-2
of	T-2
cyclosporine	O
or	O
tacrolimus	B-Chemical
and	O
is	O
accurately	O
diagnosed	T-1
by	T-1
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

Incorrect	O
diagnosis	O
of	O
the	O
syndrome	O
will	O
lead	O
to	O
a	O
significant	O
reduction	O
of	O
life	O
quality	O
in	O
patients	O
suffering	T-0
from	T-0
CIPS	B-Disease
.	O

Brain	O
natriuretic	O
peptide	O
is	O
a	O
predictor	T-1
of	T-1
anthracycline	B-Chemical
-	O
induced	T-2
cardiotoxicity	O
.	O

Brain	O
natriuretic	O
peptide	O
is	O
a	O
predictor	T-0
of	T-0
anthracycline	O
-	O
induced	T-1
cardiotoxicity	B-Disease
.	O

Anthracyclines	B-Chemical
are	T-1
effective	T-1
antineoplastic	O
drugs	O
,	O
but	T-2
they	T-2
frequently	T-2
cause	T-2
dose	O
-	O
related	O
cardiotoxicity	O
.	O

Anthracyclines	O
are	O
effective	O
antineoplastic	O
drugs	O
,	O
but	O
they	O
frequently	O
cause	T-0
dose	O
-	O
related	O
cardiotoxicity	B-Disease
.	O

The	T-0
cardiotoxicity	B-Disease
of	T-1
conventional	T-1
anthracycline	O
therapy	O
highlights	T-2
a	O
need	O
to	O
search	O
for	O
methods	O
that	O
are	O
highly	O
sensitive	O
and	O
capable	O
of	O
predicting	O
cardiac	O
dysfunction	O
.	O

The	O
cardiotoxicity	O
of	T-1
conventional	T-1
anthracycline	B-Chemical
therapy	T-0
highlights	T-0
a	O
need	O
to	O
search	O
for	O
methods	O
that	O
are	O
highly	O
sensitive	O
and	O
capable	O
of	O
predicting	O
cardiac	O
dysfunction	O
.	O

The	O
cardiotoxicity	O
of	O
conventional	O
anthracycline	O
therapy	O
highlights	O
a	O
need	O
to	O
search	O
for	O
methods	O
that	O
are	O
highly	O
sensitive	O
and	O
capable	T-0
of	T-0
predicting	T-1
cardiac	B-Disease
dysfunction	I-Disease
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	T-1
of	T-1
anthracycline	B-Chemical
-	O
induced	T-0
cardiotoxicity	O
in	O
patients	O
with	O
acute	O
leukemia	O
treated	O
with	O
a	O
daunorubicin	O
(	O
DNR	O
)	O
-	O
containing	O
regimen	O
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	O
-	O
induced	T-0
cardiotoxicity	B-Disease
in	T-1
patients	T-1
with	O
acute	O
leukemia	O
treated	O
with	O
a	O
daunorubicin	O
(	O
DNR	O
)	O
-	O
containing	O
regimen	O
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	T-0
indicator	O
of	O
anthracycline	O
-	O
induced	T-3
cardiotoxicity	O
in	O
patients	T-1
with	O
acute	B-Disease
leukemia	I-Disease
treated	T-4
with	T-4
a	O
daunorubicin	O
(	O
DNR	O
)	O
-	O
containing	O
regimen	O
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	O
-	O
induced	O
cardiotoxicity	O
in	O
patients	O
with	O
acute	O
leukemia	O
treated	T-0
with	T-0
a	O
daunorubicin	B-Chemical
(	O
DNR	O
)	O
-	O
containing	T-1
regimen	O
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	O
-	O
induced	O
cardiotoxicity	O
in	T-0
patients	T-0
with	O
acute	O
leukemia	O
treated	T-1
with	T-1
a	O
daunorubicin	O
(	O
DNR	B-Chemical
)	O
-	O
containing	O
regimen	O
.	O

Thirteen	O
patients	T-0
with	T-0
acute	B-Disease
leukemia	I-Disease
were	O
treated	T-1
with	T-1
a	O
DNR	O
-	O
containing	O
regimen	O
.	O

Thirteen	O
patients	O
with	O
acute	O
leukemia	O
were	O
treated	T-1
with	T-1
a	T-1
DNR	B-Chemical
-	O
containing	O
regimen	O
.	O

Three	O
patients	T-0
developed	T-1
congestive	B-Disease
heart	I-Disease
failure	I-Disease
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O

Five	O
patients	O
were	O
diagnosed	T-0
as	T-0
having	T-0
subclinical	T-1
heart	B-Disease
failure	I-Disease
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O

The	O
plasma	O
levels	O
of	O
BNP	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	T-0
heart	B-Disease
failure	I-Disease
increased	T-1
above	T-1
the	O
normal	O
limit	O
(	O
40	O
pg	O
/	O
ml	O
)	O
before	T-2
the	T-2
detection	T-2
of	O
clinical	O
or	O
subclinical	O
heart	O
failure	O
by	O
radionuclide	O
angiography	O
.	O

The	O
plasma	O
levels	O
of	O
BNP	O
in	O
all	O
the	O
patients	O
with	O
clinical	O
and	O
subclinical	O
heart	O
failure	O
increased	T-0
above	O
the	O
normal	O
limit	O
(	O
40	O
pg	O
/	O
ml	O
)	O
before	O
the	O
detection	T-1
of	T-1
clinical	O
or	O
subclinical	O
heart	B-Disease
failure	I-Disease
by	O
radionuclide	O
angiography	O
.	O

On	O
the	O
other	O
hand	O
,	O
BNP	O
did	O
not	O
increase	T-1
in	O
the	O
patients	O
without	T-0
heart	B-Disease
failure	I-Disease
given	O
DNR	O
,	O
even	O
at	O
more	O
than	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
BNP	O
did	O
not	O
increase	O
in	O
the	O
patients	O
without	O
heart	O
failure	O
given	T-0
DNR	B-Chemical
,	O
even	O
at	O
more	O
than	O
700	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

The	O
plasma	O
level	O
of	O
ANP	O
did	O
not	O
always	O
increase	O
in	O
all	O
the	O
patients	O
with	O
clinical	T-0
and	T-0
subclinical	T-0
heart	B-Disease
failure	I-Disease
.	O

These	O
preliminary	O
results	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
early	O
and	O
sensitive	O
indicator	T-0
of	T-0
anthracycline	B-Chemical
-	O
induced	T-1
cardiotoxicity	O
.	O

These	O
preliminary	O
results	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
early	O
and	O
sensitive	O
indicator	O
of	O
anthracycline	O
-	O
induced	T-0
cardiotoxicity	B-Disease
.	O

Nephrotoxicity	B-Disease
of	T-0
combined	T-1
cephalothin	O
-	O
gentamicin	O
regimen	O
.	O

Nephrotoxicity	O
of	T-1
combined	T-1
cephalothin	B-Chemical
-	O
gentamicin	O
regimen	O
.	O

Nephrotoxicity	O
of	O
combined	O
cephalothin	T-0
-	T-0
gentamicin	B-Chemical
regimen	O
.	O

Two	O
patients	T-2
developed	T-2
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
,	O
characterized	O
clinically	O
by	O
acute	O
oliguric	O
renal	O
failure	O
,	O
while	O
they	O
were	O
receiving	O
a	O
combination	O
of	O
cephalothin	O
sodium	O
and	O
gentamicin	O
sulfate	O
therapy	T-1
.	O

Two	O
patients	O
developed	T-0
acute	O
tubular	O
necrosis	O
,	O
characterized	O
clinically	O
by	T-3
acute	T-3
oliguric	B-Disease
renal	I-Disease
failure	I-Disease
,	O
while	O
they	O
were	O
receiving	T-1
a	O
combination	O
of	O
cephalothin	O
sodium	O
and	O
gentamicin	O
sulfate	O
therapy	O
.	O

Two	O
patients	O
developed	T-0
acute	O
tubular	O
necrosis	O
,	O
characterized	O
clinically	O
by	O
acute	O
oliguric	O
renal	O
failure	O
,	O
while	O
they	O
were	O
receiving	O
a	O
combination	T-1
of	T-1
cephalothin	B-Chemical
sodium	I-Chemical
and	T-2
gentamicin	T-2
sulfate	T-2
therapy	O
.	O

Two	O
patients	T-1
developed	T-2
acute	O
tubular	O
necrosis	O
,	O
characterized	T-3
clinically	O
by	T-4
acute	O
oliguric	O
renal	O
failure	O
,	O
while	O
they	O
were	O
receiving	T-0
a	O
combination	O
of	O
cephalothin	O
sodium	O
and	O
gentamicin	B-Chemical
sulfate	I-Chemical
therapy	T-5
.	O

Patients	O
who	O
are	O
given	O
this	O
drug	O
regimen	O
should	T-1
be	T-1
observed	T-1
very	O
carefully	O
for	O
early	T-2
signs	T-2
of	T-2
nephrotoxicity	B-Disease
.	O

Patients	T-1
with	T-1
renal	B-Disease
insufficiency	I-Disease
should	O
not	O
be	T-0
given	T-0
this	O
regimen	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	T-0
apoptotic	T-0
and	O
necrotic	B-Disease
cell	T-2
deaths	T-2
during	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	T-1
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	O
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	B-Chemical
-	T-0
induced	T-0
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	O
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	O
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	O
-	T-1
induced	T-1
nephrotoxicity	B-Disease
,	T-2
amiodarone	T-2
-	T-2
induced	T-2
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	O
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	B-Chemical
-	O
induced	T-1
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	O
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	T-1
lung	B-Disease
toxicity	I-Disease
and	T-2
doxorubicin	O
-	O
induced	T-0
cardiotoxicity	O
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	T-1
acetaminophen	O
-	O
induced	T-2
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	T-3
lung	O
toxicity	O
and	O
doxorubicin	B-Chemical
-	O
induced	T-4
cardiotoxicity	O
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	O
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	T-0
cardiotoxicity	B-Disease
by	T-1
a	T-1
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	T-0
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	O
-	O
induced	T-1
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	T-2
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	T-3
cardiotoxicity	O
by	O
a	O
novel	O
IH636	B-Chemical
grape	I-Chemical
seed	I-Chemical
proanthocyanidin	I-Chemical
extract	I-Chemical
.	O

Grape	B-Chemical
seed	I-Chemical
extract	I-Chemical
,	O
primarily	O
a	O
mixture	O
of	O
proanthocyanidins	O
,	O
has	T-1
been	T-1
shown	T-1
to	T-1
modulate	O
a	O
wide	O
-	O
range	O
of	O
biological	O
,	O
pharmacological	O
and	O
toxicological	O
effects	T-0
which	O
are	O
mainly	O
cytoprotective	O
.	O

Grape	O
seed	O
extract	O
,	O
primarily	O
a	O
mixture	T-0
of	T-0
proanthocyanidins	B-Chemical
,	O
has	O
been	O
shown	O
to	O
modulate	O
a	O
wide	O
-	O
range	O
of	O
biological	O
,	O
pharmacological	O
and	O
toxicological	O
effects	O
which	O
are	O
mainly	O
cytoprotective	O
.	O

This	O
study	O
assessed	O
the	O
ability	T-0
of	T-0
IH636	B-Chemical
grape	I-Chemical
seed	I-Chemical
proanthocyanidin	I-Chemical
extract	I-Chemical
(	O
GSPE	O
)	O
to	O
prevent	T-1
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	T-2
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	T-3
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	T-4
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	T-2
assessed	T-2
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	T-0
(	O
GSPE	B-Chemical
)	O
to	T-1
prevent	T-1
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	T-3
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	T-0
acetaminophen	B-Chemical
(	O
AAP	O
)	O
-	O
induced	T-1
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	T-2
prevent	T-2
acetaminophen	O
(	O
AAP	B-Chemical
)	O
-	O
induced	T-3
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	T-1
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	T-1
induced	T-1
nephrotoxicity	B-Disease
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	T-0
of	T-0
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	T-1
prevent	T-1
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	T-2
nephrotoxicity	O
,	O
amiodarone	B-Chemical
(	O
AMI	O
)	O
-	O
induced	T-3
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	T-1
prevent	T-1
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	T-2
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	B-Chemical
)	O
-	O
induced	T-0
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	T-0
of	T-0
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	T-1
prevent	T-1
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	T-2
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	T-4
lung	B-Disease
toxicity	I-Disease
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	T-3
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	B-Chemical
(	T-1
DOX	T-1
)	T-1
-	T-1
induced	T-1
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	T-0
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	T-1
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	B-Chemical
)	O
-	O
induced	T-2
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	T-0
prevent	T-0
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	T-1
cardiotoxicity	B-Disease
in	O
mice	O
.	O

Experimental	O
design	O
consisted	T-2
of	T-2
four	O
groups	O
:	O
control	O
(	O
vehicle	O
alone	O
)	O
,	O
GSPE	B-Chemical
alone	T-1
,	O
drug	O
alone	O
and	O
GSPE	O
+	O
drug	O
.	O

Experimental	T-0
design	O
consisted	O
of	O
four	O
groups	O
:	O
control	O
(	O
vehicle	O
alone	O
)	O
,	O
GSPE	O
alone	O
,	O
drug	O
alone	O
and	O
GSPE	B-Chemical
+	T-1
drug	T-1
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	O
gavaged	O
100	T-0
mg	T-0
/	T-0
Kg	T-0
GSPE	B-Chemical
for	O
7	O
-	O
10	O
days	O
followed	O
by	O
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	O
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	O
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	O
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	T-2
gavaged	T-2
100	O
mg	O
/	O
Kg	O
GSPE	O
for	O
7	O
-	O
10	O
days	O
followed	O
by	O
i	O
.	O
p	O
.	O
injections	T-3
of	O
organ	O
specific	O
three	O
drugs	T-0
(	O
AAP	B-Chemical
:	O
500	T-1
mg	T-1
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	O
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	O
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	O
gavaged	O
100	O
mg	O
/	O
Kg	O
GSPE	O
for	O
7	O
-	O
10	O
days	O
followed	T-0
by	T-0
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	O
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	B-Chemical
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	O
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	T-0
gavaged	T-0
100	O
mg	O
/	O
Kg	O
GSPE	O
for	O
7	O
-	O
10	O
days	O
followed	O
by	O
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	O
:	O
500	O
mg	O
/	O
Kg	O
for	O
24	O
h	O
;	O
AMI	O
:	O
50	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	B-Chemical
:	O
20	O
mg	O
/	O
Kg	O
for	O
48	O
h	O
)	O
.	O

Results	O
indicate	O
that	O
GSPE	B-Chemical
preexposure	T-0
prior	O
to	O
AAP	O
,	O
AMI	O
and	O
DOX	O
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

Results	O
indicate	T-1
that	O
GSPE	O
preexposure	T-2
prior	T-0
to	T-0
AAP	B-Chemical
,	O
AMI	O
and	O
DOX	O
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	T-3
DNA	O
fragmentation	O
.	O

Results	O
indicate	O
that	O
GSPE	O
preexposure	T-0
prior	O
to	O
AAP	O
,	O
AMI	B-Chemical
and	O
DOX	O
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

Results	O
indicate	O
that	O
GSPE	O
preexposure	T-0
prior	T-0
to	O
AAP	O
,	O
AMI	O
and	O
DOX	B-Chemical
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

Histopathological	O
examination	O
of	O
kidney	O
,	O
heart	O
and	O
lung	O
sections	O
revealed	O
moderate	O
to	O
massive	O
tissue	O
damage	O
with	O
a	O
variety	O
of	O
morphological	O
aberrations	O
by	O
all	O
the	O
three	O
drugs	O
in	O
the	O
absence	T-0
of	T-0
GSPE	B-Chemical
preexposure	T-1
than	O
in	O
its	O
presence	O
.	O

GSPE	B-Chemical
+	T-2
drug	T-2
exposed	T-1
tissues	O
exhibited	T-0
minor	O
residual	O
damage	O
or	O
near	O
total	O
recovery	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	T-1
as	T-1
,	O
AAP	B-Chemical
,	O
AMI	O
and	O
DOX	O
induced	T-0
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	O
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	T-0
,	T-0
AMI	B-Chemical
and	T-1
DOX	T-1
induced	O
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	O
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	T-0
,	O
such	O
as	O
,	O
AAP	O
,	O
AMI	O
and	O
DOX	B-Chemical
induced	T-1
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	O
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	T-2
blocked	O
by	O
GSPE	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	O
,	O
AMI	O
and	O
DOX	O
induced	O
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	B-Disease
in	T-0
the	T-0
respective	T-0
organs	T-0
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	O
,	O
AMI	O
and	O
DOX	O
induced	T-0
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	O
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	T-1
by	T-1
GSPE	B-Chemical
.	O

Since	O
AAP	B-Chemical
,	T-0
AMI	T-0
and	T-0
DOX	T-0
undergo	O
biotransformation	O
and	O
are	O
known	O
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	O
by	O
GSPE	O
may	O
be	O
linked	O
to	O
both	O
inhibition	O
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Since	O
AAP	O
,	O
AMI	B-Chemical
and	O
DOX	O
undergo	O
biotransformation	O
and	O
are	O
known	O
to	T-0
produce	T-0
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	O
by	O
GSPE	O
may	O
be	O
linked	T-1
to	T-1
both	O
inhibition	O
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Since	O
AAP	O
,	O
AMI	O
and	O
DOX	B-Chemical
undergo	O
biotransformation	O
and	O
are	T-3
known	T-3
to	T-3
produce	T-0
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	T-1
by	T-1
GSPE	O
may	O
be	O
linked	O
to	O
both	O
inhibition	T-2
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Since	O
AAP	O
,	O
AMI	O
and	O
DOX	O
undergo	O
biotransformation	O
and	O
are	O
known	O
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	T-0
by	T-0
GSPE	B-Chemical
may	O
be	O
linked	O
to	O
both	O
inhibition	O
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Additionally	O
,	O
this	O
may	O
have	O
been	O
the	O
first	O
report	O
on	O
AMI	B-Chemical
-	O
induced	T-1
apoptotic	O
death	O
in	O
the	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
events	O
undoubtedly	O
establish	O
GSPE	B-Chemical
'	T-0
s	T-0
abundant	T-0
bioavailability	T-0
,	O
and	O
the	O
power	O
to	O
defend	O
multiple	O
target	O
organs	O
from	O
toxic	O
assaults	O
induced	O
by	O
structurally	O
diverse	O
and	O
functionally	O
different	O
entities	O
in	O
vivo	O
.	O

Antidepressant	B-Chemical
-	O
induced	T-0
mania	O
in	T-1
bipolar	O
patients	O
:	O
identification	O
of	O
risk	O
factors	O
.	O

Antidepressant	O
-	O
induced	T-3
mania	B-Disease
in	O
bipolar	O
patients	O
:	O
identification	T-1
of	T-1
risk	T-2
factors	T-2
.	O

Antidepressant	O
-	O
induced	T-1
mania	O
in	O
bipolar	B-Disease
patients	T-0
:	O
identification	T-2
of	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O
Concerns	O
about	O
possible	T-1
risks	T-1
of	T-1
switching	O
to	O
mania	B-Disease
associated	T-0
with	T-0
antidepressants	T-0
continue	O
to	O
interfere	O
with	O
the	O
establishment	O
of	O
an	O
optimal	O
treatment	T-2
paradigm	O
for	O
bipolar	O
depression	O
.	O

BACKGROUND	O
:	O
Concerns	O
about	O
possible	O
risks	O
of	O
switching	O
to	O
mania	O
associated	T-2
with	T-2
antidepressants	B-Chemical
continue	O
to	O
interfere	T-0
with	T-0
the	O
establishment	O
of	O
an	O
optimal	T-1
treatment	T-1
paradigm	T-1
for	O
bipolar	O
depression	O
.	O

BACKGROUND	O
:	O
Concerns	O
about	O
possible	O
risks	O
of	O
switching	O
to	O
mania	O
associated	T-0
with	T-0
antidepressants	O
continue	O
to	O
interfere	O
with	O
the	O
establishment	T-1
of	O
an	O
optimal	O
treatment	T-2
paradigm	O
for	T-3
bipolar	B-Disease
depression	I-Disease
.	O

METHOD	O
:	O
The	O
response	T-0
of	T-0
44	O
patients	T-1
meeting	O
DSM	O
-	O
IV	O
criteria	O
for	O
bipolar	B-Disease
disorder	I-Disease
to	O
naturalistic	O
treatment	T-2
was	O
assessed	O
for	O
at	O
least	O
6	O
weeks	O
using	O
the	O
Montgomery	O
-	O
Asberg	O
Depression	O
Rating	O
Scale	O
and	O
the	O
Bech	O
-	O
Rafaelson	O
Mania	O
Rating	O
Scale	O
.	O

Patients	T-1
who	T-1
experienced	T-1
a	T-1
manic	B-Disease
or	T-2
hypomanic	T-2
switch	T-2
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	T-0
during	T-0
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	T-1
or	T-1
hypomanic	B-Disease
switch	T-0
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	T-1
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	B-Disease
-	I-Disease
IV	I-Disease
bipolar	I-Disease
I	I-Disease
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	T-0
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	T-0
compared	T-0
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	T-1
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	B-Disease
II	I-Disease
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	B-Disease
episodes	T-0
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	B-Chemical
therapy	T-0
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	T-1
with	T-1
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	B-Chemical
drugs	T-0
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	T-1
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	T-2
drugs	T-2
and	O
,	O
more	O
particularly	O
,	O
selective	T-3
serotonin	T-3
reuptake	T-3
inhibitors	T-3
[	O
SSRIs	B-Chemical
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	T-0
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	T-1
stabilizers	T-1
(	O
lithium	B-Chemical
vs	T-0
.	T-0
anticonvulsants	T-0
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

RESULTS	O
:	O
Switches	T-0
to	T-0
hypomania	B-Disease
or	O
mania	O
occurred	O
in	O
27	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	O
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
manic	O
episodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	T-1
hypomanic	O
episodes	O
.	O

RESULTS	O
:	O
Switches	O
to	O
hypomania	O
or	O
mania	B-Disease
occurred	T-4
in	T-4
27	O
%	O
of	O
all	O
patients	T-1
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgroup	O
of	O
patients	T-2
treated	T-2
with	T-2
SSRIs	O
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	T-3
manic	O
episodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hypomanic	O
episodes	O
.	O

RESULTS	O
:	O
Switches	O
to	O
hypomania	O
or	O
mania	O
occurred	T-0
in	O
27	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	T-2
with	T-2
SSRIs	B-Chemical
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	T-1
manic	O
episodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hypomanic	O
episodes	O
.	O

RESULTS	O
:	O
Switches	O
to	O
hypomania	O
or	O
mania	O
occurred	O
in	O
27	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	O
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	T-0
manic	B-Disease
episodes	T-1
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	O
hypomanic	O
episodes	O
.	O

RESULTS	O
:	O
Switches	O
to	O
hypomania	O
or	O
mania	O
occurred	O
in	O
27	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	O
[	O
8	O
/	O
33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	O
manic	O
episodes	O
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	T-0
hypomanic	B-Disease
episodes	T-1
.	O

Sex	O
,	O
age	O
,	O
diagnosis	T-1
(	O
bipolar	B-Disease
I	I-Disease
vs	T-2
.	T-2
bipolar	T-2
II	T-2
)	O
,	O
and	O
additional	O
treatment	T-0
did	O
not	O
affect	O
the	O
risk	O
of	O
switching	O
.	O

Sex	O
,	O
age	O
,	O
diagnosis	T-0
(	T-0
bipolar	T-0
I	T-0
vs	T-0
.	T-0
bipolar	B-Disease
II	I-Disease
)	O
,	T-1
and	T-1
additional	T-1
treatment	T-1
did	O
not	O
affect	O
the	O
risk	O
of	O
switching	O
.	O

In	O
contrast	O
,	O
mood	O
switches	O
were	O
less	O
frequent	O
in	O
patients	T-0
receiving	T-1
lithium	B-Chemical
(	O
15	O
%	O
,	O
4	O
/	O
26	O
)	O
than	O
in	O
patients	O
not	T-2
treated	T-2
with	T-2
lithium	O
(	O
44	O
%	O
,	O
8	O
/	O
18	O
;	O
p	O
=	O
.	O
04	O
)	O
.	O

In	O
contrast	O
,	O
mood	O
switches	O
were	O
less	O
frequent	O
in	O
patients	O
receiving	O
lithium	O
(	O
15	O
%	O
,	O
4	O
/	O
26	O
)	O
than	O
in	O
patients	O
not	O
treated	T-1
with	T-1
lithium	B-Chemical
(	T-0
44	T-0
%	T-0
,	T-0
8	T-0
/	T-0
18	T-0
;	T-0
p	T-0
=	T-0
.	T-0
04	T-0
)	T-0
.	O

The	O
number	O
of	T-0
previous	T-0
manic	B-Disease
episodes	T-1
did	O
not	O
affect	O
the	O
probability	O
of	O
switching	O
,	O
whereas	O
a	O
high	O
score	O
on	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semistructured	O
Affective	O
Temperament	O
Interview	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
switching	O
(	O
p	O
=	O
.	O
008	O
)	O
.	O

CONCLUSION	O
:	O
The	O
frequency	O
of	O
mood	O
switching	O
associated	T-0
with	T-0
acute	T-2
antidepressant	B-Chemical
therapy	T-1
may	O
be	O
reduced	O
by	O
lithium	O
treatment	O
.	O

CONCLUSION	O
:	O
The	O
frequency	O
of	O
mood	O
switching	O
associated	O
with	O
acute	O
antidepressant	O
therapy	O
may	O
be	O
reduced	T-0
by	T-0
lithium	B-Chemical
treatment	O
.	O

Peritubular	O
capillary	O
basement	O
membrane	O
reduplication	O
in	O
allografts	O
and	O
native	T-0
kidney	B-Disease
disease	I-Disease
:	O
a	O
clinicopathologic	O
study	T-1
of	T-1
278	O
consecutive	O
renal	O
specimens	O
.	O

BACKGROUND	O
:	O
An	O
association	O
has	O
been	O
found	O
between	O
transplant	B-Disease
glomerulopathy	I-Disease
(	O
TG	O
)	O
and	O
reduplication	T-0
of	O
peritubular	O
capillary	O
basement	O
membranes	O
(	O
PTCR	O
)	O
.	O

BACKGROUND	O
:	O
An	O
association	O
has	O
been	O
found	O
between	O
transplant	O
glomerulopathy	T-1
(	O
TG	B-Disease
)	O
and	O
reduplication	T-0
of	O
peritubular	O
capillary	O
basement	O
membranes	O
(	O
PTCR	O
)	O
.	O

In	T-2
addition	T-2
to	T-2
renal	O
allografts	O
with	T-0
TG	B-Disease
,	O
we	O
also	O
examined	T-1
grafts	O
with	O
acute	O
rejection	O
,	O
recurrent	O
glomerulonephritis	O
,	O
chronic	O
allograft	O
nephropathy	O
and	O
stable	O
grafts	O
(	O
"	O
protocol	O
biopsies	O
"	O
)	O
.	O

In	T-4
addition	T-4
to	T-4
renal	O
allografts	O
with	O
TG	O
,	O
we	O
also	O
examined	O
grafts	O
with	O
acute	O
rejection	T-1
,	O
recurrent	T-2
glomerulonephritis	B-Disease
,	O
chronic	O
allograft	O
nephropathy	O
and	O
stable	T-3
grafts	O
(	O
"	O
protocol	O
biopsies	O
"	O
)	O
.	O

In	O
addition	O
to	O
renal	O
allografts	O
with	O
TG	O
,	O
we	O
also	O
examined	T-0
grafts	O
with	O
acute	O
rejection	O
,	O
recurrent	T-1
glomerulonephritis	O
,	O
chronic	B-Disease
allograft	I-Disease
nephropathy	I-Disease
and	O
stable	T-2
grafts	O
(	O
"	O
protocol	O
biopsies	O
"	O
)	O
.	O

Native	O
kidney	O
specimens	T-2
included	T-2
a	T-2
wide	T-2
range	T-2
of	T-1
glomerulopathies	B-Disease
as	T-0
well	T-0
as	T-0
cases	T-0
of	O
thrombotic	O
microangiopathy	O
,	O
malignant	O
hypertension	O
,	O
acute	O
interstitial	O
nephritis	O
,	O
and	O
acute	O
tubular	O
necrosis	O
.	O

Native	O
kidney	O
specimens	O
included	T-2
a	O
wide	O
range	O
of	O
glomerulopathies	O
as	O
well	O
as	O
cases	T-1
of	T-1
thrombotic	B-Disease
microangiopathy	I-Disease
,	O
malignant	T-0
hypertension	T-0
,	O
acute	O
interstitial	O
nephritis	O
,	O
and	O
acute	O
tubular	O
necrosis	O
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	O
as	O
well	O
as	O
cases	T-2
of	T-2
thrombotic	T-0
microangiopathy	T-0
,	T-0
malignant	B-Disease
hypertension	I-Disease
,	T-1
acute	T-1
interstitial	T-1
nephritis	T-1
,	O
and	O
acute	O
tubular	O
necrosis	O
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	O
as	O
well	O
as	O
cases	O
of	O
thrombotic	O
microangiopathy	O
,	O
malignant	O
hypertension	O
,	O
acute	T-0
interstitial	B-Disease
nephritis	I-Disease
,	O
and	O
acute	O
tubular	O
necrosis	O
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	O
as	O
well	O
as	O
cases	O
of	O
thrombotic	O
microangiopathy	O
,	O
malignant	O
hypertension	O
,	O
acute	O
interstitial	O
nephritis	O
,	O
and	T-0
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
.	O

RESULTS	O
:	O
We	O
found	T-0
PTCR	O
in	O
14	O
of	O
15	O
cases	O
of	T-1
TG	B-Disease
,	O
in	O
7	O
transplant	O
biopsy	O
specimens	O
without	O
TG	O
,	O
and	O
in	O
13	O
of	O
143	O
native	O
kidney	O
biopsy	O
specimens	O
.	O

RESULTS	O
:	O
We	O
found	O
PTCR	O
in	O
14	O
of	O
15	O
cases	O
of	O
TG	O
,	O
in	O
7	O
transplant	O
biopsy	O
specimens	T-0
without	T-0
TG	B-Disease
,	O
and	O
in	O
13	O
of	O
143	O
native	O
kidney	O
biopsy	O
specimens	O
.	O

These	O
13	O
included	O
cases	T-1
of	T-1
malignant	B-Disease
hypertension	I-Disease
,	T-0
thrombotic	T-0
microangiopathy	T-0
,	O
lupus	O
nephritis	O
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	O
glomerulonephritis	O
,	O
and	O
cocaine	O
-	O
related	O
acute	O
renal	O
failure	O
.	O

These	O
13	O
included	T-2
cases	O
of	O
malignant	T-0
hypertension	T-0
,	T-0
thrombotic	B-Disease
microangiopathy	I-Disease
,	T-1
lupus	T-1
nephritis	T-1
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	O
glomerulonephritis	O
,	O
and	O
cocaine	O
-	O
related	O
acute	O
renal	O
failure	O
.	O

These	O
13	O
included	O
cases	O
of	O
malignant	O
hypertension	O
,	O
thrombotic	T-0
microangiopathy	T-0
,	T-0
lupus	B-Disease
nephritis	I-Disease
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	O
glomerulonephritis	O
,	O
and	O
cocaine	O
-	O
related	O
acute	O
renal	O
failure	O
.	O

These	O
13	O
included	O
cases	T-1
of	T-1
malignant	O
hypertension	O
,	O
thrombotic	O
microangiopathy	O
,	O
lupus	O
nephritis	O
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	T-0
glomerulonephritis	B-Disease
,	O
and	O
cocaine	O
-	O
related	O
acute	O
renal	O
failure	O
.	O

These	O
13	O
included	O
cases	O
of	O
malignant	O
hypertension	O
,	O
thrombotic	O
microangiopathy	O
,	O
lupus	O
nephritis	O
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	O
glomerulonephritis	O
,	O
and	T-0
cocaine	B-Chemical
-	O
related	T-1
acute	O
renal	O
failure	O
.	O

These	O
13	O
included	O
cases	O
of	O
malignant	O
hypertension	O
,	O
thrombotic	O
microangiopathy	O
,	O
lupus	O
nephritis	O
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	O
glomerulonephritis	O
,	O
and	O
cocaine	O
-	O
related	T-0
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

Mild	O
PTCR	O
in	O
allografts	O
without	T-0
TG	B-Disease
did	O
not	O
predict	O
renal	O
failure	O
or	O
significant	O
proteinuria	O
after	O
follow	O
-	O
up	O
periods	O
of	O
between	O
3	O
months	O
and	O
1	O
year	O
.	O

Mild	O
PTCR	O
in	O
allografts	O
without	O
TG	O
did	T-1
not	T-1
predict	T-1
renal	B-Disease
failure	I-Disease
or	O
significant	O
proteinuria	O
after	O
follow	O
-	O
up	O
periods	O
of	O
between	O
3	O
months	O
and	O
1	O
year	O
.	O

Mild	O
PTCR	O
in	O
allografts	O
without	O
TG	O
did	O
not	O
predict	T-0
renal	O
failure	O
or	O
significant	O
proteinuria	B-Disease
after	O
follow	O
-	O
up	O
periods	O
of	O
between	O
3	O
months	O
and	O
1	O
year	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
transplants	O
,	O
there	O
is	O
a	O
strong	O
association	T-0
between	T-0
well	O
-	O
developed	O
PTCR	O
and	O
TG	B-Disease
,	O
while	O
the	O
significance	O
of	O
mild	O
PTCR	O
and	O
its	O
predictive	T-1
value	O
in	O
the	O
absence	O
of	O
TG	O
is	O
unclear	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
in	O
transplants	O
,	O
there	O
is	O
a	O
strong	O
association	T-0
between	O
well	O
-	O
developed	O
PTCR	O
and	O
TG	O
,	O
while	O
the	O
significance	O
of	O
mild	O
PTCR	O
and	O
its	O
predictive	T-1
value	O
in	O
the	O
absence	T-2
of	T-2
TG	B-Disease
is	O
unclear	O
.	O

PTCR	O
also	O
occurs	T-0
in	T-0
certain	O
native	O
kidney	B-Disease
diseases	I-Disease
,	O
though	O
the	O
association	T-1
is	O
not	O
as	O
strong	O
as	O
that	O
for	O
TG	O
.	O

PTCR	O
also	O
occurs	O
in	O
certain	O
native	O
kidney	O
diseases	O
,	O
though	O
the	O
association	O
is	O
not	O
as	O
strong	O
as	O
that	T-0
for	T-0
TG	B-Disease
.	O

We	O
suggest	T-0
that	T-0
repeated	O
endothelial	B-Disease
injury	I-Disease
,	T-2
including	T-2
immunologic	T-2
injury	T-2
,	O
may	T-1
be	T-1
the	O
cause	O
of	O
this	O
lesion	O
both	O
in	O
allografts	O
and	O
native	O
kidneys	O
.	O

We	O
suggest	O
that	O
repeated	T-0
endothelial	O
injury	O
,	O
including	O
immunologic	B-Disease
injury	I-Disease
,	O
may	O
be	O
the	O
cause	T-1
of	O
this	O
lesion	O
both	O
in	O
allografts	O
and	O
native	O
kidneys	O
.	O

Caffeine	B-Chemical
-	O
induced	T-0
cardiac	O
arrhythmia	O
:	O
an	O
unrecognised	O
danger	O
of	O
healthfood	O
products	O
.	O

Caffeine	O
-	O
induced	T-0
cardiac	B-Disease
arrhythmia	I-Disease
:	O
an	O
unrecognised	O
danger	O
of	O
healthfood	O
products	O
.	O

We	O
describe	O
a	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	T-1
pre	T-1
-	T-1
existing	T-1
mitral	B-Disease
valve	I-Disease
prolapse	I-Disease
who	O
developed	O
intractable	O
ventricular	O
fibrillation	O
after	O
consuming	O
a	O
"	O
natural	O
energy	O
"	O
guarana	O
health	O
drink	O
containing	O
a	O
high	O
concentration	O
of	O
caffeine	O
.	O

We	O
describe	O
a	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
pre	O
-	O
existing	O
mitral	O
valve	O
prolapse	O
who	O
developed	O
intractable	T-0
ventricular	B-Disease
fibrillation	I-Disease
after	T-1
consuming	T-1
a	O
"	O
natural	O
energy	O
"	O
guarana	O
health	O
drink	O
containing	O
a	O
high	O
concentration	O
of	O
caffeine	O
.	O

We	O
describe	O
a	O
25	O
-	O
year	O
-	O
old	O
woman	O
with	O
pre	O
-	O
existing	O
mitral	O
valve	O
prolapse	O
who	O
developed	T-0
intractable	O
ventricular	O
fibrillation	O
after	O
consuming	T-1
a	O
"	O
natural	O
energy	O
"	O
guarana	O
health	O
drink	O
containing	O
a	O
high	O
concentration	T-2
of	T-2
caffeine	B-Chemical
.	O

Conformationally	T-1
restricted	T-2
analogs	T-2
of	T-0
BD1008	B-Chemical
and	O
an	O
antisense	O
oligodeoxynucleotide	O
targeting	O
sigma1	O
receptors	O
produce	T-3
anti	O
-	O
cocaine	O
effects	O
in	O
mice	O
.	O

Conformationally	O
restricted	T-0
analogs	O
of	O
BD1008	O
and	O
an	O
antisense	O
oligodeoxynucleotide	B-Chemical
targeting	T-2
sigma1	O
receptors	O
produce	T-1
anti	O
-	O
cocaine	O
effects	O
in	O
mice	O
.	O

Conformationally	O
restricted	O
analogs	O
of	O
BD1008	O
and	O
an	O
antisense	O
oligodeoxynucleotide	O
targeting	O
sigma1	O
receptors	O
produce	T-0
anti	T-1
-	T-1
cocaine	B-Chemical
effects	T-2
in	O
mice	O
.	O

Cocaine	B-Chemical
'	O
s	O
ability	T-0
to	T-0
interact	O
with	O
sigma	O
receptors	O
suggests	T-1
that	O
these	O
proteins	O
mediate	O
some	O
of	O
its	O
behavioral	O
effects	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	B-Chemical
(	T-0
3S	T-0
-	T-0
1	T-0
-	T-0
[	T-0
2	T-0
-	T-0
(	T-0
3	T-0
,	T-0
4	T-0
-	T-0
dichlorophenyl	T-0
)	T-0
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
,	O
BD1063	O
(	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
4	O
-	O
methylpiperazine	O
)	O
,	O
and	O
LR132	O
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	T-0
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	O
(	O
3S	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
diazabicyclo	I-Chemical
[	I-Chemical
4	I-Chemical
.	I-Chemical
3	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
nonane	I-Chemical
)	O
,	O
BD1063	O
(	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
4	O
-	O
methylpiperazine	O
)	O
,	O
and	O
LR132	O
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	O
(	O
3S	T-0
-	T-0
1	T-0
-	T-0
[	T-0
2	T-0
-	T-0
(	T-0
3	T-0
,	T-0
4	T-0
-	T-0
dichlorophenyl	T-0
)	T-0
ethyl	T-0
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
,	O
BD1063	B-Chemical
(	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
4	O
-	O
methylpiperazine	O
)	O
,	O
and	O
LR132	O
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	T-2
receptor	T-2
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	T-1
in	O
Swiss	O
Webster	O
mice	O
:	O
BD1018	O
(	O
3S	T-0
-	T-0
1	T-0
-	T-0
[	T-0
2	T-0
-	T-0
(	T-0
3	T-0
,	T-0
4	T-0
-	T-0
dichlorophenyl	T-0
)	T-0
ethyl	T-0
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
,	O
BD1063	O
(	O
1	B-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methylpiperazine	I-Chemical
)	O
,	O
and	O
LR132	O
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	T-0
in	T-0
Swiss	O
Webster	O
mice	O
:	O
BD1018	O
(	O
3S	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
,	O
BD1063	O
(	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
4	O
-	O
methylpiperazine	O
)	O
,	O
and	O
LR132	B-Chemical
(	O
1R	O
,	O
2S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
2	O
-	O
(	O
1	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O

The	O
three	O
compounds	O
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	O
and	O
exhibit	T-1
negligible	O
affinities	O
for	O
dopamine	B-Chemical
,	O
opioid	O
,	O
GABA	T-0
(	O
A	O
)	O
and	O
NMDA	O
receptors	O
.	O

The	O
three	O
compounds	O
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	O
and	O
exhibit	O
negligible	O
affinities	O
for	O
dopamine	O
,	O
opioid	T-0
,	O
GABA	B-Chemical
(	T-2
A	T-2
)	T-2
and	O
NMDA	O
receptors	O
.	O

The	O
three	O
compounds	O
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	O
and	O
exhibit	T-0
negligible	O
affinities	O
for	O
dopamine	T-3
,	T-3
opioid	T-3
,	T-3
GABA	T-3
(	T-3
A	T-3
)	T-3
and	O
NMDA	B-Chemical
receptors	T-4
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	T-2
BD1018	B-Chemical
,	O
BD1063	O
,	O
or	O
LR132	O
significantly	T-0
attenuated	T-0
cocaine	O
-	O
induced	T-1
convulsions	O
and	O
lethality	O
.	O

In	O
behavioral	T-1
studies	T-1
,	O
pre	O
-	O
treatment	T-2
of	O
mice	O
with	O
BD1018	O
,	O
BD1063	B-Chemical
,	O
or	O
LR132	O
significantly	O
attenuated	O
cocaine	O
-	O
induced	T-3
convulsions	O
and	O
lethality	O
.	O

In	O
behavioral	O
studies	O
,	O
pre	T-1
-	T-1
treatment	T-1
of	T-1
mice	T-1
with	O
BD1018	O
,	O
BD1063	T-0
,	O
or	O
LR132	B-Chemical
significantly	T-2
attenuated	T-2
cocaine	T-3
-	T-3
induced	T-3
convulsions	T-3
and	T-3
lethality	T-3
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	O
BD1018	O
,	O
BD1063	O
,	O
or	O
LR132	O
significantly	T-1
attenuated	T-1
cocaine	B-Chemical
-	O
induced	T-2
convulsions	T-2
and	O
lethality	T-3
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	O
BD1018	O
,	O
BD1063	O
,	O
or	O
LR132	O
significantly	O
attenuated	T-1
cocaine	O
-	O
induced	T-2
convulsions	B-Disease
and	O
lethality	T-0
.	O

Moreover	O
,	O
post	O
-	O
treatment	O
with	O
LR132	B-Chemical
prevented	T-2
cocaine	T-0
-	O
induced	T-3
lethality	O
in	O
a	O
significant	O
proportion	O
of	O
animals	O
.	O

Moreover	O
,	O
post	O
-	O
treatment	T-2
with	O
LR132	O
prevented	T-1
cocaine	B-Chemical
-	O
induced	T-3
lethality	O
in	O
a	O
significant	O
proportion	O
of	O
animals	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	T-1
by	T-1
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	B-Chemical
-	I-Chemical
o	I-Chemical
-	I-Chemical
tolylguanidine	I-Chemical
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	O
(	O
3R	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	T-2
the	O
behavioral	O
toxicity	O
of	O
cocaine	O
.	O

In	O
contrast	T-1
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	T-2
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	O
DTG	B-Chemical
)	O
and	O
the	O
novel	T-0
sigma	T-0
receptor	T-0
agonist	T-0
BD1031	T-0
(	O
3R	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	T-3
of	O
cocaine	O
.	O

In	O
contrast	O
to	O
the	O
protection	T-2
provided	T-2
by	T-2
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	O
DTG	O
)	O
and	O
the	O
novel	T-5
sigma	T-5
receptor	T-5
agonist	T-5
BD1031	B-Chemical
(	O
3R	T-0
-	T-0
1	T-0
-	T-0
[	T-0
2	T-0
-	T-0
(	T-0
3	T-0
,	T-0
4	T-0
-	T-0
dichlorophenyl	T-0
)	O
ethyl	T-1
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
each	T-6
worsened	T-6
the	O
behavioral	T-4
toxicity	T-4
of	O
cocaine	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	T-1
by	T-1
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	T-3
-	T-3
o	T-3
-	T-3
tolylguanidine	T-3
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	T-4
(	O
3R	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
diazabicyclo	I-Chemical
[	I-Chemical
4	I-Chemical
.	I-Chemical
3	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
nonane	I-Chemical
)	O
each	O
worsened	T-2
the	O
behavioral	T-0
toxicity	T-0
of	O
cocaine	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	O
(	O
3R	T-0
-	T-0
1	T-0
-	T-0
[	T-0
2	T-0
-	T-0
(	T-0
3	T-0
,	T-0
4	T-0
-	T-0
dichlorophenyl	T-0
)	T-0
ethyl	T-0
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	T-2
the	O
behavioral	O
toxicity	B-Disease
of	T-3
cocaine	T-3
.	T-2

In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	T-1
DTG	T-1
)	T-1
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	O
(	O
3R	O
-	O
1	O
-	O
[	O
2	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
1	O
,	O
4	O
-	O
diazabicyclo	O
[	O
4	O
.	O
3	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	T-0
the	O
behavioral	O
toxicity	T-3
of	T-3
cocaine	B-Chemical
.	O

At	O
doses	O
where	O
alone	O
,	O
they	T-2
produced	T-2
no	T-3
significant	T-3
effects	T-3
on	O
locomotion	O
,	O
BD1018	B-Chemical
,	O
BD1063	T-0
and	O
LR132	T-1
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	O
.	O

At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	T-1
significant	T-1
effects	T-1
on	O
locomotion	O
,	O
BD1018	O
,	O
BD1063	B-Chemical
and	O
LR132	O
significantly	T-0
attenuated	T-0
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	O
.	O

At	O
doses	T-3
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	T-4
effects	T-4
on	O
locomotion	O
,	O
BD1018	T-0
,	O
BD1063	T-1
and	O
LR132	B-Chemical
significantly	T-6
attenuated	T-6
the	O
locomotor	O
stimulatory	T-5
effects	T-5
of	O
cocaine	T-2
.	O

At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	O
on	O
locomotion	O
,	O
BD1018	T-0
,	O
BD1063	T-1
and	O
LR132	T-2
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	T-3
of	T-3
cocaine	B-Chemical
.	O

To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	O
anti	O
-	O
cocaine	B-Chemical
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	O
against	O
sigma1	O
receptors	O
was	O
also	O
shown	O
to	O
significantly	O
attenuate	O
the	O
convulsive	T-0
and	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	O
.	O

To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	O
anti	O
-	O
cocaine	O
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	B-Chemical
against	O
sigma1	T-1
receptors	O
was	T-0
also	T-0
shown	T-0
to	O
significantly	O
attenuate	O
the	O
convulsive	O
and	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	O
.	O

To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	O
anti	O
-	O
cocaine	O
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	O
against	O
sigma1	O
receptors	O
was	O
also	O
shown	O
to	O
significantly	O
attenuate	T-2
the	T-2
convulsive	B-Disease
and	O
locomotor	T-0
stimulatory	T-0
effects	T-0
of	O
cocaine	O
.	O

To	O
further	O
validate	O
the	O
hypothesis	O
that	O
the	O
anti	O
-	O
cocaine	O
effects	O
of	O
the	O
novel	O
ligands	O
involved	O
antagonism	O
of	O
sigma	O
receptors	O
,	O
an	O
antisense	O
oligodeoxynucleotide	T-0
against	O
sigma1	O
receptors	O
was	O
also	O
shown	O
to	O
significantly	O
attenuate	O
the	O
convulsive	O
and	O
locomotor	O
stimulatory	O
effects	T-1
of	T-1
cocaine	B-Chemical
.	O

Together	O
,	O
the	O
data	O
suggests	O
that	O
functional	O
antagonism	O
of	O
sigma	O
receptors	T-0
is	O
capable	O
of	O
attenuating	T-2
a	T-2
number	T-2
of	O
cocaine	B-Chemical
-	O
induced	T-3
behaviors	T-3
.	O

Ranitidine	B-Chemical
-	O
induced	T-2
acute	T-2
interstitial	T-2
nephritis	T-2
in	O
a	O
cadaveric	O
renal	O
allograft	O
.	O

Ranitidine	T-2
-	T-2
induced	T-2
acute	T-2
interstitial	B-Disease
nephritis	I-Disease
in	O
a	O
cadaveric	T-3
renal	T-3
allograft	T-3
.	O

Ranitidine	B-Chemical
frequently	O
is	T-0
used	T-0
for	O
preventing	O
peptic	T-1
ulceration	T-1
after	O
renal	O
transplantation	O
.	O

This	O
drug	T-0
occasionally	O
has	O
been	O
associated	O
with	O
acute	T-1
interstitial	B-Disease
nephritis	I-Disease
in	O
native	O
kidneys	O
.	O

We	O
report	O
a	O
case	O
of	O
ranitidine	B-Chemical
-	O
induced	T-2
acute	T-2
interstitial	T-2
nephritis	T-2
in	O
a	O
recipient	O
of	O
a	O
cadaveric	O
renal	O
allograft	O
presenting	O
with	O
acute	O
allograft	O
dysfunction	O
within	O
48	O
hours	O
of	O
exposure	O
to	O
the	O
drug	T-1
.	O

We	O
report	T-0
a	T-0
case	T-0
of	O
ranitidine	O
-	O
induced	T-2
acute	O
interstitial	B-Disease
nephritis	I-Disease
in	T-3
a	T-3
recipient	T-3
of	O
a	O
cadaveric	O
renal	O
allograft	O
presenting	O
with	O
acute	O
allograft	O
dysfunction	O
within	O
48	O
hours	O
of	O
exposure	O
to	O
the	O
drug	O
.	O

Liver	B-Disease
disease	I-Disease
caused	T-1
by	T-1
propylthiouracil	T-0
.	O

Liver	T-0
disease	O
caused	T-1
by	T-1
propylthiouracil	B-Chemical
.	O

This	O
report	O
presents	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
light	O
and	O
electron	O
microscopic	O
observations	O
on	T-2
a	T-2
patient	T-2
with	T-2
chronic	B-Disease
active	I-Disease
(	I-Disease
aggressive	I-Disease
)	I-Disease
hepatitis	I-Disease
caused	T-3
by	T-3
the	T-3
administration	O
of	O
propylthiouracil	T-0
.	O

This	O
report	O
presents	O
the	O
clinical	O
,	O
laboratory	O
,	O
and	O
light	O
and	O
electron	O
microscopic	O
observations	O
on	O
a	O
patient	O
with	O
chronic	O
active	O
(	T-0
aggressive	T-0
)	T-0
hepatitis	T-3
caused	T-2
by	T-2
the	O
administration	T-1
of	T-1
propylthiouracil	B-Chemical
.	O

This	O
is	O
an	O
addition	O
to	O
the	O
list	O
of	O
drugs	O
that	O
must	O
be	O
considered	O
in	O
the	O
evaluation	T-0
of	T-0
chronic	T-1
liver	B-Disease
disease	I-Disease
.	O

Withdrawal	B-Disease
-	I-Disease
emergent	I-Disease
rabbit	I-Disease
syndrome	I-Disease
during	T-1
dose	O
reduction	O
of	O
risperidone	T-0
.	O

Withdrawal	O
-	O
emergent	O
rabbit	O
syndrome	T-1
during	T-0
dose	T-2
reduction	T-2
of	O
risperidone	B-Chemical
.	O

Rabbit	B-Disease
syndrome	I-Disease
(	O
RS	O
)	O
is	O
a	O
rare	T-2
extrapyramidal	T-2
side	T-2
effect	T-2
caused	T-1
by	O
prolonged	T-3
neuroleptic	T-3
medication	T-3
.	O

Rabbit	T-1
syndrome	T-1
(	O
RS	B-Disease
)	O
is	T-0
a	T-0
rare	T-0
extrapyramidal	T-0
side	O
effect	O
caused	O
by	O
prolonged	O
neuroleptic	O
medication	O
.	O

Here	O
we	O
present	O
a	O
case	T-2
of	T-2
withdrawal	B-Disease
-	I-Disease
emergent	I-Disease
RS	I-Disease
,	O
which	T-1
is	T-1
the	T-1
first	T-1
of	T-1
its	T-1
kind	T-1
to	T-1
be	T-1
reported	T-1
.	O

The	O
patient	O
developed	O
RS	B-Disease
during	T-0
dose	T-0
reduction	T-0
of	T-0
risperidone	T-0
.	O

The	O
patient	O
developed	O
RS	O
during	O
dose	T-0
reduction	T-0
of	T-0
risperidone	B-Chemical
.	O

The	O
symptom	O
was	T-0
treated	T-1
successfully	O
with	O
trihexyphenidyl	B-Chemical
anticholinergic	O
therapy	O
.	O

The	O
underlying	O
mechanism	T-1
of	T-1
withdrawal	B-Disease
-	I-Disease
emergent	I-Disease
RS	I-Disease
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	O
,	O
a	O
serotonin	O
-	O
dopamine	O
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	T-2
of	T-2
the	O
serotonin	O
system	O
in	O
the	O
development	O
of	O
RS	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	B-Chemical
,	O
a	T-0
serotonin	T-0
-	O
dopamine	O
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	O
system	O
in	O
the	O
development	O
of	O
RS	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	O
,	O
a	O
serotonin	O
-	O
dopamine	B-Chemical
antagonist	T-1
,	O
suggesting	T-0
the	T-0
pathophysiologic	O
influence	O
of	O
the	O
serotonin	O
system	O
in	O
the	O
development	O
of	O
RS	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	O
,	O
a	O
serotonin	O
-	O
dopamine	O
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	T-0
influence	T-2
of	T-2
the	O
serotonin	B-Chemical
system	T-1
in	O
the	O
development	O
of	O
RS	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	O
,	O
a	O
serotonin	O
-	O
dopamine	O
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	O
system	O
in	O
the	O
development	T-0
of	T-0
RS	B-Disease
.	O

Pharmacokinetic	O
/	O
pharmacodynamic	O
assessment	O
of	O
the	O
effects	T-1
of	T-1
E4031	B-Chemical
,	O
cisapride	O
,	O
terfenadine	O
and	O
terodiline	O
on	O
monophasic	O
action	O
potential	T-0
duration	T-0
in	T-0
dog	T-0
.	O

Pharmacokinetic	O
/	O
pharmacodynamic	O
assessment	O
of	O
the	O
effects	T-0
of	O
E4031	O
,	O
cisapride	B-Chemical
,	O
terfenadine	O
and	O
terodiline	O
on	O
monophasic	T-2
action	T-2
potential	T-2
duration	T-2
in	T-2
dog	T-2
.	T-2

Pharmacokinetic	O
/	O
pharmacodynamic	O
assessment	T-0
of	T-0
the	T-0
effects	T-1
of	T-1
E4031	O
,	O
cisapride	O
,	O
terfenadine	B-Chemical
and	O
terodiline	O
on	O
monophasic	O
action	O
potential	O
duration	O
in	O
dog	O
.	O

Pharmacokinetic	O
/	O
pharmacodynamic	O
assessment	O
of	O
the	O
effects	T-1
of	T-1
E4031	O
,	O
cisapride	O
,	O
terfenadine	O
and	O
terodiline	B-Chemical
on	O
monophasic	T-0
action	T-0
potential	O
duration	O
in	O
dog	O
.	O

Torsades	B-Disease
de	I-Disease
pointes	I-Disease
(	O
TDP	O
)	O
is	O
a	O
potentially	T-0
fatal	O
ventricular	O
tachycardia	O
associated	T-1
with	O
increases	O
in	O
QT	O
interval	O
and	O
monophasic	O
action	O
potential	O
duration	O
(	O
MAPD	O
)	O
.	O

Torsades	O
de	O
pointes	O
(	O
TDP	B-Disease
)	O
is	T-1
a	T-1
potentially	O
fatal	O
ventricular	O
tachycardia	O
associated	O
with	O
increases	O
in	O
QT	O
interval	O
and	O
monophasic	O
action	O
potential	O
duration	O
(	O
MAPD	O
)	O
.	T-0

TDP	B-Disease
is	O
a	O
side	T-0
-	T-0
effect	T-0
that	O
has	O
led	O
to	O
withdrawal	T-1
of	O
several	O
drugs	O
from	O
the	O
market	O
(	O
e	O
.	O
g	O
.	O
terfenadine	O
and	O
terodiline	O
)	O
.	O

TDP	O
is	O
a	O
side	T-1
-	T-1
effect	T-1
that	O
has	O
led	T-2
to	T-2
withdrawal	T-2
of	T-0
several	O
drugs	O
from	O
the	O
market	O
(	O
e	O
.	O
g	O
.	O
terfenadine	B-Chemical
and	O
terodiline	O
)	O
.	O

TDP	O
is	O
a	O
side	T-0
-	T-0
effect	T-0
that	O
has	O
led	O
to	O
withdrawal	O
of	O
several	O
drugs	T-1
from	O
the	O
market	O
(	O
e	O
.	O
g	O
.	O
terfenadine	O
and	T-2
terodiline	B-Chemical
)	O
.	O

The	O
potential	O
of	O
compounds	O
to	O
cause	T-0
TDP	B-Disease
was	O
evaluated	T-1
by	O
monitoring	O
their	O
effects	T-2
on	O
MAPD	O
in	O
dog	O
.	O

Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	T-0
TDP	B-Disease
were	O
investigated	O
:	O
terfenadine	O
,	O
terodiline	O
,	O
cisapride	O
and	O
E4031	O
.	O

Four	O
compounds	T-0
known	T-0
to	T-0
increase	T-0
QT	O
interval	O
and	O
cause	O
TDP	O
were	O
investigated	O
:	O
terfenadine	B-Chemical
,	O
terodiline	O
,	O
cisapride	O
and	O
E4031	O
.	O

Four	O
compounds	T-2
known	O
to	O
increase	T-0
QT	O
interval	O
and	O
cause	T-1
TDP	O
were	O
investigated	T-3
:	O
terfenadine	O
,	O
terodiline	B-Chemical
,	O
cisapride	O
and	O
E4031	O
.	O

Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	O
TDP	O
were	O
investigated	O
:	O
terfenadine	O
,	O
terodiline	T-0
,	O
cisapride	B-Chemical
and	T-1
E4031	T-1
.	O

Four	T-0
compounds	T-0
known	O
to	T-1
increase	T-1
QT	O
interval	O
and	O
cause	T-2
TDP	O
were	T-3
investigated	T-3
:	O
terfenadine	O
,	O
terodiline	O
,	O
cisapride	O
and	O
E4031	B-Chemical
.	O

These	O
data	O
indicate	O
that	O
the	O
free	O
ED50	O
in	T-1
plasma	T-1
for	T-0
terfenadine	B-Chemical
(	O
1	O
.	O
9	O
nM	O
)	O
,	O
terodiline	O
(	O
76	O
nM	O
)	O
,	O
cisapride	O
(	O
11	O
nM	O
)	O
and	O
E4031	O
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correlate	O
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	O
.	O

These	O
data	O
indicate	O
that	O
the	O
free	O
ED50	O
in	O
plasma	O
for	O
terfenadine	O
(	O
1	O
.	O
9	O
nM	O
)	O
,	O
terodiline	B-Chemical
(	O
76	O
nM	O
)	O
,	O
cisapride	O
(	O
11	O
nM	O
)	O
and	O
E4031	O
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correlate	T-0
with	T-0
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	O
.	O

These	T-0
data	T-0
indicate	T-0
that	O
the	O
free	O
ED50	O
in	O
plasma	O
for	O
terfenadine	O
(	O
1	O
.	O
9	O
nM	O
)	O
,	O
terodiline	T-1
(	T-1
76	T-1
nM	T-1
)	T-1
,	O
cisapride	B-Chemical
(	O
11	O
nM	O
)	O
and	T-2
E4031	T-2
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correlate	O
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	O
.	O

These	O
data	O
indicate	T-3
that	O
the	O
free	T-0
ED50	T-0
in	T-0
plasma	T-0
for	T-0
terfenadine	T-0
(	O
1	O
.	O
9	O
nM	O
)	O
,	O
terodiline	T-1
(	T-1
76	T-1
nM	T-1
)	T-1
,	T-1
cisapride	T-1
(	T-1
11	T-1
nM	T-1
)	T-1
and	T-2
E4031	B-Chemical
(	O
1	O
.	O
9	O
nM	O
)	O
closely	O
correlate	T-4
with	O
the	O
free	O
concentration	O
in	O
man	O
causing	O
QT	O
effects	T-5
.	O

For	O
compounds	O
that	T-1
have	T-1
shown	T-1
TDP	B-Disease
in	T-2
the	T-2
clinic	T-2
(	O
terfenadine	O
,	O
terodiline	O
,	O
cisapride	O
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O

For	O
compounds	T-0
that	O
have	O
shown	O
TDP	O
in	O
the	O
clinic	O
(	O
terfenadine	B-Chemical
,	O
terodiline	O
,	O
cisapride	O
)	O
there	O
is	O
little	O
differentiation	T-1
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	T-2
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O

For	O
compounds	T-0
that	O
have	O
shown	O
TDP	O
in	O
the	O
clinic	O
(	O
terfenadine	O
,	O
terodiline	B-Chemical
,	O
cisapride	O
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O

For	O
compounds	O
that	O
have	O
shown	T-0
TDP	T-0
in	O
the	O
clinic	O
(	O
terfenadine	O
,	O
terodiline	O
,	O
cisapride	B-Chemical
)	O
there	T-1
is	T-1
little	T-1
differentiation	T-1
between	O
the	O
dog	O
ED50	O
and	O
the	O
efficacious	O
free	O
plasma	O
concentrations	O
in	O
man	O
(	O
<	O
10	O
-	O
fold	O
)	O
reflecting	O
their	O
limited	O
safety	O
margins	O
.	O

These	O
data	O
underline	O
the	O
need	O
to	O
maximize	O
the	O
therapeutic	T-0
ratio	T-0
with	O
respect	O
to	O
TDP	B-Disease
in	O
potential	O
development	O
candidates	O
and	O
the	O
importance	O
of	O
using	O
free	O
drug	O
concentrations	O
in	O
pharmacokinetic	O
/	O
pharmacodynamic	O
studies	O
.	O

Bladder	T-0
retention	B-Disease
of	I-Disease
urine	I-Disease
as	T-1
a	T-1
result	T-1
of	O
continuous	O
intravenous	O
infusion	O
of	O
fentanyl	O
:	O
2	O
case	T-2
reports	T-2
.	O

Bladder	O
retention	O
of	O
urine	O
as	O
a	O
result	O
of	O
continuous	O
intravenous	O
infusion	T-1
of	T-1
fentanyl	B-Chemical
:	O
2	O
case	O
reports	O
.	O

Sedation	O
has	O
been	O
commonly	O
used	O
in	O
the	O
neonate	O
to	O
decrease	T-1
the	T-1
stress	O
and	O
pain	B-Disease
from	T-2
the	O
noxious	O
stimuli	O
and	O
invasive	O
procedures	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
,	O
as	O
well	O
as	O
to	O
facilitate	O
synchrony	O
between	O
ventilator	O
and	O
spontaneous	O
breaths	O
.	O

Fentanyl	B-Chemical
,	O
an	T-0
opioid	T-0
analgesic	T-0
,	O
is	O
frequently	O
used	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
setting	O
for	O
these	O
very	O
purposes	O
.	O

Various	O
reported	O
side	T-1
effects	T-1
of	T-0
fentanyl	B-Chemical
administration	T-2
include	O
chest	O
wall	O
rigidity	O
,	O
hypotension	O
,	O
respiratory	O
depression	O
,	O
and	O
bradycardia	O
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	O
administration	T-3
include	T-3
chest	B-Disease
wall	I-Disease
rigidity	I-Disease
,	O
hypotension	T-1
,	O
respiratory	T-2
depression	O
,	O
and	O
bradycardia	O
.	T-2

Various	T-2
reported	T-2
side	T-2
effects	T-2
of	O
fentanyl	O
administration	O
include	T-3
chest	T-0
wall	T-0
rigidity	T-0
,	O
hypotension	B-Disease
,	O
respiratory	T-1
depression	T-1
,	O
and	O
bradycardia	O
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	O
administration	O
include	O
chest	O
wall	O
rigidity	O
,	O
hypotension	T-0
,	O
respiratory	B-Disease
depression	I-Disease
,	O
and	T-1
bradycardia	T-1
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	O
administration	O
include	O
chest	O
wall	O
rigidity	O
,	O
hypotension	O
,	O
respiratory	O
depression	O
,	O
and	T-0
bradycardia	B-Disease
.	O

Here	O
,	O
2	T-1
cases	T-1
of	T-1
urinary	B-Disease
bladder	I-Disease
retention	I-Disease
leading	O
to	O
renal	O
pelvocalyceal	O
dilatation	O
mimicking	O
hydronephrosis	O
as	O
a	O
result	O
of	O
continuous	O
infusion	O
of	O
fentanyl	O
are	O
reported	O
.	O

Here	O
,	O
2	O
cases	O
of	O
urinary	O
bladder	O
retention	O
leading	O
to	O
renal	O
pelvocalyceal	O
dilatation	O
mimicking	O
hydronephrosis	B-Disease
as	T-0
a	T-0
result	T-0
of	T-0
continuous	T-0
infusion	T-0
of	O
fentanyl	O
are	O
reported	O
.	O

Here	O
,	O
2	O
cases	O
of	O
urinary	O
bladder	O
retention	O
leading	O
to	O
renal	O
pelvocalyceal	O
dilatation	O
mimicking	O
hydronephrosis	O
as	O
a	O
result	O
of	O
continuous	O
infusion	T-0
of	T-0
fentanyl	B-Chemical
are	O
reported	O
.	O

Fatal	T-1
myeloencephalopathy	B-Disease
due	T-0
to	T-0
accidental	O
intrathecal	O
vincristin	O
administration	O
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

Fatal	O
myeloencephalopathy	O
due	O
to	O
accidental	T-0
intrathecal	T-0
vincristin	B-Chemical
administration	T-1
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

We	O
report	O
on	O
two	O
fatal	O
cases	O
of	O
accidental	O
intrathecal	T-0
vincristine	B-Chemical
instillation	T-1
in	O
a	O
5	O
-	O
year	O
old	O
girl	O
with	O
recurrent	O
acute	O
lymphoblastic	O
leucemia	O
and	O
a	O
57	O
-	O
year	O
old	O
man	O
with	O
lymphoblastic	O
lymphoma	O
.	O

We	O
report	O
on	O
two	O
fatal	O
cases	O
of	O
accidental	O
intrathecal	O
vincristine	O
instillation	O
in	O
a	O
5	O
-	O
year	O
old	O
girl	O
with	O
recurrent	T-0
acute	B-Disease
lymphoblastic	I-Disease
leucemia	I-Disease
and	O
a	O
57	O
-	O
year	O
old	O
man	O
with	O
lymphoblastic	O
lymphoma	O
.	O

We	O
report	O
on	O
two	O
fatal	O
cases	O
of	O
accidental	O
intrathecal	O
vincristine	O
instillation	O
in	O
a	O
5	O
-	O
year	O
old	O
girl	O
with	O
recurrent	O
acute	O
lymphoblastic	O
leucemia	O
and	O
a	O
57	O
-	O
year	O
old	T-0
man	T-0
with	T-0
lymphoblastic	B-Disease
lymphoma	I-Disease
.	O

The	O
girl	O
died	T-0
seven	T-0
days	T-0
,	O
the	O
man	O
four	O
weeks	O
after	T-1
intrathecal	T-1
injection	T-1
of	T-1
vincristine	B-Chemical
.	O

Clinically	O
,	O
the	O
onset	O
was	O
characterized	T-0
by	T-0
the	T-0
signs	T-0
of	T-0
opistothonus	B-Disease
,	I-Disease
sensory	I-Disease
and	I-Disease
motor	I-Disease
dysfunction	I-Disease
and	O
ascending	O
paralysis	O
.	O

Clinically	O
,	O
the	O
onset	O
was	O
characterized	O
by	O
the	O
signs	O
of	O
opistothonus	O
,	O
sensory	O
and	O
motor	O
dysfunction	O
and	T-0
ascending	T-0
paralysis	B-Disease
.	O

Histological	O
and	O
immunohistochemical	O
investigations	T-0
(	O
HE	O
-	O
LFB	O
,	O
CD	O
-	O
68	O
,	O
Neurofilament	O
)	O
revealed	T-1
degeneration	B-Disease
of	I-Disease
myelin	I-Disease
and	I-Disease
axons	I-Disease
as	O
well	O
as	O
pseudocystic	O
transformation	O
in	O
areas	O
exposed	O
to	O
vincristine	O
,	O
accompanied	O
by	O
secondary	O
changes	O
with	O
numerous	O
prominent	O
macrophages	T-2
.	T-2

Histological	O
and	O
immunohistochemical	O
investigations	O
(	O
HE	O
-	O
LFB	O
,	O
CD	O
-	O
68	O
,	O
Neurofilament	O
)	O
revealed	T-0
degeneration	O
of	O
myelin	O
and	O
axons	O
as	O
well	O
as	O
pseudocystic	B-Disease
transformation	I-Disease
in	O
areas	O
exposed	T-1
to	O
vincristine	O
,	O
accompanied	O
by	O
secondary	O
changes	O
with	O
numerous	O
prominent	O
macrophages	O
.	O

Histological	O
and	O
immunohistochemical	O
investigations	O
(	O
HE	O
-	O
LFB	O
,	O
CD	O
-	O
68	O
,	O
Neurofilament	O
)	O
revealed	O
degeneration	O
of	O
myelin	O
and	O
axons	O
as	O
well	O
as	O
pseudocystic	O
transformation	O
in	O
areas	O
exposed	T-0
to	T-0
vincristine	B-Chemical
,	O
accompanied	T-1
by	T-1
secondary	O
changes	O
with	O
numerous	O
prominent	O
macrophages	O
.	O

A	O
better	T-2
controlled	T-2
regimen	T-2
for	T-2
administering	T-2
vincristine	B-Chemical
and	T-1
intrathecal	T-3
chemotherapy	T-3
is	T-3
recommended	T-3
.	T-3

Palpebral	O
twitching	O
in	T-0
a	T-0
depressed	B-Disease
adolescent	O
on	O
citalopram	O
.	O

Palpebral	O
twitching	O
in	O
a	O
depressed	O
adolescent	T-0
on	T-0
citalopram	B-Chemical
.	O

Current	O
estimates	O
suggest	O
that	O
between	O
0	O
.	O
4	O
%	O
and	O
8	O
.	O
3	O
%	O
of	O
children	T-0
and	T-0
adolescents	T-0
are	T-0
affected	T-0
by	T-0
major	B-Disease
depression	I-Disease
.	O

We	O
report	O
a	O
favorable	O
response	O
to	T-0
treatment	T-0
with	T-0
citalopram	B-Chemical
by	T-1
a	T-1
15	T-1
-	T-1
year	T-1
-	O
old	O
boy	O
with	O
major	O
depression	O
who	O
exhibited	O
palpebral	O
twitching	O
during	O
his	O
first	O
2	O
weeks	O
of	O
treatment	O
.	O

We	O
report	O
a	O
favorable	O
response	T-0
to	O
treatment	O
with	O
citalopram	O
by	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
major	B-Disease
depression	I-Disease
who	O
exhibited	T-1
palpebral	O
twitching	O
during	O
his	O
first	O
2	O
weeks	O
of	O
treatment	O
.	O

We	O
report	O
a	O
favorable	T-0
response	T-0
to	T-0
treatment	T-0
with	O
citalopram	O
by	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
major	O
depression	O
who	O
exhibited	T-3
palpebral	B-Disease
twitching	I-Disease
during	O
his	O
first	T-2
2	T-2
weeks	T-2
of	T-2
treatment	T-2
.	O

This	O
may	O
have	O
been	O
a	O
side	T-1
effect	T-1
of	T-1
citalopram	B-Chemical
as	T-0
it	T-0
remitted	T-0
with	O
redistribution	O
of	O
doses	O
.	O

The	O
3	O
-	O
week	O
sulphasalazine	B-Chemical
syndrome	T-0
strikes	T-1
again	T-1
.	O

A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	T-2
a	T-2
constellation	T-2
of	T-2
dermatitis	B-Disease
,	O
fever	T-1
,	O
lymphadenopathy	O
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	O
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	T-1
a	O
constellation	O
of	O
dermatitis	O
,	O
fever	B-Disease
,	O
lymphadenopathy	O
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	T-0
of	T-0
oral	T-0
sulphasalazine	T-0
for	T-0
sero	T-0
-	O
negative	O
rheumatoid	O
arthritis	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	T-0
a	T-0
constellation	O
of	O
dermatitis	O
,	O
fever	T-1
,	O
lymphadenopathy	B-Disease
and	T-2
hepatitis	T-2
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	O
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	O
,	O
fever	O
,	O
lymphadenopathy	O
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	T-1
of	T-1
oral	T-1
sulphasalazine	B-Chemical
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	O
,	O
fever	O
,	O
lymphadenopathy	O
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	O
for	O
sero	O
-	O
negative	T-0
rheumatoid	B-Disease
arthritis	I-Disease
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	T-2
of	T-2
severe	T-2
necrotising	T-2
lymphadenitis	B-Disease
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	O
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	O
-	O
induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi	T-1
-	T-1
organ	T-1
failure	T-1
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	O
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	B-Disease
drug	I-Disease
reaction	I-Disease
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	O
-	O
induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi	T-0
-	T-0
organ	T-0
failure	T-0
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	T-0
and	T-0
inguinal	T-0
lymph	T-0
node	T-0
biopsies	T-0
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	O
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	O
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	B-Disease
-	I-Disease
induced	I-Disease
hepatitis	I-Disease
,	O
associated	T-1
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi	O
-	O
organ	O
failure	O
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	O
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	O
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	O
-	O
induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	T-0
markers	T-0
of	T-0
autoimmunity	B-Disease
)	O
,	O
and	T-1
accompanied	T-1
by	O
multi	O
-	O
organ	O
failure	O
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	O
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	O
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	O
-	O
induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	T-0
by	T-0
multi	B-Disease
-	I-Disease
organ	I-Disease
failure	I-Disease
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	O
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	O
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	T-3
-	T-3
induced	T-3
hepatitis	T-3
,	O
associated	O
with	O
the	O
presence	T-2
of	T-2
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi	T-4
-	T-4
organ	T-4
failure	T-4
and	T-0
sepsis	B-Disease
,	O
supervened	T-1
.	O

She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy	O
.	O
Post	T-2
-	T-2
mortem	T-2
examination	T-2
showed	T-2
evidence	T-2
of	T-2
massive	B-Disease
hepatocellular	I-Disease
necrosis	I-Disease
,	O
acute	T-1
hypersensitivity	T-1
myocarditis	T-1
,	O
focal	O
acute	O
tubulo	O
-	O
interstitial	O
nephritis	O
and	O
extensive	O
bone	O
marrow	O
necrosis	O
,	O
with	O
no	O
evidence	O
of	O
malignancy	O
.	O

She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy	O
.	O
Post	O
-	O
mortem	O
examination	O
showed	O
evidence	O
of	O
massive	O
hepatocellular	O
necrosis	O
,	O
acute	O
hypersensitivity	O
myocarditis	O
,	O
focal	O
acute	O
tubulo	O
-	O
interstitial	T-0
nephritis	B-Disease
and	T-1
extensive	T-1
bone	O
marrow	O
necrosis	O
,	O
with	O
no	O
evidence	O
of	O
malignancy	O
.	O

She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy	O
.	O
Post	O
-	O
mortem	O
examination	O
showed	O
evidence	O
of	O
massive	O
hepatocellular	O
necrosis	O
,	O
acute	O
hypersensitivity	O
myocarditis	O
,	O
focal	O
acute	O
tubulo	O
-	O
interstitial	O
nephritis	O
and	O
extensive	T-0
bone	B-Disease
marrow	I-Disease
necrosis	I-Disease
,	O
with	O
no	O
evidence	O
of	O
malignancy	O
.	O

She	O
subsequently	O
died	O
some	O
5	O
weeks	O
after	O
the	O
commencement	O
of	O
her	O
drug	O
therapy	O
.	O
Post	O
-	O
mortem	O
examination	O
showed	O
evidence	O
of	O
massive	O
hepatocellular	O
necrosis	O
,	O
acute	O
hypersensitivity	O
myocarditis	O
,	O
focal	O
acute	O
tubulo	O
-	O
interstitial	O
nephritis	O
and	O
extensive	O
bone	O
marrow	O
necrosis	O
,	O
with	O
no	T-1
evidence	T-1
of	T-1
malignancy	B-Disease
.	O

It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	T-0
"	T-0
3	T-0
-	T-0
week	T-0
sulphasalazine	B-Chemical
syndrome	T-1
"	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	O
.	O

It	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
"	O
3	O
-	O
week	O
sulphasalazine	O
syndrome	O
"	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	T-1
reaction	T-1
to	T-1
sulphasalazine	B-Chemical
.	O

Intravenous	T-0
administration	T-0
of	T-0
prochlorperazine	B-Chemical
by	O
15	O
-	O
minute	O
infusion	O
versus	O
2	O
-	O
minute	O
bolus	O
does	O
not	O
affect	O
the	O
incidence	O
of	O
akathisia	O
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

Intravenous	O
administration	O
of	O
prochlorperazine	O
by	O
15	O
-	O
minute	O
infusion	O
versus	O
2	O
-	O
minute	O
bolus	O
does	O
not	O
affect	O
the	O
incidence	T-0
of	T-0
akathisia	B-Disease
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

STUDY	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
compare	O
the	O
rate	O
of	O
akathisia	B-Disease
after	O
administration	O
of	O
intravenous	T-0
prochlorperazine	T-0
as	O
a	O
2	O
-	O
minute	O
bolus	O
or	O
15	O
-	O
minute	O
infusion	O
.	O

STUDY	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
compare	O
the	O
rate	O
of	O
akathisia	O
after	O
administration	O
of	T-0
intravenous	T-0
prochlorperazine	B-Chemical
as	O
a	O
2	T-1
-	T-1
minute	T-1
bolus	T-1
or	T-1
15	T-1
-	T-1
minute	T-1
infusion	T-1
.	O

Patients	O
aged	O
18	O
years	O
or	O
older	O
treated	T-0
with	T-0
prochlorperazine	O
for	T-1
headache	B-Disease
,	O
nausea	O
,	O
or	O
vomiting	O
were	O
eligible	O
for	O
inclusion	O
.	O

Patients	T-0
aged	T-0
18	O
years	O
or	O
older	O
treated	T-1
with	O
prochlorperazine	O
for	O
headache	T-2
,	O
nausea	B-Disease
,	O
or	O
vomiting	T-3
were	O
eligible	O
for	O
inclusion	O
.	O

Patients	T-0
aged	O
18	O
years	O
or	O
older	O
treated	O
with	O
prochlorperazine	O
for	O
headache	O
,	O
nausea	O
,	O
or	O
vomiting	B-Disease
were	O
eligible	O
for	O
inclusion	O
.	O

Study	O
participants	O
were	O
randomized	O
to	O
receive	T-1
10	O
mg	O
of	O
prochlorperazine	B-Chemical
administered	T-2
intravenously	O
by	O
means	O
of	O
2	O
-	O
minute	O
push	O
(	O
bolus	O
group	O
)	O
or	O
10	T-0
mg	T-0
diluted	T-0
in	T-0
50	T-0
mL	T-0
of	O
normal	O
saline	O
solution	O
administered	O
by	O
means	O
of	O
intravenous	O
infusion	O
during	O
a	O
15	O
-	O
minute	O
period	O
(	O
infusion	O
group	O
)	O
.	O

The	O
main	O
outcome	O
was	O
the	O
number	O
of	O
study	O
participants	O
experiencing	T-1
akathisia	B-Disease
within	T-0
60	T-0
minutes	T-0
of	T-0
administration	T-0
.	O

Akathisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneous	O
report	O
of	O
restlessness	O
or	O
agitation	B-Disease
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patient	O
-	O
reported	T-0
akathisia	T-0
rating	T-0
scale	T-0
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigator	O
-	O
observed	O
akathisia	O
rating	O
scale	O
.	O

Akathisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneous	O
report	O
of	O
restlessness	O
or	O
agitation	O
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patient	T-0
-	T-0
reported	T-0
akathisia	B-Disease
rating	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigator	O
-	O
observed	O
akathisia	O
rating	O
scale	O
.	O

Akathisia	O
was	O
defined	O
as	O
either	O
a	O
spontaneous	O
report	O
of	O
restlessness	O
or	O
agitation	O
or	O
a	O
change	O
of	O
2	O
or	O
more	O
in	O
the	O
patient	O
-	O
reported	O
akathisia	O
rating	O
scale	O
and	O
a	O
change	O
of	O
at	O
least	O
1	O
in	O
the	O
investigator	O
-	O
observed	T-0
akathisia	B-Disease
rating	T-1
scale	T-1
.	O

The	O
intensity	T-1
of	T-1
headache	B-Disease
and	O
nausea	T-0
was	O
measured	O
with	O
a	O
100	O
-	O
mm	O
visual	O
analog	O
scale	O
.	O

The	O
intensity	O
of	O
headache	O
and	O
nausea	B-Disease
was	O
measured	T-0
with	T-0
a	O
100	O
-	O
mm	O
visual	O
analog	O
scale	O
.	O

Seventy	O
-	O
three	O
percent	O
(	O
73	O
/	O
99	O
)	O
of	O
the	O
study	O
participants	O
were	O
treated	T-1
for	T-1
headache	B-Disease
and	T-0
70	T-0
%	T-0
(	O
70	O
/	O
99	O
)	O
for	O
nausea	O
.	O

Seventy	O
-	O
three	O
percent	O
(	O
73	O
/	O
99	O
)	O
of	O
the	O
study	O
participants	O
were	O
treated	O
for	O
headache	O
and	O
70	O
%	O
(	O
70	O
/	O
99	O
)	O
for	T-0
nausea	B-Disease
.	O

In	O
the	O
bolus	O
group	T-0
,	O
26	O
.	O
0	O
%	O
(	O
13	O
/	O
50	O
)	O
had	T-1
akathisia	B-Disease
compared	O
with	O
32	O
.	O
7	O
%	O
(	O
16	O
/	O
49	O
)	O
in	O
the	O
infusion	O
group	O
(	O
Delta	O
=	O
-	O
6	O
.	O
7	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
-	O
24	O
.	O
6	O
%	O
to	O
11	O
.	O
2	O
%	O
)	O
.	O

The	O
difference	O
between	O
the	O
bolus	O
and	O
infusion	O
groups	O
in	O
the	O
percentage	O
of	O
participants	O
who	O
saw	O
a	O
50	O
%	O
reduction	T-0
in	T-0
their	T-0
headache	B-Disease
intensity	T-1
within	O
30	O
minutes	O
was	O
11	O
.	O
8	O
%	O
(	O
95	O
%	O
CI	O
-	O
9	O
.	O
6	O
%	O
to	O
33	O
.	O
3	O
%	O
)	O
.	O

The	O
difference	O
in	O
the	O
percentage	O
of	O
patients	O
with	O
a	O
50	O
%	O
reduction	T-0
in	T-0
their	T-0
nausea	B-Disease
was	T-1
12	T-1
.	T-1
6	T-1
%	T-1
(	O
95	O
%	O
CI	O
-	O
4	O
.	O
6	O
%	O
to	O
29	O
.	O
8	O
%	O
)	O
.	O

CONCLUSION	O
:	O
A	O
50	O
%	O
reduction	T-1
in	T-1
the	T-1
incidence	T-1
of	T-1
akathisia	B-Disease
when	O
prochlorperazine	O
was	O
administered	T-0
by	O
means	O
of	O
15	O
-	O
minute	O
intravenous	O
infusion	O
versus	O
a	O
2	O
-	O
minute	O
intravenous	O
push	O
was	O
not	O
detected	O
.	O

CONCLUSION	O
:	O
A	O
50	O
%	O
reduction	O
in	O
the	O
incidence	O
of	O
akathisia	O
when	O
prochlorperazine	B-Chemical
was	O
administered	T-0
by	O
means	O
of	O
15	O
-	O
minute	O
intravenous	T-1
infusion	T-1
versus	O
a	O
2	O
-	O
minute	O
intravenous	O
push	O
was	O
not	O
detected	O
.	O

The	O
efficacy	T-0
of	T-0
prochlorperazine	B-Chemical
in	O
the	O
treatment	T-1
of	T-1
headache	O
and	O
nausea	O
likewise	O
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
rate	O
of	O
administration	O
,	O
although	O
no	O
formal	O
statistical	O
comparisons	O
were	O
made	O
.	O

The	O
efficacy	O
of	O
prochlorperazine	O
in	O
the	O
treatment	T-1
of	T-1
headache	B-Disease
and	T-2
nausea	T-2
likewise	O
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
rate	O
of	O
administration	O
,	O
although	O
no	O
formal	O
statistical	O
comparisons	O
were	O
made	O
.	O

The	O
efficacy	O
of	O
prochlorperazine	O
in	O
the	O
treatment	T-1
of	T-1
headache	O
and	O
nausea	B-Disease
likewise	O
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
rate	O
of	O
administration	O
,	O
although	O
no	O
formal	O
statistical	O
comparisons	O
were	O
made	O
.	O

Combined	O
antiretroviral	O
therapy	T-0
causes	T-1
cardiomyopathy	B-Disease
and	O
elevates	T-2
plasma	O
lactate	O
in	O
transgenic	O
AIDS	O
mice	O
.	O

Combined	O
antiretroviral	T-0
therapy	T-0
causes	O
cardiomyopathy	O
and	O
elevates	O
plasma	O
lactate	B-Chemical
in	O
transgenic	O
AIDS	O
mice	O
.	O

Combined	O
antiretroviral	O
therapy	O
causes	O
cardiomyopathy	O
and	O
elevates	T-2
plasma	O
lactate	O
in	O
transgenic	T-0
AIDS	B-Disease
mice	T-1
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	T-1
in	T-1
cardiomyopathy	B-Disease
(	T-2
CM	T-2
)	T-2
and	T-0
in	T-0
elevated	T-0
plasma	T-0
lactate	T-0
(	O
LA	O
)	O
in	O
AIDS	O
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	T-0
in	O
cardiomyopathy	O
(	O
CM	B-Disease
)	O
and	O
in	O
elevated	O
plasma	O
lactate	O
(	O
LA	O
)	O
in	O
AIDS	O
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	O
(	O
CM	O
)	O
and	O
in	O
elevated	T-1
plasma	O
lactate	B-Chemical
(	O
LA	O
)	O
in	T-0
AIDS	T-0
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	O
(	O
CM	O
)	O
and	O
in	O
elevated	T-1
plasma	T-0
lactate	T-0
(	O
LA	B-Chemical
)	O
in	O
AIDS	O
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	O
(	O
CM	O
)	O
and	O
in	O
elevated	T-0
plasma	O
lactate	O
(	O
LA	O
)	O
in	O
AIDS	B-Disease
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	O
(	O
CM	O
)	O
and	O
in	O
elevated	O
plasma	O
lactate	O
(	O
LA	O
)	O
in	O
AIDS	O
through	O
mechanisms	T-0
of	T-0
mitochondrial	B-Disease
dysfunction	I-Disease
.	O

To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	O
hemizygous	O
transgenic	T-1
AIDS	B-Disease
mice	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wild	O
-	O
type	O
FVB	O
/	O
n	O
littermates	T-0
were	T-0
treated	T-0
with	O
the	O
HAART	O
combination	O
of	O
zidovudine	O
,	O
lamivudine	O
,	O
and	O
indinavir	O
or	O
vehicle	O
control	O
for	O
10	O
days	O
or	O
35	O
days	O
.	O

To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	O
hemizygous	O
transgenic	O
AIDS	O
mice	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wild	O
-	O
type	O
FVB	O
/	O
n	O
littermates	O
were	O
treated	O
with	O
the	O
HAART	O
combination	T-1
of	T-1
zidovudine	B-Chemical
,	O
lamivudine	T-0
,	O
and	O
indinavir	O
or	O
vehicle	O
control	O
for	O
10	O
days	O
or	O
35	O
days	O
.	O

To	O
determine	O
mitochondrial	O
events	O
from	O
HAART	O
in	O
vivo	O
,	O
8	O
-	O
week	O
-	O
old	O
hemizygous	O
transgenic	O
AIDS	O
mice	O
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	O
)	O
and	O
wild	O
-	O
type	O
FVB	O
/	O
n	O
littermates	O
were	O
treated	T-0
with	T-0
the	O
HAART	O
combination	O
of	O
zidovudine	O
,	O
lamivudine	O
,	O
and	O
indinavir	B-Chemical
or	O
vehicle	T-1
control	T-1
for	T-1
10	T-1
days	T-1
or	T-1
35	T-1
days	T-1
.	O

At	O
termination	O
of	O
the	O
experiments	O
,	O
mice	O
underwent	O
echocardiography	O
,	O
quantitation	O
of	O
abundance	O
of	O
molecular	T-0
markers	T-0
of	T-0
CM	B-Disease
(	O
ventricular	O
mRNA	O
encoding	O
atrial	O
natriuretic	O
factor	O
[	O
ANF	O
]	O
and	O
sarcoplasmic	O
calcium	O
ATPase	O
[	O
SERCA2	O
]	O
)	O
,	O
and	O
determination	O
of	O
plasma	O
LA	O
.	O

At	O
termination	O
of	O
the	O
experiments	O
,	O
mice	O
underwent	O
echocardiography	O
,	O
quantitation	O
of	O
abundance	O
of	O
molecular	O
markers	O
of	O
CM	O
(	O
ventricular	O
mRNA	O
encoding	O
atrial	O
natriuretic	O
factor	O
[	O
ANF	O
]	O
and	O
sarcoplasmic	T-0
calcium	B-Chemical
ATPase	O
[	O
SERCA2	O
]	O
)	O
,	O
and	O
determination	T-1
of	T-1
plasma	T-1
LA	T-1
.	O

At	O
termination	O
of	O
the	O
experiments	O
,	O
mice	O
underwent	O
echocardiography	O
,	O
quantitation	O
of	O
abundance	O
of	O
molecular	O
markers	O
of	O
CM	O
(	O
ventricular	O
mRNA	O
encoding	O
atrial	O
natriuretic	O
factor	O
[	O
ANF	O
]	O
and	O
sarcoplasmic	O
calcium	O
ATPase	O
[	O
SERCA2	O
]	O
)	O
,	O
and	O
determination	T-0
of	T-0
plasma	T-0
LA	B-Chemical
.	O

Biochemically	T-0
,	O
LA	B-Chemical
was	T-1
elevated	T-1
(	O
8	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
0	O
mM	O
)	O
.	O

Results	T-2
show	T-2
that	O
cumulative	O
HAART	O
caused	T-0
mitochondrial	O
CM	B-Disease
with	T-1
elevated	T-1
LA	O
in	O
AIDS	O
transgenic	O
mice	O
.	O

Results	O
show	O
that	O
cumulative	O
HAART	O
caused	T-0
mitochondrial	O
CM	O
with	O
elevated	T-1
LA	B-Chemical
in	O
AIDS	O
transgenic	O
mice	O
.	O

Results	T-0
show	O
that	O
cumulative	O
HAART	O
caused	O
mitochondrial	O
CM	O
with	O
elevated	T-1
LA	T-1
in	T-1
AIDS	B-Disease
transgenic	O
mice	O
.	O

A	O
Phase	O
II	O
trial	T-2
of	T-2
cisplatin	B-Chemical
plus	T-0
WR	T-0
-	T-0
2721	T-0
(	O
amifostine	O
)	O
for	T-1
metastatic	T-1
breast	T-1
carcinoma	T-1
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(	O
E8188	O
)	O
.	O

A	O
Phase	T-0
II	T-0
trial	T-0
of	O
cisplatin	O
plus	O
WR	B-Chemical
-	I-Chemical
2721	I-Chemical
(	O
amifostine	O
)	O
for	O
metastatic	O
breast	O
carcinoma	O
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(	O
E8188	O
)	O
.	O

A	T-1
Phase	T-1
II	T-1
trial	T-1
of	T-1
cisplatin	O
plus	O
WR	O
-	O
2721	O
(	O
amifostine	B-Chemical
)	O
for	T-0
metastatic	T-0
breast	O
carcinoma	O
:	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
Study	O
(	O
E8188	O
)	O
.	O

A	O
Phase	O
II	O
trial	O
of	O
cisplatin	O
plus	O
WR	O
-	O
2721	O
(	O
amifostine	O
)	O
for	O
metastatic	T-1
breast	B-Disease
carcinoma	I-Disease
:	O
an	O
Eastern	T-0
Cooperative	T-0
Oncology	T-0
Group	T-0
Study	T-0
(	O
E8188	O
)	O
.	O

BACKGROUND	T-0
:	O
Cisplatin	B-Chemical
has	T-1
minimal	T-1
antitumor	T-1
activity	T-1
when	O
used	O
as	O
second	O
-	O
or	O
third	O
-	O
line	O
treatment	O
of	O
metastatic	O
breast	O
carcinoma	O
.	O

BACKGROUND	O
:	O
Cisplatin	O
has	O
minimal	O
antitumor	O
activity	O
when	O
used	O
as	O
second	O
-	O
or	O
third	O
-	O
line	O
treatment	T-0
of	T-0
metastatic	T-0
breast	B-Disease
carcinoma	I-Disease
.	O

Older	O
reports	O
suggest	O
an	O
objective	O
response	T-0
rate	T-0
of	T-0
8	O
%	O
when	O
60	O
-	O
120	O
mg	O
/	O
m2	O
of	O
cisplatin	B-Chemical
is	O
administered	T-1
every	O
3	O
-	O
4	O
weeks	O
.	O

Although	O
a	O
dose	T-3
-	T-3
response	T-3
effect	T-3
has	T-1
been	T-1
observed	T-1
with	T-1
cisplatin	B-Chemical
,	O
the	T-2
dose	T-2
-	O
limiting	O
toxicities	O
associated	O
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	T-0
dose	T-1
-	T-1
limiting	T-1
toxicities	B-Disease
associated	T-2
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	T-0
with	T-0
cisplatin	B-Chemical
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	T-2
with	T-2
cisplatin	T-0
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	B-Disease
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	T-1
limited	T-1
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	O
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	B-Disease
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	T-0
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	T-1
with	T-1
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	B-Disease
)	O
have	T-0
limited	T-0
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	O
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	T-1
for	T-1
breast	B-Disease
carcinoma	I-Disease
.	O

WR	B-Chemical
-	I-Chemical
2721	I-Chemical
or	T-0
amifostine	O
initially	O
was	T-1
developed	T-1
to	O
protect	O
military	O
personnel	O
in	O
the	O
event	O
of	O
nuclear	O
war	O
.	O

WR	O
-	O
2721	O
or	O
amifostine	B-Chemical
initially	T-1
was	T-1
developed	T-1
to	O
protect	O
military	O
personnel	O
in	O
the	O
event	O
of	O
nuclear	O
war	O
.	O

Amifostine	B-Chemical
subsequently	O
was	T-1
shown	T-1
to	T-1
protect	T-1
normal	T-1
tissues	T-1
from	O
the	O
toxic	O
effects	O
of	O
alkylating	T-0
agents	T-0
and	O
cisplatin	O
without	O
decreasing	O
the	O
antitumor	O
effect	O
of	O
the	O
chemotherapy	O
.	O

Amifostine	O
subsequently	O
was	O
shown	O
to	O
protect	O
normal	O
tissues	O
from	O
the	O
toxic	T-0
effects	T-1
of	T-1
alkylating	B-Chemical
agents	I-Chemical
and	O
cisplatin	O
without	O
decreasing	O
the	O
antitumor	O
effect	O
of	O
the	O
chemotherapy	O
.	O

Amifostine	O
subsequently	O
was	O
shown	O
to	O
protect	O
normal	O
tissues	O
from	O
the	O
toxic	O
effects	O
of	O
alkylating	O
agents	O
and	O
cisplatin	B-Chemical
without	O
decreasing	O
the	O
antitumor	O
effect	T-0
of	T-0
the	T-0
chemotherapy	O
.	O

Early	O
trials	T-0
of	T-0
cisplatin	B-Chemical
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	O
-	O
induced	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neuropathy	O
were	O
reduced	O
.	O

Early	O
trials	O
of	O
cisplatin	T-0
and	T-0
amifostine	B-Chemical
also	T-1
suggested	T-1
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	O
-	O
induced	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neuropathy	O
were	O
reduced	O
.	O

Early	O
trials	O
of	O
cisplatin	O
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	T-2
and	T-2
severity	T-2
of	T-2
cisplatin	B-Chemical
-	O
induced	T-1
nephrotoxicity	T-1
,	O
ototoxicity	O
,	O
and	O
neuropathy	O
were	O
reduced	O
.	O

Early	O
trials	O
of	O
cisplatin	O
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	O
-	O
induced	T-0
nephrotoxicity	B-Disease
,	O
ototoxicity	O
,	O
and	O
neuropathy	O
were	O
reduced	O
.	O

Early	O
trials	O
of	O
cisplatin	O
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	T-0
and	T-0
severity	T-1
of	T-1
cisplatin	O
-	O
induced	O
nephrotoxicity	O
,	O
ototoxicity	B-Disease
,	O
and	O
neuropathy	O
were	T-2
reduced	T-2
.	O

Early	O
trials	O
of	O
cisplatin	O
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	O
-	O
induced	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neuropathy	B-Disease
were	T-0
reduced	T-1
.	O

METHODS	O
:	O
A	O
Phase	O
II	O
study	O
of	O
the	O
combination	T-2
of	T-2
cisplatin	B-Chemical
plus	T-1
amifostine	O
was	O
conducted	O
in	O
patients	O
with	O
progressive	O
metastatic	O
breast	O
carcinoma	O
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease	O
.	O

METHODS	O
:	O
A	O
Phase	O
II	O
study	O
of	O
the	O
combination	T-2
of	T-2
cisplatin	T-0
plus	T-0
amifostine	B-Chemical
was	T-1
conducted	T-1
in	T-1
patients	T-1
with	O
progressive	O
metastatic	O
breast	O
carcinoma	O
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease	O
.	O

METHODS	O
:	O
A	T-0
Phase	T-0
II	T-0
study	T-2
of	O
the	O
combination	O
of	O
cisplatin	O
plus	O
amifostine	O
was	O
conducted	O
in	O
patients	T-3
with	O
progressive	O
metastatic	T-1
breast	B-Disease
carcinoma	I-Disease
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherapy	O
regimen	O
for	O
metastatic	O
disease	O
.	O

Patients	O
received	T-1
amifostine	B-Chemical
,	O
910	O
mg	O
/	O
m2	O
intravenously	T-0
over	T-0
15	T-0
minutes	T-0
.	O

After	O
completion	T-1
of	T-1
the	T-1
amifostine	B-Chemical
infusion	T-0
,	O
cisplatin	O
120	O
mg	O
/	O
m2	O
was	O
administered	O
over	O
30	O
minutes	O
.	O

After	O
completion	O
of	O
the	O
amifostine	O
infusion	T-0
,	O
cisplatin	B-Chemical
120	O
mg	O
/	O
m2	O
was	O
administered	T-1
over	O
30	O
minutes	O
.	O

Intravenous	T-0
hydration	T-0
and	O
mannitol	B-Chemical
was	O
administered	T-1
before	T-1
and	T-1
after	T-1
cisplatin	O
.	O

Intravenous	O
hydration	O
and	O
mannitol	O
was	O
administered	O
before	T-0
and	T-0
after	T-0
cisplatin	B-Chemical
.	O

Neurologic	B-Disease
toxicity	I-Disease
was	O
reported	T-0
in	O
52	O
%	O
of	O
patients	T-1
.	O

Seven	O
different	O
life	T-0
-	T-0
threatening	T-0
toxicities	B-Disease
were	O
observed	O
in	O
patients	O
while	O
receiving	T-1
treatment	T-1
.	O

CONCLUSIONS	O
:	O
The	O
combination	T-0
of	T-0
cisplatin	B-Chemical
and	T-1
amifostine	O
in	O
this	O
study	O
resulted	O
in	O
an	O
overall	O
response	O
rate	O
of	O
16	O
%	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	T-0
of	T-0
cisplatin	O
and	O
amifostine	B-Chemical
in	O
this	O
study	O
resulted	T-1
in	T-1
an	O
overall	O
response	O
rate	O
of	O
16	O
%	O
.	O

Neither	T-0
a	T-0
tumor	B-Disease
-	O
protective	O
effect	O
nor	O
reduced	O
toxicity	O
to	O
normal	O
tissues	O
was	O
observed	O
with	O
the	O
addition	O
of	O
amifostine	O
to	O
cisplatin	O
in	O
this	O
trial	O
.	O

Neither	O
a	O
tumor	O
-	O
protective	O
effect	O
nor	O
reduced	T-2
toxicity	B-Disease
to	T-1
normal	O
tissues	O
was	O
observed	O
with	O
the	O
addition	O
of	O
amifostine	O
to	O
cisplatin	O
in	O
this	O
trial	O
.	O

Neither	O
a	O
tumor	O
-	O
protective	O
effect	O
nor	O
reduced	O
toxicity	O
to	O
normal	O
tissues	O
was	O
observed	O
with	O
the	T-0
addition	T-0
of	T-0
amifostine	B-Chemical
to	O
cisplatin	O
in	O
this	O
trial	O
.	O

Neither	O
a	O
tumor	O
-	O
protective	O
effect	O
nor	O
reduced	O
toxicity	O
to	O
normal	O
tissues	O
was	O
observed	T-1
with	O
the	O
addition	T-0
of	T-0
amifostine	O
to	O
cisplatin	B-Chemical
in	O
this	O
trial	T-2
.	O

Oral	B-Chemical
contraceptives	I-Chemical
and	O
the	T-0
risk	T-0
of	T-0
myocardial	O
infarction	O
.	O

Oral	O
contraceptives	O
and	O
the	O
risk	T-0
of	T-0
myocardial	B-Disease
infarction	I-Disease
.	O

BACKGROUND	O
:	O
An	O
association	T-1
between	T-1
the	T-1
use	T-1
of	T-0
oral	B-Chemical
contraceptives	I-Chemical
and	O
the	O
risk	O
of	O
myocardial	O
infarction	O
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studies	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	T-2
of	T-2
progestagen	B-Chemical
included	T-3
in	T-3
third	T-3
-	T-3
generation	T-3
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	T-4
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	T-0
or	T-0
gestodene	B-Chemical
)	O
and	T-1
second	T-1
-	T-1
generation	T-1
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	T-1
to	T-1
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	B-Chemical
)	O
oral	O
contraceptives	O
,	O
the	T-0
dose	T-0
of	T-0
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	T-0
of	T-0
estrogen	B-Chemical
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	T-0
a	T-0
first	T-0
myocardial	B-Disease
infarction	I-Disease
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	T-1
had	T-1
a	T-1
myocardial	T-1
infarction	T-1
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
248	O
women	O
18	O
through	O
49	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
1990	O
and	O
1995	O
and	O
925	O
control	O
women	O
who	O
had	O
not	O
had	T-1
a	T-1
myocardial	B-Disease
infarction	I-Disease
and	O
who	O
were	T-0
matched	T-0
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

Subjects	O
supplied	O
information	T-0
on	T-0
oral	B-Chemical
-	I-Chemical
contraceptive	I-Chemical
use	T-2
and	T-2
major	T-2
cardiovascular	T-2
risk	T-2
factors	T-2
.	O

An	O
analysis	O
for	O
factor	O
V	O
Leiden	O
and	O
the	O
G20210A	O
mutation	O
in	O
the	O
prothrombin	O
gene	O
was	O
conducted	O
in	O
217	O
patients	O
and	O
763	O
controls	O
RESULTS	O
:	O
The	O
odds	O
ratio	O
for	O
myocardial	O
infarction	O
among	O
women	O
who	O
used	O
any	O
type	O
of	T-0
combined	T-0
oral	B-Chemical
contraceptive	I-Chemical
,	O
as	T-1
compared	T-1
with	T-1
nonusers	T-1
,	O
was	O
2	O
.	O
0	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
2	O
.	O
8	O
)	O
.	O

The	O
adjusted	O
odds	O
ratio	O
was	O
2	O
.	O
5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
4	O
.	O
1	O
)	O
among	O
women	O
who	O
used	O
second	T-0
-	T-0
generation	T-0
oral	B-Chemical
contraceptives	I-Chemical
and	O
1	O
.	O
3	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
7	O
to	O
2	O
.	O
5	O
)	O
among	O
those	O
who	O
used	O
third	T-1
-	T-1
generation	T-1
oral	O
contraceptives	O
.	O

The	O
adjusted	O
odds	O
ratio	T-1
was	O
2	O
.	O
5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
4	O
.	O
1	O
)	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	O
contraceptives	O
and	O
1	O
.	O
3	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
7	O
to	O
2	O
.	O
5	O
)	O
among	O
those	O
who	O
used	T-0
third	T-2
-	T-2
generation	T-2
oral	B-Chemical
contraceptives	I-Chemical
.	O

Among	O
women	O
who	T-0
used	T-0
oral	B-Chemical
contraceptives	I-Chemical
,	O
the	O
odds	O
ratio	O
was	O
2	O
.	O
1	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
3	O
.	O
0	O
)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	O
and	O
1	O
.	O
9	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
6	O
to	O
5	O
.	O
5	O
)	O
for	O
those	O
with	O
a	O
mutation	O
CONCLUSIONS	O
:	O
The	O
risk	O
of	O
myocardial	O
infarction	O
was	O
increased	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	O
contraceptives	O
.	O

Among	O
women	O
who	O
used	O
oral	O
contraceptives	O
,	O
the	O
odds	O
ratio	O
was	O
2	O
.	O
1	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
3	O
.	O
0	O
)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	O
and	O
1	O
.	O
9	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
6	O
to	O
5	O
.	O
5	O
)	O
for	O
those	O
with	O
a	O
mutation	O
CONCLUSIONS	O
:	O
The	O
risk	T-0
of	T-0
myocardial	B-Disease
infarction	I-Disease
was	O
increased	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	O
contraceptives	O
.	O

Among	O
women	O
who	O
used	O
oral	T-0
contraceptives	O
,	O
the	O
odds	O
ratio	O
was	O
2	O
.	O
1	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
to	O
3	O
.	O
0	O
)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	O
and	O
1	O
.	O
9	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
6	O
to	O
5	O
.	O
5	O
)	O
for	O
those	O
with	O
a	O
mutation	O
CONCLUSIONS	O
:	O
The	O
risk	O
of	O
myocardial	O
infarction	O
was	O
increased	O
among	O
women	O
who	O
used	O
second	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	T-0

The	O
results	O
with	O
respect	T-1
to	T-1
the	T-1
use	T-1
of	T-1
third	T-1
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
were	T-0
inconclusive	T-0
but	O
suggested	O
that	O
the	O
risk	O
was	O
lower	O
than	O
the	O
risk	O
associated	O
with	O
second	O
-	O
generation	O
oral	O
contraceptives	O
.	O

The	O
results	O
with	O
respect	O
to	O
the	O
use	O
of	O
third	O
-	O
generation	O
oral	O
contraceptives	O
were	O
inconclusive	O
but	O
suggested	O
that	O
the	O
risk	O
was	O
lower	O
than	O
the	O
risk	O
associated	T-0
with	T-0
second	O
-	O
generation	O
oral	B-Chemical
contraceptives	I-Chemical
.	O

The	O
risk	T-1
of	T-1
myocardial	B-Disease
infarction	I-Disease
was	O
similar	O
among	O
women	O
who	O
used	O
oral	O
contraceptives	O
whether	O
or	O
not	O
they	O
had	O
a	O
prothrombotic	T-0
mutation	T-0
.	O

The	O
risk	O
of	O
myocardial	T-0
infarction	T-0
was	O
similar	O
among	O
women	O
who	T-1
used	T-1
oral	B-Chemical
contraceptives	I-Chemical
whether	T-2
or	T-2
not	T-2
they	T-2
had	T-2
a	O
prothrombotic	O
mutation	O
.	O

End	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	T-0
ESRD	T-0
)	T-0
after	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
using	O
calcineurin	O
-	O
based	O
immunotherapy	O
:	O
risk	O
of	O
development	O
and	O
treatment	O
.	O

End	O
-	O
stage	O
renal	O
disease	T-2
(	O
ESRD	B-Disease
)	O
after	T-3
orthotopic	T-3
liver	O
transplantation	O
(	O
OLTX	O
)	O
using	O
calcineurin	O
-	O
based	O
immunotherapy	O
:	O
risk	O
of	O
development	T-1
and	O
treatment	O
.	O

BACKGROUND	O
:	O
The	O
calcineurin	T-1
inhibitors	T-1
cyclosporine	B-Chemical
and	O
tacrolimus	O
are	O
both	O
known	T-2
to	T-2
be	T-2
nephrotoxic	T-2
.	O

BACKGROUND	O
:	O
The	O
calcineurin	O
inhibitors	O
cyclosporine	O
and	O
tacrolimus	B-Chemical
are	O
both	O
known	O
to	O
be	O
nephrotoxic	T-0
.	O

BACKGROUND	O
:	O
The	O
calcineurin	T-0
inhibitors	T-0
cyclosporine	O
and	O
tacrolimus	O
are	O
both	O
known	T-1
to	T-1
be	T-1
nephrotoxic	B-Disease
.	O

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	O
who	O
are	O
presenting	O
after	O
OLTX	T-0
with	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	T-1
)	T-1
.	T-1

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	T-2
who	O
are	O
presenting	O
after	O
OLTX	O
with	O
end	T-1
-	T-1
stage	T-1
renal	T-0
disease	T-0
(	O
ESRD	B-Disease
)	O
.	O

This	O
retrospective	O
study	T-0
examines	O
the	O
incidence	T-1
and	O
treatment	T-2
of	O
ESRD	B-Disease
and	O
chronic	O
renal	O
failure	O
(	O
CRF	O
)	O
in	O
OLTX	O
patients	O
.	O

This	O
retrospective	O
study	O
examines	O
the	O
incidence	T-0
and	T-0
treatment	T-2
of	T-2
ESRD	O
and	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
(	O
CRF	O
)	O
in	T-3
OLTX	O
patients	T-1
.	O

This	O
retrospective	O
study	O
examines	O
the	O
incidence	O
and	O
treatment	T-1
of	T-1
ESRD	O
and	T-0
chronic	T-0
renal	T-0
failure	T-0
(	O
CRF	B-Disease
)	O
in	T-2
OLTX	T-2
patients	T-2
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	B-Disease
or	O
ESRD	T-0
,	T-0
n	T-0
=	T-0
748	T-0
;	O
CRF	O
,	O
sustained	O
serum	O
creatinine	O
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	O
,	O
n	O
=	O
45	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	T-0
,	O
no	O
CRF	O
or	O
ESRD	B-Disease
,	O
n	O
=	O
748	O
;	O
CRF	O
,	O
sustained	O
serum	O
creatinine	O
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	O
,	O
n	O
=	O
45	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	T-0
,	O
no	O
CRF	O
or	O
ESRD	O
,	O
n	O
=	O
748	O
;	O
CRF	B-Disease
,	O
sustained	O
serum	O
creatinine	O
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	O
,	O
n	O
=	O
45	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	O
or	O
ESRD	O
,	O
n	O
=	O
748	O
;	O
CRF	O
,	O
sustained	T-1
serum	O
creatinine	B-Chemical
>	O
2	T-0
.	T-0
5	T-0
mg	T-0
/	T-0
dl	T-0
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	O
,	O
n	O
=	O
45	O
.	O

Patients	T-0
were	T-0
divided	T-0
into	T-0
three	O
groups	T-1
:	O
Controls	O
,	O
no	O
CRF	O
or	O
ESRD	O
,	O
n	O
=	O
748	O
;	O
CRF	O
,	O
sustained	O
serum	O
creatinine	O
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	T-2
=	T-2
41	T-2
;	T-2
and	T-2
ESRD	B-Disease
,	O
n	T-3
=	T-3
45	T-3
.	O

Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables	O
,	O
diagnosis	O
,	O
postoperative	O
variables	O
,	O
survival	O
,	O
type	T-2
of	T-2
ESRD	B-Disease
therapy	T-0
,	O
and	O
survival	T-1
from	O
onset	O
of	O
ESRD	O
.	O

Groups	O
were	O
compared	O
for	O
preoperative	T-1
laboratory	T-1
variables	O
,	O
diagnosis	O
,	O
postoperative	O
variables	O
,	O
survival	O
,	O
type	O
of	O
ESRD	O
therapy	O
,	O
and	O
survival	T-0
from	T-0
onset	T-0
of	O
ESRD	B-Disease
.	O

RESULTS	O
:	O
At	O
13	O
years	O
after	O
OLTX	O
,	O
the	O
incidence	O
of	O
severe	T-1
renal	B-Disease
dysfunction	I-Disease
was	T-2
18	T-0
.	T-0
1	T-0
%	T-0
(	T-0
CRF	T-0
8	T-0
.	T-0
6	T-0
%	T-0
and	T-0
ESRD	T-0
9	T-0
.	T-0
5	T-0
%	T-0
)	T-0
.	T-0

RESULTS	O
:	O
At	O
13	O
years	O
after	O
OLTX	O
,	O
the	O
incidence	O
of	O
severe	O
renal	O
dysfunction	T-0
was	T-1
18	T-1
.	T-1
1	T-1
%	T-1
(	O
CRF	B-Disease
8	T-2
.	T-2
6	T-2
%	T-2
and	O
ESRD	O
9	O
.	O
5	O
%	O
)	O
.	O

RESULTS	O
:	O
At	O
13	O
years	O
after	T-0
OLTX	T-0
,	O
the	O
incidence	T-1
of	T-1
severe	O
renal	O
dysfunction	O
was	O
18	O
.	O
1	O
%	O
(	O
CRF	O
8	O
.	O
6	O
%	O
and	O
ESRD	B-Disease
9	O
.	O
5	O
%	O
)	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	B-Disease
and	O
ESRD	O
patients	O
had	O
higher	T-0
preoperative	T-0
serum	T-0
creatinine	T-0
levels	T-0
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	O
syndrome	O
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	O
.	O

Compared	T-2
with	T-2
control	T-0
patients	T-0
,	O
CRF	O
and	O
ESRD	B-Disease
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	O
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	T-1
with	T-1
hepatorenal	T-1
syndrome	T-1
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	O
and	O
ESRD	O
patients	O
had	O
higher	O
preoperative	T-0
serum	T-2
creatinine	B-Chemical
levels	T-1
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	O
syndrome	O
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	O
and	O
ESRD	O
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	O
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	T-1
with	T-1
hepatorenal	B-Disease
syndrome	I-Disease
,	O
higher	T-2
percentage	T-2
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	O
and	O
ESRD	O
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	O
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	O
syndrome	O
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	T-1
a	T-1
higher	T-1
1	T-0
-	T-0
year	T-0
serum	T-0
creatinine	B-Chemical
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	T-0
creatinine	B-Chemical
compared	T-1
with	T-1
average	T-1
at	T-1
1	T-1
year	T-1
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	O
or	O
ESRD	O
with	O
odds	O
ratios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	O
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	T-0
of	T-0
CRF	B-Disease
or	O
ESRD	O
with	O
odds	O
ratios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	O
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	T-0
of	T-0
CRF	O
or	O
ESRD	B-Disease
with	O
odds	O
ratios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

Overall	O
survival	O
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
groups	O
,	O
but	O
by	O
year	O
13	O
,	O
the	O
survival	O
of	O
the	O
patients	O
who	T-1
had	T-1
ESRD	B-Disease
was	O
only	O
28	O
.	O
2	O
%	O
compared	O
with	O
54	O
.	O
6	O
%	O
in	O
the	O
control	O
group	O
.	O

Patients	T-0
developing	T-0
ESRD	B-Disease
had	O
a	O
6	O
-	O
year	O
survival	O
after	O
onset	O
of	O
ESRD	O
of	O
27	O
%	O
for	O
the	O
patients	T-1
receiving	T-1
hemodialysis	T-1
versus	O
71	O
.	O
4	O
%	O
for	O
the	O
patients	T-2
developing	T-2
ESRD	O
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O

Patients	O
developing	T-1
ESRD	O
had	O
a	O
6	O
-	O
year	O
survival	O
after	O
onset	T-0
of	T-0
ESRD	B-Disease
of	O
27	O
%	O
for	O
the	O
patients	O
receiving	O
hemodialysis	O
versus	O
71	O
.	O
4	O
%	O
for	O
the	O
patients	O
developing	O
ESRD	O
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O

Patients	O
developing	O
ESRD	O
had	O
a	O
6	O
-	O
year	O
survival	O
after	O
onset	O
of	O
ESRD	O
of	O
27	O
%	O
for	O
the	O
patients	O
receiving	O
hemodialysis	O
versus	O
71	O
.	O
4	O
%	O
for	O
the	O
patients	O
developing	T-0
ESRD	B-Disease
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O

CONCLUSIONS	O
:	O
Patients	O
who	O
are	O
more	T-1
than	T-1
10	T-1
years	T-1
post	T-1
-	O
OLTX	T-0
have	O
CRF	B-Disease
and	O
ESRD	O
at	T-2
a	T-2
high	T-2
rate	T-2
.	O

CONCLUSIONS	O
:	O
Patients	T-2
who	O
are	O
more	O
than	O
10	O
years	O
post	O
-	O
OLTX	O
have	O
CRF	T-0
and	T-0
ESRD	B-Disease
at	T-1
a	T-1
high	T-1
rate	T-1
.	O

The	T-1
development	T-1
of	T-1
ESRD	B-Disease
decreases	T-2
survival	O
,	O
particularly	O
in	O
those	O
patients	O
treated	O
with	O
dialysis	O
only	O
.	O

Patients	T-0
who	T-0
develop	T-0
ESRD	B-Disease
have	O
a	O
higher	O
preoperative	O
and	O
1	O
-	O
year	O
serum	O
creatinine	O
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	O
syndrome	O
.	O

Patients	O
who	O
develop	O
ESRD	O
have	O
a	O
higher	O
preoperative	O
and	O
1	T-1
-	T-1
year	T-1
serum	T-0
creatinine	B-Chemical
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	O
syndrome	O
.	O

Patients	T-0
who	T-0
develop	T-0
ESRD	O
have	O
a	O
higher	O
preoperative	O
and	O
1	O
-	O
year	O
serum	O
creatinine	O
and	O
are	O
more	O
likely	O
to	T-1
have	T-1
hepatorenal	B-Disease
syndrome	I-Disease
.	O

However	O
,	O
an	T-0
increase	T-1
of	T-1
serum	T-1
creatinine	B-Chemical
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	O
of	O
CRF	O
or	O
ESRD	O
.	O

However	O
,	O
an	O
increase	O
of	O
serum	O
creatinine	O
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	T-0
of	T-0
CRF	B-Disease
or	O
ESRD	O
.	O

However	O
,	O
an	O
increase	O
of	O
serum	O
creatinine	O
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	T-0
of	T-0
CRF	O
or	O
ESRD	B-Disease
.	O

Epileptic	B-Disease
seizures	I-Disease
following	T-2
cortical	O
application	O
of	O
fibrin	T-1
sealants	T-1
containing	O
tranexamic	O
acid	O
in	O
rats	O
.	O

Epileptic	O
seizures	O
following	O
cortical	O
application	O
of	O
fibrin	O
sealants	O
containing	T-1
tranexamic	B-Chemical
acid	I-Chemical
in	T-0
rats	T-0
.	O

Recently	O
,	O
synthetic	O
fibrinolysis	O
inhibitors	T-1
such	O
as	O
tranexamic	B-Chemical
acid	I-Chemical
(	T-0
tAMCA	T-0
)	T-0
have	O
been	O
considered	O
as	O
substitutes	T-2
for	O
aprotinin	O
.	O

Recently	O
,	O
synthetic	O
fibrinolysis	O
inhibitors	T-1
such	O
as	O
tranexamic	O
acid	O
(	O
tAMCA	B-Chemical
)	O
have	T-0
been	T-0
considered	T-2
as	T-2
substitutes	T-2
for	O
aprotinin	O
.	O

However	O
,	O
tAMCA	B-Chemical
has	T-0
been	T-0
shown	T-0
to	O
cause	O
epileptic	O
seizures	O
.	O

However	O
,	O
tAMCA	O
has	O
been	O
shown	T-0
to	T-0
cause	T-0
epileptic	B-Disease
seizures	I-Disease
.	O

We	O
wanted	O
to	O
study	O
whether	O
tAMCA	B-Chemical
retains	T-1
its	O
convulsive	O
action	O
if	O
incorporated	O
into	O
a	O
FS	O
.	O

We	O
wanted	O
to	O
study	O
whether	O
tAMCA	O
retains	T-1
its	T-1
convulsive	B-Disease
action	T-0
if	O
incorporated	O
into	O
a	O
FS	O
.	O

METHOD	O
:	O
FS	O
containing	O
aprotinin	O
or	O
different	O
concentrations	T-0
of	T-0
tAMCA	B-Chemical
(	O
0	O
.	O
5	O
-	O
47	O
.	O
5	O
mg	O
/	O
ml	O
)	O
were	O
applied	O
to	O
the	O
pial	O
surface	O
of	O
the	O
cortex	O
of	O
anaesthetized	O
rats	O
.	O

FINDINGS	O
:	O
FS	T-0
containing	T-2
tAMCA	B-Chemical
caused	O
paroxysmal	O
brain	O
activity	O
which	O
was	O
associated	T-1
with	T-1
distinct	T-1
convulsive	T-1
behaviours	T-1
.	O

FINDINGS	O
:	O
FS	O
containing	O
tAMCA	O
caused	O
paroxysmal	T-2
brain	T-2
activity	T-2
which	O
was	O
associated	T-0
with	T-0
distinct	T-1
convulsive	B-Disease
behaviours	T-3
.	O

The	O
degree	O
of	O
these	T-0
seizures	B-Disease
increased	T-1
with	O
increasing	O
concentration	O
of	O
tAMCA	O
.	O

The	O
degree	O
of	O
these	O
seizures	O
increased	O
with	O
increasing	T-0
concentration	T-0
of	T-0
tAMCA	B-Chemical
.	O

Thus	O
,	O
FS	O
containing	T-0
47	O
.	O
5	O
mg	O
/	O
ml	O
tAMCA	B-Chemical
evoked	O
generalized	O
seizures	O
in	O
all	O
tested	O
rats	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	O
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk	O
-	O
correlated	O
convulsive	O
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O

Thus	O
,	O
FS	O
containing	O
47	O
.	O
5	O
mg	O
/	O
ml	O
tAMCA	O
evoked	T-0
generalized	B-Disease
seizures	I-Disease
in	O
all	O
tested	O
rats	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	O
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk	O
-	O
correlated	O
convulsive	O
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O

Thus	O
,	O
FS	O
containing	O
47	O
.	O
5	O
mg	O
/	O
ml	O
tAMCA	O
evoked	O
generalized	O
seizures	O
in	O
all	O
tested	O
rats	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
lowest	O
concentration	T-0
of	T-0
tAMCA	B-Chemical
(	T-1
0	T-1
.	T-1
5	T-1
mg	T-1
/	T-1
ml	T-1
)	T-1
only	O
evoked	O
brief	O
episodes	O
of	O
jerk	O
-	O
correlated	O
convulsive	O
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O

Thus	O
,	O
FS	O
containing	O
47	O
.	O
5	O
mg	O
/	O
ml	O
tAMCA	O
evoked	O
generalized	O
seizures	O
in	O
all	O
tested	O
rats	O
(	O
n	O
=	O
6	O
)	O
while	O
the	O
lowest	O
concentration	O
of	O
tAMCA	O
(	O
0	O
.	O
5	O
mg	O
/	O
ml	O
)	O
only	O
evoked	O
brief	O
episodes	O
of	O
jerk	O
-	O
correlated	T-0
convulsive	B-Disease
potentials	O
in	O
1	O
of	O
6	O
rats	O
.	O

INTERPRETATION	T-1
:	O
Tranexamic	B-Chemical
acid	I-Chemical
retains	T-0
its	O
convulsive	O
action	O
within	O
FS	O
.	O

INTERPRETATION	O
:	O
Tranexamic	T-0
acid	T-0
retains	T-0
its	O
convulsive	B-Disease
action	T-1
within	T-1
FS	T-1
.	O

Thus	O
,	O
use	O
of	O
FS	O
containing	T-0
tAMCA	B-Chemical
for	O
surgery	O
within	O
or	O
close	O
to	O
the	O
CNS	O
may	O
pose	O
a	O
substantial	O
risk	O
to	O
the	O
patient	O
.	O

Sequential	O
observations	T-0
of	T-0
exencephaly	B-Disease
and	O
subsequent	O
morphological	O
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system	O
:	O
analysis	O
of	O
the	O
mechanism	O
of	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

Sequential	O
observations	O
of	O
exencephaly	O
and	O
subsequent	O
morphological	O
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system	O
:	O
analysis	T-0
of	T-0
the	T-0
mechanism	T-0
of	T-0
transformation	T-2
from	T-2
exencephaly	B-Disease
to	O
anencephaly	T-1
.	O

Sequential	O
observations	O
of	O
exencephaly	O
and	O
subsequent	O
morphological	O
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system	O
:	O
analysis	O
of	O
the	O
mechanism	O
of	O
transformation	T-1
from	O
exencephaly	T-0
to	T-0
anencephaly	B-Disease
.	O

Anencephaly	B-Disease
has	T-0
been	T-0
suggested	T-0
to	O
develop	O
from	O
exencephaly	O
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
experimental	O
evidence	O
to	O
support	O
this	O
,	O
and	O
the	O
mechanism	O
of	O
transformation	O
remains	O
unclear	O
.	O

Anencephaly	O
has	O
been	O
suggested	O
to	O
develop	T-0
from	T-0
exencephaly	B-Disease
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
experimental	O
evidence	O
to	O
support	O
this	O
,	O
and	O
the	O
mechanism	O
of	O
transformation	O
remains	O
unclear	O
.	O

We	O
observed	T-1
the	T-1
exencephaly	B-Disease
induced	T-2
by	O
5	O
-	O
azacytidine	O
at	O
embryonic	O
day	O
13	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
,	O
let	O
the	O
embryos	O
develop	O
exo	O
utero	O
until	O
E18	O
.	O
5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embryos	O
at	O
E18	O
.	O
5	O
.	O

We	O
observed	O
the	O
exencephaly	T-1
induced	T-1
by	T-0
5	B-Chemical
-	I-Chemical
azacytidine	I-Chemical
at	O
embryonic	T-2
day	T-2
13	T-2
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
,	O
let	O
the	O
embryos	O
develop	O
exo	O
utero	O
until	O
E18	O
.	O
5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embryos	O
at	O
E18	O
.	O
5	O
.	O

We	O
confirmed	O
several	O
cases	T-2
of	T-2
transformation	T-2
from	T-0
exencephaly	B-Disease
to	T-1
anencephaly	T-1
.	O

We	O
confirmed	O
several	O
cases	O
of	O
transformation	T-0
from	T-0
exencephaly	T-0
to	T-0
anencephaly	B-Disease
.	O

However	O
,	O
in	O
many	O
cases	O
,	O
the	O
exencephalic	B-Disease
brain	O
tissue	O
was	O
preserved	O
with	O
more	T-0
or	T-0
less	T-0
reduction	T-0
during	O
this	O
period	O
.	O

To	O
analyze	O
the	O
transformation	O
patterns	O
,	O
we	T-0
classified	T-0
the	T-0
exencephaly	B-Disease
by	O
size	O
and	O
shape	O
of	O
the	O
exencephalic	O
tissue	O
into	O
several	O
types	O
at	O
E13	O
.	O
5	O
and	O
E18	O
.	O
5	O
.	O

To	O
analyze	O
the	O
transformation	O
patterns	O
,	O
we	O
classified	T-1
the	T-1
exencephaly	T-1
by	O
size	O
and	O
shape	O
of	O
the	O
exencephalic	B-Disease
tissue	T-2
into	O
several	O
types	O
at	O
E13	O
.	O
5	O
and	O
E18	O
.	O
5	O
.	O

It	O
was	O
found	O
that	O
the	O
transformation	T-0
of	O
exencephalic	B-Disease
tissue	O
was	O
not	O
simply	O
size	O
-	O
dependent	O
,	O
and	O
all	O
cases	O
of	O
anencephaly	O
at	O
E18	O
.	O
5	O
resulted	T-1
from	T-1
embryos	O
with	O
a	O
large	O
amount	O
of	O
exencephalic	O
tissue	O
at	O
E13	O
.	O
5	O
.	O

It	O
was	O
found	O
that	O
the	O
transformation	O
of	O
exencephalic	O
tissue	O
was	O
not	O
simply	O
size	O
-	O
dependent	O
,	O
and	O
all	O
cases	T-0
of	T-0
anencephaly	B-Disease
at	T-1
E18	T-1
.	O
5	O
resulted	O
from	O
embryos	O
with	O
a	O
large	O
amount	O
of	O
exencephalic	O
tissue	O
at	O
E13	O
.	O
5	O
.	O

It	O
was	O
found	O
that	O
the	O
transformation	O
of	O
exencephalic	O
tissue	O
was	O
not	O
simply	O
size	O
-	O
dependent	O
,	O
and	O
all	O
cases	O
of	O
anencephaly	O
at	O
E18	O
.	O
5	O
resulted	O
from	O
embryos	O
with	O
a	O
large	T-0
amount	T-0
of	T-0
exencephalic	B-Disease
tissue	T-1
at	O
E13	O
.	O
5	O
.	O

Microscopic	O
observation	T-0
showed	O
the	O
configuration	T-3
of	T-3
exencephaly	B-Disease
at	O
E13	O
.	O
5	O
,	O
frequent	O
hemorrhaging	O
and	O
detachment	O
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	O
head	O
at	O
E15	O
.	O
5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	T-2
in	O
the	O
exencephalic	O
tissue	O
at	O
E18	O
.	O
5	O
.	O

Microscopic	O
observation	O
showed	O
the	O
configuration	O
of	O
exencephaly	O
at	O
E13	O
.	O
5	O
,	O
frequent	T-0
hemorrhaging	B-Disease
and	O
detachment	O
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	O
head	O
at	O
E15	O
.	O
5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	O
tissue	O
at	O
E18	O
.	O
5	O
.	O

Microscopic	O
observation	O
showed	O
the	O
configuration	O
of	O
exencephaly	O
at	O
E13	O
.	O
5	O
,	O
frequent	O
hemorrhaging	O
and	O
detachment	O
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	T-0
the	T-0
exencephalic	B-Disease
head	T-1
at	O
E15	O
.	O
5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	O
tissue	O
at	O
E18	O
.	O
5	O
.	O

Microscopic	O
observation	O
showed	O
the	O
configuration	O
of	O
exencephaly	O
at	O
E13	O
.	O
5	O
,	O
frequent	O
hemorrhaging	O
and	O
detachment	O
of	O
the	O
neural	O
plate	O
from	O
surface	O
ectoderm	O
in	O
the	O
exencephalic	O
head	O
at	O
E15	O
.	O
5	O
,	O
and	O
multiple	O
modes	O
of	O
reduction	T-0
in	T-0
the	O
exencephalic	B-Disease
tissue	T-1
at	O
E18	O
.	O
5	O
.	O

From	O
observations	O
of	O
the	O
vasculature	O
,	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
were	O
identified	T-0
in	T-0
the	T-0
exencephalic	B-Disease
head	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	T-1
of	T-1
the	O
exencephalic	B-Disease
neural	T-0
tissue	T-0
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	O
failure	O
and	O
/	O
or	O
hemorrhaging	O
in	O
various	O
parts	O
of	O
the	O
exencephalic	O
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	O
neural	O
tissue	O
causes	T-0
the	T-0
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	T-1
peripheral	T-1
circulatory	B-Disease
failure	I-Disease
and	O
/	O
or	O
hemorrhaging	O
in	O
various	O
parts	O
of	O
the	O
exencephalic	O
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	T-3
of	T-3
the	O
exencephalic	O
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	T-1
peripheral	T-1
circulatory	T-1
failure	T-1
and	O
/	O
or	O
hemorrhaging	B-Disease
in	O
various	T-2
parts	T-2
of	T-2
the	T-2
exencephalic	T-2
head	T-2
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	O
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	T-0
circulatory	T-0
failure	T-2
and	T-2
/	T-2
or	T-2
hemorrhaging	T-2
in	T-2
various	T-2
parts	T-2
of	O
the	O
exencephalic	B-Disease
head	O
,	O
leading	T-3
to	T-3
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	T-0
of	O
the	O
exencephalic	O
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	O
failure	O
and	O
/	O
or	O
hemorrhaging	O
in	O
various	O
parts	O
of	O
the	O
exencephalic	O
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	T-1
from	O
exencephaly	B-Disease
to	O
anencephaly	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	O
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	O
failure	O
and	O
/	O
or	O
hemorrhaging	O
in	O
various	O
parts	O
of	O
the	O
exencephalic	O
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	T-1
from	T-1
exencephaly	T-0
to	O
anencephaly	B-Disease
.	O

99mTc	B-Chemical
-	I-Chemical
glucarate	I-Chemical
for	O
detection	O
of	O
isoproterenol	O
-	O
induced	T-0
myocardial	O
infarction	O
in	O
rats	O
.	O

99mTc	O
-	O
glucarate	O
for	O
detection	T-0
of	T-0
isoproterenol	B-Chemical
-	O
induced	T-1
myocardial	O
infarction	O
in	O
rats	O
.	O

99mTc	O
-	O
glucarate	O
for	O
detection	O
of	O
isoproterenol	O
-	O
induced	T-1
myocardial	B-Disease
infarction	I-Disease
in	T-0
rats	T-0
.	O

Infarct	O
-	O
avid	O
radiopharmaceuticals	O
are	O
necessary	O
for	O
rapid	O
and	O
timely	O
diagnosis	T-0
of	T-0
acute	T-1
myocardial	B-Disease
infarction	I-Disease
.	O

The	O
animal	O
model	O
used	O
to	T-0
produce	T-1
infarction	B-Disease
implies	T-2
artery	O
ligation	O
but	O
chemical	O
induction	O
can	O
be	O
easily	O
obtained	O
with	O
isoproterenol	O
.	O

The	O
animal	O
model	T-0
used	T-0
to	T-0
produce	T-0
infarction	T-0
implies	O
artery	O
ligation	O
but	O
chemical	O
induction	O
can	O
be	O
easily	O
obtained	T-1
with	T-1
isoproterenol	B-Chemical
.	O

A	O
new	O
infarct	B-Disease
-	O
avid	T-0
radiopharmaceutical	O
based	O
on	O
glucaric	O
acid	O
was	O
prepared	O
in	O
the	O
hospital	O
radiopharmacy	O
of	O
the	O
INCMNSZ	O
.	O

A	O
new	O
infarct	O
-	O
avid	O
radiopharmaceutical	O
based	T-1
on	T-1
glucaric	B-Chemical
acid	I-Chemical
was	T-0
prepared	T-0
in	T-0
the	T-0
hospital	T-0
radiopharmacy	T-0
of	O
the	O
INCMNSZ	O
.	O

99mTc	B-Chemical
-	I-Chemical
glucarate	I-Chemical
was	T-0
easy	T-0
to	T-0
prepare	T-0
,	O
stable	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	O
its	O
biodistribution	O
in	O
rats	O
with	O
isoproterenol	O
-	O
induced	T-1
acute	O
myocardial	O
infarction	O
.	O

99mTc	O
-	O
glucarate	O
was	O
easy	O
to	O
prepare	O
,	O
stable	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	O
its	O
biodistribution	O
in	O
rats	T-0
with	T-0
isoproterenol	B-Chemical
-	O
induced	T-1
acute	O
myocardial	O
infarction	O
.	O

99mTc	O
-	O
glucarate	O
was	O
easy	O
to	O
prepare	O
,	O
stable	O
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	O
its	O
biodistribution	O
in	O
rats	O
with	O
isoproterenol	O
-	O
induced	T-0
acute	T-0
myocardial	B-Disease
infarction	I-Disease
.	O

Histological	O
studies	O
demonstrated	O
that	O
the	O
rats	O
developed	T-2
an	T-2
infarct	B-Disease
18	O
h	O
after	T-1
isoproterenol	O
administration	O
.	O

Histological	O
studies	O
demonstrated	O
that	O
the	O
rats	O
developed	O
an	O
infarct	O
18	O
h	O
after	T-0
isoproterenol	B-Chemical
administration	T-1
.	O

Thirty	O
minutes	O
after	O
99mTc	B-Chemical
-	I-Chemical
glucarate	I-Chemical
administration	T-0
the	O
standardised	O
heart	O
uptake	O
value	O
S	O
(	O
h	O
)	O
UV	O
was	O
4	O
.	O
7	O
in	O
infarcted	O
rat	O
heart	O
which	O
is	O
six	O
times	O
more	O
than	O
in	O
normal	O
rats	O
.	O

The	O
high	O
image	O
quality	O
suggests	O
that	O
high	O
contrast	O
images	O
can	O
be	O
obtained	O
in	O
humans	O
and	O
the	O
96	O
h	O
stability	O
makes	O
it	O
an	O
ideal	O
agent	O
to	T-0
detect	T-0
,	O
in	O
patients	O
,	O
early	O
cardiac	B-Disease
infarction	I-Disease
.	O

Bupropion	B-Chemical
(	O
Zyban	O
)	O
toxicity	T-0
.	O

Bupropion	T-0
(	O
Zyban	B-Chemical
)	O
toxicity	T-1
.	O

Bupropion	T-0
(	O
Zyban	O
)	O
toxicity	B-Disease
.	O

Bupropion	B-Chemical
is	T-0
a	T-0
monocyclic	O
antidepressant	O
structurally	O
related	O
to	O
amphetamine	O
.	O

Bupropion	T-1
is	T-1
a	T-1
monocyclic	T-1
antidepressant	B-Chemical
structurally	T-2
related	T-2
to	T-2
amphetamine	T-2
.	O

Bupropion	O
is	O
a	O
monocyclic	O
antidepressant	T-0
structurally	O
related	T-1
to	T-1
amphetamine	B-Chemical
.	O

Zyban	B-Chemical
,	O
a	T-1
sustained	T-1
-	T-0
release	T-0
formulation	T-0
of	O
bupropion	O
hydrochloride	O
,	O
was	O
recently	O
released	O
in	O
Ireland	O
,	O
as	O
a	O
smoking	O
cessation	O
aid	O
.	O

Zyban	O
,	O
a	O
sustained	O
-	O
release	O
formulation	T-0
of	T-0
bupropion	B-Chemical
hydrochloride	I-Chemical
,	O
was	O
recently	O
released	O
in	O
Ireland	O
,	O
as	O
a	O
smoking	O
cessation	O
aid	O
.	O

In	O
the	O
initial	O
6	O
months	O
since	O
it	O
'	O
s	O
introduction	O
,	O
12	O
overdose	B-Disease
cases	T-0
have	O
been	O
reported	O
to	O
The	O
National	O
Poisons	O
Information	O
Centre	O
.	O

8	O
patients	O
developed	O
symptoms	T-0
of	T-0
toxicity	B-Disease
.	O

Common	O
features	O
included	T-0
tachycardia	B-Disease
,	O
drowsiness	T-1
,	O
hallucinations	O
and	O
convulsions	O
.	O

Common	T-2
features	T-2
included	T-0
tachycardia	O
,	O
drowsiness	T-1
,	O
hallucinations	B-Disease
and	O
convulsions	O
.	O

Common	T-1
features	T-1
included	O
tachycardia	T-0
,	O
drowsiness	O
,	O
hallucinations	O
and	O
convulsions	B-Disease
.	O

Two	O
patients	O
developed	T-1
severe	T-1
cardiac	B-Disease
arrhythmias	I-Disease
,	O
including	T-0
one	T-0
patient	T-0
who	O
was	O
resuscitated	O
following	O
a	O
cardiac	O
arrest	O
.	O

Two	O
patients	O
developed	O
severe	O
cardiac	O
arrhythmias	O
,	O
including	O
one	O
patient	O
who	O
was	O
resuscitated	T-0
following	T-0
a	T-0
cardiac	B-Disease
arrest	I-Disease
.	O

We	O
report	O
a	O
case	O
of	O
a	O
31	O
year	O
old	O
female	O
who	O
required	O
admission	O
to	O
the	O
Intensive	O
Care	O
Unit	O
for	O
ventilation	O
and	O
full	O
supportive	O
therapy	O
,	O
following	O
ingestion	T-0
of	T-0
13	O
.	O
5g	O
bupropion	B-Chemical
.	O

Recurrent	T-1
seizures	B-Disease
were	T-0
treated	T-0
with	O
diazepam	O
and	O
broad	O
complex	O
tachycardia	O
was	O
successfully	O
treated	O
with	O
adenosine	O
.	O

Recurrent	T-2
seizures	T-2
were	T-0
treated	T-3
with	T-3
diazepam	B-Chemical
and	O
broad	O
complex	O
tachycardia	O
was	O
successfully	T-1
treated	T-1
with	T-1
adenosine	O
.	O

Recurrent	O
seizures	O
were	O
treated	T-0
with	O
diazepam	O
and	O
broad	O
complex	O
tachycardia	B-Disease
was	O
successfully	O
treated	T-1
with	O
adenosine	O
.	O

Recurrent	O
seizures	O
were	O
treated	O
with	O
diazepam	T-1
and	O
broad	O
complex	O
tachycardia	O
was	O
successfully	T-0
treated	T-2
with	T-2
adenosine	B-Chemical
.	O

Zyban	B-Chemical
caused	O
significant	O
neurological	O
and	O
cardiovascular	O
toxicity	T-1
in	T-0
overdose	T-0
.	O

Zyban	O
caused	T-0
significant	T-0
neurological	B-Disease
and	I-Disease
cardiovascular	I-Disease
toxicity	I-Disease
in	O
overdose	O
.	O

Zyban	O
caused	T-0
significant	O
neurological	O
and	O
cardiovascular	O
toxicity	O
in	O
overdose	B-Disease
.	O

GLEPP1	T-0
receptor	T-0
tyrosine	B-Chemical
phosphatase	O
(	O
Ptpro	O
)	O
in	T-1
rat	T-1
PAN	T-1
nephrosis	T-1
.	O

GLEPP1	O
receptor	O
tyrosine	O
phosphatase	O
(	O
Ptpro	O
)	O
in	T-0
rat	T-0
PAN	B-Chemical
nephrosis	T-1
.	T-1

GLEPP1	O
receptor	O
tyrosine	O
phosphatase	O
(	O
Ptpro	O
)	O
in	T-0
rat	O
PAN	O
nephrosis	B-Disease
.	O

Glomerular	O
epithelial	O
protein	O
1	O
(	O
GLEPP1	O
)	O
is	O
a	O
podocyte	O
receptor	T-0
membrane	T-0
protein	T-0
tyrosine	B-Chemical
phosphatase	T-1
located	O
on	O
the	O
apical	O
cell	O
membrane	O
of	O
visceral	O
glomerular	O
epithelial	O
cell	O
and	O
foot	O
processes	O
.	O

To	O
better	O
understand	O
the	O
utility	T-2
of	T-2
GLEPP1	T-2
as	T-2
a	T-2
marker	T-2
of	T-1
glomerular	B-Disease
injury	I-Disease
,	O
the	T-0
amount	T-0
and	T-0
distribution	T-0
of	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
examined	O
by	O
immunohistochemistry	O
,	O
Western	O
blot	O
and	O
RNase	O
protection	O
assay	O
in	O
a	O
model	O
of	O
podocyte	O
injury	O
in	O
the	O
rat	O
.	O

Puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	O
was	T-1
induced	T-1
by	T-1
single	O
intraperitoneal	T-0
injection	T-0
of	T-0
puromycin	O
aminonucleoside	O
(	O
PAN	O
,	O
20	O
mg	O
/	O
100g	O
BW	O
)	O
.	O

Puromycin	O
aminonucleoside	O
nephrosis	B-Disease
was	T-0
induced	T-0
by	O
single	O
intraperitoneal	O
injection	O
of	O
puromycin	O
aminonucleoside	O
(	O
PAN	O
,	O
20	O
mg	O
/	O
100g	O
BW	O
)	O
.	O

Puromycin	O
aminonucleoside	O
nephrosis	O
was	O
induced	O
by	O
single	O
intraperitoneal	O
injection	T-1
of	T-1
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	O
,	O
20	O
mg	O
/	O
100g	O
BW	O
)	O
.	O

Puromycin	O
aminonucleoside	O
nephrosis	O
was	O
induced	O
by	O
single	O
intraperitoneal	O
injection	T-0
of	T-0
puromycin	O
aminonucleoside	O
(	O
PAN	B-Chemical
,	O
20	O
mg	O
/	O
100g	O
BW	O
)	O
.	O

Tissues	O
were	O
analyzed	T-0
at	T-0
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	T-3
126	T-3
days	T-3
after	T-3
PAN	B-Chemical
injection	T-4
so	O
as	O
to	T-2
include	T-2
both	O
the	O
acute	O
phase	O
of	O
proteinuria	O
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	O
-	O
11	O
)	O
and	O
the	O
chronic	O
phase	O
of	O
proteinuria	O
associated	O
with	O
glomerulosclerosis	O
(	O
days	O
45	O
-	O
126	O
)	O
.	O

Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	O
after	O
PAN	O
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	O
phase	T-0
of	T-0
proteinuria	B-Disease
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	O
-	O
11	O
)	O
and	O
the	O
chronic	O
phase	O
of	O
proteinuria	O
associated	O
with	O
glomerulosclerosis	O
(	O
days	O
45	O
-	O
126	O
)	O
.	O

Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	O
after	O
PAN	O
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	T-0
phase	T-0
of	O
proteinuria	O
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	O
-	O
11	O
)	O
and	O
the	O
chronic	T-1
phase	T-1
of	O
proteinuria	B-Disease
associated	T-2
with	O
glomerulosclerosis	O
(	O
days	O
45	O
-	O
126	O
)	O
.	O

Tissues	O
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	O
after	O
PAN	O
injection	O
so	O
as	O
to	O
include	O
both	O
the	O
acute	O
phase	O
of	O
proteinuria	O
associated	O
with	O
foot	O
process	O
effacement	O
(	O
days	O
5	O
-	O
11	O
)	O
and	O
the	O
chronic	O
phase	O
of	O
proteinuria	O
associated	T-0
with	T-0
glomerulosclerosis	B-Disease
(	O
days	O
45	O
-	O
126	O
)	O
.	O

We	O
conclude	O
that	O
GLEPP1	O
expression	O
,	O
unlike	O
podocalyxin	O
,	O
reflects	O
podocyte	O
injury	O
induced	T-1
by	T-1
PAN	B-Chemical
.	O

Antithymocyte	B-Chemical
globulin	I-Chemical
in	T-0
the	T-0
treatment	T-0
of	T-0
D	O
-	O
penicillamine	O
-	O
induced	O
aplastic	O
anemia	O
.	O

Antithymocyte	O
globulin	O
in	O
the	O
treatment	T-0
of	T-0
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
-	O
induced	T-2
aplastic	O
anemia	O
.	O

Antithymocyte	O
globulin	O
in	O
the	O
treatment	T-0
of	T-0
D	O
-	O
penicillamine	O
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
.	O

A	O
patient	T-0
who	O
received	T-1
antithymocyte	B-Chemical
globulin	I-Chemical
therapy	O
for	O
aplastic	O
anemia	O
due	O
to	O
D	O
-	O
penicillamine	O
therapy	O
is	O
described	O
.	O

A	T-0
patient	T-0
who	O
received	T-3
antithymocyte	T-3
globulin	T-3
therapy	T-3
for	T-1
aplastic	B-Disease
anemia	I-Disease
due	T-4
to	T-4
D	T-4
-	T-4
penicillamine	T-4
therapy	T-4
is	O
described	O
.	O

A	O
patient	O
who	O
received	O
antithymocyte	O
globulin	O
therapy	O
for	O
aplastic	O
anemia	O
due	T-1
to	T-1
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
therapy	T-0
is	O
described	O
.	O

Use	T-0
of	T-0
antithymocyte	B-Chemical
globulin	I-Chemical
may	O
be	O
the	O
optimal	O
treatment	O
of	O
D	O
-	O
penicillamine	O
-	O
induced	T-1
aplastic	O
anemia	O
.	O

Use	O
of	O
antithymocyte	O
globulin	O
may	O
be	O
the	O
optimal	O
treatment	T-0
of	T-0
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
-	O
induced	T-1
aplastic	O
anemia	O
.	O

Use	O
of	O
antithymocyte	O
globulin	O
may	O
be	O
the	O
optimal	O
treatment	O
of	O
D	O
-	O
penicillamine	O
-	O
induced	T-1
aplastic	B-Disease
anemia	I-Disease
.	O

Metamizol	B-Chemical
potentiates	T-0
morphine	O
antinociception	O
but	O
not	O
constipation	O
after	T-1
chronic	T-1
treatment	T-1
.	O

Metamizol	O
potentiates	T-0
morphine	B-Chemical
antinociception	O
but	O
not	O
constipation	O
after	O
chronic	O
treatment	O
.	O

Metamizol	T-3
potentiates	T-3
morphine	T-3
antinociception	T-3
but	T-2
not	T-2
constipation	B-Disease
after	O
chronic	T-1
treatment	T-1
.	O

This	O
work	O
evaluates	O
the	O
antinociceptive	T-0
and	O
constipating	B-Disease
effects	T-2
of	T-2
the	O
combination	O
of	O
3	O
.	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
morphine	O
with	O
177	O
.	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
metamizol	O
in	O
acutely	O
and	O
chronically	O
treated	O
(	O
once	O
a	O
day	O
for	O
12	O
days	O
)	O
rats	O
.	O

This	O
work	O
evaluates	O
the	O
antinociceptive	O
and	O
constipating	T-0
effects	T-0
of	O
the	O
combination	T-1
of	T-1
3	O
.	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
morphine	B-Chemical
with	O
177	O
.	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
metamizol	O
in	O
acutely	O
and	O
chronically	O
treated	O
(	O
once	O
a	O
day	O
for	O
12	O
days	O
)	O
rats	O
.	O

This	O
work	O
evaluates	O
the	O
antinociceptive	O
and	O
constipating	O
effects	O
of	O
the	O
combination	T-2
of	T-2
3	O
.	O
2	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
morphine	O
with	O
177	O
.	O
8	T-0
mg	T-0
/	T-0
kg	T-0
s	T-0
.	T-0
c	T-0
.	T-0
metamizol	B-Chemical
in	T-1
acutely	T-1
and	O
chronically	O
treated	O
(	O
once	O
a	O
day	O
for	O
12	O
days	O
)	O
rats	O
.	O

On	O
the	O
13th	O
day	O
,	O
antinociceptive	O
effects	O
were	O
assessed	O
using	O
a	O
model	O
of	O
inflammatory	O
nociception	O
,	O
pain	B-Disease
-	O
induced	T-0
functional	O
impairment	O
model	O
,	O
and	O
the	O
charcoal	O
meal	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
intestinal	O
transit	O
.	O

On	O
the	O
13th	O
day	O
,	O
antinociceptive	O
effects	O
were	O
assessed	O
using	O
a	O
model	O
of	O
inflammatory	O
nociception	O
,	O
pain	O
-	O
induced	O
functional	O
impairment	O
model	O
,	O
and	T-0
the	T-0
charcoal	B-Chemical
meal	O
test	T-1
was	O
used	O
to	O
evaluate	O
the	O
intestinal	O
transit	O
.	O

Simultaneous	O
administration	T-0
of	T-0
morphine	B-Chemical
with	O
metamizol	O
resulted	O
in	O
a	O
markedly	O
antinociceptive	O
potentiation	O
and	O
an	O
increasing	O
of	O
the	O
duration	O
of	O
action	O
after	O
a	O
single	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
139	O
+	O
/	O
-	O
36	O
units	O
area	O
(	O
ua	O
)	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
repeated	O
administration	O
(	O
280	O
+	O
/	O
-	O
17	O
vs	O
.	O
131	O
+	O
/	O
-	O
22	O
ua	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Simultaneous	O
administration	T-0
of	T-0
morphine	O
with	O
metamizol	B-Chemical
resulted	O
in	O
a	O
markedly	O
antinociceptive	O
potentiation	O
and	O
an	O
increasing	O
of	O
the	O
duration	T-1
of	T-1
action	T-1
after	O
a	O
single	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
139	O
+	O
/	O
-	O
36	O
units	O
area	O
(	O
ua	O
)	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
repeated	T-2
administration	T-2
(	O
280	O
+	O
/	O
-	O
17	O
vs	O
.	O
131	O
+	O
/	O
-	O
22	O
ua	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Antinociceptive	O
effect	T-0
of	T-0
morphine	B-Chemical
was	O
reduced	O
in	O
chronically	T-1
treated	T-1
rats	O
(	O
39	O
+	O
/	O
-	O
10	O
vs	O
.	O
18	O
+	O
/	O
-	O
5	O
au	O
)	O
while	O
the	O
combination	O
-	O
induced	O
antinociception	O
was	O
remained	O
similar	O
as	O
an	O
acute	O
treatment	O
(	O
298	O
+	O
/	O
-	O
7	O
vs	O
.	O
280	O
+	O
/	O
-	O
17	O
au	O
)	O
.	O

Acute	O
antinociceptive	O
effects	O
of	O
the	O
combination	O
were	O
partially	O
prevented	T-0
by	T-0
3	O
.	O
2	O
mg	O
/	O
kg	O
naloxone	B-Chemical
s	O
.	O
c	O
.	O

In	O
independent	T-0
groups	T-0
,	O
morphine	B-Chemical
inhibited	O
the	O
intestinal	O
transit	O
in	O
48	O
+	O
/	O
-	O
4	O
%	O
and	O
38	O
+	O
/	O
-	O
4	O
%	O
after	O
acute	O
and	O
chronic	O
treatment	O
,	O
respectively	O
,	O
suggesting	O
that	O
tolerance	O
did	O
not	O
develop	O
to	O
the	O
constipating	O
effects	O
.	O

In	O
independent	O
groups	O
,	O
morphine	O
inhibited	O
the	O
intestinal	O
transit	O
in	O
48	O
+	O
/	O
-	O
4	O
%	O
and	O
38	O
+	O
/	O
-	O
4	O
%	O
after	O
acute	O
and	O
chronic	O
treatment	O
,	O
respectively	O
,	O
suggesting	O
that	O
tolerance	T-0
did	O
not	O
develop	O
to	O
the	O
constipating	B-Disease
effects	T-1
.	O

The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	T-0
by	T-0
morphine	B-Chemical
regardless	T-1
of	T-1
the	T-1
time	T-1
of	T-1
treatment	T-1
,	O
suggesting	O
that	O
metamizol	O
did	O
not	O
potentiate	O
morphine	O
-	O
induced	O
constipation	O
.	O

The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	O
by	O
morphine	T-0
regardless	O
of	O
the	O
time	O
of	O
treatment	O
,	O
suggesting	T-2
that	T-2
metamizol	B-Chemical
did	T-3
not	T-3
potentiate	T-3
morphine	T-3
-	O
induced	O
constipation	O
.	O

The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	O
by	O
morphine	O
regardless	O
of	O
the	O
time	O
of	O
treatment	O
,	O
suggesting	O
that	O
metamizol	O
did	O
not	O
potentiate	O
morphine	B-Chemical
-	O
induced	T-0
constipation	T-0
.	O

The	O
combination	O
inhibited	O
intestinal	O
transit	O
similar	O
to	O
that	O
produced	O
by	O
morphine	O
regardless	O
of	O
the	O
time	O
of	O
treatment	O
,	O
suggesting	O
that	O
metamizol	O
did	O
not	O
potentiate	O
morphine	T-1
-	T-1
induced	T-1
constipation	B-Disease
.	O

These	O
findings	O
show	O
a	O
significant	O
interaction	T-0
between	T-1
morphine	B-Chemical
and	T-2
metamizol	O
in	O
chronically	O
treated	O
rats	O
,	O
suggesting	O
that	O
this	O
combination	O
could	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	O
pain	O
.	O

These	O
findings	O
show	O
a	O
significant	O
interaction	O
between	O
morphine	T-1
and	T-1
metamizol	B-Chemical
in	T-2
chronically	T-2
treated	T-2
rats	T-2
,	O
suggesting	O
that	O
this	O
combination	O
could	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
chronic	O
pain	O
.	O

These	O
findings	O
show	O
a	O
significant	O
interaction	O
between	O
morphine	O
and	O
metamizol	O
in	O
chronically	O
treated	O
rats	O
,	O
suggesting	O
that	O
this	O
combination	O
could	O
be	O
useful	O
for	O
the	O
treatment	T-0
of	O
chronic	B-Disease
pain	I-Disease
.	O

Ifosfamide	B-Chemical
encephalopathy	O
presenting	T-0
with	O
asterixis	O
.	O

Ifosfamide	T-0
encephalopathy	B-Disease
presenting	T-1
with	O
asterixis	O
.	O

Ifosfamide	T-0
encephalopathy	T-0
presenting	T-1
with	T-1
asterixis	B-Disease
.	O

CNS	O
toxic	T-0
effects	T-0
of	O
the	O
antineoplastic	O
agent	T-2
ifosfamide	B-Chemical
(	O
IFX	O
)	O
are	T-3
frequent	T-3
and	O
include	O
a	O
variety	O
of	O
neurological	O
symptoms	O
that	O
can	O
limit	T-1
drug	T-1
use	T-1
.	O

CNS	O
toxic	T-0
effects	T-0
of	O
the	O
antineoplastic	O
agent	O
ifosfamide	O
(	O
IFX	B-Chemical
)	O
are	O
frequent	O
and	O
include	O
a	O
variety	O
of	O
neurological	O
symptoms	O
that	O
can	O
limit	O
drug	O
use	O
.	O

We	O
report	O
a	T-1
case	T-1
of	O
a	O
51	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	T-2
severe	O
,	O
disabling	O
negative	O
myoclonus	B-Disease
of	O
the	O
upper	O
and	O
lower	O
extremities	O
after	O
the	O
infusion	O
of	O
ifosfamide	O
for	O
plasmacytoma	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
51	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
severe	O
,	O
disabling	O
negative	O
myoclonus	O
of	O
the	O
upper	O
and	O
lower	O
extremities	O
after	O
the	O
infusion	T-1
of	O
ifosfamide	B-Chemical
for	T-0
plasmacytoma	T-0
.	O

We	O
report	O
a	O
case	O
of	O
a	O
51	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
severe	O
,	O
disabling	O
negative	O
myoclonus	O
of	O
the	O
upper	O
and	O
lower	O
extremities	O
after	O
the	O
infusion	T-1
of	T-1
ifosfamide	T-0
for	T-0
plasmacytoma	B-Disease
.	O

Cranial	O
magnetic	O
resonance	O
imaging	O
and	O
extensive	O
laboratory	O
studies	O
failed	O
to	O
reveal	T-1
structural	B-Disease
lesions	I-Disease
of	I-Disease
the	I-Disease
brain	I-Disease
and	O
metabolic	T-0
abnormalities	T-0
.	O

Cranial	O
magnetic	O
resonance	O
imaging	O
and	O
extensive	O
laboratory	O
studies	T-0
failed	T-0
to	T-0
reveal	T-0
structural	O
lesions	O
of	O
the	O
brain	O
and	O
metabolic	B-Disease
abnormalities	I-Disease
.	O

An	O
electroencephalogram	O
showed	O
continuous	O
,	O
generalized	O
irregular	O
slowing	O
with	O
admixed	O
periodic	O
triphasic	O
waves	O
indicating	O
symptomatic	T-0
encephalopathy	B-Disease
.	O

The	T-0
administration	T-0
of	T-0
ifosfamide	B-Chemical
was	O
discontinued	O
and	O
within	O
12	O
h	O
the	O
asterixis	O
resolved	O
completely	O
.	O

The	O
administration	O
of	O
ifosfamide	O
was	O
discontinued	O
and	O
within	O
12	O
h	O
the	T-0
asterixis	B-Disease
resolved	T-1
completely	O
.	O

In	O
the	O
patient	O
described	O
,	O
the	O
presence	T-1
of	T-1
asterixis	B-Disease
during	T-0
infusion	T-0
of	T-0
ifosfamide	T-0
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	O
that	O
negative	O
myoclonus	O
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	O
.	O

In	O
the	O
patient	O
described	O
,	O
the	O
presence	O
of	O
asterixis	O
during	O
infusion	T-0
of	O
ifosfamide	B-Chemical
,	O
normal	O
laboratory	O
findings	T-1
and	O
imaging	O
studies	T-2
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	O
that	O
negative	O
myoclonus	O
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	O
.	O

In	O
the	O
patient	O
described	O
,	O
the	O
presence	O
of	O
asterixis	O
during	O
infusion	O
of	O
ifosfamide	O
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	O
that	O
negative	T-1
myoclonus	B-Disease
is	T-0
associated	T-0
with	O
the	O
use	O
of	O
IFX	O
.	O

In	O
the	O
patient	O
described	O
,	O
the	O
presence	O
of	O
asterixis	O
during	O
infusion	O
of	O
ifosfamide	O
,	O
normal	O
laboratory	O
findings	O
and	O
imaging	O
studies	O
and	O
the	O
resolution	O
of	O
symptoms	O
following	O
the	O
discontinuation	O
of	O
the	O
drug	O
suggest	O
that	O
negative	O
myoclonus	O
is	O
associated	O
with	O
the	O
use	T-0
of	T-0
IFX	B-Chemical
.	O

Antagonism	O
between	O
interleukin	O
3	O
and	O
erythropoietin	O
in	O
mice	T-0
with	T-0
azidothymidine	B-Chemical
-	O
induced	T-1
anemia	O
and	O
in	O
bone	O
marrow	O
endothelial	O
cells	O
.	O

Antagonism	T-0
between	O
interleukin	O
3	O
and	O
erythropoietin	O
in	O
mice	O
with	O
azidothymidine	O
-	O
induced	O
anemia	B-Disease
and	O
in	O
bone	T-1
marrow	T-1
endothelial	T-1
cells	T-1
.	O

Azidothymidine	B-Chemical
(	O
AZT	O
)	O
-	O
induced	T-1
anemia	O
in	O
mice	O
can	O
be	O
reversed	O
by	O
the	O
administration	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
(	O
fusion	O
protein	O
of	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleukin	O
3	O
)	O
.	O

Azidothymidine	O
(	O
AZT	B-Chemical
)	O
-	O
induced	T-0
anemia	O
in	O
mice	O
can	O
be	O
reversed	O
by	O
the	O
administration	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
(	O
fusion	O
protein	O
of	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleukin	O
3	O
)	O
.	O

Azidothymidine	O
(	T-0
AZT	T-0
)	T-0
-	T-0
induced	T-0
anemia	B-Disease
in	O
mice	O
can	T-1
be	T-1
reversed	T-1
by	O
the	O
administration	O
of	O
IGF	O
-	O
IL	O
-	O
3	O
(	O
fusion	O
protein	O
of	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
(	O
IGF	O
II	O
)	O
and	O
interleukin	O
3	O
)	O
.	O

Although	O
interleukin	O
3	O
(	O
IL	O
-	O
3	O
)	O
and	O
erythropoietin	O
(	O
EPO	O
)	O
are	O
known	O
to	O
act	O
synergistically	O
on	O
hematopoietic	O
cell	O
proliferation	O
in	O
vitro	O
,	O
injection	T-1
of	T-1
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
in	T-0
AZT	B-Chemical
-	O
treated	T-2
mice	T-2
resulted	O
in	O
a	O
reduction	O
of	O
red	O
cells	O
and	O
an	O
increase	O
of	O
plasma	O
EPO	O
levels	O
as	O
compared	O
to	O
animals	O
treated	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
or	O
EPO	O
alone	O
.	O

There	O
was	O
a	O
significant	O
reduction	T-1
of	T-1
thymidine	B-Chemical
incorporation	T-2
into	T-2
both	O
erythroid	O
and	O
endothelial	O
cells	O
in	O
cultures	O
pre	O
-	O
treated	O
with	O
IGF	O
-	O
IL	O
-	O
3	O
and	O
EPO	O
.	O

Endothelial	O
cell	O
culture	O
supernatants	O
separated	O
by	O
ultrafiltration	O
and	O
ultracentrifugation	O
from	O
cells	O
treated	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
significantly	T-0
reduced	T-0
thymidine	B-Chemical
incorporation	O
into	O
erythroid	O
cells	O
as	O
compared	O
to	O
identical	O
fractions	O
obtained	O
from	O
the	O
media	O
of	O
cells	O
cultured	O
with	O
EPO	O
alone	O
.	O

The	O
relationship	O
between	O
hippocampal	O
acetylcholine	O
release	O
and	O
cholinergic	O
convulsant	O
sensitivity	O
in	T-0
withdrawal	T-0
seizure	B-Disease
-	O
prone	T-1
and	T-1
withdrawal	T-1
seizure	T-1
-	O
resistant	O
selected	O
mouse	O
lines	O
.	O

The	O
relationship	O
between	O
hippocampal	O
acetylcholine	O
release	O
and	O
cholinergic	O
convulsant	O
sensitivity	O
in	O
withdrawal	O
seizure	O
-	O
prone	O
and	O
withdrawal	T-0
seizure	B-Disease
-	O
resistant	T-1
selected	T-1
mouse	T-1
lines	T-1
.	O

BACKGROUND	O
:	O
The	O
septo	O
-	O
hippocampal	O
cholinergic	O
pathway	O
has	O
been	O
implicated	O
in	O
epileptogenesis	O
,	O
and	O
genetic	O
factors	O
influence	O
the	O
response	O
to	O
cholinergic	O
agents	O
,	O
but	O
limited	O
data	O
are	O
available	O
on	O
cholinergic	O
involvement	O
in	T-1
alcohol	B-Chemical
withdrawal	T-2
severity	T-2
.	T-1

Thus	O
,	O
the	O
relationship	O
between	O
cholinergic	O
activity	O
and	O
responsiveness	O
and	O
alcohol	B-Chemical
withdrawal	T-0
was	O
investigated	O
in	O
a	O
genetic	O
animal	O
model	O
of	O
ethanol	O
withdrawal	O
severity	O
.	O

Thus	O
,	O
the	O
relationship	O
between	O
cholinergic	T-0
activity	T-0
and	O
responsiveness	O
and	O
alcohol	T-1
withdrawal	T-1
was	O
investigated	O
in	O
a	O
genetic	O
animal	O
model	T-4
of	T-4
ethanol	B-Chemical
withdrawal	T-3
severity	T-3
.	T-3

METHODS	O
:	O
Cholinergic	O
convulsant	O
sensitivity	O
was	O
examined	T-0
in	O
alcohol	B-Chemical
-	O
na	T-1
ve	T-1
Withdrawal	T-1
Seizure	T-1
-	O
Prone	O
(	O
WSP	O
)	O
and	O
-	O
Resistant	O
(	O
WSR	O
)	O
mice	O
.	O

METHODS	O
:	O
Cholinergic	O
convulsant	O
sensitivity	O
was	O
examined	O
in	O
alcohol	O
-	O
na	O
ve	O
Withdrawal	T-0
Seizure	B-Disease
-	O
Prone	T-1
(	T-1
WSP	T-1
)	T-1
and	T-1
-	T-1
Resistant	T-1
(	T-1
WSR	T-1
)	T-1
mice	T-1
.	O

Animals	O
were	O
administered	T-1
nicotine	B-Chemical
,	O
carbachol	T-2
,	O
or	O
neostigmine	O
via	O
timed	O
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	O
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose	O
.	O

Animals	O
were	O
administered	T-0
nicotine	O
,	O
carbachol	B-Chemical
,	O
or	O
neostigmine	O
via	O
timed	O
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	O
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose	O
.	O

Animals	O
were	O
administered	T-1
nicotine	O
,	O
carbachol	O
,	O
or	O
neostigmine	B-Chemical
via	T-0
timed	T-0
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	O
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	T-2
dose	T-2
.	O

Animals	O
were	O
administered	O
nicotine	O
,	O
carbachol	O
,	O
or	O
neostigmine	O
via	O
timed	O
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	O
to	O
onset	T-0
of	T-0
tremor	B-Disease
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose	O
.	O

We	O
also	O
used	T-3
microdialysis	T-0
to	O
measure	O
basal	O
and	O
potassium	B-Chemical
-	O
stimulated	T-1
acetylcholine	O
(	O
ACh	O
)	O
release	T-2
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O

We	O
also	O
used	O
microdialysis	O
to	O
measure	O
basal	O
and	O
potassium	O
-	O
stimulated	T-0
acetylcholine	B-Chemical
(	O
ACh	O
)	O
release	T-1
in	T-1
the	T-1
CA1	T-1
region	T-1
of	O
the	O
hippocampus	O
.	O

We	O
also	O
used	O
microdialysis	O
to	O
measure	O
basal	O
and	O
potassium	O
-	O
stimulated	O
acetylcholine	O
(	O
ACh	B-Chemical
)	O
release	T-0
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O

Potassium	B-Chemical
was	T-0
applied	T-1
by	O
reverse	O
dialysis	O
twice	O
,	O
separated	O
by	O
75	O
min	O
.	O

Hippocampal	O
ACh	B-Chemical
also	O
was	T-0
measured	T-0
during	O
testing	O
for	O
handling	O
-	O
induced	O
convulsions	O
.	O

Hippocampal	O
ACh	O
also	O
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	T-0
convulsions	B-Disease
.	O

RESULTS	O
:	O
Sensitivity	T-0
to	T-0
several	O
convulsion	B-Disease
endpoints	O
induced	T-2
by	O
nicotine	O
,	O
carbachol	O
,	O
and	O
neostigmine	O
were	O
significantly	O
greater	O
in	O
WSR	O
versus	T-3
WSP	O
mice	O
.	O

RESULTS	O
:	O
Sensitivity	O
to	O
several	O
convulsion	O
endpoints	O
induced	T-0
by	O
nicotine	B-Chemical
,	O
carbachol	O
,	O
and	O
neostigmine	O
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mice	O
.	O

RESULTS	O
:	O
Sensitivity	O
to	O
several	O
convulsion	O
endpoints	O
induced	T-2
by	T-2
nicotine	T-0
,	O
carbachol	B-Chemical
,	O
and	T-1
neostigmine	T-1
were	O
significantly	O
greater	O
in	O
WSR	O
versus	O
WSP	O
mice	O
.	O

RESULTS	O
:	O
Sensitivity	O
to	O
several	O
convulsion	O
endpoints	O
induced	T-1
by	T-1
nicotine	O
,	O
carbachol	O
,	O
and	O
neostigmine	B-Chemical
were	T-0
significantly	T-0
greater	O
in	O
WSR	O
versus	O
WSP	O
mice	O
.	O

In	O
microdialysis	O
experiments	O
,	O
the	O
lines	O
did	O
not	O
differ	O
in	O
basal	T-2
release	T-2
of	T-2
ACh	B-Chemical
,	O
and	O
50	O
mM	O
KCl	O
increased	T-0
ACh	O
output	O
in	O
both	O
lines	O
of	O
mice	O
.	O

In	O
microdialysis	O
experiments	O
,	O
the	O
lines	O
did	O
not	O
differ	O
in	O
basal	O
release	O
of	O
ACh	O
,	O
and	O
50	O
mM	O
KCl	B-Chemical
increased	T-0
ACh	O
output	O
in	O
both	O
lines	O
of	O
mice	O
.	O

In	O
microdialysis	O
experiments	O
,	O
the	O
lines	O
did	O
not	O
differ	O
in	O
basal	O
release	O
of	O
ACh	O
,	O
and	O
50	O
mM	O
KCl	O
increased	T-0
ACh	B-Chemical
output	T-1
in	O
both	O
lines	O
of	O
mice	O
.	O

However	O
,	O
the	O
increase	O
in	O
release	T-0
of	T-0
ACh	B-Chemical
produced	T-1
by	T-1
the	O
first	O
application	O
of	O
KCl	O
was	O
2	O
-	O
fold	O
higher	O
in	O
WSP	O
versus	O
WSR	O
mice	O
.	O

However	O
,	O
the	O
increase	O
in	O
release	O
of	O
ACh	O
produced	O
by	O
the	O
first	T-0
application	T-0
of	T-0
KCl	B-Chemical
was	T-1
2	T-1
-	O
fold	O
higher	O
in	O
WSP	O
versus	O
WSR	O
mice	O
.	O

When	T-0
hippocampal	T-0
ACh	B-Chemical
was	O
measured	T-1
during	O
testing	O
for	O
handling	O
-	O
induced	T-2
convulsions	O
,	O
extracellular	O
ACh	O
was	O
significantly	O
elevated	O
(	O
192	O
%	O
)	O
in	O
WSP	O
mice	O
,	O
but	O
was	O
nonsignificantly	O
elevated	O
(	O
59	O
%	O
)	O
in	O
WSR	O
mice	O
.	O

When	O
hippocampal	O
ACh	O
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	T-0
convulsions	B-Disease
,	O
extracellular	O
ACh	O
was	O
significantly	O
elevated	O
(	O
192	O
%	O
)	O
in	O
WSP	O
mice	O
,	O
but	O
was	O
nonsignificantly	O
elevated	O
(	O
59	O
%	O
)	O
in	O
WSR	O
mice	O
.	O

When	O
hippocampal	O
ACh	O
was	O
measured	O
during	O
testing	O
for	O
handling	O
-	O
induced	O
convulsions	O
,	O
extracellular	O
ACh	B-Chemical
was	T-1
significantly	T-1
elevated	T-1
(	O
192	O
%	O
)	O
in	O
WSP	O
mice	O
,	O
but	O
was	O
nonsignificantly	O
elevated	O
(	O
59	O
%	O
)	O
in	O
WSR	O
mice	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
differences	O
in	O
cholinergic	O
activity	O
and	O
postsynaptic	O
sensitivity	T-0
to	T-0
cholinergic	T-0
convulsants	B-Disease
may	O
be	O
associated	O
with	O
ethanol	O
withdrawal	O
severity	O
and	O
implicate	O
cholinergic	O
mechanisms	O
in	O
alcohol	O
withdrawal	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
differences	O
in	O
cholinergic	O
activity	O
and	O
postsynaptic	O
sensitivity	O
to	O
cholinergic	T-0
convulsants	T-0
may	O
be	O
associated	T-1
with	T-1
ethanol	B-Chemical
withdrawal	T-2
severity	T-2
and	O
implicate	O
cholinergic	O
mechanisms	O
in	O
alcohol	O
withdrawal	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
differences	O
in	O
cholinergic	O
activity	O
and	O
postsynaptic	O
sensitivity	O
to	O
cholinergic	O
convulsants	O
may	O
be	O
associated	O
with	O
ethanol	O
withdrawal	O
severity	O
and	O
implicate	O
cholinergic	T-0
mechanisms	T-0
in	O
alcohol	B-Chemical
withdrawal	O
.	O

Specifically	O
,	O
WSP	O
mice	O
may	O
have	O
lower	O
sensitivity	T-0
to	O
cholinergic	O
convulsants	B-Disease
compared	O
with	O
WSR	O
because	O
of	O
postsynaptic	O
receptor	O
desensitization	O
brought	O
on	O
by	O
higher	O
activity	O
of	O
cholinergic	O
neurons	O
.	O

Capsaicin	B-Chemical
-	O
induced	T-0
muscle	O
pain	O
alters	O
the	O
excitability	O
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
.	O

Capsaicin	T-0
-	T-0
induced	T-0
muscle	B-Disease
pain	I-Disease
alters	O
the	O
excitability	O
of	O
the	O
human	O
jaw	O
-	O
stretch	O
reflex	O
.	O

The	O
pathophysiology	O
of	T-0
painful	T-0
temporomandibular	B-Disease
disorders	I-Disease
is	O
not	O
fully	O
understood	O
,	O
but	O
evidence	O
suggests	O
that	O
muscle	O
pain	O
modulates	O
motor	O
function	O
in	O
characteristic	O
ways	O
.	O

The	O
pathophysiology	O
of	O
painful	O
temporomandibular	T-0
disorders	T-0
is	O
not	O
fully	O
understood	O
,	O
but	O
evidence	O
suggests	O
that	O
muscle	B-Disease
pain	I-Disease
modulates	T-1
motor	O
function	O
in	O
characteristic	O
ways	O
.	O

Capsaicin	B-Chemical
(	O
10	O
micro	O
g	O
)	O
was	T-0
injected	T-0
into	O
the	O
masseter	O
muscle	O
to	O
induce	O
pain	O
in	O
11	O
healthy	O
volunteers	O
.	O

Capsaicin	O
(	O
10	O
micro	O
g	O
)	O
was	O
injected	O
into	O
the	O
masseter	O
muscle	O
to	T-0
induce	T-0
pain	B-Disease
in	T-1
11	T-1
healthy	T-1
volunteers	T-1
.	O

Short	O
-	O
latency	O
reflex	O
responses	O
were	O
evoked	O
in	O
the	O
masseter	O
and	O
temporalis	O
muscles	O
by	O
a	O
stretch	O
device	O
with	O
different	O
velocities	O
and	O
displacements	T-0
before	T-0
,	T-0
during	T-0
,	T-0
and	T-0
after	T-1
the	T-1
pain	B-Disease
.	O

The	O
normalized	T-0
reflex	O
amplitude	O
was	O
significantly	O
higher	O
during	T-1
pain	B-Disease
,	O
but	O
only	O
at	O
faster	O
stretches	O
in	O
the	O
painful	O
muscle	O
.	O

The	O
normalized	O
reflex	O
amplitude	O
was	O
significantly	O
higher	O
during	O
pain	O
,	O
but	O
only	O
at	O
faster	O
stretches	O
in	T-0
the	T-0
painful	B-Disease
muscle	I-Disease
.	O

Increased	O
sensitivity	O
of	O
the	O
fusimotor	O
system	O
during	O
acute	T-0
muscle	B-Disease
pain	I-Disease
could	O
be	O
one	O
likely	O
mechanism	O
to	O
explain	O
the	O
findings	O
.	O

Effects	T-1
of	T-1
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	T-0
into	O
the	O
accumbal	O
shell	O
or	O
core	O
on	O
the	O
cocaine	B-Chemical
-	O
induced	T-2
locomotor	O
hyperactivity	O
in	O
rats	O
.	O

Effects	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbal	O
shell	O
or	O
core	O
on	O
the	O
cocaine	O
-	O
induced	T-0
locomotor	B-Disease
hyperactivity	I-Disease
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effect	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
subregions	O
of	O
the	O
nucleus	O
accumbens	O
(	O
the	O
shell	O
and	O
the	O
core	O
)	O
on	T-0
the	T-0
locomotor	B-Disease
hyperactivity	I-Disease
induced	T-1
by	T-1
cocaine	O
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effect	O
of	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
subregions	O
of	O
the	O
nucleus	O
accumbens	O
(	O
the	O
shell	O
and	O
the	O
core	O
)	O
on	O
the	O
locomotor	O
hyperactivity	O
induced	T-0
by	T-0
cocaine	B-Chemical
in	T-1
rats	T-1
.	O

Male	O
Wistar	O
rats	O
were	O
implanted	O
bilaterally	O
with	O
cannulae	O
into	O
the	O
accumbens	O
shell	O
or	O
core	O
,	O
and	O
then	O
were	O
locally	O
injected	T-1
with	T-1
GR	B-Chemical
55562	I-Chemical
(	O
an	O
antagonist	O
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
or	O
CP	O
93129	O
(	O
an	O
agonist	O
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
.	O

Male	O
Wistar	O
rats	O
were	O
implanted	O
bilaterally	O
with	O
cannulae	O
into	O
the	O
accumbens	O
shell	O
or	O
core	O
,	O
and	O
then	O
were	O
locally	T-0
injected	T-0
with	T-0
GR	O
55562	O
(	O
an	O
antagonist	O
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
an	O
agonist	O
of	O
5	O
-	O
HT1B	O
receptors	O
)	O
.	O

Given	T-1
alone	T-1
to	O
any	O
accumbal	O
subregion	T-0
,	O
GR	B-Chemical
55562	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
or	O
CP	O
93129	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
did	O
not	O
change	O
basal	O
locomotor	O
activity	O
.	O

Given	O
alone	O
to	O
any	O
accumbal	O
subregion	O
,	O
GR	O
55562	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
did	T-0
not	T-0
change	T-0
basal	O
locomotor	O
activity	O
.	O

Systemic	T-0
cocaine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
significantly	T-1
increased	T-1
the	O
locomotor	O
activity	O
of	O
rats	O
.	O

GR	B-Chemical
55562	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
,	O
administered	T-0
intra	O
-	O
accumbens	O
shell	O
prior	O
to	O
cocaine	O
,	O
dose	O
-	O
dependently	O
attenuated	O
the	O
psychostimulant	O
-	O
induced	T-1
locomotor	O
hyperactivity	O
.	O

GR	O
55562	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
,	O
administered	O
intra	O
-	O
accumbens	O
shell	O
prior	T-0
to	T-0
cocaine	B-Chemical
,	O
dose	O
-	O
dependently	O
attenuated	O
the	O
psychostimulant	O
-	O
induced	T-1
locomotor	T-1
hyperactivity	T-1
.	T-1

GR	O
55562	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
,	O
administered	O
intra	O
-	O
accumbens	O
shell	O
prior	O
to	O
cocaine	O
,	O
dose	O
-	O
dependently	O
attenuated	T-0
the	T-0
psychostimulant	O
-	O
induced	T-1
locomotor	B-Disease
hyperactivity	I-Disease
.	O

Such	O
attenuation	O
was	O
not	O
found	O
in	O
animals	O
which	O
had	O
been	O
injected	T-0
with	T-0
GR	B-Chemical
55562	I-Chemical
into	T-1
the	T-1
accumbens	T-1
core	T-1
.	O

When	T-0
injected	T-0
into	O
the	O
accumbens	O
shell	O
(	O
but	O
not	O
the	O
core	O
)	O
before	T-3
cocaine	B-Chemical
,	T-4
CP	T-4
93129	T-4
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
enhanced	T-1
the	T-1
locomotor	T-1
response	T-1
to	O
cocaine	O
;	O
the	O
maximum	T-2
effect	T-2
being	O
observed	O
after	O
10	O
microg	O
/	O
side	O
of	O
the	O
agonist	O
.	O

When	O
injected	O
into	O
the	O
accumbens	O
shell	O
(	O
but	O
not	O
the	O
core	O
)	O
before	T-0
cocaine	T-0
,	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
enhanced	O
the	O
locomotor	O
response	O
to	O
cocaine	O
;	O
the	O
maximum	O
effect	O
being	O
observed	O
after	O
10	O
microg	O
/	O
side	O
of	O
the	O
agonist	O
.	O

When	O
injected	T-0
into	O
the	O
accumbens	O
shell	O
(	O
but	O
not	O
the	O
core	O
)	O
before	O
cocaine	O
,	O
CP	O
93129	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
enhanced	O
the	O
locomotor	O
response	T-1
to	T-1
cocaine	B-Chemical
;	O
the	T-2
maximum	T-2
effect	O
being	O
observed	O
after	O
10	O
microg	O
/	O
side	O
of	O
the	O
agonist	O
.	O

The	O
later	O
enhancement	O
was	O
attenuated	O
after	O
intra	O
-	O
accumbens	O
shell	O
treatment	T-1
with	T-1
GR	B-Chemical
55562	I-Chemical
(	O
1	O
microg	O
/	O
side	O
)	O
.	O

Our	O
findings	O
indicate	O
that	O
cocaine	B-Chemical
induced	T-2
hyperlocomotion	O
is	O
modified	O
by	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	T-0
into	T-0
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	T-1
and	T-1
facilitatory	T-1
effects	T-1
of	O
the	O
5	O
-	O
HT1B	O
receptor	O
antagonist	O
(	O
GR	O
55562	O
)	O
and	O
agonist	O
(	O
CP	O
93129	O
)	O
,	O
respectively	O
.	O

Our	O
findings	O
indicate	O
that	O
cocaine	O
induced	T-2
hyperlocomotion	B-Disease
is	T-1
modified	T-1
by	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	O
of	O
the	O
5	O
-	O
HT1B	O
receptor	O
antagonist	O
(	O
GR	O
55562	O
)	O
and	O
agonist	O
(	O
CP	O
93129	O
)	O
,	O
respectively	O
.	O

Our	O
findings	O
indicate	O
that	O
cocaine	O
induced	O
hyperlocomotion	O
is	O
modified	O
by	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	T-0
effects	T-0
of	T-0
the	O
5	O
-	O
HT1B	O
receptor	O
antagonist	O
(	O
GR	B-Chemical
55562	I-Chemical
)	O
and	O
agonist	O
(	O
CP	O
93129	O
)	O
,	O
respectively	O
.	O

Our	O
findings	O
indicate	O
that	O
cocaine	O
induced	O
hyperlocomotion	O
is	O
modified	O
by	O
5	O
-	O
HT1B	O
receptor	O
ligands	O
microinjected	O
into	O
the	O
accumbens	O
shell	O
,	O
but	O
not	O
core	O
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	O
and	O
facilitatory	O
effects	O
of	O
the	O
5	O
-	O
HT1B	O
receptor	O
antagonist	O
(	O
GR	O
55562	O
)	O
and	O
agonist	T-0
(	O
CP	B-Chemical
93129	I-Chemical
)	O
,	O
respectively	O
.	O

Cocaine	B-Chemical
related	T-0
chest	T-0
pain	T-0
:	O
are	O
we	O
seeing	O
the	O
tip	O
of	O
an	O
iceberg	O
?	O

Cocaine	O
related	T-0
chest	B-Disease
pain	I-Disease
:	O
are	O
we	O
seeing	O
the	O
tip	O
of	O
an	O
iceberg	O
?	O

The	O
recreational	O
use	T-1
of	T-1
cocaine	B-Chemical
is	T-0
on	T-0
the	T-0
increase	T-0
.	O

The	O
emergency	O
nurse	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardiovascular	O
consequences	T-2
of	T-2
cocaine	B-Chemical
use	T-1
.	O

In	O
particular	O
,	O
the	O
tendency	T-1
of	T-1
cocaine	B-Chemical
to	T-0
produce	T-0
chest	O
pain	O
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergency	O
nurse	O
when	O
faced	O
with	O
a	O
young	O
victim	O
of	O
chest	O
pain	O
who	O
is	O
otherwise	O
at	O
low	O
risk	O
.	O

In	O
particular	O
,	O
the	O
tendency	O
of	O
cocaine	O
to	T-0
produce	T-0
chest	B-Disease
pain	I-Disease
ought	T-1
to	T-1
be	T-1
in	O
the	O
mind	O
of	O
the	O
emergency	O
nurse	O
when	O
faced	O
with	O
a	O
young	O
victim	O
of	O
chest	O
pain	O
who	O
is	O
otherwise	O
at	O
low	O
risk	O
.	O

In	O
particular	O
,	O
the	O
tendency	O
of	O
cocaine	O
to	O
produce	O
chest	O
pain	O
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergency	O
nurse	O
when	O
faced	O
with	O
a	O
young	O
victim	T-1
of	T-1
chest	B-Disease
pain	I-Disease
who	T-0
is	T-0
otherwise	T-0
at	T-0
low	T-0
risk	T-0
.	O

The	T-1
mechanism	T-1
of	O
chest	B-Disease
pain	I-Disease
related	O
to	O
cocaine	O
use	O
is	O
discussed	O
and	O
treatment	O
dilemmas	O
are	O
discussed	O
.	O

The	O
mechanism	O
of	O
chest	O
pain	O
related	T-1
to	T-1
cocaine	B-Chemical
use	T-0
is	O
discussed	O
and	O
treatment	T-2
dilemmas	T-2
are	O
discussed	O
.	O

Finally	O
,	O
moral	O
issues	O
relating	O
to	T-1
the	T-1
testing	T-1
of	T-1
potential	T-1
cocaine	B-Chemical
users	T-2
will	T-2
be	T-2
addressed	T-2
.	O

Crossover	O
comparison	T-1
of	O
efficacy	T-0
and	T-0
preference	O
for	O
rizatriptan	B-Chemical
10	O
mg	O
versus	O
ergotamine	O
/	O
caffeine	O
in	O
migraine	O
.	O

Crossover	O
comparison	T-2
of	T-2
efficacy	T-2
and	O
preference	O
for	O
rizatriptan	O
10	O
mg	O
versus	T-0
ergotamine	B-Chemical
/	O
caffeine	T-3
in	T-3
migraine	T-3
.	O

Crossover	O
comparison	T-1
of	T-1
efficacy	T-1
and	O
preference	O
for	O
rizatriptan	O
10	O
mg	O
versus	O
ergotamine	O
/	O
caffeine	B-Chemical
in	T-0
migraine	T-0
.	O

Crossover	T-1
comparison	T-1
of	O
efficacy	O
and	O
preference	O
for	O
rizatriptan	O
10	O
mg	O
versus	T-2
ergotamine	O
/	O
caffeine	O
in	T-0
migraine	B-Disease
.	O

Rizatriptan	B-Chemical
is	T-0
a	T-0
selective	O
5	O
-	O
HT	O
(	O
1B	O
/	O
1D	O
)	O
receptor	O
agonist	T-1
with	T-1
rapid	O
oral	O
absorption	O
and	O
early	O
onset	O
of	O
action	O
in	O
the	O
acute	O
treatment	O
of	O
migraine	O
.	O

Rizatriptan	O
is	T-0
a	T-0
selective	T-0
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	O
1B	O
/	O
1D	O
)	O
receptor	T-1
agonist	O
with	O
rapid	O
oral	O
absorption	O
and	O
early	O
onset	O
of	O
action	O
in	O
the	O
acute	O
treatment	T-2
of	O
migraine	O
.	O

Rizatriptan	O
is	O
a	O
selective	O
5	O
-	O
HT	O
(	O
1B	O
/	O
1D	O
)	O
receptor	O
agonist	O
with	O
rapid	T-0
oral	T-0
absorption	T-2
and	O
early	O
onset	T-1
of	O
action	O
in	O
the	O
acute	O
treatment	O
of	O
migraine	B-Disease
.	O

This	O
randomized	O
double	O
-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	O
the	O
preference	T-1
for	T-1
1	T-1
rizatriptan	B-Chemical
10	T-2
mg	T-2
tablet	T-2
to	O
2	O
ergotamine	O
1	O
mg	O
/	O
caffeine	O
100	O
mg	O
tablets	O
in	O
439	O
patients	O
treating	O
a	O
single	O
migraine	O
attack	O
with	O
each	O
therapy	O
.	O

This	O
randomized	O
double	O
-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	T-0
the	T-0
preference	T-0
for	O
1	O
rizatriptan	O
10	O
mg	O
tablet	O
to	O
2	O
ergotamine	B-Chemical
1	O
mg	O
/	O
caffeine	O
100	O
mg	O
tablets	O
in	O
439	O
patients	O
treating	O
a	O
single	O
migraine	O
attack	O
with	O
each	O
therapy	O
.	O

This	O
randomized	O
double	O
-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	O
the	O
preference	O
for	O
1	O
rizatriptan	O
10	O
mg	O
tablet	O
to	O
2	O
ergotamine	T-0
1	T-0
mg	T-0
/	T-0
caffeine	B-Chemical
100	T-1
mg	T-1
tablets	T-1
in	O
439	O
patients	O
treating	O
a	O
single	O
migraine	O
attack	O
with	O
each	O
therapy	O
.	O

This	O
randomized	O
double	O
-	O
blind	O
crossover	O
outpatient	O
study	O
assessed	O
the	O
preference	O
for	O
1	O
rizatriptan	O
10	O
mg	O
tablet	O
to	O
2	O
ergotamine	O
1	O
mg	O
/	O
caffeine	O
100	O
mg	O
tablets	O
in	O
439	O
patients	O
treating	T-0
a	T-0
single	T-0
migraine	B-Disease
attack	T-1
with	T-1
each	T-1
therapy	T-1
.	O

Of	O
patients	O
expressing	O
a	O
preference	O
(	O
89	O
.	O
1	O
%	O
)	O
,	O
more	O
than	O
twice	T-1
as	T-1
many	T-1
preferred	T-1
rizatriptan	B-Chemical
to	O
ergotamine	O
/	O
caffeine	O
(	O
69	O
.	O
9	O
vs	O
.	O
30	O
.	O
1	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Of	O
patients	O
expressing	O
a	O
preference	O
(	O
89	O
.	O
1	O
%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	T-0
preferred	T-0
rizatriptan	O
to	O
ergotamine	B-Chemical
/	O
caffeine	O
(	O
69	O
.	O
9	O
vs	O
.	O
30	O
.	O
1	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Of	O
patients	O
expressing	O
a	O
preference	O
(	O
89	O
.	O
1	O
%	O
)	O
,	O
more	O
than	O
twice	T-0
as	T-0
many	T-0
preferred	T-0
rizatriptan	O
to	T-1
ergotamine	T-1
/	O
caffeine	B-Chemical
(	O
69	O
.	O
9	O
vs	O
.	O
30	O
.	O
1	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Faster	O
relief	T-1
of	T-1
headache	B-Disease
was	O
the	O
most	O
important	O
reason	O
for	O
preference	O
,	O
cited	O
by	O
67	O
.	O
3	O
%	O
of	O
patients	O
preferring	O
rizatriptan	O
and	O
54	O
.	O
2	O
%	O
of	O
patients	O
who	O
preferred	O
ergotamine	O
/	O
caffeine	O
.	O

Faster	O
relief	O
of	O
headache	O
was	O
the	O
most	O
important	O
reason	O
for	O
preference	O
,	O
cited	O
by	O
67	O
.	O
3	O
%	O
of	O
patients	O
preferring	O
rizatriptan	O
and	O
54	O
.	O
2	O
%	O
of	O
patients	O
who	O
preferred	T-0
ergotamine	B-Chemical
/	O
caffeine	O
.	O

Faster	T-0
relief	T-0
of	T-0
headache	T-0
was	O
the	O
most	O
important	O
reason	O
for	O
preference	O
,	O
cited	O
by	O
67	O
.	O
3	O
%	O
of	O
patients	O
preferring	T-1
rizatriptan	T-1
and	O
54	O
.	O
2	O
%	O
of	O
patients	T-2
who	T-2
preferred	T-2
ergotamine	O
/	O
caffeine	B-Chemical
.	O

The	O
co	O
-	O
primary	O
endpoint	O
of	T-0
being	T-0
pain	B-Disease
free	T-1
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rizatriptan	O
.	O

Forty	O
-	O
nine	T-0
percent	T-0
of	T-0
patients	T-0
were	O
pain	B-Disease
free	O
2	O
h	O
after	O
rizatriptan	O
,	O
compared	O
with	O
24	O
.	O
3	O
%	O
treated	O
with	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
rizatriptan	O
being	O
superior	O
within	O
1	O
h	O
of	O
treatment	O
.	O

Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	O
free	O
2	O
h	O
after	T-0
rizatriptan	B-Chemical
,	O
compared	T-1
with	T-1
24	O
.	O
3	O
%	O
treated	O
with	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
rizatriptan	O
being	O
superior	O
within	O
1	O
h	O
of	O
treatment	O
.	O

Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	O
free	O
2	O
h	O
after	O
rizatriptan	O
,	O
compared	O
with	O
24	O
.	O
3	O
%	O
treated	T-0
with	T-0
ergotamine	B-Chemical
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
rizatriptan	O
being	O
superior	O
within	O
1	O
h	O
of	O
treatment	O
.	O

Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	O
free	O
2	O
h	O
after	O
rizatriptan	O
,	O
compared	O
with	O
24	O
.	O
3	O
%	O
treated	T-0
with	T-0
ergotamine	O
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
rizatriptan	O
being	O
superior	O
within	O
1	O
h	O
of	O
treatment	O
.	O

Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	O
free	O
2	O
h	O
after	O
rizatriptan	O
,	O
compared	O
with	O
24	O
.	O
3	O
%	O
treated	T-0
with	T-0
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
rizatriptan	B-Chemical
being	T-1
superior	T-1
within	O
1	O
h	O
of	O
treatment	O
.	O

Headache	B-Disease
relief	O
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizatriptan	O
and	O
47	O
.	O
3	O
%	O
for	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizatriptan	O
being	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
within	O
30	O
min	O
of	O
dosing	T-0
.	O

Headache	O
relief	O
at	O
2	O
h	O
was	O
75	T-0
.	T-0
9	T-0
%	T-0
for	T-0
rizatriptan	B-Chemical
and	T-1
47	T-1
.	T-1
3	T-1
%	T-1
for	T-1
ergotamine	T-1
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizatriptan	O
being	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
within	O
30	O
min	O
of	O
dosing	O
.	O

Headache	T-1
relief	T-1
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizatriptan	O
and	O
47	O
.	O
3	O
%	O
for	T-0
ergotamine	B-Chemical
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizatriptan	O
being	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
within	T-2
30	T-2
min	T-2
of	T-2
dosing	T-2
.	O

Headache	T-0
relief	T-0
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizatriptan	O
and	O
47	O
.	O
3	O
%	O
for	O
ergotamine	T-1
/	O
caffeine	B-Chemical
(	T-2
p	T-2
<	T-2
or	T-2
=	T-2
0	T-2
.	T-2
001	T-2
)	T-2
,	O
with	O
rizatriptan	O
being	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
within	O
30	O
min	O
of	O
dosing	O
.	O

Headache	O
relief	O
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizatriptan	O
and	O
47	O
.	O
3	O
%	O
for	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizatriptan	B-Chemical
being	T-0
superior	T-0
to	O
ergotamine	O
/	O
caffeine	O
within	O
30	O
min	O
of	O
dosing	O
.	O

Headache	O
relief	O
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizatriptan	O
and	O
47	O
.	O
3	O
%	O
for	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizatriptan	O
being	O
superior	T-0
to	T-0
ergotamine	B-Chemical
/	O
caffeine	O
within	O
30	O
min	O
of	O
dosing	T-1
.	O

Headache	T-0
relief	T-0
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizatriptan	O
and	O
47	O
.	O
3	O
%	O
for	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizatriptan	O
being	O
superior	O
to	O
ergotamine	O
/	O
caffeine	B-Chemical
within	O
30	O
min	O
of	O
dosing	T-1
.	O

Almost	O
36	O
%	O
of	O
patients	T-0
taking	T-2
rizatriptan	B-Chemical
were	T-3
pain	T-3
free	O
at	O
2	O
h	O
and	O
had	O
no	O
recurrence	O
or	O
need	O
for	O
additional	O
medication	O
within	O
24	O
h	O
,	O
compared	O
to	O
20	O
%	O
of	O
patients	T-1
on	T-1
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Almost	O
36	O
%	O
of	O
patients	O
taking	T-0
rizatriptan	O
were	O
pain	B-Disease
free	T-1
at	O
2	O
h	O
and	O
had	O
no	O
recurrence	T-2
or	O
need	O
for	O
additional	O
medication	O
within	O
24	O
h	O
,	O
compared	O
to	O
20	O
%	O
of	O
patients	O
on	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Almost	O
36	O
%	O
of	O
patients	O
taking	O
rizatriptan	O
were	O
pain	O
free	O
at	O
2	O
h	O
and	O
had	O
no	O
recurrence	O
or	O
need	O
for	O
additional	O
medication	O
within	O
24	O
h	O
,	O
compared	O
to	O
20	O
%	O
of	O
patients	T-0
on	T-0
ergotamine	B-Chemical
/	O
caffeine	T-1
(	T-1
p	T-1
<	T-1
or	T-1
=	T-1
0	T-1
.	T-1
001	T-1
)	O
.	O

Almost	O
36	O
%	O
of	O
patients	O
taking	O
rizatriptan	O
were	O
pain	O
free	O
at	O
2	O
h	O
and	O
had	O
no	O
recurrence	O
or	O
need	O
for	O
additional	O
medication	O
within	O
24	O
h	O
,	O
compared	O
to	O
20	O
%	O
of	O
patients	T-0
on	T-0
ergotamine	O
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizatriptan	B-Chemical
was	T-1
also	T-1
superior	T-1
to	O
ergotamine	O
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	O
,	O
vomiting	O
,	O
phonophobia	O
or	O
photophobia	O
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	T-0
drug	T-0
intake	T-0
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	T-1
to	T-1
ergotamine	B-Chemical
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	O
,	O
vomiting	O
,	O
phonophobia	O
or	O
photophobia	O
and	O
for	O
patients	T-0
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	T-0
to	T-0
ergotamine	O
/	O
caffeine	B-Chemical
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	O
,	O
vomiting	O
,	O
phonophobia	O
or	O
photophobia	O
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	O
with	T-0
no	T-0
nausea	B-Disease
,	O
vomiting	O
,	O
phonophobia	O
or	O
photophobia	O
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	T-1
nausea	T-1
,	T-1
vomiting	T-1
,	O
phonophobia	B-Disease
or	O
photophobia	T-2
and	O
for	O
patients	O
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	T-3
to	T-3
ergotamine	O
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	T-2
with	T-2
no	O
nausea	O
,	O
vomiting	O
,	O
phonophobia	T-0
or	T-0
photophobia	B-Disease
and	T-1
for	T-1
patients	T-1
with	O
normal	O
function	O
2	O
h	O
after	O
drug	O
intake	T-4
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

More	O
patients	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
satisfied	O
2	O
h	O
after	O
treatment	T-0
with	T-0
rizatriptan	B-Chemical
(	O
69	O
.	O
8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
treatment	O
with	O
ergotamine	O
/	O
caffeine	O
(	O
38	O
.	O
6	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

More	O
patients	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
satisfied	O
2	O
h	O
after	O
treatment	O
with	O
rizatriptan	O
(	O
69	O
.	O
8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
treatment	T-1
with	T-1
ergotamine	B-Chemical
/	T-0
caffeine	T-0
(	O
38	O
.	O
6	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

More	O
patients	O
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
satisfied	O
2	O
h	O
after	O
treatment	O
with	O
rizatriptan	O
(	O
69	O
.	O
8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
treatment	T-0
with	T-0
ergotamine	O
/	O
caffeine	B-Chemical
(	O
38	O
.	O
6	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Recurrence	T-0
rates	T-0
were	O
31	O
.	O
4	O
%	O
with	O
rizatriptan	B-Chemical
and	O
15	O
.	O
3	O
%	O
with	O
ergotamine	O
/	O
caffeine	O
.	O

Recurrence	T-0
rates	T-0
were	T-0
31	O
.	O
4	O
%	O
with	O
rizatriptan	O
and	O
15	O
.	O
3	O
%	O
with	T-1
ergotamine	B-Chemical
/	O
caffeine	O
.	O

Recurrence	T-1
rates	T-1
were	T-1
31	O
.	O
4	O
%	O
with	O
rizatriptan	O
and	O
15	O
.	O
3	O
%	O
with	T-2
ergotamine	O
/	O
caffeine	B-Chemical
.	O

The	O
most	O
common	O
adverse	O
events	O
(	O
incidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
group	O
)	O
after	T-0
rizatriptan	B-Chemical
and	T-1
ergotamine	T-1
/	O
caffeine	O
,	O
respectively	O
,	O
were	O
dizziness	O
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
nausea	O
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	O
somnolence	O
(	O
5	O
.	O
5	O
and	O
2	O
.	O
3	O
%	O
)	O
.	O

The	T-1
most	T-1
common	T-1
adverse	T-1
events	T-1
(	O
incidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
group	O
)	O
after	T-0
rizatriptan	O
and	O
ergotamine	B-Chemical
/	O
caffeine	O
,	O
respectively	O
,	O
were	O
dizziness	O
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
nausea	O
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	O
somnolence	O
(	O
5	O
.	O
5	O
and	O
2	O
.	O
3	O
%	O
)	O
.	O

The	O
most	O
common	O
adverse	T-0
events	T-0
(	O
incidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
group	O
)	O
after	O
rizatriptan	O
and	O
ergotamine	T-1
/	O
caffeine	B-Chemical
,	O
respectively	T-2
,	O
were	O
dizziness	O
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
nausea	O
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	O
somnolence	O
(	O
5	O
.	O
5	O
and	O
2	O
.	O
3	O
%	O
)	O
.	O

The	O
most	O
common	O
adverse	T-0
events	T-0
(	O
incidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
group	O
)	O
after	O
rizatriptan	O
and	O
ergotamine	O
/	O
caffeine	O
,	O
respectively	O
,	O
were	O
dizziness	B-Disease
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
nausea	O
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	O
somnolence	O
(	O
5	O
.	O
5	O
and	O
2	O
.	O
3	O
%	O
)	O
.	O

The	O
most	O
common	O
adverse	T-1
events	T-1
(	O
incidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
group	O
)	O
after	O
rizatriptan	O
and	O
ergotamine	O
/	O
caffeine	O
,	O
respectively	O
,	O
were	O
dizziness	O
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
nausea	B-Disease
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	T-0
somnolence	T-0
(	O
5	O
.	O
5	O
and	O
2	O
.	O
3	O
%	O
)	O
.	O

The	O
most	O
common	O
adverse	T-0
events	T-0
(	O
incidence	O
>	O
or	O
=	O
5	O
%	O
in	O
one	O
group	O
)	O
after	T-1
rizatriptan	T-1
and	T-1
ergotamine	T-1
/	O
caffeine	O
,	O
respectively	O
,	O
were	O
dizziness	O
(	O
6	O
.	O
7	O
and	O
5	O
.	O
3	O
%	O
)	O
,	O
nausea	O
(	O
4	O
.	O
2	O
and	O
8	O
.	O
5	O
%	O
)	O
and	O
somnolence	B-Disease
(	T-2
5	T-2
.	T-2
5	T-2
and	T-2
2	T-2
.	T-2
3	T-2
%	T-2
)	T-2
.	O

Severe	T-0
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
after	O
intracarotid	O
injection	O
of	O
carboplatin	O
for	O
recurrent	O
glioblastomas	O
.	O

Severe	O
ocular	O
and	O
orbital	O
toxicity	O
after	O
intracarotid	O
injection	T-1
of	T-1
carboplatin	B-Chemical
for	T-0
recurrent	T-0
glioblastomas	T-0
.	O

Severe	O
ocular	O
and	O
orbital	O
toxicity	O
after	O
intracarotid	O
injection	O
of	O
carboplatin	O
for	O
recurrent	T-0
glioblastomas	B-Disease
.	O

BACKGROUND	T-0
:	T-0
Glioblastoma	B-Disease
is	T-1
a	T-1
malignant	T-1
tumor	T-1
that	O
occurs	O
in	O
the	O
cerebrum	O
during	O
adulthood	O
.	O

BACKGROUND	O
:	O
Glioblastoma	O
is	T-1
a	T-1
malignant	B-Disease
tumor	I-Disease
that	O
occurs	T-0
in	O
the	O
cerebrum	O
during	O
adulthood	O
.	O

Therefore	O
,	O
patients	T-0
with	T-0
glioblastoma	B-Disease
sometimes	O
have	O
intracarotid	O
injection	O
of	O
carcinostatics	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O

Generally	T-0
,	O
carboplatin	B-Chemical
is	O
said	O
to	O
have	O
milder	T-1
side	T-1
effects	T-1
than	O
cisplatin	O
,	O
whose	O
ocular	O
and	O
orbital	O
toxicity	O
are	O
well	O
known	O
.	O

Generally	O
,	O
carboplatin	O
is	O
said	O
to	O
have	O
milder	O
side	T-2
effects	T-2
than	O
cisplatin	O
,	O
whose	T-0
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
are	T-1
well	T-1
known	T-1
.	T-1

However	O
,	O
we	O
experienced	O
a	O
case	T-0
of	T-0
severe	T-0
ocular	B-Disease
and	I-Disease
orbital	I-Disease
toxicity	I-Disease
after	O
intracarotid	O
injection	O
of	O
carboplatin	O
,	O
which	O
is	O
infrequently	O
reported	O
.	O

However	O
,	O
we	O
experienced	O
a	O
case	O
of	O
severe	O
ocular	O
and	O
orbital	O
toxicity	O
after	O
intracarotid	O
injection	T-0
of	T-0
carboplatin	B-Chemical
,	O
which	O
is	O
infrequently	O
reported	O
.	O

CASE	O
:	O
A	O
58	O
-	O
year	O
-	O
old	O
man	O
received	O
an	O
intracarotid	O
injection	T-0
of	T-0
carboplatin	B-Chemical
for	O
recurrent	O
glioblastomas	O
in	O
his	O
left	O
temporal	O
lobe	O
.	O

CASE	O
:	O
A	O
58	O
-	O
year	O
-	O
old	O
man	O
received	O
an	O
intracarotid	O
injection	O
of	O
carboplatin	O
for	O
recurrent	T-0
glioblastomas	B-Disease
in	T-1
his	T-1
left	T-1
temporal	T-1
lobe	T-1
.	T-1

He	O
complained	T-1
of	T-1
pain	B-Disease
and	I-Disease
visual	I-Disease
disturbance	I-Disease
in	I-Disease
the	I-Disease
ipsilateral	I-Disease
eye	I-Disease
30	O
h	O
after	O
the	O
injection	O
.	O

Various	O
ocular	T-0
symptoms	T-0
and	O
findings	O
caused	T-1
by	T-1
carboplatin	B-Chemical
toxicity	T-2
were	O
seen	O
.	O

Various	O
ocular	O
symptoms	O
and	O
findings	O
caused	T-0
by	O
carboplatin	O
toxicity	B-Disease
were	O
seen	O
.	O

RESULTS	O
:	O
He	O
was	O
treated	T-0
with	T-0
intravenous	O
administration	O
of	O
corticosteroids	T-2
and	O
glycerin	B-Chemical
for	O
6	O
days	O
after	O
the	O
injection	T-1
.	O

Although	O
the	O
intraocular	O
pressure	O
elevation	O
caused	T-0
by	T-0
secondary	O
acute	O
angle	O
-	O
closure	O
glaucoma	B-Disease
decreased	O
and	O
ocular	O
pain	O
diminished	O
,	O
inexorable	O
papilledema	O
and	O
exudative	O
retinal	O
detachment	O
continued	O
for	O
3	O
weeks	O
.	O

Although	O
the	O
intraocular	O
pressure	O
elevation	O
caused	O
by	O
secondary	O
acute	O
angle	O
-	O
closure	O
glaucoma	O
decreased	O
and	O
ocular	B-Disease
pain	I-Disease
diminished	T-0
,	O
inexorable	O
papilledema	O
and	O
exudative	O
retinal	O
detachment	O
continued	O
for	O
3	O
weeks	O
.	O

Although	O
the	O
intraocular	O
pressure	O
elevation	O
caused	O
by	O
secondary	O
acute	T-1
angle	O
-	O
closure	O
glaucoma	O
decreased	O
and	O
ocular	O
pain	O
diminished	O
,	O
inexorable	T-2
papilledema	B-Disease
and	T-0
exudative	T-0
retinal	O
detachment	O
continued	O
for	O
3	O
weeks	O
.	O

Although	O
the	O
intraocular	T-1
pressure	T-1
elevation	T-1
caused	O
by	O
secondary	O
acute	O
angle	O
-	O
closure	O
glaucoma	O
decreased	O
and	O
ocular	O
pain	O
diminished	O
,	O
inexorable	O
papilledema	O
and	O
exudative	T-0
retinal	B-Disease
detachment	I-Disease
continued	O
for	O
3	O
weeks	O
.	O

Finally	O
,	O
6	O
weeks	O
later	O
,	O
diffuse	T-2
chorioretinal	B-Disease
atrophy	I-Disease
with	T-1
optic	O
atrophy	O
occurred	O
and	O
the	O
vision	O
in	O
his	O
left	O
eye	O
was	O
lost	O
.	O

Finally	O
,	O
6	O
weeks	O
later	O
,	O
diffuse	O
chorioretinal	O
atrophy	T-0
with	T-0
optic	B-Disease
atrophy	I-Disease
occurred	T-1
and	O
the	O
vision	O
in	O
his	O
left	O
eye	O
was	O
lost	O
.	O

CONCLUSION	O
:	O
When	O
performing	O
intracarotid	T-0
injection	T-0
of	T-0
carboplatin	B-Chemical
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blinding	O
ocular	O
toxicity	O
.	O

CONCLUSION	O
:	O
When	O
performing	O
intracarotid	O
injection	O
of	O
carboplatin	O
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blinding	T-0
ocular	B-Disease
toxicity	I-Disease
.	O

Visual	O
hallucinations	O
associated	T-0
with	T-0
zonisamide	B-Chemical
.	O

Zonisamide	B-Chemical
is	T-1
a	T-1
broad	T-1
-	O
spectrum	O
antiepileptic	O
drug	T-0
used	O
to	O
treat	O
various	O
types	O
of	O
seizures	O
.	O

Zonisamide	O
is	O
a	O
broad	O
-	O
spectrum	O
antiepileptic	O
drug	O
used	O
to	O
treat	O
various	O
types	T-0
of	T-0
seizures	B-Disease
.	O

Although	T-0
visual	B-Disease
hallucinations	I-Disease
have	T-1
not	T-1
been	T-1
reported	T-1
as	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patients	O
who	O
experienced	O
complex	O
visual	O
hallucinations	O
and	O
altered	O
mental	O
status	O
after	O
zonisamide	O
treatment	O
was	O
begun	O
or	O
its	O
dosage	O
increased	O
.	O

Although	O
visual	O
hallucinations	O
have	O
not	O
been	O
reported	O
as	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patients	O
who	O
experienced	O
complex	T-2
visual	B-Disease
hallucinations	I-Disease
and	O
altered	O
mental	O
status	O
after	O
zonisamide	O
treatment	T-0
was	T-0
begun	T-0
or	O
its	O
dosage	T-1
increased	T-1
.	O

Although	O
visual	O
hallucinations	O
have	O
not	O
been	O
reported	O
as	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patients	O
who	O
experienced	O
complex	O
visual	O
hallucinations	O
and	O
altered	O
mental	O
status	O
after	O
zonisamide	B-Chemical
treatment	T-0
was	O
begun	O
or	O
its	O
dosage	T-1
increased	T-1
.	O

All	O
three	O
had	O
been	O
diagnosed	T-0
earlier	O
with	T-1
epilepsy	B-Disease
,	O
and	O
their	O
electroencephalogram	O
(	O
EEG	O
)	O
findings	O
were	O
abnormal	O
.	O

During	T-1
monitoring	T-1
,	O
visual	B-Disease
hallucinations	I-Disease
did	T-0
not	T-0
correlate	T-0
with	O
EEG	O
readings	O
,	O
nor	O
did	O
video	O
recording	O
capture	O
any	O
of	O
the	O
described	O
events	O
.	O

None	T-0
of	T-0
the	T-0
patients	T-1
had	T-1
experienced	O
visual	B-Disease
hallucinations	I-Disease
before	O
this	O
event	O
.	O

The	O
only	O
recent	O
change	O
in	O
their	O
treatment	O
was	O
the	O
introduction	T-0
or	O
increased	T-1
dosage	T-1
of	O
zonisamide	B-Chemical
.	O

Until	O
then	O
,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
possible	T-1
complication	T-1
associated	T-1
with	T-0
zonisamide	B-Chemical
.	O

Anti	O
-	O
epileptic	B-Disease
drugs	O
-	O
induced	T-0
de	O
novo	O
absence	O
seizures	O
.	O

Anti	O
-	O
epileptic	O
drugs	O
-	O
induced	T-0
de	O
novo	O
absence	B-Disease
seizures	I-Disease
.	O

The	O
authors	O
present	T-0
three	O
patients	T-1
with	T-1
de	O
novo	O
absence	B-Disease
epilepsy	I-Disease
after	O
administration	T-2
of	T-2
carbamazepine	O
and	O
vigabatrin	O
.	O

The	O
authors	O
present	O
three	O
patients	O
with	O
de	T-0
novo	T-0
absence	T-0
epilepsy	T-0
after	O
administration	T-1
of	T-1
carbamazepine	B-Chemical
and	O
vigabatrin	O
.	O

The	O
authors	O
present	O
three	O
patients	O
with	O
de	O
novo	O
absence	O
epilepsy	O
after	O
administration	T-0
of	T-0
carbamazepine	O
and	O
vigabatrin	B-Chemical
.	O

Despite	O
the	O
underlying	T-2
diseases	T-2
,	O
the	T-3
prognosis	T-3
for	O
drug	O
-	O
induced	T-0
de	T-1
novo	T-1
absence	B-Disease
seizure	I-Disease
is	O
good	O
because	O
it	O
subsides	O
rapidly	O
after	O
discontinuing	O
the	O
use	O
of	O
the	O
offending	O
drugs	O
.	O

The	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
-	O
transmitted	T-0
thalamocortical	O
circuitry	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	O
underlying	O
neurophysiology	O
of	O
the	O
absence	O
epilepsy	O
.	O

The	O
gamma	O
-	O
aminobutyric	O
acid	O
-	O
transmitted	O
thalamocortical	O
circuitry	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	T-0
underlying	T-0
neurophysiology	T-1
of	T-1
the	T-1
absence	B-Disease
epilepsy	I-Disease
.	O

Because	O
drug	T-1
-	T-1
induced	T-1
de	O
novo	O
absence	B-Disease
seizure	I-Disease
is	O
rare	O
,	O
pro	O
-	O
absence	O
drugs	O
can	O
only	O
be	O
considered	O
a	O
promoting	O
factor	O
.	O

The	O
underlying	O
epileptogenecity	O
of	O
the	O
patients	T-1
or	O
the	O
synergistic	O
effects	O
of	O
the	O
accompanying	O
drugs	O
is	O
required	O
to	O
trigger	T-0
the	O
de	O
novo	O
absence	B-Disease
seizure	I-Disease
.	O

The	O
possibility	O
of	O
drug	O
-	O
induced	T-0
aggravation	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
increase	T-1
in	O
seizure	B-Disease
frequency	O
and	O
/	O
or	O
new	O
seizure	O
types	O
appear	O
following	O
a	O
change	O
in	O
drug	O
treatment	T-2
.	O

The	O
possibility	O
of	O
drug	O
-	O
induced	O
aggravation	O
should	O
be	O
considered	O
whenever	O
an	O
unexpected	O
increase	T-0
in	O
seizure	O
frequency	O
and	O
/	O
or	O
new	O
seizure	B-Disease
types	T-1
appear	O
following	O
a	O
change	O
in	O
drug	O
treatment	O
.	O

By	O
understanding	O
the	O
underlying	T-2
mechanism	T-2
of	T-2
absence	B-Disease
epilepsy	I-Disease
,	O
we	O
can	O
avoid	O
the	O
inappropriate	O
use	O
of	O
anticonvulsants	O
in	O
children	O
with	O
epilepsy	O
and	O
prevent	O
drug	O
-	O
induced	O
absence	O
seizures	O
.	O

By	O
understanding	O
the	O
underlying	O
mechanism	O
of	O
absence	O
epilepsy	O
,	O
we	O
can	O
avoid	O
the	O
inappropriate	T-1
use	T-1
of	O
anticonvulsants	O
in	O
children	O
with	O
epilepsy	B-Disease
and	T-0
prevent	T-0
drug	O
-	O
induced	T-2
absence	O
seizures	O
.	O

By	O
understanding	O
the	O
underlying	O
mechanism	O
of	O
absence	T-0
epilepsy	T-0
,	O
we	O
can	O
avoid	O
the	O
inappropriate	O
use	O
of	O
anticonvulsants	O
in	O
children	O
with	O
epilepsy	T-1
and	O
prevent	O
drug	T-2
-	T-2
induced	T-2
absence	B-Disease
seizures	I-Disease
.	O

Prenatal	T-1
dexamethasone	T-1
programs	O
hypertension	B-Disease
and	O
renal	O
injury	T-0
in	O
the	O
rat	O
.	O

Prenatal	T-0
dexamethasone	O
programs	T-3
hypertension	T-1
and	T-1
renal	B-Disease
injury	I-Disease
in	T-2
the	T-2
rat	T-2
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
prenatal	T-0
dexamethasone	B-Chemical
programmed	T-2
a	T-2
progressive	T-2
increase	T-2
in	O
blood	O
pressure	O
and	O
renal	O
injury	O
in	O
rats	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
prenatal	T-0
dexamethasone	T-0
programmed	T-0
a	T-0
progressive	T-0
increase	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
renal	T-1
injury	T-1
in	T-1
rats	T-1
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
prenatal	O
dexamethasone	O
programmed	O
a	O
progressive	O
increase	T-0
in	O
blood	O
pressure	O
and	O
renal	B-Disease
injury	I-Disease
in	O
rats	O
.	O

Pregnant	O
rats	O
were	O
given	O
either	O
vehicle	O
or	O
2	O
daily	O
intraperitoneal	O
injections	T-1
of	T-1
dexamethasone	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	T-2
gestational	T-2
days	T-2
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

Offspring	O
of	O
rats	O
administered	T-0
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
gestation	O
had	O
a	O
20	O
%	O
reduction	O
in	O
glomerular	O
number	O
compared	O
with	O
control	O
at	O
6	O
to	O
9	O
months	O
of	O
age	O
(	O
22	O
527	O
+	O
/	O
-	O
509	O
versus	O
28	O
050	O
+	O
/	O
-	O
561	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
reduction	O
in	O
glomeruli	O
measured	O
at	O
3	O
weeks	O
of	O
age	O
.	O

Offspring	O
of	O
rats	O
administered	O
dexamethasone	O
on	O
days	O
15	O
and	O
16	O
gestation	T-1
had	T-1
a	T-1
20	O
%	O
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
compared	T-0
with	T-0
control	O
at	O
6	O
to	O
9	O
months	O
of	O
age	O
(	O
22	O
527	O
+	O
/	O
-	O
509	O
versus	O
28	O
050	O
+	O
/	O
-	O
561	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	O
reduction	O
in	O
glomeruli	O
measured	O
at	O
3	O
weeks	O
of	O
age	O
.	O

Six	O
-	O
to	O
9	O
-	O
month	O
old	O
rats	O
receiving	O
prenatal	O
dexamethasone	B-Chemical
on	O
days	O
17	O
and	O
18	O
of	O
gestation	O
had	O
a	O
17	O
%	O
reduction	T-0
in	O
glomeruli	O
(	O
23	O
380	O
+	O
/	O
-	O
587	O
)	O
compared	O
with	O
control	O
rats	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Male	O
rats	O
that	O
received	T-1
prenatal	O
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gestation	O
had	O
elevated	T-0
blood	T-0
pressures	T-0
at	O
6	O
months	O
of	O
age	O
;	O
the	O
latter	O
group	O
did	O
not	O
have	O
a	O
reduction	T-2
in	T-2
glomerular	O
number	O
.	O

Male	O
rats	O
that	O
received	O
prenatal	O
dexamethasone	O
on	O
days	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gestation	O
had	O
elevated	O
blood	O
pressures	O
at	O
6	O
months	O
of	O
age	O
;	O
the	O
latter	O
group	O
did	T-1
not	T-1
have	T-1
a	T-1
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
.	O

Adult	O
rats	O
given	T-0
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
of	O
gestation	O
had	O
more	O
glomeruli	O
with	O
glomerulosclerosis	O
than	O
control	O
rats	O
.	O

Adult	O
rats	O
given	T-0
dexamethasone	T-0
on	O
days	O
15	O
and	O
16	O
of	O
gestation	O
had	T-2
more	T-2
glomeruli	T-2
with	T-2
glomerulosclerosis	B-Disease
than	O
control	O
rats	O
.	O

This	O
study	O
shows	T-1
that	T-1
prenatal	T-1
dexamethasone	B-Chemical
in	T-2
rats	T-2
results	T-0
in	T-0
a	O
reduction	O
in	O
glomerular	O
number	O
,	O
glomerulosclerosis	O
,	O
and	O
hypertension	O
when	O
administered	O
at	O
specific	O
points	O
during	O
gestation	O
.	O

This	O
study	O
shows	O
that	O
prenatal	O
dexamethasone	O
in	O
rats	O
results	T-0
in	T-0
a	T-0
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
,	O
glomerulosclerosis	O
,	O
and	O
hypertension	O
when	O
administered	O
at	O
specific	O
points	O
during	O
gestation	O
.	O

This	O
study	O
shows	O
that	O
prenatal	O
dexamethasone	O
in	O
rats	O
results	T-0
in	T-0
a	T-0
reduction	T-0
in	T-0
glomerular	O
number	O
,	O
glomerulosclerosis	B-Disease
,	O
and	O
hypertension	O
when	O
administered	O
at	O
specific	O
points	O
during	O
gestation	O
.	O

This	O
study	O
shows	O
that	O
prenatal	O
dexamethasone	O
in	O
rats	O
results	O
in	O
a	O
reduction	T-1
in	T-1
glomerular	O
number	O
,	O
glomerulosclerosis	O
,	O
and	O
hypertension	B-Disease
when	T-2
administered	T-2
at	O
specific	O
points	O
during	O
gestation	O
.	O

Hypertension	B-Disease
was	T-1
observed	T-1
in	O
animals	O
that	O
had	O
a	O
reduction	O
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	O
that	O
did	O
not	O
have	O
a	O
reduction	O
in	O
glomerular	O
number	O
,	O
suggesting	O
that	O
a	O
reduction	O
in	O
glomerular	O
number	O
is	O
not	O
the	O
sole	T-0
cause	T-0
for	T-0
the	T-0
development	T-0
of	T-0
hypertension	O
.	O

Hypertension	O
was	O
observed	O
in	O
animals	O
that	O
had	O
a	O
reduction	T-0
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	O
that	O
did	T-3
not	T-3
have	T-3
a	T-3
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
,	T-3
suggesting	O
that	O
a	O
reduction	T-1
in	O
glomerular	O
number	O
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
development	T-2
of	O
hypertension	O
.	O

Hypertension	O
was	O
observed	O
in	O
animals	O
that	O
had	O
a	O
reduction	O
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	O
that	O
did	O
not	O
have	O
a	O
reduction	O
in	O
glomerular	O
number	O
,	O
suggesting	T-0
that	T-2
a	T-2
reduction	B-Disease
in	I-Disease
glomerular	I-Disease
number	I-Disease
is	T-3
not	T-3
the	T-1
sole	T-1
cause	T-1
for	O
the	O
development	O
of	O
hypertension	O
.	O

Hypertension	O
was	O
observed	O
in	O
animals	O
that	O
had	O
a	O
reduction	O
in	O
glomeruli	O
as	O
well	O
as	O
in	O
a	O
group	O
that	O
did	O
not	O
have	O
a	O
reduction	O
in	O
glomerular	O
number	O
,	O
suggesting	O
that	O
a	O
reduction	O
in	O
glomerular	O
number	O
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
development	T-0
of	T-0
hypertension	B-Disease
.	O

Kidney	O
function	O
and	O
morphology	O
after	O
short	O
-	O
term	O
combination	O
therapy	O
with	T-0
cyclosporine	B-Chemical
A	I-Chemical
,	O
tacrolimus	O
and	O
sirolimus	O
in	O
the	O
rat	O
.	O

Kidney	O
function	O
and	O
morphology	O
after	O
short	O
-	O
term	O
combination	O
therapy	T-2
with	T-2
cyclosporine	T-0
A	T-0
,	O
tacrolimus	B-Chemical
and	T-1
sirolimus	T-1
in	T-1
the	T-1
rat	T-1
.	O

Kidney	O
function	O
and	O
morphology	O
after	O
short	O
-	O
term	O
combination	O
therapy	T-1
with	T-0
cyclosporine	T-0
A	T-0
,	O
tacrolimus	O
and	O
sirolimus	B-Chemical
in	O
the	O
rat	O
.	O

BACKGROUND	O
:	O
Sirolimus	B-Chemical
(	O
SRL	O
)	O
may	T-0
supplement	T-0
calcineurin	O
inhibitors	O
in	O
clinical	O
organ	O
transplantation	O
.	O

BACKGROUND	O
:	O
Sirolimus	T-0
(	O
SRL	B-Chemical
)	O
may	T-1
supplement	T-1
calcineurin	O
inhibitors	O
in	O
clinical	O
organ	O
transplantation	O
.	O

These	O
are	O
nephrotoxic	B-Disease
,	O
but	O
SRL	O
seems	O
to	O
act	T-0
differently	T-0
displaying	O
only	O
minor	O
nephrotoxic	O
effects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

These	O
are	O
nephrotoxic	O
,	O
but	O
SRL	B-Chemical
seems	T-0
to	T-0
act	T-0
differently	O
displaying	O
only	O
minor	O
nephrotoxic	O
effects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

These	O
are	O
nephrotoxic	O
,	O
but	O
SRL	O
seems	O
to	O
act	O
differently	O
displaying	O
only	O
minor	T-0
nephrotoxic	B-Disease
effects	T-1
,	O
although	O
this	O
question	O
is	O
still	O
open	O
.	O

In	O
a	O
number	O
of	O
treatment	O
protocols	T-0
where	T-0
SRL	B-Chemical
was	T-1
combined	T-1
with	O
a	O
calcineurin	O
inhibitor	O
indications	O
of	O
a	O
synergistic	O
nephrotoxic	O
effect	O
were	O
described	O
.	O

In	O
a	O
number	O
of	O
treatment	O
protocols	O
where	O
SRL	O
was	O
combined	O
with	O
a	O
calcineurin	O
inhibitor	O
indications	O
of	O
a	O
synergistic	T-0
nephrotoxic	B-Disease
effect	T-1
were	O
described	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	T-0
with	T-0
either	O
cyclosporine	B-Chemical
A	I-Chemical
(	O
CsA	O
)	O
,	O
tacrolimus	O
(	O
FK506	O
)	O
or	O
SRL	O
as	O
monotherapies	O
or	O
in	O
different	O
combinations	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	T-1
with	T-1
either	T-1
cyclosporine	T-0
A	T-0
(	T-0
CsA	B-Chemical
)	O
,	O
tacrolimus	O
(	O
FK506	O
)	O
or	O
SRL	O
as	O
monotherapies	O
or	O
in	O
different	O
combinations	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
either	T-0
cyclosporine	T-0
A	T-0
(	T-0
CsA	T-0
)	T-0
,	O
tacrolimus	B-Chemical
(	T-1
FK506	T-1
)	T-1
or	O
SRL	O
as	O
monotherapies	O
or	O
in	O
different	O
combinations	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
further	O
the	O
renal	O
function	O
,	O
including	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	T-0
with	T-0
either	O
cyclosporine	O
A	O
(	O
CsA	O
)	O
,	O
tacrolimus	O
(	O
FK506	B-Chemical
)	O
or	O
SRL	O
as	T-1
monotherapies	T-1
or	O
in	O
different	O
combinations	O
.	O

METHODS	O
:	O
For	O
a	O
period	O
of	O
2	O
weeks	O
,	O
CsA	O
15	T-0
mg	T-0
/	T-0
kg	T-0
/	T-0
day	T-0
(	O
given	O
orally	O
)	O
,	O
FK506	B-Chemical
3	O
.	O
0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	T-1
orally	T-1
)	O
or	O
SRL	O
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
intraperitoneally	O
)	O
was	O
administered	O
once	O
a	O
day	O
as	O
these	O
doses	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppressive	O
effect	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

METHODS	O
:	O
For	O
a	O
period	O
of	O
2	O
weeks	O
,	O
CsA	O
15	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
,	O
FK506	O
3	O
.	O
0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
orally	O
)	O
or	T-0
SRL	B-Chemical
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
(	O
given	O
intraperitoneally	O
)	O
was	T-1
administered	T-1
once	O
a	O
day	O
as	O
these	O
doses	O
have	O
earlier	O
been	O
found	O
to	O
achieve	O
a	O
significant	O
immunosuppressive	O
effect	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

The	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
included	O
a	O
semi	O
-	O
quantitative	O
scoring	O
system	O
analysing	O
the	O
degree	T-2
of	T-2
striped	T-0
fibrosis	B-Disease
,	O
subcapsular	T-1
fibrosis	T-1
and	O
the	O
number	O
of	O
basophilic	O
tubules	O
,	O
plus	O
an	O
additional	O
stereological	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	O
in	O
the	O
cortex	O
stained	O
with	O
Sirius	O
Red	O
.	O

The	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
included	O
a	O
semi	O
-	O
quantitative	O
scoring	O
system	O
analysing	O
the	O
degree	O
of	O
striped	O
fibrosis	O
,	O
subcapsular	T-0
fibrosis	B-Disease
and	O
the	O
number	O
of	O
basophilic	O
tubules	O
,	O
plus	O
an	O
additional	O
stereological	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	O
in	O
the	O
cortex	O
stained	O
with	O
Sirius	O
Red	O
.	O

The	O
morphological	O
analysis	O
of	O
the	O
kidneys	O
included	O
a	O
semi	O
-	O
quantitative	O
scoring	O
system	O
analysing	O
the	O
degree	O
of	O
striped	O
fibrosis	O
,	O
subcapsular	O
fibrosis	O
and	O
the	O
number	O
of	O
basophilic	O
tubules	O
,	O
plus	O
an	O
additional	O
stereological	O
analysis	O
of	O
the	O
total	T-0
grade	T-0
of	T-0
fibrosis	B-Disease
in	T-1
the	T-1
cortex	T-1
stained	O
with	O
Sirius	O
Red	O
.	O

RESULTS	O
:	O
CsA	B-Chemical
,	O
FK506	O
and	O
SRL	O
all	T-1
significantly	T-1
decreased	T-1
the	T-0
GFR	T-0
.	O

RESULTS	O
:	O
CsA	T-2
,	O
FK506	B-Chemical
and	T-1
SRL	T-3
all	T-3
significantly	T-3
decreased	T-3
the	T-3
GFR	T-3
.	O

RESULTS	O
:	O
CsA	O
,	O
FK506	O
and	O
SRL	B-Chemical
all	O
significantly	T-0
decreased	T-0
the	T-0
GFR	T-0
.	O

A	O
further	O
deterioration	T-1
was	T-1
seen	T-1
when	T-1
CsA	B-Chemical
was	T-2
combined	T-2
with	T-2
either	O
FK506	O
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK506	O
plus	O
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	O
was	O
combined	T-0
with	T-0
either	O
FK506	B-Chemical
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK506	O
plus	O
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	O
was	O
combined	O
with	O
either	O
FK506	O
or	O
SRL	B-Chemical
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK506	O
plus	O
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	T-0
of	T-0
the	T-0
single	T-0
substances	T-0
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	O
was	O
combined	O
with	O
either	O
FK506	O
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	T-0
with	T-0
FK506	B-Chemical
plus	O
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	O
was	O
combined	O
with	O
either	O
FK506	O
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	T-1
with	T-1
FK506	O
plus	O
SRL	B-Chemical
when	O
compared	O
with	O
treatment	T-2
with	T-2
any	T-2
of	T-2
the	T-2
single	T-2
substances	T-2
.	O

The	O
semi	O
-	O
quantitative	O
scoring	O
was	O
significantly	O
worst	O
in	O
the	O
group	O
treated	T-0
with	T-0
CsA	B-Chemical
plus	O
SRL	O
(	O
P	O
<	O
0	O
.	O
001	O
compared	O
with	O
controls	O
)	O
and	O
the	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	O
also	O
showed	O
the	O
highest	O
proportion	O
in	O
the	O
same	O
group	O
and	O
was	O
significantly	O
different	O
from	O
controls	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

The	O
semi	O
-	O
quantitative	O
scoring	O
was	O
significantly	O
worst	O
in	O
the	O
group	O
treated	T-0
with	T-0
CsA	O
plus	O
SRL	B-Chemical
(	O
P	O
<	O
0	O
.	O
001	O
compared	O
with	O
controls	O
)	O
and	O
the	O
analysis	O
of	O
the	O
total	O
grade	O
of	O
fibrosis	O
also	O
showed	O
the	O
highest	O
proportion	O
in	O
the	O
same	O
group	O
and	O
was	O
significantly	O
different	O
from	O
controls	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

The	O
semi	O
-	O
quantitative	O
scoring	O
was	O
significantly	O
worst	O
in	O
the	O
group	O
treated	O
with	O
CsA	O
plus	O
SRL	O
(	O
P	O
<	O
0	O
.	O
001	O
compared	O
with	O
controls	O
)	O
and	O
the	O
analysis	O
of	O
the	O
total	T-1
grade	T-1
of	T-1
fibrosis	B-Disease
also	O
showed	O
the	O
highest	O
proportion	O
in	O
the	O
same	O
group	O
and	O
was	O
significantly	O
different	O
from	O
controls	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

The	T-0
FK506	B-Chemical
plus	T-1
SRL	T-1
combination	T-1
showed	T-2
only	T-2
a	O
marginally	O
higher	O
degree	O
of	O
fibrosis	O
as	O
compared	O
with	O
controls	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

The	O
FK506	O
plus	T-0
SRL	B-Chemical
combination	T-1
showed	O
only	O
a	O
marginally	O
higher	O
degree	O
of	O
fibrosis	O
as	O
compared	O
with	O
controls	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

The	O
FK506	O
plus	O
SRL	O
combination	O
showed	O
only	O
a	O
marginally	O
higher	T-0
degree	T-1
of	T-1
fibrosis	B-Disease
as	O
compared	O
with	O
controls	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	T-0
synergistic	T-0
nephrotoxic	B-Disease
effect	O
of	O
CsA	O
plus	O
SRL	O
,	O
whereas	O
FK506	O
plus	O
SRL	O
was	O
better	O
tolerated	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	T-0
nephrotoxic	T-0
effect	T-1
of	T-1
CsA	B-Chemical
plus	O
SRL	O
,	O
whereas	O
FK506	O
plus	O
SRL	O
was	O
better	O
tolerated	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	O
effect	T-0
of	T-0
CsA	O
plus	O
SRL	B-Chemical
,	O
whereas	O
FK506	O
plus	O
SRL	O
was	O
better	O
tolerated	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	O
effect	T-2
of	O
CsA	O
plus	O
SRL	O
,	O
whereas	T-0
FK506	B-Chemical
plus	T-1
SRL	T-1
was	O
better	O
tolerated	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	O
effect	O
of	O
CsA	O
plus	O
SRL	O
,	O
whereas	O
FK506	O
plus	O
SRL	B-Chemical
was	O
better	T-0
tolerated	T-0
.	O

Evaluation	O
of	O
cardiac	O
troponin	O
I	O
and	O
T	O
levels	O
as	O
markers	T-0
of	T-0
myocardial	B-Disease
damage	I-Disease
in	T-1
doxorubicin	O
-	O
induced	O
cardiomyopathy	O
rats	O
,	O
and	O
their	O
relationship	O
with	O
echocardiographic	O
and	O
histological	O
findings	O
.	O

Evaluation	O
of	O
cardiac	O
troponin	O
I	O
and	O
T	O
levels	O
as	O
markers	O
of	O
myocardial	O
damage	T-0
in	T-0
doxorubicin	B-Chemical
-	O
induced	O
cardiomyopathy	O
rats	O
,	O
and	O
their	O
relationship	O
with	O
echocardiographic	O
and	O
histological	O
findings	O
.	O

Evaluation	O
of	O
cardiac	O
troponin	O
I	O
and	O
T	O
levels	O
as	O
markers	O
of	O
myocardial	O
damage	T-2
in	T-2
doxorubicin	T-2
-	T-2
induced	T-2
cardiomyopathy	B-Disease
rats	T-1
,	O
and	O
their	O
relationship	O
with	O
echocardiographic	O
and	O
histological	O
findings	O
.	O

BACKGROUND	O
:	O
Cardiac	O
troponins	O
I	O
(	O
cTnI	O
)	O
and	O
T	O
(	O
cTnT	O
)	O
have	O
been	O
shown	O
to	O
be	O
highly	O
sensitive	O
and	O
specific	T-1
markers	T-1
of	T-1
myocardial	B-Disease
cell	I-Disease
injury	I-Disease
.	O

We	O
investigated	O
the	O
diagnostic	O
value	T-0
of	T-0
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	B-Disease
damage	I-Disease
in	O
a	O
rat	O
model	O
of	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiomyopathy	O
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	O
disorders	O
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	O
damage	O
in	O
a	O
rat	O
model	O
of	O
doxorubicin	B-Chemical
(	T-0
DOX	T-0
)	T-0
-	O
induced	T-1
cardiomyopathy	T-1
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	O
disorders	O
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

We	O
investigated	O
the	O
diagnostic	T-2
value	T-2
of	T-2
cTnI	T-2
and	T-2
cTnT	T-2
for	O
the	O
diagnosis	O
of	O
myocardial	T-0
damage	T-0
in	T-0
a	T-0
rat	T-0
model	T-0
of	T-0
doxorubicin	T-0
(	O
DOX	B-Chemical
)	O
-	O
induced	T-1
cardiomyopathy	T-1
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	O
disorders	O
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

We	O
investigated	O
the	O
diagnostic	T-0
value	T-0
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	T-1
of	T-1
myocardial	T-1
damage	O
in	O
a	O
rat	O
model	O
of	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	T-3
cardiomyopathy	B-Disease
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	O
disorders	O
monitored	O
by	O
echocardiography	O
and	O
histological	T-2
examinations	T-2
in	O
this	O
model	O
.	O

We	O
investigated	O
the	O
diagnostic	T-0
value	T-0
of	T-0
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	T-1
of	T-1
myocardial	T-1
damage	T-1
in	O
a	O
rat	O
model	O
of	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiomyopathy	O
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	T-3
of	T-3
cardiac	B-Disease
disorders	I-Disease
monitored	O
by	O
echocardiography	O
and	O
histological	T-2
examinations	T-2
in	O
this	O
model	O
.	O

METHODS	O
:	O
Thirty	O
-	O
five	O
Wistar	O
rats	O
were	T-1
given	T-1
1	T-0
.	T-0
5	T-0
mg	T-0
/	T-0
kg	T-0
DOX	B-Chemical
,	O
i	O
.	O
v	O
.	O
,	O
weekly	O
for	O
up	O
to	O
8	O
weeks	O
for	O
a	O
total	O
cumulative	O
dose	O
of	O
12	O
mg	O
/	O
kg	O
BW	O
.	O

By	O
using	O
transthoracic	O
echocardiography	O
,	O
anterior	O
and	O
posterior	O
wall	O
thickness	O
,	O
LV	O
diameters	O
and	O
LV	O
fractional	O
shortening	O
(	O
FS	O
)	O
were	O
measured	O
in	O
all	O
rats	O
before	T-0
DOX	B-Chemical
or	T-1
saline	T-1
,	O
and	O
at	O
weeks	O
6	O
and	O
9	O
after	O
treatment	O
in	O
all	O
surviving	O
rats	O
.	O

Histology	O
was	O
performed	O
in	O
DOX	O
-	O
rats	O
at	O
6	O
and	O
9	O
weeks	O
after	T-0
the	T-0
last	T-0
DOX	B-Chemical
dose	T-1
and	T-1
in	T-1
all	T-1
controls	T-1
.	T-1

RESULTS	O
:	O
Eighteen	O
of	O
the	O
DOX	B-Chemical
rats	O
died	O
prematurely	O
of	O
general	O
toxicity	T-0
during	O
the	O
9	O
-	O
week	O
period	O
.	O

RESULTS	O
:	O
Eighteen	O
of	O
the	O
DOX	O
rats	O
died	O
prematurely	O
of	O
general	T-0
toxicity	B-Disease
during	O
the	O
9	O
-	O
week	O
period	O
.	O

End	O
-	O
diastolic	O
(	O
ED	O
)	O
and	O
end	O
-	O
systolic	O
(	O
ES	O
)	O
LV	O
diameters	O
/	O
BW	O
significantly	O
increased	O
,	O
whereas	O
LV	O
FS	O
was	O
decreased	O
after	O
9	O
weeks	O
in	O
the	O
DOX	B-Chemical
group	T-0
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Histological	O
evaluation	O
of	O
hearts	O
from	O
all	O
rats	O
given	T-0
DOX	B-Chemical
revealed	T-1
significant	T-1
slight	T-1
degrees	O
of	O
perivascular	O
and	O
interstitial	O
fibrosis	O
.	O

Histological	O
evaluation	O
of	O
hearts	O
from	O
all	O
rats	O
given	O
DOX	O
revealed	O
significant	O
slight	O
degrees	O
of	O
perivascular	O
and	O
interstitial	T-0
fibrosis	B-Disease
.	O

Only	O
five	O
of	O
the	O
controls	O
exhibited	O
evidence	O
of	O
very	O
slight	O
perivascular	T-0
fibrosis	B-Disease
.	O

A	O
significant	O
rise	O
in	O
cTnT	O
was	O
found	T-1
in	T-1
DOX	B-Chemical
rats	T-0
after	T-0
cumulative	T-0
doses	T-0
of	O
7	O
.	O
5	O
and	O
12	O
mg	O
/	O
kg	O
in	O
comparison	O
with	O
baseline	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

cTnT	O
found	O
in	O
rats	O
after	O
12	O
mg	O
/	O
kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	T-0
after	T-0
7	O
.	O
5	O
mg	O
/	O
kg	O
DOX	B-Chemical
.	O

Maximal	O
cTnI	O
(	O
pg	O
/	O
ml	O
)	O
and	O
cTnT	O
levels	O
were	O
significantly	O
increased	O
in	T-0
DOX	B-Chemical
rats	O
compared	O
with	O
controls	O
(	O
p	O
=	O
0	O
.	O
006	O
,	O
0	O
.	O
007	O
)	O
.	T-0

cTnI	O
(	O
ng	O
/	O
ml	O
)	O
,	O
CK	O
-	O
MB	O
mass	O
and	O
CK	O
remained	T-1
unchanged	T-1
in	T-0
DOX	B-Chemical
rats	O
compared	O
with	O
controls	O
.	O

CONCLUSIONS	O
:	O
Among	T-1
markers	T-1
of	T-1
ischemic	B-Disease
injury	I-Disease
after	O
DOX	T-0
in	O
rats	O
,	O
cTnT	O
showed	O
the	O
greatest	O
ability	O
to	O
detect	O
myocardial	O
damage	O
assessed	O
by	O
echocardiographic	O
detection	O
and	O
histological	O
changes	O
.	O

CONCLUSIONS	O
:	O
Among	O
markers	O
of	O
ischemic	T-1
injury	T-1
after	T-0
DOX	B-Chemical
in	O
rats	O
,	O
cTnT	O
showed	O
the	O
greatest	O
ability	O
to	O
detect	O
myocardial	O
damage	O
assessed	O
by	O
echocardiographic	O
detection	O
and	O
histological	O
changes	O
.	O

CONCLUSIONS	O
:	O
Among	O
markers	O
of	O
ischemic	O
injury	O
after	O
DOX	O
in	O
rats	O
,	O
cTnT	O
showed	O
the	O
greatest	O
ability	O
to	T-1
detect	T-1
myocardial	B-Disease
damage	I-Disease
assessed	O
by	O
echocardiographic	T-0
detection	T-0
and	O
histological	O
changes	O
.	O

Although	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
amount	O
of	O
cTnI	O
and	O
cTnT	O
after	T-0
DOX	B-Chemical
,	O
probably	T-1
due	T-1
to	T-1
heterogeneity	T-1
in	T-1
cross	T-1
-	O
reactivities	O
of	O
mAbs	O
to	O
various	O
cTnI	O
and	O
cTnT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
rats	O
after	O
DOX	O
indicates	O
cell	O
damage	O
determined	O
by	O
the	O
magnitude	O
of	O
injury	O
induced	O
and	O
that	O
cTnT	O
should	O
be	O
a	O
useful	O
marker	O
for	O
the	O
prediction	O
of	O
experimentally	O
induced	O
cardiotoxicity	O
and	O
possibly	O
for	O
cardioprotective	O
experiments	O
.	O

Although	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
amount	O
of	O
cTnI	O
and	O
cTnT	O
after	O
DOX	O
,	O
probably	O
due	O
to	O
heterogeneity	O
in	O
cross	O
-	O
reactivities	T-1
of	O
mAbs	O
to	O
various	O
cTnI	O
and	O
cTnT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
rats	O
after	O
DOX	B-Chemical
indicates	T-3
cell	O
damage	O
determined	O
by	O
the	O
magnitude	O
of	O
injury	O
induced	T-2
and	O
that	O
cTnT	O
should	O
be	O
a	O
useful	T-0
marker	T-0
for	O
the	O
prediction	O
of	O
experimentally	O
induced	O
cardiotoxicity	O
and	O
possibly	O
for	O
cardioprotective	O
experiments	O
.	O

Although	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
amount	O
of	O
cTnI	O
and	O
cTnT	O
after	O
DOX	O
,	O
probably	O
due	O
to	O
heterogeneity	O
in	O
cross	O
-	O
reactivities	O
of	O
mAbs	O
to	O
various	O
cTnI	O
and	O
cTnT	O
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	O
in	O
rats	O
after	O
DOX	O
indicates	O
cell	O
damage	O
determined	O
by	O
the	O
magnitude	O
of	O
injury	O
induced	O
and	O
that	O
cTnT	O
should	O
be	O
a	O
useful	O
marker	O
for	O
the	O
prediction	O
of	O
experimentally	T-0
induced	T-0
cardiotoxicity	B-Disease
and	O
possibly	O
for	O
cardioprotective	O
experiments	O
.	O

Octreotide	B-Chemical
-	O
induced	T-0
hypoxemia	O
and	O
pulmonary	O
hypertension	O
in	O
premature	O
neonates	O
.	O

Octreotide	O
-	O
induced	T-0
hypoxemia	B-Disease
and	O
pulmonary	O
hypertension	O
in	O
premature	O
neonates	O
.	O

Octreotide	O
-	O
induced	T-1
hypoxemia	O
and	O
pulmonary	B-Disease
hypertension	I-Disease
in	O
premature	T-0
neonates	T-0
.	O

The	O
authors	O
report	O
2	O
cases	T-0
of	T-0
premature	O
neonates	O
who	O
had	O
enterocutaneous	T-2
fistula	B-Disease
complicating	T-1
necrotizing	O
enterocolitis	O
.	O

The	O
authors	O
report	O
2	O
cases	O
of	O
premature	O
neonates	O
who	O
had	O
enterocutaneous	O
fistula	O
complicating	T-0
necrotizing	B-Disease
enterocolitis	I-Disease
.	O

Pulmonary	B-Disease
hypertension	I-Disease
developed	T-0
after	O
administration	O
of	O
a	O
somatostatin	O
analogue	O
,	O
octreotide	O
,	O
to	O
enhance	O
resolution	O
of	O
the	O
fistula	O
.	O

Pulmonary	O
hypertension	O
developed	O
after	O
administration	O
of	O
a	O
somatostatin	O
analogue	O
,	O
octreotide	B-Chemical
,	O
to	O
enhance	T-0
resolution	T-0
of	T-0
the	T-0
fistula	T-0
.	O

Pulmonary	T-0
hypertension	T-0
developed	O
after	O
administration	O
of	O
a	O
somatostatin	O
analogue	O
,	O
octreotide	O
,	O
to	O
enhance	O
resolution	T-1
of	T-1
the	T-1
fistula	B-Disease
.	O

The	O
risk	T-0
of	T-0
venous	B-Disease
thromboembolism	I-Disease
in	O
women	O
prescribed	O
cyproterone	O
acetate	O
in	O
combination	O
with	O
ethinyl	O
estradiol	O
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
.	O

The	O
risk	O
of	O
venous	O
thromboembolism	O
in	O
women	O
prescribed	T-1
cyproterone	B-Chemical
acetate	I-Chemical
in	O
combination	O
with	O
ethinyl	O
estradiol	O
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
.	O

The	O
risk	O
of	O
venous	O
thromboembolism	O
in	O
women	O
prescribed	O
cyproterone	O
acetate	O
in	O
combination	O
with	O
ethinyl	B-Chemical
estradiol	I-Chemical
:	O
a	O
nested	O
cohort	O
analysis	O
and	O
case	T-0
-	T-0
control	T-0
study	T-0
.	O

BACKGROUND	O
:	O
Cyproterone	B-Chemical
acetate	I-Chemical
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	T-0
in	O
the	O
UK	O
for	T-1
the	T-1
treatment	T-1
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	T-0
acetate	T-0
combined	T-1
with	T-1
ethinyl	B-Chemical
estradiol	I-Chemical
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	T-2
in	T-2
the	O
UK	O
for	T-3
the	T-3
treatment	T-3
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	T-0
with	T-0
ethinyl	T-1
estradiol	T-1
(	O
CPA	B-Chemical
/	O
EE	O
)	O
is	T-2
licensed	T-2
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	T-0
with	T-0
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	B-Chemical
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	T-0
with	T-0
acne	B-Disease
and	T-1
hirsutism	T-1
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	T-2
of	O
women	T-0
with	T-0
acne	T-0
and	T-0
hirsutism	B-Disease
and	T-1
is	T-1
also	T-1
a	T-1
treatment	T-1
option	T-1
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	T-0
polycystic	B-Disease
ovary	I-Disease
syndrome	I-Disease
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	T-0
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	B-Disease
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	T-0
of	T-0
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	O
)	O
associated	T-1
with	T-1
CPA	O
/	O
EE	O
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	T-1
risk	T-1
of	T-1
venous	T-1
thromboembolism	T-1
(	O
VTE	B-Disease
)	O
associated	T-0
with	T-0
CPA	T-0
/	O
EE	O
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	T-0
with	T-0
CPA	B-Chemical
/	O
EE	O
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	T-0
with	T-0
CPA	O
/	O
EE	B-Chemical
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	O
with	O
CPA	O
/	O
EE	O
compared	O
with	O
conventional	T-1
combined	T-1
oral	B-Chemical
contraceptives	I-Chemical
(	O
COCs	O
)	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	T-0
15	T-0
and	T-0
39	T-0
years	T-0
with	T-0
acne	B-Disease
,	O
hirsutism	T-1
or	T-1
PCOS	T-1
to	O
estimate	O
the	O
risk	O
of	O
VTE	O
associated	O
with	O
CPA	O
/	O
EE	O
.	O

METHODS	O
:	O
Using	O
the	O
General	T-2
Practice	T-2
Research	T-2
Database	T-2
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	T-0
study	T-0
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	O
,	O
hirsutism	B-Disease
or	O
PCOS	O
to	O
estimate	O
the	O
risk	T-1
of	T-1
VTE	O
associated	O
with	O
CPA	O
/	O
EE	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	T-0
analysis	T-0
and	T-0
case	T-0
-	T-0
control	T-0
study	T-0
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	B-Disease
to	T-2
estimate	T-2
the	T-1
risk	T-1
of	O
VTE	O
associated	O
with	O
CPA	O
/	O
EE	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
to	O
estimate	O
the	O
risk	T-0
of	O
VTE	B-Disease
associated	O
with	O
CPA	O
/	O
EE	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
15	O
and	O
39	O
years	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
to	O
estimate	O
the	O
risk	O
of	O
VTE	O
associated	T-0
with	T-0
CPA	B-Chemical
/	O
EE	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	T-1
analysis	T-1
and	T-1
case	T-1
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	T-2
15	T-2
and	T-2
39	T-2
years	T-2
with	T-2
acne	T-2
,	O
hirsutism	O
or	O
PCOS	O
to	O
estimate	O
the	O
risk	O
of	O
VTE	O
associated	T-0
with	T-0
CPA	O
/	O
EE	B-Chemical
.	O

RESULTS	O
:	O
The	O
age	O
-	O
adjusted	O
incidence	O
rate	O
ratio	T-1
for	T-0
CPA	B-Chemical
/	O
EE	O
versus	T-2
conventional	O
COCs	O
was	O
2	O
.	O
20	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
35	O
-	O
3	O
.	O
58	O
]	O
.	O

RESULTS	O
:	O
The	O
age	O
-	O
adjusted	O
incidence	O
rate	O
ratio	T-0
for	T-0
CPA	O
/	O
EE	B-Chemical
versus	O
conventional	O
COCs	O
was	O
2	O
.	O
20	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
35	O
-	O
3	O
.	O
58	O
]	O
.	O

Using	O
as	O
the	O
reference	O
group	O
women	O
who	O
were	O
not	O
using	O
oral	O
contraception	O
,	O
had	O
no	O
recent	O
pregnancy	O
or	O
menopausal	O
symptoms	O
,	O
the	O
case	O
-	O
control	O
analysis	O
gave	O
an	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
(	O
adj	O
)	O
)	O
of	O
7	O
.	O
44	O
(	O
95	O
%	O
CI	O
3	O
.	O
67	O
-	O
15	O
.	O
08	O
)	O
for	T-2
CPA	B-Chemical
/	O
EE	O
use	T-1
compared	O
with	O
an	O
OR	O
(	O
adj	O
)	O
of	O
2	O
.	O
58	O
(	O
95	O
%	O
CI	O
1	O
.	O
60	O
-	O
4	O
.	O
18	O
)	O
for	O
use	O
of	O
conventional	O
COCs	O
.	O

Using	O
as	O
the	O
reference	O
group	O
women	O
who	O
were	O
not	O
using	O
oral	O
contraception	O
,	O
had	O
no	O
recent	O
pregnancy	O
or	O
menopausal	O
symptoms	O
,	O
the	O
case	O
-	O
control	O
analysis	O
gave	O
an	O
adjusted	T-0
odds	T-0
ratio	T-0
(	O
OR	O
(	O
adj	O
)	O
)	O
of	O
7	O
.	O
44	O
(	O
95	O
%	O
CI	O
3	O
.	O
67	O
-	O
15	O
.	O
08	O
)	O
for	O
CPA	O
/	O
EE	B-Chemical
use	O
compared	O
with	O
an	O
OR	O
(	O
adj	O
)	O
of	O
2	O
.	O
58	O
(	O
95	O
%	O
CI	O
1	O
.	O
60	O
-	O
4	O
.	O
18	O
)	O
for	O
use	O
of	O
conventional	O
COCs	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	T-0
risk	T-0
of	T-0
VTE	B-Disease
associated	O
with	O
the	O
use	O
of	O
CPA	O
/	O
EE	O
in	O
women	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	O
with	O
the	O
use	T-0
of	T-0
CPA	B-Chemical
/	O
EE	O
in	O
women	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	O
with	O
the	T-0
use	T-0
of	T-0
CPA	O
/	O
EE	B-Chemical
in	O
women	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	O
with	O
the	O
use	T-1
of	T-1
CPA	O
/	O
EE	O
in	O
women	O
with	O
acne	B-Disease
,	O
hirsutism	O
or	O
PCOS	O
although	O
residual	O
confounding	T-0
by	T-0
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	T-0
risk	T-0
of	T-0
VTE	O
associated	O
with	O
the	O
use	O
of	O
CPA	O
/	O
EE	O
in	O
women	O
with	O
acne	O
,	O
hirsutism	B-Disease
or	O
PCOS	O
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	O
with	O
the	O
use	O
of	O
CPA	O
/	O
EE	O
in	O
women	O
with	O
acne	O
,	O
hirsutism	O
or	T-1
PCOS	B-Disease
although	T-0
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

The	O
effect	O
of	O
treatment	T-0
with	T-0
gum	B-Chemical
Arabic	I-Chemical
on	O
gentamicin	T-1
nephrotoxicity	T-1
in	T-1
rats	T-1
:	O
a	O
preliminary	O
study	O
.	O

The	O
effect	O
of	O
treatment	T-0
with	T-0
gum	T-2
Arabic	T-2
on	T-2
gentamicin	B-Chemical
nephrotoxicity	T-3
in	O
rats	O
:	O
a	O
preliminary	O
study	O
.	O

The	O
effect	T-1
of	T-1
treatment	T-1
with	O
gum	O
Arabic	O
on	O
gentamicin	O
nephrotoxicity	B-Disease
in	O
rats	O
:	O
a	O
preliminary	O
study	O
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	T-0
of	T-0
treatment	T-0
of	O
rats	T-2
with	T-3
gum	B-Chemical
Arabic	I-Chemical
on	O
acute	O
renal	O
failure	O
induced	O
by	O
gentamicin	O
(	O
GM	O
)	O
nephrotoxicity	O
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	T-0
of	O
rats	O
with	O
gum	O
Arabic	O
on	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
induced	T-1
by	O
gentamicin	O
(	O
GM	O
)	O
nephrotoxicity	O
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	O
Arabic	O
on	O
acute	O
renal	O
failure	O
induced	T-0
by	T-0
gentamicin	B-Chemical
(	T-1
GM	T-1
)	T-1
nephrotoxicity	O
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	O
Arabic	O
on	O
acute	O
renal	O
failure	O
induced	T-0
by	T-0
gentamicin	T-0
(	O
GM	B-Chemical
)	O
nephrotoxicity	T-1
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	O
Arabic	O
on	O
acute	O
renal	O
failure	O
induced	T-0
by	T-0
gentamicin	O
(	O
GM	O
)	O
nephrotoxicity	B-Disease
.	O

Rats	O
were	O
treated	T-1
with	T-1
the	O
vehicle	O
(	O
2	O
mL	O
/	O
kg	O
of	O
distilled	O
water	O
and	O
5	O
%	O
w	O
/	O
v	O
cellulose	O
,	O
10	O
days	O
)	O
,	O
gum	B-Chemical
Arabic	I-Chemical
(	O
2	O
mL	O
/	O
kg	O
of	O
a	O
10	O
%	O
w	O
/	O
v	O
aqueous	O
suspension	O
of	O
gum	O
Arabic	O
powder	O
,	O
orally	O
for	O
10	O
days	O
)	O
,	O
or	O
gum	O
Arabic	O
concomitantly	O
with	O
GM	O
(	O
80mg	O
/	O
kg	O
/	O
day	O
intramuscularly	O
,	O
during	O
the	O
last	O
six	O
days	O
of	O
the	O
treatment	O
period	O
)	O
.	O

Rats	O
were	O
treated	O
with	O
the	O
vehicle	O
(	O
2	O
mL	O
/	O
kg	O
of	O
distilled	O
water	O
and	O
5	O
%	O
w	O
/	O
v	O
cellulose	O
,	O
10	O
days	O
)	O
,	O
gum	O
Arabic	O
(	O
2	O
mL	O
/	O
kg	O
of	O
a	O
10	O
%	O
w	O
/	O
v	O
aqueous	T-0
suspension	T-0
of	T-0
gum	B-Chemical
Arabic	I-Chemical
powder	T-1
,	O
orally	O
for	O
10	O
days	O
)	O
,	O
or	O
gum	O
Arabic	O
concomitantly	O
with	O
GM	O
(	O
80mg	O
/	O
kg	O
/	O
day	O
intramuscularly	O
,	O
during	O
the	O
last	O
six	O
days	O
of	O
the	O
treatment	O
period	O
)	O
.	O

Rats	O
were	O
treated	T-1
with	O
the	O
vehicle	O
(	O
2	O
mL	O
/	O
kg	O
of	O
distilled	O
water	O
and	O
5	O
%	O
w	O
/	O
v	O
cellulose	O
,	O
10	O
days	O
)	O
,	O
gum	O
Arabic	O
(	O
2	O
mL	O
/	O
kg	O
of	O
a	O
10	O
%	O
w	O
/	O
v	O
aqueous	O
suspension	O
of	O
gum	O
Arabic	O
powder	O
,	O
orally	O
for	O
10	O
days	O
)	O
,	O
or	O
gum	B-Chemical
Arabic	I-Chemical
concomitantly	T-0
with	T-0
GM	T-0
(	O
80mg	O
/	O
kg	O
/	O
day	O
intramuscularly	O
,	O
during	O
the	O
last	O
six	O
days	O
of	O
the	O
treatment	O
period	O
)	O
.	O

Rats	O
were	O
treated	O
with	O
the	O
vehicle	O
(	O
2	O
mL	O
/	O
kg	O
of	O
distilled	O
water	O
and	O
5	O
%	O
w	O
/	O
v	O
cellulose	T-0
,	O
10	O
days	O
)	O
,	O
gum	O
Arabic	O
(	O
2	O
mL	O
/	O
kg	O
of	O
a	O
10	O
%	O
w	O
/	O
v	O
aqueous	T-1
suspension	T-1
of	O
gum	O
Arabic	O
powder	O
,	O
orally	O
for	O
10	O
days	O
)	O
,	O
or	O
gum	O
Arabic	O
concomitantly	O
with	O
GM	B-Chemical
(	O
80mg	T-2
/	T-2
kg	T-2
/	T-2
day	T-2
intramuscularly	O
,	O
during	O
the	O
last	O
six	O
days	O
of	O
the	O
treatment	O
period	O
)	O
.	O

Nephrotoxicity	B-Disease
was	T-0
assessed	T-0
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	O
and	O
urea	O
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

Nephrotoxicity	O
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	T-1
of	T-1
creatinine	B-Chemical
and	T-2
urea	T-2
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

Nephrotoxicity	O
was	O
assessed	T-0
by	O
measuring	T-1
the	O
concentrations	T-2
of	O
creatinine	O
and	O
urea	B-Chemical
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

Nephrotoxicity	O
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	O
and	O
urea	O
in	O
the	O
plasma	O
and	O
reduced	T-0
glutathione	B-Chemical
(	O
GSH	O
)	O
in	T-1
the	T-1
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

Nephrotoxicity	O
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	O
and	O
urea	O
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	T-0
(	O
GSH	B-Chemical
)	O
in	T-1
the	T-1
kidney	T-1
cortex	T-1
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	T-1
with	O
gum	B-Chemical
Arabic	I-Chemical
and	O
GM	O
significantly	T-0
increased	T-0
creatinine	O
and	O
urea	O
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	T-2
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	T-1
Arabic	T-1
and	T-1
GM	B-Chemical
significantly	T-2
increased	T-2
creatinine	T-2
and	T-2
urea	T-2
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	B-Chemical
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	T-0
with	T-0
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	T-0
treatment	T-0
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	B-Chemical
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	T-1
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	T-0
cortical	T-0
GSH	B-Chemical
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	T-1
that	O
of	O
cortical	O
GSH	O
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	T-0
the	T-0
cellulose	T-0
plus	T-0
GM	B-Chemical
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	T-0
treatment	T-0
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	T-1
GM	B-Chemical
-	O
induced	T-2
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	T-0
-	T-0
induced	T-0
proximal	T-0
tubular	B-Disease
necrosis	I-Disease
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	T-0
severe	T-0
in	T-0
rats	T-0
given	T-0
GM	B-Chemical
together	T-1
with	T-1
gum	T-1
Arabic	T-1
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	T-0
Arabic	T-0
and	O
GM	O
significantly	O
increased	O
creatinine	T-1
and	O
urea	T-2
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	T-3
together	T-3
with	T-3
gum	B-Chemical
Arabic	I-Chemical
than	T-4
in	T-4
those	T-4
given	T-4
GM	T-4
and	T-4
cellulose	T-4
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	T-2
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	T-3
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	T-4
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	T-1
given	T-1
GM	B-Chemical
and	O
cellulose	O
.	O

It	O
could	O
be	O
inferred	O
that	O
gum	O
Arabic	O
treatment	O
has	O
induced	T-0
a	T-0
modest	T-0
amelioration	T-0
of	O
some	O
of	O
the	O
histological	O
and	O
biochemical	O
indices	O
of	O
GM	B-Chemical
nephrotoxicity	O
.	O

It	O
could	O
be	O
inferred	O
that	O
gum	O
Arabic	O
treatment	O
has	O
induced	T-0
a	T-0
modest	T-0
amelioration	T-0
of	T-0
some	O
of	O
the	O
histological	O
and	O
biochemical	O
indices	T-1
of	O
GM	O
nephrotoxicity	B-Disease
.	O

Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	T-0
of	T-0
the	T-0
treatments	T-0
on	T-0
renal	O
functional	O
aspects	O
in	O
models	T-1
of	T-1
chronic	B-Disease
renal	I-Disease
failure	I-Disease
,	O
and	O
on	O
the	O
mechanism	T-2
(	T-2
s	T-2
)	T-2
involved	T-2
.	O

Increased	T-1
frequency	T-1
of	T-1
venous	B-Disease
thromboembolism	I-Disease
with	O
the	O
combination	O
of	O
docetaxel	O
and	O
thalidomide	O
in	O
patients	O
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
.	O

Increased	O
frequency	O
of	O
venous	O
thromboembolism	O
with	O
the	O
combination	T-1
of	T-1
docetaxel	B-Chemical
and	T-0
thalidomide	T-0
in	O
patients	O
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
.	O

Increased	T-0
frequency	T-0
of	T-0
venous	T-0
thromboembolism	T-0
with	O
the	O
combination	T-1
of	T-1
docetaxel	O
and	O
thalidomide	B-Chemical
in	O
patients	O
with	O
metastatic	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
.	O

Increased	O
frequency	O
of	O
venous	O
thromboembolism	O
with	O
the	O
combination	O
of	O
docetaxel	O
and	O
thalidomide	O
in	O
patients	O
with	O
metastatic	O
androgen	O
-	O
independent	T-0
prostate	B-Disease
cancer	I-Disease
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	T-0
of	T-0
venous	B-Disease
thromboembolism	I-Disease
(	T-1
VTE	T-1
)	T-1
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
who	O
were	O
treated	O
with	O
docetaxel	O
alone	O
or	O
in	O
combination	O
with	O
thalidomide	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	T-2
of	T-2
venous	T-0
thromboembolism	T-0
(	O
VTE	B-Disease
)	O
in	T-1
patients	T-1
with	T-1
advanced	T-1
androgen	T-1
-	O
independent	O
prostate	O
cancer	O
who	O
were	O
treated	O
with	O
docetaxel	O
alone	O
or	O
in	O
combination	O
with	O
thalidomide	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	T-0
prostate	B-Disease
cancer	I-Disease
who	O
were	O
treated	T-1
with	T-1
docetaxel	O
alone	O
or	O
in	O
combination	O
with	O
thalidomide	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
who	O
were	O
treated	T-0
with	T-0
docetaxel	B-Chemical
alone	O
or	O
in	O
combination	O
with	O
thalidomide	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
who	O
were	O
treated	T-1
with	O
docetaxel	O
alone	O
or	O
in	T-2
combination	T-2
with	T-2
thalidomide	B-Chemical
.	O

PATIENTS	T-0
:	O
Seventy	O
men	O
,	O
aged	O
50	O
-	O
80	O
years	O
,	O
with	T-3
advanced	T-3
androgen	O
-	O
independent	T-2
prostate	B-Disease
cancer	I-Disease
.	O

INTERVENTION	O
:	O
Each	O
patient	O
received	O
either	O
intravenous	T-1
docetaxel	B-Chemical
30	O
mg	T-0
/	T-0
m2	T-0
/	T-0
week	T-0
for	T-0
3	T-0
consecutive	T-0
weeks	T-0
,	O
followed	O
by	O
1	O
week	O
off	O
,	O
or	O
the	O
combination	O
of	O
continuous	O
oral	O
thalidomide	O
200	O
mg	O
every	O
evening	O
plus	O
the	O
same	O
docetaxel	O
regimen	O
.	O

INTERVENTION	O
:	O
Each	O
patient	O
received	T-0
either	T-0
intravenous	T-0
docetaxel	O
30	O
mg	O
/	O
m2	O
/	O
week	O
for	O
3	O
consecutive	O
weeks	O
,	O
followed	O
by	O
1	O
week	O
off	O
,	O
or	O
the	O
combination	O
of	O
continuous	T-1
oral	T-1
thalidomide	B-Chemical
200	O
mg	O
every	O
evening	O
plus	O
the	O
same	O
docetaxel	O
regimen	O
.	O

INTERVENTION	O
:	O
Each	O
patient	O
received	O
either	O
intravenous	O
docetaxel	O
30	O
mg	O
/	O
m2	O
/	O
week	O
for	O
3	O
consecutive	O
weeks	O
,	O
followed	O
by	O
1	O
week	O
off	O
,	O
or	O
the	O
combination	O
of	O
continuous	O
oral	O
thalidomide	O
200	O
mg	O
every	O
evening	O
plus	O
the	T-1
same	T-1
docetaxel	B-Chemical
regimen	O
.	O

This	O
4	O
-	O
week	O
cycle	O
was	O
repeated	O
until	O
there	O
was	O
evidence	O
of	O
excessive	T-0
toxicity	B-Disease
or	O
disease	T-1
progression	T-1
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	O
patients	T-1
who	O
received	T-0
docetaxel	B-Chemical
alone	O
developed	O
VTE	O
,	O
whereas	O
9	O
of	O
47	O
patients	T-2
(	O
19	O
%	O
)	O
who	O
received	O
docetaxel	O
plus	O
thalidomide	O
developed	O
VTE	O
(	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	T-1
patients	T-1
who	O
received	O
docetaxel	O
alone	O
developed	T-0
VTE	B-Disease
,	O
whereas	O
9	T-2
of	T-2
47	T-2
patients	T-2
(	O
19	O
%	O
)	O
who	O
received	O
docetaxel	O
plus	O
thalidomide	O
developed	O
VTE	O
(	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	O
patients	T-0
who	T-0
received	T-0
docetaxel	O
alone	O
developed	O
VTE	O
,	O
whereas	O
9	O
of	O
47	O
patients	O
(	O
19	O
%	O
)	O
who	O
received	T-1
docetaxel	B-Chemical
plus	T-2
thalidomide	T-2
developed	O
VTE	O
(	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	O
patients	O
who	O
received	O
docetaxel	O
alone	O
developed	O
VTE	O
,	O
whereas	O
9	O
of	O
47	O
patients	O
(	O
19	O
%	O
)	O
who	O
received	T-1
docetaxel	O
plus	O
thalidomide	B-Chemical
developed	T-0
VTE	T-0
(	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
23	O
patients	O
who	O
received	O
docetaxel	O
alone	O
developed	O
VTE	O
,	O
whereas	O
9	O
of	O
47	O
patients	O
(	O
19	O
%	O
)	O
who	O
received	O
docetaxel	O
plus	O
thalidomide	O
developed	T-0
VTE	B-Disease
(	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O

CONCLUSION	O
:	O
The	O
addition	T-0
of	T-0
thalidomide	B-Chemical
to	O
docetaxel	O
in	O
the	O
treatment	O
of	O
prostate	O
cancer	O
significantly	O
increases	O
the	O
frequency	O
of	O
VTE	O
.	O

CONCLUSION	O
:	O
The	O
addition	T-2
of	T-2
thalidomide	O
to	T-0
docetaxel	B-Chemical
in	T-1
the	O
treatment	T-3
of	T-3
prostate	O
cancer	O
significantly	O
increases	O
the	O
frequency	O
of	O
VTE	O
.	O

CONCLUSION	O
:	O
The	O
addition	O
of	O
thalidomide	O
to	O
docetaxel	O
in	O
the	O
treatment	T-0
of	T-0
prostate	B-Disease
cancer	I-Disease
significantly	T-1
increases	T-1
the	O
frequency	O
of	O
VTE	O
.	O

CONCLUSION	O
:	O
The	O
addition	O
of	O
thalidomide	O
to	O
docetaxel	O
in	O
the	O
treatment	O
of	O
prostate	O
cancer	O
significantly	O
increases	T-0
the	T-0
frequency	T-0
of	T-0
VTE	B-Disease
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
complication	O
when	O
adding	T-0
thalidomide	B-Chemical
to	O
chemotherapeutic	O
regimens	O
.	O

Ticlopidine	B-Chemical
-	O
induced	T-0
cholestatic	O
hepatitis	O
.	O

Ticlopidine	O
-	O
induced	T-0
cholestatic	B-Disease
hepatitis	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	T-0
of	T-0
ticlopidine	B-Chemical
-	O
induced	T-2
cholestatic	O
hepatitis	O
,	O
investigate	T-3
its	T-3
mechanism	T-3
,	O
and	O
compare	O
the	O
observed	O
main	O
characteristics	O
with	O
those	O
of	O
the	O
published	O
cases	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
2	O
cases	T-0
of	T-0
ticlopidine	T-2
-	T-2
induced	T-2
cholestatic	B-Disease
hepatitis	I-Disease
,	O
investigate	O
its	O
mechanism	O
,	O
and	O
compare	O
the	O
observed	O
main	O
characteristics	O
with	O
those	O
of	O
the	O
published	O
cases	O
.	O

CASE	O
SUMMARIES	O
:	O
Two	O
patients	T-0
developed	O
prolonged	O
cholestatic	B-Disease
hepatitis	I-Disease
after	O
receiving	O
ticlopidine	O
following	O
percutaneous	O
coronary	O
angioplasty	O
,	O
with	O
complete	O
remission	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

CASE	O
SUMMARIES	O
:	O
Two	O
patients	O
developed	O
prolonged	O
cholestatic	O
hepatitis	O
after	O
receiving	T-0
ticlopidine	B-Chemical
following	O
percutaneous	O
coronary	O
angioplasty	O
,	O
with	O
complete	O
remission	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

T	O
-	O
cell	O
stimulation	O
by	O
therapeutic	O
concentration	T-0
of	T-0
ticlopidine	B-Chemical
was	O
demonstrated	O
in	O
vitro	O
in	O
the	O
patients	O
,	O
but	O
not	O
in	O
healthy	O
controls	O
.	O

DISCUSSION	O
:	O
Cholestatic	B-Disease
hepatitis	I-Disease
is	O
a	O
rare	O
complication	T-0
of	O
the	O
antiplatelet	O
agent	O
ticlopidine	O
;	O
several	O
cases	O
have	O
been	T-1
reported	T-1
but	O
few	O
in	O
the	O
English	O
literature	O
.	O

DISCUSSION	O
:	O
Cholestatic	O
hepatitis	O
is	O
a	O
rare	O
complication	O
of	O
the	O
antiplatelet	O
agent	T-0
ticlopidine	B-Chemical
;	O
several	O
cases	O
have	O
been	O
reported	O
but	O
few	O
in	O
the	O
English	O
literature	O
.	O

Our	O
patients	O
developed	O
jaundice	B-Disease
following	T-0
treatment	T-0
with	O
ticlopidine	O
and	O
showed	O
the	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
cholestatic	O
hepatitis	O
,	O
which	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Our	O
patients	O
developed	O
jaundice	O
following	O
treatment	T-1
with	T-1
ticlopidine	B-Chemical
and	T-2
showed	T-2
the	T-2
clinical	T-2
and	O
laboratory	O
characteristics	O
of	O
cholestatic	O
hepatitis	O
,	O
which	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Our	T-0
patients	T-0
developed	T-0
jaundice	O
following	O
treatment	O
with	O
ticlopidine	O
and	O
showed	O
the	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
cholestatic	B-Disease
hepatitis	I-Disease
,	O
which	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

An	O
objective	O
causality	O
assessment	O
revealed	O
that	O
the	O
adverse	O
drug	O
event	O
was	O
probably	O
related	T-0
to	T-0
the	O
use	T-1
of	T-1
ticlopidine	B-Chemical
.	O

The	O
mechanisms	O
of	T-0
this	T-0
ticlopidine	B-Chemical
-	O
induced	T-1
cholestasis	O
are	O
unclear	O
.	O

The	O
mechanisms	O
of	O
this	O
ticlopidine	O
-	O
induced	T-1
cholestasis	B-Disease
are	T-0
unclear	T-0
.	O

Immune	T-1
mechanisms	T-1
may	O
be	O
involved	T-0
in	O
the	O
drug	O
'	O
s	O
hepatotoxicity	B-Disease
,	O
as	O
suggested	O
by	O
the	O
T	O
-	O
cell	O
stimulation	O
study	O
reported	O
here	O
.	O

CONCLUSIONS	O
:	O
Cholestatic	B-Disease
hepatitis	I-Disease
is	T-2
a	T-2
rare	T-2
adverse	T-0
effect	O
of	O
ticlopidine	O
that	O
may	T-1
be	T-1
immune	T-1
mediated	T-1
.	T-0

CONCLUSIONS	O
:	O
Cholestatic	O
hepatitis	O
is	O
a	O
rare	O
adverse	O
effect	T-0
of	T-0
ticlopidine	B-Chemical
that	O
may	O
be	O
immune	O
mediated	O
.	O

This	O
complication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopidine	B-Chemical
is	T-1
being	T-1
replaced	T-1
by	T-0
the	T-0
newer	T-0
antiplatelet	T-0
agent	O
clopidogrel	O
.	O

This	O
complication	O
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	O
as	O
ticlopidine	O
is	O
being	O
replaced	T-1
by	T-1
the	O
newer	O
antiplatelet	O
agent	T-0
clopidogrel	B-Chemical
.	O

Epithelial	T-2
sodium	B-Chemical
channel	T-0
(	T-3
ENaC	T-3
)	T-3
subunit	O
mRNA	O
and	O
protein	T-1
expression	T-1
in	O
rats	O
with	O
puromycin	O
aminonucleoside	O
-	O
induced	O
nephrotic	O
syndrome	O
.	O

Epithelial	T-0
sodium	T-0
channel	T-0
(	O
ENaC	O
)	O
subunit	O
mRNA	O
and	O
protein	O
expression	O
in	O
rats	O
with	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	T-1
nephrotic	O
syndrome	O
.	O

Epithelial	O
sodium	O
channel	O
(	O
ENaC	O
)	O
subunit	O
mRNA	O
and	O
protein	O
expression	O
in	O
rats	O
with	O
puromycin	O
aminonucleoside	O
-	O
induced	T-0
nephrotic	B-Disease
syndrome	I-Disease
.	O

In	T-1
experimental	T-1
nephrotic	B-Disease
syndrome	I-Disease
,	O
urinary	T-2
sodium	T-2
excretion	T-2
is	O
decreased	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O

The	O
rate	O
-	O
limiting	O
constituent	O
of	O
collecting	T-1
duct	T-1
sodium	B-Chemical
transport	O
is	O
the	O
epithelial	O
sodium	O
channel	O
(	O
ENaC	O
)	O
.	O

The	O
rate	O
-	O
limiting	O
constituent	O
of	O
collecting	O
duct	O
sodium	O
transport	O
is	T-0
the	T-0
epithelial	O
sodium	B-Chemical
channel	O
(	T-1
ENaC	T-1
)	T-1
.	O

We	O
examined	O
the	O
abundance	O
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	O
in	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	O
)	O
-	O
induced	T-0
nephrotic	O
syndrome	O
.	O

We	O
examined	O
the	O
abundance	O
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	T-0
in	T-0
puromycin	O
aminonucleoside	O
(	O
PAN	B-Chemical
)	O
-	O
induced	T-1
nephrotic	O
syndrome	O
.	O

We	O
examined	O
the	O
abundance	O
of	O
ENaC	O
subunit	O
mRNAs	O
and	O
proteins	O
in	O
puromycin	O
aminonucleoside	O
(	O
PAN	O
)	O
-	O
induced	T-0
nephrotic	B-Disease
syndrome	I-Disease
.	O

The	O
time	T-1
courses	T-1
of	O
urinary	O
sodium	B-Chemical
excretion	T-2
,	O
plasma	O
aldosterone	O
concentration	O
and	O
proteinuria	O
were	O
studied	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
a	O
single	O
dose	O
of	O
either	O
PAN	O
or	O
vehicle	O
.	O

The	O
time	O
courses	O
of	O
urinary	O
sodium	O
excretion	O
,	O
plasma	T-0
aldosterone	B-Chemical
concentration	T-1
and	O
proteinuria	O
were	O
studied	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	O
with	O
a	O
single	O
dose	O
of	O
either	O
PAN	O
or	O
vehicle	O
.	O

The	O
time	O
courses	O
of	O
urinary	O
sodium	O
excretion	O
,	O
plasma	O
aldosterone	O
concentration	O
and	O
proteinuria	B-Disease
were	O
studied	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	T-0
with	T-0
a	O
single	O
dose	O
of	O
either	O
PAN	O
or	O
vehicle	O
.	O

The	O
time	T-0
courses	T-0
of	O
urinary	O
sodium	O
excretion	O
,	O
plasma	T-2
aldosterone	T-2
concentration	O
and	O
proteinuria	O
were	O
studied	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
treated	T-1
with	T-1
a	T-1
single	T-1
dose	T-1
of	O
either	O
PAN	B-Chemical
or	O
vehicle	O
.	O

The	O
kinetics	T-0
of	T-0
urinary	T-0
sodium	B-Chemical
excretion	T-1
and	O
the	O
appearance	O
of	O
proteinuria	O
were	O
comparable	O
with	O
those	O
reported	O
previously	O
.	O

The	O
kinetics	O
of	O
urinary	O
sodium	O
excretion	O
and	O
the	O
appearance	O
of	O
proteinuria	B-Disease
were	T-0
comparable	T-0
with	T-0
those	T-0
reported	T-0
previously	T-0
.	O

Sodium	B-Chemical
retention	T-0
occurred	O
on	O
days	O
2	O
,	O
3	O
and	O
6	O
after	O
PAN	O
injection	O
.	O

Sodium	O
retention	O
occurred	O
on	O
days	O
2	O
,	O
3	O
and	O
6	O
after	O
PAN	B-Chemical
injection	T-0
.	O

A	O
significant	O
up	O
-	O
regulation	O
of	O
alphaENaC	O
and	O
betaENaC	O
mRNA	O
abundance	O
on	O
days	O
1	O
and	O
2	O
preceded	T-0
sodium	B-Chemical
retention	O
on	O
days	O
2	O
and	O
3	O
.	O

Conversely	O
,	O
down	O
-	O
regulation	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNA	O
expression	O
on	O
day	O
3	O
occurred	O
in	O
the	O
presence	T-1
of	T-1
high	T-1
aldosterone	B-Chemical
concentrations	T-2
,	O
and	O
was	O
followed	O
by	O
a	O
return	O
of	O
sodium	O
excretion	O
to	O
control	O
values	O
.	O

Conversely	O
,	O
down	O
-	O
regulation	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNA	O
expression	O
on	O
day	O
3	O
occurred	O
in	O
the	O
presence	O
of	O
high	O
aldosterone	O
concentrations	O
,	O
and	O
was	O
followed	O
by	O
a	O
return	T-1
of	T-1
sodium	B-Chemical
excretion	T-2
to	O
control	O
values	O
.	O

The	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
proteins	O
were	O
not	O
increased	T-0
during	T-0
PAN	B-Chemical
-	O
induced	T-2
sodium	T-2
retention	T-2
.	O

The	O
amounts	O
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
proteins	O
were	T-3
not	T-3
increased	T-3
during	T-3
PAN	T-3
-	O
induced	T-1
sodium	B-Chemical
retention	T-2
.	O

In	O
conclusion	O
,	O
ENaC	O
mRNA	O
expression	O
,	O
especially	O
alphaENaC	O
,	O
is	O
increased	O
in	O
the	O
very	O
early	O
phase	O
of	O
the	O
experimental	O
model	T-0
of	T-0
PAN	B-Chemical
-	O
induced	T-1
nephrotic	O
syndrome	O
in	O
rats	O
,	O
but	O
appears	O
to	O
escape	O
from	O
the	O
regulation	O
by	O
aldosterone	O
after	O
day	O
3	O
.	O

In	O
conclusion	O
,	O
ENaC	O
mRNA	O
expression	O
,	O
especially	O
alphaENaC	O
,	O
is	O
increased	O
in	O
the	O
very	O
early	O
phase	O
of	O
the	O
experimental	O
model	O
of	O
PAN	O
-	O
induced	O
nephrotic	O
syndrome	O
in	O
rats	O
,	O
but	O
appears	O
to	O
escape	O
from	O
the	O
regulation	T-1
by	T-1
aldosterone	B-Chemical
after	T-0
day	T-0
3	T-0
.	T-0

Sub	O
-	O
chronic	O
low	T-0
dose	T-0
gamma	B-Chemical
-	I-Chemical
vinyl	I-Chemical
GABA	I-Chemical
(	O
vigabatrin	O
)	O
inhibits	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
dopamine	O
.	O

Sub	O
-	O
chronic	O
low	O
dose	O
gamma	O
-	O
vinyl	O
GABA	O
(	O
vigabatrin	B-Chemical
)	O
inhibits	T-0
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
dopamine	O
.	O

Sub	O
-	O
chronic	O
low	O
dose	O
gamma	O
-	O
vinyl	O
GABA	O
(	O
vigabatrin	O
)	O
inhibits	O
cocaine	B-Chemical
-	O
induced	T-0
increases	O
in	O
nucleus	O
accumbens	O
dopamine	O
.	O

Sub	O
-	O
chronic	O
low	O
dose	O
gamma	O
-	O
vinyl	O
GABA	O
(	O
vigabatrin	O
)	O
inhibits	O
cocaine	O
-	O
induced	T-0
increases	T-1
in	T-1
nucleus	O
accumbens	O
dopamine	B-Chemical
.	O

RATIONALE	O
:	O
gamma	B-Chemical
-	I-Chemical
Vinyl	I-Chemical
GABA	I-Chemical
(	O
GVG	O
)	O
irreversibly	T-0
inhibits	T-0
GABA	O
-	O
transaminase	O
.	O

RATIONALE	O
:	O
gamma	T-0
-	T-0
Vinyl	T-0
GABA	T-0
(	O
GVG	B-Chemical
)	O
irreversibly	T-1
inhibits	T-1
GABA	T-1
-	T-1
transaminase	T-1
.	O

RATIONALE	O
:	O
gamma	T-0
-	O
Vinyl	O
GABA	O
(	O
GVG	O
)	O
irreversibly	T-2
inhibits	T-2
GABA	B-Chemical
-	O
transaminase	T-1
.	T-0

This	O
non	O
-	O
receptor	O
mediated	O
inhibition	O
requires	O
de	O
novo	O
synthesis	O
for	O
restoration	T-0
of	O
functional	O
GABA	B-Chemical
catabolism	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	T-0
treating	T-0
substance	B-Disease
abuse	I-Disease
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	T-0
risk	O
of	O
visual	B-Disease
field	I-Disease
defects	I-Disease
(	O
VFD	O
)	O
associated	T-1
with	T-1
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	T-0
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	B-Disease
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	T-2
low	T-2
dose	T-2
GVG	B-Chemical
on	T-3
cocaine	T-3
-	O
induced	T-1
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	B-Chemical
-	O
induced	T-1
increases	T-1
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	T-0
increases	T-1
in	T-1
nucleus	T-1
accumbens	T-1
(	T-1
NAcc	T-1
)	T-1
dopamine	B-Chemical
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	T-0
increases	T-1
in	T-1
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	B-Chemical
)	O
.	O

RESULTS	O
:	O
Sub	O
-	O
chronic	O
GVG	B-Chemical
exposure	T-1
inhibited	T-1
the	T-1
effect	T-1
of	O
cocaine	O
for	O
3	O
days	O
,	O
which	O
exceeded	O
in	O
magnitude	O
and	O
duration	O
the	O
identical	O
acute	O
dose	O
.	O

RESULTS	O
:	O
Sub	O
-	O
chronic	O
GVG	O
exposure	O
inhibited	T-0
the	O
effect	T-1
of	T-1
cocaine	B-Chemical
for	O
3	O
days	O
,	O
which	O
exceeded	O
in	O
magnitude	O
and	O
duration	O
the	O
identical	O
acute	O
dose	O
.	O

CONCLUSIONS	O
:	O
Sub	O
-	O
chronic	O
low	T-0
dose	T-0
GVG	B-Chemical
potentiates	T-3
and	O
extends	O
the	O
inhibition	T-1
of	T-1
cocaine	O
-	O
induced	T-2
increases	T-2
in	T-2
dopamine	O
,	O
effectively	O
reducing	O
cumulative	O
exposures	O
and	O
the	O
risk	O
for	O
VFDS	O
.	O

CONCLUSIONS	O
:	O
Sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
potentiates	O
and	O
extends	O
the	O
inhibition	T-0
of	O
cocaine	B-Chemical
-	O
induced	T-1
increases	T-1
in	T-1
dopamine	T-1
,	O
effectively	O
reducing	O
cumulative	O
exposures	O
and	O
the	O
risk	O
for	O
VFDS	O
.	O

CONCLUSIONS	O
:	O
Sub	O
-	O
chronic	T-0
low	T-0
dose	T-0
GVG	O
potentiates	O
and	O
extends	O
the	O
inhibition	O
of	O
cocaine	O
-	O
induced	T-1
increases	O
in	O
dopamine	B-Chemical
,	O
effectively	O
reducing	T-2
cumulative	O
exposures	O
and	O
the	O
risk	O
for	O
VFDS	O
.	O

MR	O
imaging	O
with	O
quantitative	O
diffusion	O
mapping	T-0
of	T-0
tacrolimus	B-Chemical
-	O
induced	T-1
neurotoxicity	O
in	O
organ	O
transplant	O
patients	O
.	O

MR	O
imaging	O
with	O
quantitative	O
diffusion	O
mapping	O
of	O
tacrolimus	O
-	O
induced	T-0
neurotoxicity	B-Disease
in	O
organ	O
transplant	O
patients	O
.	O

Our	O
objective	O
was	O
to	O
investigate	O
brain	O
MR	O
imaging	O
findings	O
and	O
the	O
utility	O
of	O
diffusion	O
-	O
weighted	O
(	O
DW	O
)	O
imaging	O
in	O
organ	O
transplant	O
patients	O
who	O
developed	O
neurologic	O
symptoms	O
during	T-0
tacrolimus	B-Chemical
therapy	T-1
.	O

Brain	O
MR	O
studies	O
,	O
including	O
DW	O
imaging	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
organ	O
transplant	O
patients	O
receiving	T-0
tacrolimus	B-Chemical
who	T-1
developed	T-1
neurologic	O
complications	O
.	O

Brain	O
MR	O
studies	O
,	O
including	O
DW	O
imaging	O
,	O
were	O
prospectively	O
performed	O
in	O
14	O
organ	O
transplant	O
patients	T-1
receiving	O
tacrolimus	O
who	O
developed	T-0
neurologic	B-Disease
complications	I-Disease
.	O

Of	O
the	O
14	O
patients	T-0
,	O
5	O
(	O
35	O
.	O
7	O
%	O
)	O
had	T-1
white	B-Disease
matter	I-Disease
abnormalities	I-Disease
,	O
1	O
(	O
7	O
.	O
1	O
%	O
)	O
had	O
putaminal	O
hemorrhage	O
,	O
and	O
8	O
(	O
57	O
.	O
1	O
%	O
)	O
had	O
normal	O
findings	O
on	O
initial	O
MR	O
images	O
.	O

Of	O
the	O
14	O
patients	O
,	O
5	O
(	O
35	O
.	O
7	O
%	O
)	O
had	O
white	O
matter	O
abnormalities	O
,	O
1	O
(	O
7	O
.	O
1	O
%	O
)	O
had	T-0
putaminal	B-Disease
hemorrhage	I-Disease
,	O
and	O
8	O
(	O
57	O
.	O
1	O
%	O
)	O
had	O
normal	O
findings	O
on	O
initial	O
MR	O
images	O
.	O

Among	T-0
the	O
5	O
patients	T-1
with	T-1
white	B-Disease
matter	I-Disease
abnormalities	I-Disease
,	O
4	O
patients	O
(	O
80	O
.	O
0	O
%	O
)	O
showed	O
higher	O
than	O
normal	O
ADC	O
values	O
on	O
initial	O
MR	O
images	O
,	O
and	O
all	O
showed	O
complete	O
resolution	O
on	O
follow	O
-	O
up	O
images	O
.	O

The	O
remaining	O
1	O
patient	T-0
(	O
20	O
.	O
0	O
%	O
)	O
showed	O
lower	O
than	O
normal	O
ADC	O
value	O
and	O
showed	O
incomplete	O
resolution	O
with	T-1
cortical	B-Disease
laminar	I-Disease
necrosis	I-Disease
.	O

Diffusion	O
-	O
weighted	O
imaging	O
may	O
be	O
useful	O
in	O
predicting	O
the	O
outcomes	O
of	O
the	O
lesions	T-0
of	T-0
tacrolimus	B-Chemical
-	O
induced	T-1
neurotoxicity	T-1
.	O

Diffusion	O
-	O
weighted	O
imaging	O
may	O
be	O
useful	O
in	O
predicting	O
the	O
outcomes	O
of	O
the	O
lesions	O
of	O
tacrolimus	O
-	O
induced	T-0
neurotoxicity	B-Disease
.	O

L	B-Chemical
-	I-Chemical
arginine	I-Chemical
transport	T-1
in	O
humans	O
with	O
cortisol	O
-	O
induced	O
hypertension	O
.	O

L	O
-	O
arginine	O
transport	O
in	O
humans	T-0
with	T-0
cortisol	B-Chemical
-	O
induced	T-1
hypertension	O
.	O

L	O
-	O
arginine	O
transport	O
in	O
humans	O
with	O
cortisol	T-2
-	T-2
induced	T-2
hypertension	B-Disease
.	O

A	O
deficient	T-0
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
-	O
nitric	O
oxide	O
system	O
is	O
implicated	T-1
in	O
cortisol	O
-	O
induced	O
hypertension	O
.	O

A	O
deficient	T-1
L	O
-	O
arginine	T-0
-	O
nitric	B-Chemical
oxide	I-Chemical
system	O
is	O
implicated	T-2
in	O
cortisol	O
-	O
induced	O
hypertension	O
.	O

A	O
deficient	O
L	O
-	O
arginine	O
-	O
nitric	O
oxide	O
system	O
is	O
implicated	T-0
in	T-0
cortisol	B-Chemical
-	O
induced	O
hypertension	O
.	O

A	O
deficient	O
L	O
-	O
arginine	O
-	O
nitric	O
oxide	O
system	O
is	O
implicated	O
in	O
cortisol	O
-	O
induced	T-0
hypertension	B-Disease
.	O

We	O
investigate	O
whether	O
abnormalities	O
in	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	T-0
contribute	O
to	O
this	O
deficiency	O
.	O

Hydrocortisone	B-Chemical
acetate	I-Chemical
(	O
50	O
mg	O
)	O
was	O
given	T-0
orally	T-0
every	O
6	O
hours	O
for	O
24	O
hours	O
after	O
a	O
5	O
-	O
day	O
fixed	O
-	O
salt	O
diet	O
(	O
150	O
mmol	O
/	O
d	O
)	O
.	O

L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	T-0
was	O
assessed	O
in	O
mononuclear	O
cells	O
incubated	O
with	O
L	O
-	O
arginine	O
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O
L	O
[	O
3H	O
]	O
-	O
l	O
-	O
arginine	O
for	O
a	O
period	O
of	O
5	O
minutes	O
at	O
37	O
degrees	O
C	O
.	O

L	O
-	O
arginine	O
uptake	O
was	O
assessed	T-0
in	T-0
mononuclear	T-0
cells	T-0
incubated	T-1
with	T-1
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O
L	O
[	O
3H	O
]	O
-	O
l	O
-	O
arginine	O
for	O
a	O
period	O
of	O
5	O
minutes	O
at	O
37	O
degrees	O
C	O
.	O

L	O
-	O
arginine	O
uptake	O
was	O
assessed	O
in	O
mononuclear	O
cells	O
incubated	T-0
with	T-0
L	O
-	O
arginine	O
(	O
1	O
to	O
300	O
micromol	O
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	O
/	O
L	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
arginine	I-Chemical
for	O
a	O
period	O
of	O
5	O
minutes	O
at	O
37	O
degrees	O
C	O
.	O

Forearm	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	T-0
was	O
calculated	O
after	O
infusion	O
of	O
[	O
3H	O
]	O
-	O
L	O
-	O
arginine	O
into	O
the	O
brachial	O
artery	O
at	O
a	O
rate	O
of	O
100	O
nCi	O
/	O
min	O
for	O
80	O
minutes	O
.	O

Forearm	O
[	O
3H	O
]	O
-	O
L	O
-	O
arginine	O
extraction	O
was	O
calculated	O
after	O
infusion	T-0
of	T-0
[	B-Chemical
3H	I-Chemical
]	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
into	O
the	O
brachial	O
artery	O
at	O
a	O
rate	O
of	O
100	O
nCi	O
/	O
min	O
for	O
80	O
minutes	O
.	O

Deep	O
forearm	O
venous	O
samples	O
were	O
collected	O
for	O
determination	T-0
of	T-0
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	T-1
.	O

Plasma	T-0
cortisol	B-Chemical
concentrations	T-1
were	O
significantly	O
raised	O
during	O
the	O
active	O
phase	O
(	O
323	O
+	O
/	O
-	O
43	O
to	O
1082	O
+	O
/	O
-	O
245	O
mmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Neither	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
transport	T-0
into	T-0
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	O
treatment	O
.	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	T-0
an	T-0
l	B-Chemical
-	I-Chemical
arginine	I-Chemical
concentration	T-1
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	O
treatment	O
.	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	T-0
of	T-0
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	T-1
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	O
treatment	O
.	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	T-0
-	T-0
arginine	T-0
concentration	T-0
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	T-1
vs	T-1
active	T-1
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	B-Chemical
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	O
treatment	O
.	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	T-0
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	T-1
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	O
treatment	O
.	O

Neither	O
L	T-0
-	T-0
arginine	T-0
transport	T-0
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
26	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
6	O
vs	O
29	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
1	O
pmol	O
/	O
10	O
000	O
cells	O
per	O
5	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	O
of	O
300	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
80	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
1	O
868	O
904	O
+	O
/	O
-	O
434	O
962	O
vs	O
2	O
013	O
910	O
+	O
/	O
-	O
770	O
619	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	T-1
affected	T-1
by	T-1
short	T-1
-	T-1
term	T-1
cortisol	B-Chemical
treatment	T-2
.	O

We	O
conclude	T-0
that	T-0
cortisol	B-Chemical
-	O
induced	T-1
increases	O
in	O
blood	O
pressure	O
are	O
not	O
associated	O
with	O
abnormalities	O
in	O
the	O
l	O
-	O
arginine	O
transport	O
system	O
.	O

We	O
conclude	O
that	O
cortisol	O
-	O
induced	T-0
increases	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
are	T-1
not	T-1
associated	T-1
with	O
abnormalities	O
in	O
the	O
l	O
-	O
arginine	O
transport	O
system	O
.	O

We	O
conclude	O
that	O
cortisol	O
-	O
induced	O
increases	O
in	O
blood	O
pressure	O
are	O
not	O
associated	O
with	O
abnormalities	T-0
in	T-0
the	T-0
l	B-Chemical
-	I-Chemical
arginine	I-Chemical
transport	T-1
system	T-1
.	O

Amount	O
of	O
bleeding	B-Disease
and	O
hematoma	O
size	O
in	O
the	O
collagenase	O
-	O
induced	T-0
intracerebral	O
hemorrhage	O
rat	O
model	O
.	O

Amount	O
of	O
bleeding	O
and	O
hematoma	B-Disease
size	O
in	O
the	O
collagenase	O
-	O
induced	T-0
intracerebral	O
hemorrhage	O
rat	O
model	O
.	O

Amount	O
of	O
bleeding	O
and	O
hematoma	O
size	O
in	O
the	O
collagenase	O
-	O
induced	T-0
intracerebral	B-Disease
hemorrhage	I-Disease
rat	T-1
model	T-1
.	O

The	O
aggravated	T-3
risk	T-3
on	T-3
intracerebral	B-Disease
hemorrhage	I-Disease
(	O
ICH	O
)	O
with	O
drugs	T-1
used	O
for	O
stroke	O
patients	T-2
should	O
be	O
estimated	O
carefully	O
.	O

The	O
aggravated	O
risk	O
on	O
intracerebral	T-1
hemorrhage	T-1
(	O
ICH	B-Disease
)	O
with	O
drugs	O
used	O
for	O
stroke	T-0
patients	T-0
should	O
be	O
estimated	O
carefully	O
.	O

The	O
aggravated	O
risk	O
on	O
intracerebral	O
hemorrhage	O
(	O
ICH	O
)	O
with	O
drugs	T-0
used	T-0
for	T-0
stroke	B-Disease
patients	O
should	O
be	O
estimated	O
carefully	O
.	O

We	O
therefore	O
established	O
sensitive	O
quantification	O
methods	O
and	O
provided	T-1
a	T-1
rat	T-1
ICH	B-Disease
model	T-2
for	T-2
detection	T-2
of	T-2
ICH	T-2
deterioration	T-2
.	O

We	O
therefore	O
established	O
sensitive	O
quantification	O
methods	O
and	O
provided	O
a	O
rat	O
ICH	O
model	O
for	O
detection	T-0
of	T-0
ICH	B-Disease
deterioration	T-1
.	O

In	O
ICH	B-Disease
intrastriatally	O
induced	T-0
by	O
0	O
.	O
014	O
-	O
unit	O
,	O
0	O
.	O
070	O
-	O
unit	O
,	O
and	O
0	O
.	O
350	O
-	O
unit	O
collagenase	O
,	O
the	O
amount	O
of	O
bleeding	O
was	O
measured	O
using	O
a	O
hemoglobin	O
assay	O
developed	O
in	O
the	O
present	O
study	O
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	O
hematoma	O
volume	O
.	O

In	O
ICH	O
intrastriatally	O
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
,	O
0	O
.	O
070	O
-	O
unit	O
,	O
and	O
0	O
.	O
350	O
-	O
unit	O
collagenase	O
,	O
the	T-0
amount	T-0
of	T-0
bleeding	B-Disease
was	T-1
measured	T-1
using	O
a	O
hemoglobin	O
assay	O
developed	O
in	O
the	O
present	O
study	O
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	O
hematoma	O
volume	O
.	O

In	O
ICH	O
intrastriatally	O
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
,	O
0	O
.	O
070	O
-	O
unit	O
,	O
and	O
0	O
.	O
350	O
-	O
unit	O
collagenase	O
,	O
the	O
amount	O
of	O
bleeding	O
was	O
measured	O
using	O
a	O
hemoglobin	O
assay	O
developed	O
in	O
the	O
present	O
study	O
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	T-0
hematoma	B-Disease
volume	T-1
.	O

The	O
blood	T-0
amounts	T-0
and	O
hematoma	B-Disease
volumes	T-1
were	O
significantly	O
correlated	O
,	O
and	O
the	O
hematoma	O
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
was	O
adequate	O
to	O
detect	O
ICH	O
deterioration	O
.	O

The	O
blood	O
amounts	O
and	O
hematoma	O
volumes	O
were	O
significantly	O
correlated	O
,	O
and	O
the	O
hematoma	B-Disease
induced	T-0
by	T-0
0	O
.	O
014	O
-	O
unit	O
collagenase	O
was	O
adequate	O
to	O
detect	O
ICH	O
deterioration	O
.	O

The	O
blood	O
amounts	O
and	O
hematoma	O
volumes	O
were	O
significantly	O
correlated	O
,	O
and	O
the	O
hematoma	O
induced	O
by	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
was	O
adequate	O
to	O
detect	T-0
ICH	B-Disease
deterioration	T-1
.	O

In	O
ICH	B-Disease
induction	T-0
using	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
,	O
heparin	O
enhanced	O
the	O
hematoma	O
volume	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	O
animals	O
and	O
the	O
bleeding	O
7	O
.	O
6	O
-	O
fold	O
.	O

In	O
ICH	O
induction	T-0
using	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
,	O
heparin	B-Chemical
enhanced	T-1
the	O
hematoma	O
volume	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	O
animals	O
and	O
the	O
bleeding	O
7	O
.	O
6	O
-	O
fold	O
.	O

In	O
ICH	O
induction	O
using	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
,	O
heparin	O
enhanced	T-0
the	O
hematoma	B-Disease
volume	T-1
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	O
animals	O
and	O
the	O
bleeding	O
7	O
.	O
6	O
-	O
fold	O
.	O

In	O
ICH	O
induction	O
using	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
,	O
heparin	O
enhanced	O
the	O
hematoma	O
volume	O
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	T-0
control	T-0
ICH	B-Disease
animals	T-1
and	O
the	O
bleeding	O
7	O
.	O
6	O
-	O
fold	O
.	O

In	O
ICH	O
induction	O
using	O
0	O
.	O
014	O
-	O
unit	O
collagenase	O
,	O
heparin	T-0
enhanced	T-0
the	T-0
hematoma	T-0
volume	T-0
3	O
.	O
4	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	O
animals	O
and	T-1
the	T-1
bleeding	B-Disease
7	O
.	O
6	O
-	O
fold	O
.	O

Data	O
suggest	O
that	O
this	O
sensitive	O
hemoglobin	O
assay	O
is	T-1
useful	T-1
for	T-1
ICH	B-Disease
detection	T-2
,	O
and	O
that	O
a	O
model	O
with	O
a	O
small	O
ICH	O
induced	O
with	O
a	O
low	O
-	O
dose	O
collagenase	O
should	O
be	O
used	O
for	O
evaluation	O
of	O
drugs	O
that	O
may	O
affect	O
ICH	O
.	O

Data	O
suggest	O
that	O
this	O
sensitive	O
hemoglobin	O
assay	O
is	O
useful	O
for	O
ICH	O
detection	O
,	O
and	O
that	O
a	O
model	O
with	T-0
a	T-0
small	T-0
ICH	B-Disease
induced	T-1
with	T-1
a	T-1
low	T-1
-	O
dose	O
collagenase	O
should	O
be	O
used	O
for	O
evaluation	O
of	O
drugs	O
that	O
may	O
affect	O
ICH	O
.	O

Data	O
suggest	O
that	O
this	O
sensitive	O
hemoglobin	O
assay	O
is	O
useful	O
for	O
ICH	O
detection	O
,	O
and	O
that	O
a	O
model	O
with	O
a	O
small	O
ICH	O
induced	O
with	O
a	O
low	O
-	O
dose	O
collagenase	O
should	O
be	O
used	O
for	O
evaluation	O
of	O
drugs	O
that	O
may	T-0
affect	T-0
ICH	B-Disease
.	O

Estradiol	B-Chemical
reduces	T-1
seizure	T-1
-	O
induced	O
hippocampal	O
injury	O
in	O
ovariectomized	O
female	O
but	O
not	O
in	O
male	O
rats	O
.	O

Estradiol	O
reduces	T-0
seizure	B-Disease
-	O
induced	T-1
hippocampal	O
injury	O
in	O
ovariectomized	O
female	O
but	O
not	O
in	O
male	O
rats	O
.	O

Estradiol	O
reduces	O
seizure	O
-	O
induced	T-1
hippocampal	B-Disease
injury	I-Disease
in	T-0
ovariectomized	T-0
female	O
but	O
not	O
in	O
male	O
rats	O
.	O

Estrogens	T-1
protect	T-1
ovariectomized	O
rats	O
from	O
hippocampal	B-Disease
injury	I-Disease
induced	T-2
by	T-2
kainic	T-2
acid	T-2
-	O
induced	O
status	O
epilepticus	O
(	O
SE	O
)	O
.	O

Estrogens	O
protect	O
ovariectomized	O
rats	O
from	O
hippocampal	O
injury	O
induced	T-0
by	T-0
kainic	B-Chemical
acid	I-Chemical
-	O
induced	O
status	O
epilepticus	O
(	O
SE	O
)	O
.	O

Estrogens	O
protect	O
ovariectomized	O
rats	O
from	O
hippocampal	O
injury	O
induced	O
by	O
kainic	O
acid	O
-	O
induced	T-0
status	B-Disease
epilepticus	I-Disease
(	O
SE	O
)	O
.	O

Estrogens	O
protect	O
ovariectomized	O
rats	O
from	O
hippocampal	O
injury	O
induced	O
by	O
kainic	O
acid	O
-	O
induced	T-0
status	T-0
epilepticus	T-0
(	O
SE	B-Disease
)	O
.	O

We	O
compared	O
the	O
effects	T-0
of	T-0
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
in	T-1
adult	T-1
male	T-1
and	O
ovariectomized	O
female	O
rats	O
subjected	O
to	O
lithium	O
-	O
pilocarpine	O
-	O
induced	O
SE	O
.	O

We	O
compared	O
the	O
effects	O
of	O
17beta	O
-	O
estradiol	O
in	O
adult	O
male	O
and	O
ovariectomized	O
female	O
rats	O
subjected	T-0
to	T-0
lithium	B-Chemical
-	O
pilocarpine	O
-	O
induced	O
SE	O
.	O

We	O
compared	T-1
the	T-1
effects	T-1
of	T-1
17beta	O
-	O
estradiol	O
in	O
adult	O
male	O
and	O
ovariectomized	O
female	O
rats	O
subjected	T-2
to	T-2
lithium	O
-	O
pilocarpine	B-Chemical
-	O
induced	T-0
SE	T-0
.	O

We	O
compared	O
the	O
effects	T-0
of	T-0
17beta	O
-	O
estradiol	O
in	O
adult	O
male	O
and	O
ovariectomized	O
female	O
rats	O
subjected	T-1
to	T-1
lithium	O
-	O
pilocarpine	O
-	O
induced	T-2
SE	B-Disease
.	O

Rats	O
received	O
subcutaneous	O
injections	T-0
of	T-0
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
(	O
2	O
microg	O
/	O
rat	O
)	O
or	O
oil	O
once	O
daily	O
for	O
four	O
consecutive	O
days	O
.	O

SE	B-Disease
was	T-1
induced	T-1
20	O
h	O
following	O
the	O
second	O
injection	O
and	O
terminated	O
3	O
h	O
later	O
.	O

The	O
extent	T-0
of	O
silver	B-Chemical
-	O
stained	T-1
CA3	O
and	O
CA1	O
hippocampal	O
neurons	O
was	O
evaluated	O
2	O
days	O
after	O
SE	O
.	O

The	O
extent	O
of	O
silver	O
-	O
stained	O
CA3	O
and	O
CA1	O
hippocampal	O
neurons	O
was	T-1
evaluated	T-1
2	T-1
days	T-1
after	T-1
SE	B-Disease
.	O

17beta	B-Chemical
-	I-Chemical
Estradiol	I-Chemical
did	T-0
not	T-0
alter	T-0
the	O
onset	O
of	O
first	O
clonus	O
in	O
ovariectomized	O
rats	O
but	O
accelerated	O
it	O
in	O
males	O
.	O

17beta	B-Chemical
-	I-Chemical
Estradiol	I-Chemical
reduced	T-1
the	O
argyrophilic	T-0
neurons	T-0
in	O
the	O
CA1	O
and	O
CA3	O
-	O
C	O
sectors	O
of	O
ovariectomized	O
rats	O
.	O

In	O
males	O
,	O
estradiol	B-Chemical
increased	O
the	O
total	T-0
damage	T-0
score	T-0
.	O

These	O
findings	O
suggest	O
that	O
the	O
effects	T-0
of	T-0
estradiol	B-Chemical
on	O
seizure	O
threshold	O
and	O
damage	O
may	O
be	O
altered	O
by	O
sex	O
-	O
related	O
differences	O
in	O
the	O
hormonal	O
environment	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
effects	O
of	O
estradiol	T-0
on	T-0
seizure	B-Disease
threshold	T-1
and	T-1
damage	T-1
may	O
be	O
altered	O
by	O
sex	O
-	O
related	O
differences	O
in	O
the	O
hormonal	O
environment	O
.	O

Pseudoacromegaly	B-Disease
induced	T-0
by	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	O
.	O

Pseudoacromegaly	T-0
induced	T-2
by	T-2
the	O
long	O
-	O
term	O
use	T-1
of	T-1
minoxidil	B-Chemical
.	O

Acromegaly	B-Disease
is	O
an	O
endocrine	O
disorder	T-0
caused	T-0
by	T-0
chronic	O
excessive	O
growth	O
hormone	O
secretion	O
from	O
the	O
anterior	O
pituitary	O
gland	O
.	O

Acromegaly	O
is	T-1
an	T-1
endocrine	B-Disease
disorder	I-Disease
caused	T-2
by	T-2
chronic	T-2
excessive	T-2
growth	O
hormone	O
secretion	O
from	O
the	O
anterior	O
pituitary	O
gland	O
.	O

Significant	O
disfiguring	O
changes	O
occur	T-1
as	T-0
a	T-0
result	T-0
of	T-0
bone	O
,	O
cartilage	O
,	O
and	O
soft	O
tissue	O
hypertrophy	O
,	O
including	O
the	O
thickening	O
of	O
the	O
skin	O
,	O
coarsening	O
of	O
facial	O
features	O
,	O
and	O
cutis	B-Disease
verticis	I-Disease
gyrata	I-Disease
.	O

Pseudoacromegaly	B-Disease
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
the	O
presence	T-0
of	T-0
similar	T-0
acromegaloid	T-0
features	O
in	O
the	O
absence	O
of	O
elevated	O
growth	O
hormone	O
or	O
insulin	O
-	O
like	O
growth	O
factor	O
levels	O
.	O

We	O
present	O
a	O
patient	T-1
with	T-1
pseudoacromegaly	B-Disease
that	O
resulted	O
from	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	O
at	O
an	O
unusually	O
high	O
dose	O
.	O

We	O
present	O
a	O
patient	T-0
with	O
pseudoacromegaly	O
that	O
resulted	O
from	O
the	O
long	T-3
-	T-3
term	T-3
use	T-3
of	T-3
minoxidil	B-Chemical
at	O
an	O
unusually	O
high	T-2
dose	T-2
.	O

This	O
is	O
the	O
first	T-0
case	T-0
report	T-0
of	O
pseudoacromegaly	B-Disease
as	O
a	O
side	T-1
effect	T-1
of	T-1
minoxidil	O
use	O
.	O

This	O
is	O
the	O
first	O
case	O
report	O
of	O
pseudoacromegaly	O
as	O
a	O
side	T-1
effect	T-1
of	T-1
minoxidil	B-Chemical
use	T-0
.	O

Combined	O
androgen	T-1
blockade	T-1
-	T-1
induced	T-1
anemia	B-Disease
in	O
prostate	O
cancer	O
patients	O
without	O
bone	O
involvement	O
.	O

Combined	T-1
androgen	T-1
blockade	T-1
-	T-1
induced	T-1
anemia	T-1
in	O
prostate	B-Disease
cancer	I-Disease
patients	T-2
without	T-2
bone	T-2
involvement	T-2
.	T-2

BACKGROUND	O
:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
combined	O
androgen	O
blockade	O
(	O
CAB	O
)	O
-	O
induced	T-0
anemia	B-Disease
in	T-1
prostate	T-1
cancer	T-1
patients	T-1
without	O
bone	O
involvement	O
.	O

BACKGROUND	O
:	O
To	O
determine	O
the	O
onset	O
and	O
extent	O
of	O
combined	O
androgen	O
blockade	O
(	O
CAB	O
)	O
-	O
induced	T-1
anemia	T-0
in	T-0
prostate	B-Disease
cancer	I-Disease
patients	O
without	O
bone	O
involvement	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	T-1
-	T-1
two	T-1
patients	T-1
with	T-1
biopsy	T-1
-	T-1
proven	T-1
prostatic	B-Disease
adenocarcinoma	I-Disease
[	O
26	O
with	O
stage	O
C	O
(	O
T3N0M0	O
)	O
and	O
16	O
with	O
stage	O
D1	O
(	O
T3N1M0	O
)	O
]	O
were	O
included	O
in	O
this	O
study	O
.	O

All	O
patients	O
received	T-0
CAB	T-1
[	O
leuprolide	B-Chemical
acetate	I-Chemical
(	O
LHRH	O
-	O
A	O
)	O
3	O
.	O
75	O
mg	O
,	O
intramuscularly	O
,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	O
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	O
for	O
anemia	O
by	O
physical	O
examination	O
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
)	O
.	O

All	O
patients	T-0
received	T-0
CAB	O
[	O
leuprolide	O
acetate	O
(	O
LHRH	B-Chemical
-	I-Chemical
A	I-Chemical
)	O
3	O
.	O
75	O
mg	O
,	O
intramuscularly	O
,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	O
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	O
for	O
anemia	O
by	O
physical	O
examination	O
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
)	O
.	O

All	O
patients	T-0
received	T-0
CAB	O
[	O
leuprolide	O
acetate	O
(	O
LHRH	O
-	O
A	O
)	O
3	O
.	O
75	O
mg	O
,	O
intramuscularly	O
,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	B-Chemical
,	O
tid	T-1
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	O
for	O
anemia	O
by	O
physical	O
examination	O
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
)	O
.	O

All	O
patients	O
received	O
CAB	O
[	O
leuprolide	O
acetate	O
(	O
LHRH	O
-	O
A	O
)	O
3	O
.	O
75	O
mg	O
,	O
intramuscularly	O
,	O
every	O
28	O
days	O
plus	O
250	O
mg	O
flutamide	O
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	T-0
for	T-0
anemia	B-Disease
by	T-1
physical	T-1
examination	T-1
and	O
laboratory	O
tests	O
at	O
baseline	O
and	O
4	O
subsequent	O
intervals	O
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	O
post	O
-	O
CAB	O
)	O
.	O

Hb	O
,	O
PSA	O
and	O
Testosterone	B-Chemical
measurements	T-0
were	O
recorded	T-1
.	O

Severe	O
and	O
clinically	O
evident	T-0
anemia	B-Disease
of	O
Hb	O
<	O
11	O
g	O
/	O
dl	O
with	O
clinical	O
symptoms	O
was	O
detected	O
in	O
6	O
patients	O
(	O
14	O
.	O
3	O
%	O
)	O
.	O

This	O
CAB	T-3
-	T-3
induced	T-3
anemia	B-Disease
was	O
normochromic	T-1
and	O
normocytic	T-2
.	O

At	O
six	O
months	O
post	O
-	O
CAB	O
,	O
patients	O
with	O
severe	T-0
anemia	B-Disease
had	T-1
a	T-1
Hb	O
mean	O
value	O
of	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
g	O
/	O
dl	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
,	O
whereas	O
the	O
other	O
patients	O
had	O
mild	O
anemia	O
with	O
Hb	O
mean	O
value	O
of	O
13	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
17	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
.	O

At	O
six	O
months	O
post	O
-	O
CAB	O
,	O
patients	T-0
with	O
severe	O
anemia	O
had	O
a	O
Hb	O
mean	O
value	O
of	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
g	O
/	O
dl	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
,	O
whereas	O
the	O
other	O
patients	T-2
had	T-2
mild	O
anemia	B-Disease
with	O
Hb	O
mean	O
value	O
of	O
13	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
17	O
(	O
X	O
+	O
/	O
-	O
SE	O
)	O
.	O

The	T-2
development	T-2
of	T-2
severe	T-2
anemia	B-Disease
at	O
6	O
months	O
post	O
-	O
CAB	O
was	O
predictable	O
by	O
the	O
reduction	T-0
of	O
Hb	O
baseline	O
value	O
of	O
more	O
than	O
2	O
.	O
5	O
g	O
/	O
dl	O
after	O
3	O
months	O
of	O
CAB	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

The	O
development	T-2
of	T-2
severe	T-2
CAB	O
-	O
induced	T-0
anemia	B-Disease
in	T-1
prostate	T-1
cancer	T-1
patients	T-1
did	O
not	O
correlate	O
with	O
T	O
baseline	O
values	O
(	O
T	O
<	O
3	O
ng	O
/	O
ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng	O
/	O
ml	O
)	O
,	O
with	O
age	O
(	O
<	O
76	O
yrs	O
versus	O
>	O
or	O
=	O
76	O
yrs	O
)	O
,	O
and	O
clinical	O
stage	O
(	O
stage	O
C	O
versus	O
stage	O
D1	O
)	O
.	O

The	O
development	O
of	O
severe	O
CAB	O
-	O
induced	O
anemia	T-1
in	T-1
prostate	B-Disease
cancer	I-Disease
patients	T-0
did	O
not	O
correlate	O
with	O
T	O
baseline	O
values	O
(	O
T	O
<	O
3	O
ng	O
/	O
ml	O
versus	O
T	O
>	O
or	O
=	O
3	O
ng	O
/	O
ml	O
)	O
,	O
with	O
age	O
(	O
<	O
76	O
yrs	O
versus	O
>	O
or	O
=	O
76	O
yrs	O
)	O
,	O
and	O
clinical	O
stage	O
(	O
stage	O
C	O
versus	O
stage	O
D1	O
)	O
.	O

Severe	O
and	O
clinically	T-1
evident	T-1
anemia	B-Disease
was	O
easily	O
corrected	O
by	O
subcutaneous	T-0
injections	T-0
(	O
3	O
times	O
/	O
week	O
for	O
1	O
month	O
)	O
of	O
recombinant	O
erythropoietin	O
(	O
rHuEPO	O
-	O
beta	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
rHuEPO	O
-	O
beta	O
correctable	O
CAB	O
-	O
induced	T-2
anemia	B-Disease
occurs	T-0
in	T-0
14	T-0
.	T-0
3	T-0
%	T-0
of	T-0
prostate	O
cancer	O
patients	T-1
after	T-1
6	T-1
months	T-1
of	O
therapy	T-3
.	O

CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
rHuEPO	O
-	O
beta	O
correctable	O
CAB	O
-	O
induced	T-2
anemia	O
occurs	T-0
in	T-0
14	T-3
.	T-3
3	T-3
%	T-3
of	T-3
prostate	B-Disease
cancer	I-Disease
patients	T-4
after	O
6	O
months	O
of	O
therapy	O
.	O

Delirium	B-Disease
during	T-0
clozapine	O
treatment	O
:	O
incidence	O
and	O
associated	O
risk	O
factors	O
.	O

Delirium	O
during	T-1
clozapine	B-Chemical
treatment	T-2
:	O
incidence	O
and	O
associated	O
risk	T-0
factors	T-0
.	O

BACKGROUND	O
:	O
Incidence	O
and	O
risk	T-2
factors	T-2
for	T-2
delirium	B-Disease
during	T-3
clozapine	T-3
treatment	O
require	O
further	O
clarification	O
.	O

BACKGROUND	O
:	O
Incidence	O
and	O
risk	O
factors	O
for	O
delirium	T-0
during	T-0
clozapine	B-Chemical
treatment	T-1
require	O
further	O
clarification	O
.	O

METHODS	O
:	O
We	O
used	O
computerized	T-0
pharmacy	T-0
records	T-0
to	O
identify	T-2
all	O
adult	O
psychiatric	B-Disease
inpatients	O
treated	T-3
with	O
clozapine	O
(	O
1995	O
-	O
96	O
)	O
,	O
reviewed	O
their	O
medical	O
records	O
to	O
score	O
incidence	T-4
and	T-4
severity	T-4
of	O
delirium	O
,	O
and	O
tested	O
associations	O
with	O
potential	T-1
risk	T-1
factors	T-1
.	O

METHODS	O
:	O
We	O
used	O
computerized	O
pharmacy	O
records	O
to	O
identify	O
all	O
adult	O
psychiatric	O
inpatients	O
treated	T-0
with	T-0
clozapine	B-Chemical
(	O
1995	O
-	O
96	O
)	O
,	O
reviewed	O
their	O
medical	O
records	O
to	O
score	O
incidence	O
and	O
severity	O
of	O
delirium	O
,	O
and	O
tested	O
associations	O
with	O
potential	O
risk	O
factors	O
.	O

METHODS	O
:	O
We	O
used	O
computerized	O
pharmacy	O
records	O
to	O
identify	O
all	O
adult	O
psychiatric	O
inpatients	O
treated	O
with	O
clozapine	O
(	O
1995	O
-	O
96	O
)	O
,	O
reviewed	O
their	O
medical	O
records	O
to	O
score	O
incidence	T-0
and	O
severity	T-1
of	O
delirium	B-Disease
,	O
and	O
tested	T-2
associations	O
with	O
potential	O
risk	O
factors	O
.	O

RESULTS	O
:	O
Subjects	O
(	O
n	O
=	O
139	O
)	O
were	O
72	O
women	O
and	O
67	O
men	O
,	O
aged	O
40	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
1	O
years	O
,	O
hospitalized	O
for	O
24	O
.	O
9	O
+	O
/	O
-	O
23	O
.	O
3	O
days	O
,	O
and	O
given	O
clozapine	B-Chemical
,	O
gradually	T-1
increased	T-1
to	O
an	O
average	O
daily	T-0
dose	T-0
of	T-0
282	O
+	O
/	O
-	O
203	O
mg	O
(	O
3	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
45	O
mg	O
/	O
kg	O
)	O
for	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
4	O
days	O
.	O

Delirium	B-Disease
was	O
diagnosed	T-0
in	T-0
14	O
(	O
10	O
.	O
1	O
%	O
incidence	O
,	O
or	O
1	O
.	O
48	O
cases	O
/	O
person	O
-	O
years	O
of	O
exposure	O
)	O
;	O
71	O
.	O
4	O
%	O
of	O
cases	O
were	O
moderate	O
or	O
severe	O
.	O

Associated	O
factors	O
were	O
co	O
-	O
treatment	O
with	O
other	O
centrally	O
antimuscarinic	O
agents	O
,	O
poor	O
clinical	O
outcome	O
,	O
older	O
age	O
,	O
and	O
longer	O
hospitalization	O
(	O
by	O
17	O
.	O
5	O
days	O
,	O
increasing	O
cost	O
)	O
;	O
sex	O
,	O
diagnosis	O
or	O
medical	O
co	O
-	O
morbidity	O
,	O
and	T-0
daily	T-0
clozapine	B-Chemical
dose	O
,	O
which	O
fell	O
with	O
age	O
,	O
were	O
unrelated	O
.	O

CONCLUSIONS	O
:	O
Delirium	B-Disease
was	T-1
found	T-1
in	O
10	O
%	O
of	O
clozapine	T-0
-	T-0
treated	T-0
inpatients	T-0
,	O
particularly	O
in	O
older	O
patients	O
exposed	O
to	O
other	O
central	O
anticholinergics	O
.	O

CONCLUSIONS	O
:	O
Delirium	O
was	O
found	O
in	O
10	O
%	O
of	O
clozapine	B-Chemical
-	O
treated	T-0
inpatients	T-0
,	O
particularly	O
in	O
older	O
patients	T-1
exposed	T-1
to	O
other	O
central	O
anticholinergics	O
.	O

Delirium	B-Disease
was	O
inconsistently	O
recognized	T-0
clinically	T-0
in	O
milder	O
cases	O
and	O
was	O
associated	O
with	O
increased	O
length	O
-	O
of	O
-	O
stay	O
and	O
higher	O
costs	O
,	O
and	O
inferior	O
clinical	O
outcome	O
.	O

Neuroprotective	O
action	T-3
of	T-3
MPEP	B-Chemical
,	O
a	O
selective	T-1
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	O
-	O
induced	T-2
dopaminergic	O
neurotoxicity	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
dopamine	O
outflow	O
and	O
inhibition	O
of	O
hyperthermia	O
in	O
rats	O
.	O

Neuroprotective	T-0
action	T-0
of	O
MPEP	O
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	B-Chemical
-	O
induced	O
dopaminergic	O
neurotoxicity	O
is	O
associated	O
with	O
a	O
decrease	T-1
in	T-1
dopamine	T-1
outflow	T-1
and	O
inhibition	O
of	O
hyperthermia	O
in	O
rats	O
.	O

Neuroprotective	O
action	O
of	O
MPEP	O
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	O
-	O
induced	T-0
dopaminergic	O
neurotoxicity	B-Disease
is	T-1
associated	T-1
with	O
a	O
decrease	O
in	O
dopamine	O
outflow	O
and	O
inhibition	O
of	O
hyperthermia	O
in	O
rats	O
.	O

Neuroprotective	O
action	O
of	O
MPEP	O
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	O
-	O
induced	O
dopaminergic	O
neurotoxicity	O
is	O
associated	O
with	O
a	O
decrease	T-0
in	T-0
dopamine	B-Chemical
outflow	O
and	O
inhibition	O
of	O
hyperthermia	O
in	O
rats	O
.	O

Neuroprotective	O
action	O
of	O
MPEP	O
,	O
a	O
selective	O
mGluR5	O
antagonist	O
,	O
in	O
methamphetamine	O
-	O
induced	O
dopaminergic	O
neurotoxicity	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
dopamine	O
outflow	O
and	O
inhibition	T-1
of	T-1
hyperthermia	B-Disease
in	T-2
rats	T-2
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
role	T-0
of	T-0
metabotropic	T-0
glutamate	B-Chemical
receptor	T-0
5	O
(	O
mGluR5	O
)	O
in	O
the	O
toxic	O
action	O
of	O
methamphetamine	O
on	O
dopaminergic	O
neurones	O
in	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
role	O
of	O
metabotropic	O
glutamate	O
receptor	O
5	O
(	O
mGluR5	O
)	O
in	O
the	O
toxic	T-1
action	T-1
of	T-1
methamphetamine	B-Chemical
on	T-0
dopaminergic	T-0
neurones	T-0
in	O
rats	O
.	O

Methamphetamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
,	O
administered	T-0
five	O
times	O
,	O
reduced	T-1
the	O
levels	O
of	O
dopamine	O
and	O
its	O
metabolites	O
in	O
striatal	O
tissue	O
when	O
measured	O
72	O
h	O
after	O
the	O
last	O
injection	O
.	O

Methamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
,	O
administered	O
five	O
times	O
,	O
reduced	O
the	O
levels	T-1
of	T-1
dopamine	B-Chemical
and	T-0
its	T-0
metabolites	T-0
in	O
striatal	O
tissue	O
when	O
measured	O
72	O
h	O
after	O
the	O
last	O
injection	O
.	O

A	O
selective	T-0
antagonist	T-3
of	T-3
mGluR5	T-1
,	O
2	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
(	I-Chemical
phenylethynyl	I-Chemical
)	I-Chemical
pyridine	I-Chemical
(	O
MPEP	T-2
;	T-2
5	T-2
mg	T-2
/	T-2
kg	T-2
ip	T-2
)	O
,	O
when	O
administered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamine	O
injection	O
reversed	O
the	O
above	O
-	O
mentioned	O
methamphetamine	O
effects	O
.	O

A	O
selective	O
antagonist	T-2
of	T-2
mGluR5	O
,	O
2	O
-	O
methyl	O
-	O
6	O
-	O
(	O
phenylethynyl	O
)	O
pyridine	T-0
(	O
MPEP	B-Chemical
;	O
5	T-1
mg	T-1
/	T-1
kg	T-1
ip	T-1
)	O
,	O
when	O
administered	O
five	O
times	O
immediately	O
before	O
each	O
methamphetamine	O
injection	O
reversed	O
the	O
above	O
-	O
mentioned	O
methamphetamine	O
effects	O
.	O

A	O
selective	O
antagonist	O
of	O
mGluR5	O
,	O
2	O
-	O
methyl	O
-	O
6	O
-	O
(	O
phenylethynyl	O
)	O
pyridine	O
(	O
MPEP	O
;	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
when	O
administered	O
five	O
times	O
immediately	O
before	T-0
each	T-0
methamphetamine	B-Chemical
injection	O
reversed	O
the	O
above	O
-	O
mentioned	O
methamphetamine	O
effects	O
.	O

A	O
selective	O
antagonist	O
of	O
mGluR5	O
,	O
2	O
-	O
methyl	O
-	O
6	O
-	O
(	O
phenylethynyl	O
)	O
pyridine	O
(	O
MPEP	O
;	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
when	O
administered	T-0
five	O
times	O
immediately	O
before	O
each	O
methamphetamine	O
injection	O
reversed	O
the	O
above	O
-	O
mentioned	O
methamphetamine	B-Chemical
effects	T-1
.	O

A	O
single	T-0
MPEP	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	T-1
the	O
basal	O
extracellular	O
dopamine	O
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	O
release	O
stimulated	O
either	O
by	O
methamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	T-2
administered	T-2
veratridine	T-2
(	O
100	O
microM	O
)	O
.	O

A	O
single	O
MPEP	O
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	T-0
dopamine	B-Chemical
level	T-1
in	T-1
the	T-1
striatum	T-1
,	O
as	O
well	O
as	O
dopamine	O
release	O
stimulated	O
either	O
by	O
methamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	O
(	O
100	O
microM	O
)	O
.	O

A	O
single	O
MPEP	O
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	O
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	B-Chemical
release	T-0
stimulated	O
either	O
by	O
methamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	O
(	O
100	O
microM	O
)	O
.	O

A	O
single	O
MPEP	O
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	O
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	O
release	O
stimulated	T-0
either	T-0
by	T-0
methamphetamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	O
(	O
100	O
microM	O
)	O
.	O

A	O
single	O
MPEP	O
(	O
5	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	O
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	O
release	O
stimulated	O
either	O
by	O
methamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	T-0
veratridine	B-Chemical
(	O
100	O
microM	O
)	O
.	O

Moreover	O
,	O
it	O
transiently	O
diminished	T-0
the	T-0
methamphetamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
-	O
induced	O
hyperthermia	O
and	O
reduced	O
basal	O
body	O
temperature	O
.	O

Moreover	O
,	O
it	O
transiently	O
diminished	O
the	O
methamphetamine	O
(	O
10	O
mg	O
/	O
kg	O
sc	O
)	O
-	O
induced	T-1
hyperthermia	B-Disease
and	O
reduced	O
basal	O
body	O
temperature	O
.	O

MPEP	B-Chemical
administered	T-1
into	O
the	O
striatum	O
at	O
high	O
concentrations	T-2
(	O
500	O
microM	O
)	O
increased	T-0
extracellular	T-0
dopamine	T-0
levels	T-0
,	O
while	O
lower	O
concentrations	O
(	O
50	O
-	O
100	O
microM	O
)	O
were	O
devoid	O
of	O
any	O
effect	O
.	O

MPEP	O
administered	O
into	O
the	O
striatum	O
at	O
high	O
concentrations	O
(	O
500	O
microM	O
)	O
increased	T-1
extracellular	T-1
dopamine	B-Chemical
levels	T-2
,	O
while	O
lower	T-0
concentrations	T-0
(	O
50	O
-	O
100	O
microM	O
)	O
were	O
devoid	O
of	O
any	O
effect	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
blockade	O
of	O
mGluR5	O
by	T-0
MPEP	B-Chemical
may	O
protect	O
dopaminergic	O
neurones	O
against	O
methamphetamine	O
-	O
induced	O
toxicity	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	T-0
that	O
the	O
blockade	O
of	O
mGluR5	O
by	O
MPEP	O
may	O
protect	O
dopaminergic	O
neurones	O
against	O
methamphetamine	B-Chemical
-	O
induced	T-2
toxicity	T-2
.	T-2

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
blockade	O
of	O
mGluR5	O
by	O
MPEP	O
may	O
protect	O
dopaminergic	O
neurones	O
against	O
methamphetamine	O
-	O
induced	T-0
toxicity	B-Disease
.	O

Neuroprotection	T-2
rendered	T-2
by	T-2
MPEP	B-Chemical
may	O
be	O
associated	O
with	O
the	O
reduction	O
of	O
the	O
methamphetamine	O
-	O
induced	T-1
dopamine	T-1
efflux	T-1
in	O
the	O
striatum	O
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	O
in	O
hyperthermia	O
.	O

Neuroprotection	T-1
rendered	T-1
by	T-1
MPEP	T-1
may	O
be	O
associated	O
with	O
the	O
reduction	T-0
of	T-0
the	T-0
methamphetamine	B-Chemical
-	O
induced	O
dopamine	O
efflux	O
in	O
the	O
striatum	O
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	O
in	O
hyperthermia	O
.	O

Neuroprotection	O
rendered	O
by	O
MPEP	O
may	O
be	O
associated	O
with	O
the	O
reduction	O
of	O
the	O
methamphetamine	O
-	O
induced	T-2
dopamine	B-Chemical
efflux	T-1
in	T-1
the	T-1
striatum	T-1
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	O
in	O
hyperthermia	O
.	O

Neuroprotection	O
rendered	O
by	O
MPEP	O
may	O
be	O
associated	O
with	O
the	O
reduction	O
of	O
the	O
methamphetamine	O
-	O
induced	O
dopamine	O
efflux	O
in	O
the	O
striatum	O
due	O
to	O
the	O
blockade	O
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	T-0
in	T-0
hyperthermia	B-Disease
.	O

Protective	T-0
efficacy	T-0
of	T-0
neuroactive	T-0
steroids	B-Chemical
against	O
cocaine	T-1
kindled	T-1
-	T-1
seizures	T-1
in	T-1
mice	T-1
.	T-1

Protective	T-1
efficacy	T-1
of	O
neuroactive	O
steroids	O
against	T-2
cocaine	B-Chemical
kindled	T-0
-	T-0
seizures	T-0
in	T-0
mice	T-0
.	O

Protective	O
efficacy	T-0
of	O
neuroactive	O
steroids	O
against	O
cocaine	O
kindled	T-1
-	O
seizures	B-Disease
in	O
mice	O
.	O

Neuroactive	O
steroids	B-Chemical
demonstrate	T-0
pharmacological	O
actions	O
that	O
have	O
relevance	O
for	O
a	O
host	O
of	O
neurological	O
and	O
psychiatric	O
disorders	O
.	O

Neuroactive	O
steroids	O
demonstrate	T-0
pharmacological	T-0
actions	T-0
that	O
have	O
relevance	O
for	O
a	O
host	O
of	O
neurological	B-Disease
and	I-Disease
psychiatric	I-Disease
disorders	I-Disease
.	O

They	O
offer	O
protection	T-0
against	T-1
seizures	B-Disease
in	O
a	O
range	O
of	O
models	O
and	O
seem	O
to	O
inhibit	O
certain	O
stages	O
of	O
drug	O
dependence	O
in	O
preclinical	O
assessments	O
.	O

They	O
offer	O
protection	O
against	O
seizures	O
in	O
a	O
range	O
of	O
models	O
and	O
seem	O
to	O
inhibit	T-1
certain	O
stages	T-0
of	T-0
drug	B-Disease
dependence	I-Disease
in	O
preclinical	O
assessments	O
.	T-1

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	T-1
neuroactive	T-1
steroid	B-Chemical
that	O
positively	T-2
modulate	T-2
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	O
by	O
repeated	O
cocaine	O
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	O
modulate	T-1
the	T-1
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	T-0
against	T-0
the	T-0
increase	T-0
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	O
by	O
repeated	O
cocaine	O
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

The	O
present	O
study	O
was	O
designed	T-0
to	T-0
evaluate	T-0
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	T-1
modulate	T-1
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	B-Chemical
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	O
by	O
repeated	O
cocaine	O
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	O
modulate	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	T-0
of	T-0
cocaine	B-Chemical
engendered	T-1
by	O
repeated	O
cocaine	O
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	T-2
neuroactive	T-2
steroid	T-2
that	O
positively	O
modulate	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	T-3
of	T-3
cocaine	T-0
engendered	T-1
by	T-1
repeated	T-1
cocaine	B-Chemical
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	O
modulate	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	O
by	O
repeated	O
cocaine	O
administration	T-1
(	O
seizure	B-Disease
kindling	T-0
)	O
.	O

Allopregnanolone	B-Chemical
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	O
tested	O
for	O
their	O
ability	T-0
to	T-0
suppress	T-0
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	T-0
(	O
3alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
5alpha	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
,	O
pregnanolone	T-1
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	T-2
tested	T-2
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolone	B-Chemical
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	O
tested	T-0
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolone	T-1
(	O
3alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
5beta	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
and	T-2
ganaxolone	T-2
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	B-Chemical
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	T-1
tested	T-1
for	O
their	O
ability	O
to	O
suppress	T-0
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	T-2
of	T-2
allopregnanolone	B-Chemical
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	T-3
tested	T-3
for	O
their	O
ability	T-0
to	T-0
suppress	T-0
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	T-1
seizures	T-1
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	T-0
of	T-0
allopregnanolone	T-1
3alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
3beta	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
5alpha	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
20	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
were	T-2
tested	T-2
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	B-Chemical
-	O
kindled	T-0
seizures	T-0
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
3alpha	O
-	O
hydroxy	O
-	O
5beta	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	O
-	O
hydroxy	O
-	O
3beta	O
-	O
methyl	O
-	O
5alpha	O
-	O
pregnan	O
-	O
20	O
-	O
one	O
)	O
were	O
tested	T-1
for	O
their	O
ability	O
to	O
suppress	T-2
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	T-0
-	T-0
kindled	T-0
seizures	B-Disease
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Kindled	T-1
seizures	B-Disease
were	T-1
induced	T-1
by	O
daily	O
administration	O
of	O
60	O
mg	O
/	O
kg	O
cocaine	O
for	O
5	O
days	O
.	O

Kindled	O
seizures	O
were	O
induced	O
by	O
daily	O
administration	T-0
of	T-0
60	O
mg	O
/	O
kg	O
cocaine	B-Chemical
for	O
5	O
days	O
.	O

All	O
of	O
these	O
positive	T-0
GABA	B-Chemical
(	O
A	O
)	O
modulators	T-1
suppressed	O
the	O
expression	O
of	O
kindled	O
seizures	O
,	O
whereas	O
only	O
allopregnanolone	O
and	O
ganaxolone	O
inhibited	O
the	O
development	O
of	O
kindling	O
.	O

All	O
of	O
these	O
positive	O
GABA	O
(	O
A	O
)	O
modulators	O
suppressed	O
the	O
expression	O
of	O
kindled	T-0
seizures	B-Disease
,	O
whereas	O
only	O
allopregnanolone	O
and	O
ganaxolone	O
inhibited	O
the	O
development	O
of	O
kindling	O
.	O

All	O
of	O
these	O
positive	O
GABA	O
(	O
A	O
)	O
modulators	O
suppressed	O
the	O
expression	O
of	O
kindled	O
seizures	O
,	O
whereas	O
only	O
allopregnanolone	B-Chemical
and	O
ganaxolone	O
inhibited	T-0
the	O
development	O
of	O
kindling	O
.	O

All	O
of	O
these	O
positive	O
GABA	O
(	O
A	O
)	O
modulators	O
suppressed	O
the	O
expression	O
of	O
kindled	O
seizures	O
,	O
whereas	O
only	O
allopregnanolone	O
and	O
ganaxolone	B-Chemical
inhibited	T-1
the	T-1
development	T-1
of	T-1
kindling	T-1
.	O

Allopregnanolone	B-Chemical
and	O
pregnanolone	O
,	O
but	O
not	O
ganaxolone	O
,	O
also	O
reduced	T-0
cumulative	O
lethality	O
associated	T-1
with	O
kindling	O
.	O

Allopregnanolone	T-3
and	T-3
pregnanolone	B-Chemical
,	O
but	T-4
not	T-4
ganaxolone	T-4
,	O
also	O
reduced	T-0
cumulative	T-0
lethality	T-0
associated	O
with	O
kindling	O
.	O

Allopregnanolone	O
and	O
pregnanolone	O
,	O
but	O
not	T-1
ganaxolone	B-Chemical
,	O
also	T-0
reduced	T-0
cumulative	O
lethality	O
associated	O
with	O
kindling	O
.	O

These	O
findings	O
demonstrate	O
that	O
some	O
neuroactive	O
steroids	B-Chemical
attenuate	O
convulsant	O
and	O
sensitizing	O
properties	O
of	O
cocaine	O
and	O
add	O
to	O
a	O
growing	O
literature	O
on	O
their	O
potential	O
use	T-0
in	O
the	O
modulation	O
of	O
effects	O
of	O
drugs	T-1
of	O
abuse	O
.	O

These	O
findings	O
demonstrate	O
that	O
some	O
neuroactive	O
steroids	O
attenuate	O
convulsant	O
and	O
sensitizing	O
properties	T-0
of	T-0
cocaine	B-Chemical
and	O
add	O
to	O
a	O
growing	O
literature	O
on	O
their	O
potential	O
use	O
in	O
the	O
modulation	O
of	O
effects	O
of	O
drugs	O
of	O
abuse	O
.	O

Effect	O
of	O
humoral	T-0
modulators	T-2
of	T-2
morphine	B-Chemical
-	O
induced	T-3
increase	T-3
in	O
locomotor	O
activity	O
of	O
mice	O
.	O

Effect	O
of	O
humoral	O
modulators	O
of	O
morphine	O
-	O
induced	T-0
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
of	O
mice	O
.	O

The	O
effect	O
of	O
humoral	O
modulators	O
on	O
the	O
morphine	B-Chemical
-	O
induced	T-0
increase	O
in	O
locomotor	O
activity	O
of	O
mice	O
was	O
studied	O
.	O

The	O
effect	O
of	O
humoral	O
modulators	O
on	O
the	O
morphine	O
-	O
induced	T-0
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
of	O
mice	O
was	O
studied	O
.	O

The	O
subcutaneous	O
administration	T-1
of	T-1
10	O
mg	O
/	O
kg	O
of	O
morphine	B-Chemical
-	O
HC1	O
produced	T-2
a	O
marked	O
increase	O
in	O
locomotor	O
activity	O
in	O
mice	O
.	O

The	O
subcutaneous	O
administration	O
of	O
10	O
mg	O
/	O
kg	O
of	O
morphine	O
-	O
HC1	O
produced	T-1
a	T-0
marked	T-2
increase	B-Disease
in	I-Disease
locomotor	I-Disease
activity	I-Disease
in	O
mice	O
.	O

The	O
morphine	B-Chemical
-	O
induced	T-0
hyperactivity	O
was	O
potentiated	O
by	O
scopolamine	O
and	O
attenuated	O
by	O
physostigmine	O
.	O

The	O
morphine	T-0
-	T-0
induced	T-0
hyperactivity	B-Disease
was	T-1
potentiated	T-1
by	O
scopolamine	O
and	O
attenuated	O
by	O
physostigmine	O
.	O

The	O
morphine	O
-	O
induced	O
hyperactivity	O
was	O
potentiated	T-1
by	T-1
scopolamine	B-Chemical
and	O
attenuated	T-0
by	T-0
physostigmine	O
.	O

The	O
morphine	O
-	O
induced	O
hyperactivity	O
was	O
potentiated	O
by	O
scopolamine	O
and	O
attenuated	T-0
by	T-0
physostigmine	B-Chemical
.	O

In	O
contrast	O
,	O
both	T-0
methscopolamine	B-Chemical
and	O
neostigmine	O
,	O
which	T-1
do	T-1
not	T-1
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
had	T-2
no	T-2
effect	T-2
on	O
the	O
hyperactivity	O
produced	O
by	O
morphine	O
.	O

In	O
contrast	O
,	O
both	O
methscopolamine	T-1
and	T-1
neostigmine	B-Chemical
,	O
which	O
do	O
not	O
penetrate	T-2
the	O
blood	O
-	O
brain	O
barrier	O
,	O
had	T-0
no	T-0
effect	T-3
on	T-3
the	O
hyperactivity	O
produced	O
by	O
morphine	O
.	O

In	O
contrast	O
,	O
both	O
methscopolamine	O
and	O
neostigmine	O
,	O
which	O
do	O
not	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
had	O
no	O
effect	O
on	O
the	O
hyperactivity	B-Disease
produced	T-0
by	O
morphine	O
.	O

In	O
contrast	O
,	O
both	O
methscopolamine	O
and	O
neostigmine	O
,	O
which	O
do	O
not	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
had	O
no	O
effect	O
on	O
the	O
hyperactivity	O
produced	T-1
by	T-1
morphine	B-Chemical
.	O

Pretreatment	T-1
of	O
mice	T-0
with	T-0
alpha	B-Chemical
-	I-Chemical
methyltyrosine	I-Chemical
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	O
inhibitor	T-2
of	T-2
tyrosine	T-2
hydroxylase	T-2
,	O
significantly	O
decreased	O
the	O
activity	O
-	O
increasing	O
effects	O
of	O
morphine	O
.	O

Pretreatment	T-0
of	O
mice	O
with	O
alpha	O
-	O
methyltyrosine	O
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	T-1
inhibitor	T-3
of	T-3
tyrosine	B-Chemical
hydroxylase	O
,	O
significantly	T-2
decreased	T-2
the	T-2
activity	T-2
-	O
increasing	O
effects	O
of	O
morphine	O
.	O

Pretreatment	O
of	O
mice	O
with	O
alpha	O
-	O
methyltyrosine	O
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
one	O
hour	O
)	O
,	O
an	O
inhibitor	O
of	O
tyrosine	O
hydroxylase	O
,	O
significantly	O
decreased	O
the	O
activity	O
-	O
increasing	O
effects	T-0
of	T-0
morphine	B-Chemical
.	O

On	O
the	O
other	O
hand	O
,	O
pretreatment	T-0
with	O
p	B-Chemical
-	I-Chemical
chlorophenylalamine	I-Chemical
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
serotonin	O
depletor	O
,	O
caused	T-1
no	O
significant	O
change	O
in	O
the	O
hyperactivity	O
.	O

On	O
the	O
other	O
hand	O
,	O
pretreatment	T-0
with	T-0
p	O
-	O
chlorophenylalamine	O
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
serotonin	B-Chemical
depletor	O
,	O
caused	T-1
no	O
significant	O
change	O
in	O
the	O
hyperactivity	O
.	O

On	O
the	O
other	O
hand	O
,	O
pretreatment	O
with	O
p	O
-	O
chlorophenylalamine	O
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
serotonin	O
depletor	O
,	O
caused	T-1
no	T-0
significant	T-0
change	T-0
in	T-0
the	T-0
hyperactivity	B-Disease
.	O

